Meeting Program - Pdf Format

HEALTH CARE: MEASURING VALUE AND MANAGING RISK

May 16-19, 2004Crystal Gateway Marriott

Arlington, VA, USA

I N T E R N ATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH

Dear Colleagues:

Welcome to Washington, DC and ISPOR’s Ninth Annual

International Meeting.

The theme of this year’s international meeting is "Health Care: Measuring

Value and Managing Risk" and will showcase contemporary methods and

applied research presented by some of the world’s leading authorities in the

fields of economic evaluation, psychometrics, biostatistics, epidemiology, out-

comes research and policy analysis. Three timely and provocative plenary ses-

sions, featuring invited experts and ISPOR member scientists, will focus on dif-

ferent themes. The first session titled "Medicare Drug Benefit and Cost

Effectiveness: Who Pays and Who Plays?" chaired by Bryan Luce PhD, MBA

will address the potential role of outcomes research and cost-effectiveness in

pharmaceutical reimbursement. The second plenary session "New Directions in

Risk Sharing and Post-Marketing Economic Evaluation" chaired by Newell

McElwee PharmD, MSPH seeks to better understand emerging risk sharing

models between payers and manufacturers. The final plenary session chaired by

Peter Neumann ScD, raises the frequently discussed question of a cost-

effectiveness threshold - "What Are We Willing to Pay For a QALY?"

Numerous people have contributed substantial time and effort to this year’s

meeting, and I would like to thank them all, especially the late Bernie O’Brien

PhD (McMaster University), Mark Sculpher MSc, PhD (University of York),

Andy Briggs Dphil (Oxford University) and Adrian Levy PhD (University of

British Columbia), who chaired the program planning committee and the scien-

tific program and shouldered much of the responsibility and burden for the plan-

ning and execution of this year’s meeting. I also would like to extend my sincere

thanks to Marilyn Dix Smith PhD, Executive Director of ISPOR, as well as her

staff. We are fortunate as a society to have these dedicated and tireless individ-

uals working on our behalf.

Please enjoy Washington and the meeting.

Sincerely,

Sean D. Sullivan, PhD

President, 2003-2004

I n t e rnational Society for Pharmacoeconomics and Outcomes Researc h

ISP O R

I S P O R3100 Princeton Pike Building 3, Suite EL a w renceville, NJ 08648 USA Tel: 609-219-0773 Fax: 609-219-0774 email: info@ispor. o rg I n t e rnet: www. i s p o r. o rg

2003-2004 Board of Dire c t o r s

P re s i d e n tSean Sullivan PhDUniversity of Wa s h i n g t o ns d s u l l @ u . w a s h i n g t o n . e d u

P re s i d e n t - e l e c tLieven Annemans PhDH E D ML i e v e n . a n n e m a n s @ h e d m . b e

Past Pre s i d e n tPeter Davey MD, FRCPUniversity of Dundee and MEMOP e t e r @ m e m o . d u n d e e . a c . u k

D i re c t o r sKerstin (Chris) Bingefors PhDUppsala UniversityC h r i s . B i n g e f o r s @ f a rm a c i . u u . s e

D.S. (Pete) Fullerton RPh, PhDUniversity of Wa s h i n g t o nP e t e F u l @ m s n . c o m

Randel E. Richner BSN, MPHBoston Scientific Corp.r i c h n e r R @ b s c i . c o m

Mark Nuijten MD, MBAM E D TAP Intern a t i o n a ln u i j t e n @ m e d t a p . n l

M a rcus Wilson Pharm DHealth Core, Inc.m w i l s o n @ h e a l t h c o re . c o m

Tre a s u re rJean Paul Gagnon PhDAventis Pharm a c e u t i c a l sJ e a n . G a g n o n @ a v e n t i s . c o m

Executive Dire c t o rMarilyn Dix Smith RPh, PhDI S P O Rm d s m i t h @ i s p o r. o rg

3

2 0 0 5

ISPOR 10T H A N N U A LI N T E R N ATIONAL MEETINGM a rriott Wa rdman Park,

Washington, DC, USA

May 15-18, 2005

Abstract Submission Deadline: January 10, 2005

Early Registration Deadline: April 20, 2005

2 0 0 6

ISPOR 11T H A N N U A LI N T E R N ATIONAL MEETINGM a rriott Philadelphia,

Philadelphia, Pennsylvania, USA

May 20-24, 2006



2 0 0 7

ISPOR 12T H A N N U A LI N T E R N ATIONAL MEETINGM a rriott Crystal Gateway

Arlington, Vi rginia, USA

May 19 - 23, 2007



2008ISPOR 13TH ANNUALINTERNATIONAL MEETING Sheraton Centre To ronto,

To ronto, Canada

May 4-7, 2008

Abstract Submission Deadline: April 8, 2008

Early Registration Deadline: January 7, 2008

UPCOMING ISPOR MEETINGS:

I S P OR 7th A n n ua lE u ropean Con g r e s s

24-26 OCTOBER 2004CCH CONGRESS CENTRUM HAMBURG, HAMBURG, GERMANY

ABSTRACT SUBMISSION DEADLINE: 21 JUNE 2004 | EARLY REGISTRATION DEADLINE: 28 SEPTEMBER 2004

ADDITIONAL INFORMATION AT WWW.ISPOR.ORG

4

UPCOMING ISPOR ANNUAL INTERNATIONAL MEETINGS

w w w. i s p o r. o rg

SUNDAY, MAY 16, 2004 5:00 PM - 7:00 PMCRYSTAL GATEWAY MARRIOTT ARLINGTON, VA, USA

Benefit /Risk: In Search of the Proper Balance

A Pre-Meeting Symposium

CO-SPONSORED BY ISPOR AND PhRMA HEALTH OUTCOMES COMMITTEE

T he majority of activity regardingrisk/benefit has centered around

the qualification and measurement ofrisk and potential system changes inreporting of risk. Important for consid-eration in this equation are the adversehealth consequences that result fromnot using medicines properly, i.e. bene-fits foregone. In addition, the FDAMA-mandated Centers for Education andResearch in Therapeutics have con-ducted and disseminated results from alandmark series of think tanks on risk inthe context of benefit. This session willprovide an overview of the current envi-ronment, discuss a pharmaceuticalindustry case study and provide onegovernment agency's approach toaddressing benefit/risk.

5:00 - 5:15 INTRODUCTIONModerator: Kathleen Gondek PhD, Head, Global Health Economics & Outcomes Research, Therapeutic Areas,North America, Bayer Pharmaceuticals, West Haven, CT, USA

5:15 - 5:45 BENEFIT-RISK IN THE BALANCE: WHERE DO WE STAND? Speaker: Hugh Tilson MD, DrPH, Senior Advisor to the Dean and Chair, National Steering Committee, Centers forEducation and Research on Therapeutics, University of North Carolina, Chapel Hill, NC, USAAn update on the latest regulatory framework, the emerging strategic plan from CERTS to improve the nation’s thera-peutics and the results from a landmark series of ThinkTanks on Risk in the context of benefit will be discussed.

5:45 - 6:15 BENEFIT-RISK IN PERSPECTIVE Speaker: Lynn Bosco MD, MPH, Director, Pharmaceutical Studies, Agency for Healthcare Research and Quality,Rockville, MD, USACapturing of both clinically important benefits, as well as risk, is key to interpreting the value of findings consideredin the context of risk-benefit. There is a tendency, presently, to focus on risk, thus developing risk management pro-grams. The goal is to broaden the focus to consider broader patient health status.

6:15 - 6:45 LESSONS FROM ALOSETRON: USING PROS TO INFORM BENEFIT-RISK DECISIONS Speaker: Maria Watson PhD, Manager, Global Health Outcomes, Glaxo Smith Kline, Research Triangle Park, NC, USAHow can patients’ experiences of a disease and its treatment contribute to the assessment of benefit? A case studyfrom alosetron will illustrate the use of patient-reported outcomes to support benefit-risk analysis and decision making.

6:45-7:00 OPEN DISCUSSION

7:00- 7:30 RECEPTION

• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • a d v e r t i s e m e n t s • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

5

The International Society for Pharmacoeconomics and Outcomes Research gratefully acknowledges financial support from the following ISPOR Institutional Council Members:

PLATINUM

Pfizer Pharmaceuticals

GOLD

Aventis GlaxoSmithKline Roche Pharmaceuticals

Healthcare/Bayer plc Merck & Company Wyeth-Ayerst Research

Novartis Pharmaceuticals Corporation

BRONZE

3M Pharmaceuticals Bristol-Myers Squibb Boston Scientific

AstraZeneca Janssen Abbott Labs

Ingenix Abt Associates RTI Health Solutions

MEDTAP International PAI Takeda Pharmaceuticals

IMS America Centocor, Inc. Sanofi-Synthelabo

Genentech Medtronic Health Core

ISPOR 9TH ANNUAL INTERNATIONAL MEETING M AY 16-19, 2004 | C RY S TAL GAT E WAY MARRIOTT, ARLINGTON, VA, USA

2004 INSTI TUT IONAL COUNCIL MEMBERS

6

Letter from ISPOR President . . . . . . . . . . . . . . . . . . . . . . . . . .3

Upcoming ISPOR Meetings . . . . . . . . . . . . . . . . . . . . . . . . . .4

Pre-Meeting Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . .5

2004 ISPOR Institutional Council . . . . . . . . . . . . . . . . . . . . . .6

Table of Contents and Event Sponsors . . . . . . . . . . . . . . . . . . .7

Pre-Meeting Short Course Program . . . . . . . . . . . . . . . . . . . . .8

Letter from Chairs, Program Committee . . . . . . . . . . . . . . . . .11

9th Annual International Program Committee . . . . . . . . . . . . .12

ISPOR Mission Statement & Objectives . . . . . . . . . . . . . . . . .14

Key Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .15

Meeting-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . . .16-17

Program Schedule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18

Contributed Poster Presentations . . . . . . . . . . . . . . . . . . . . . .31

Issue Panel Descriptions . . . . . . . . . . . . . . . . . . . . . . . . . . .53

Contributed Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . .55

In Memorium, Bernard J. O’Brien . . . . . . . . . . . . . . . . . . . . .64

ISPOR Service Awardees . . . . . . . . . . . . . . . . . . . . . . . . . . .65

2004 ISPOR Research Excellence Awards . . . . . . . . . . . . . . .66

ISPOR President & President-elect Biosummary . . . . . . . . . . . .67

Plenary Speaker Biographical Information . . . . . . . . . . . . . . .67

ISPOR Professional Recruitment Assistance

Program (PRAP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .69

Exhibitors Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .73

ISPOR Leadership Directory . . . . . . . . . . . . . . . . . . . . . . . . .93

Research Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .98

Hotel Information & Meeting Room Floor Plan . . . . . . . . . . .102

Monday Coffee Breaks

Monday Lunch

Tuesday Coffee Breaks

Tuesday Lunch

Wednesday Coffee Breaks

Exhibitors’ Open HouseReception

Registration Bags

Water Bottles

Lanyards

Pad Holders


TABLE OF CONTENTS

EVENT SPONSORS

ISPOR thanks the following sponsors for their generous contributions:

NDCH E A LT H®

7

S AT U R D AY, MAY 15TH8:00AM-5:00PM Full Day Short Courses

Pharmacoeconomics

PHARMACOECONOMICS FOR DECISION-MAKERSACPE# 328-999-04-009-L04 SALON HFaculty: Lorne Basskin PharmD, President, Tr i n k aPublications, Cooper City, FL, USA and ClinicalC o o r d i n a t o r, North Shore Medical Center, Miami, FL, USACourse description: This course is designed to teachclinicians and new researchers how to incorporatepharmacoeconomics into study design and dataanalysis. Participants will learn how to collect andcalculate the costs of different alternatives, deter-mine the economic impact of clinical outcomes, andhow to identify, track and assign costs to differenttypes of health care resources used. The develop-ment of economic protocols and data collectionsheets will be discussed. Different pharmacoeconom-ic models and techniques will be demonstrated andpracticed in lectures and case studies. These includecost-minimization, cost-of-illness, cost-effectiveness,cost-benefit, and cost-utility analysis. Decision analy-sis, sensitivity analysis, and discounting, will all bedemonstrated and practiced. Participants will alsolearn to compare and evaluate interventions such asdrugs, devices and clinical services. This course issuitable for those with little or no experience withpharmacoeconomics.

ModelingMODELING: STRUCTURE & DESIGN OF MODELACPE # 328-999-04-007-L04 SALON JFaculty: Marc Botteman MA, Executive Director, AbtAssociates, HERCULES, Bethesda, MD, USA; Ben vanHout PhD, Scientific Director, PharMerit, Capelle a/dIJssel, The Netherlands; Bart Heeg MSc, PharMerit,Capelle a/d IJssel, The NetherlandsCourse Description: Models are mathematical frame-works in which knowledge from a variety of sourcescan be brought together in a structured framework.Modeling provides an analytic tool that enablesresearchers to estimate the costs and outcomes ofdifferent treatment options, as well as the uncertain-ties surrounding those outcomes. In the first part ofthis full day course, participants will learn when andhow to use, implement, simulate, and evaluateMarkov models, discrete event models, and othermodeling techniques used to conduct burden-of-ill -ness and cost-effectiveness analyses. This will beaccomplished by first providing a review of thesemethods and their appropriate use, in light of theISPOR Principles of Good Practice for DecisionAnalytic Modeling in Health Care Evaluations. Then,using a series of related examples, the course willcarefully review the practical steps involved in devel-oping and using these kinds of models. These exam-ples will be presented using predominantly MicrosoftExcel, supplemented with add on simulation software,as opposed to dedicated, stand-alone decision analy-

sis software, as the goal of the course is to providean in depth understanding of the simple yet powerfulmathematical underpinnings of each of these meth-ods using a relatively transparent tool rather than toteach a new programming language. The secondsection of this course will cover in details the practi-cal steps involved in the selection and modeling ofdata inputs and practical aspects related to thedetermination of when, why and how to handle sto-chastic (i.e., first order Monte Carlo Simulations) andprobabilistic uncertainty (i.e., second order MonteCarlo Simulations). The ISPOR Principles of GoodPractice will again be reviewed and discussed in thiscontext. These will include in particular data identifi-cation, data modeling, and data incorporation consid-erations. Issues related to the selection of modelinput parameters and their distributions for use inprobabilistic sensitivity analyses will be considered.Participants will learn the steps required conducting,analyzing, interpreting, and presenting results fromprobabilistic sensitivity analyses (e.g. using analysesof the cost-effectiveness plane, the "ellipses", andacceptability curves). An introduction to the expectedvalue of perfect information [EVPI] will be provided inthe context of the use of probabilistic sensitivityanalyses. The above concepts will be illustrated witha series of related examples using Microsoft Excel.Publications from health care journals presentingadditional examples and theoretical considerationswill be provided as a course supplement. This inter-mediate course requires basic understanding of deci-sion analysis. The course will be conducted more asa seminar, rather than as a hands-on modeling work-shop. However, we encourage participants to bringtheir own laptop computers (with a CD ROM driveand Microsoft Excel) to facilitate the use of the exam-ples and add-on software demo that will be provided.Additionally, we encourage early course registrationto allow for early distribution of the examples andadd-on software. This intermediate course requiresbasic understanding of decision analysis.

MORNING COFFEE BREAK SPONSORED BY

Saturday, May 15th8:00AM-12:00PM Morning Short Courses

Quality of Life / Patient-reportedOutcomes

INTRODUCTION TO QUALITY OF LIFE / PATIENT-REPORTED OUTCOMESACPE# 328-012-03-010-L04 SALON BFaculty: Linda Abetz MA, Research Director, MapiValues, Bollington, UK; Bruce Crawford MA, MPH,Senior Project Director/Manager US Operations,Mapi Values, Boston, MA, USACourse description: Basic concepts of health-relatedquality of life, patient satisfaction, work performancein clinical trial and health services research will be

presented. Participants will be asked to identify PROdomains and sub-domains from an anonymouspatient interview. The advantages and disadvantagesof different types of questionnaires will be provided,with examples provided for each type (an exhaustivelist of questionnaires will NOT be provided). Finally,the practical methods and issues to consider whenchoosing or developing an instrument for a clinicalstudy will be discussed, including cross-culturalissues. Participants will be asked to choose a ques-tionnaire for a hypothetical study and develop aquestionnaire based on a patient interview.This course is suitable for those with little or noexperience with quality of life or patient-reportedoutcomes measurement.

Economic Analysis

COST ESTIMATION: FINDING AND EXTRACTINGCOST DATAACPE# 328-999-04-004-L04 SALON AFaculty: Judith A. O’Brien RN, BSPA, Vice President,Director of Cost Development Research, CaroResearch Institute, Concord, MA, USA Course Description: This course will focus on practi -cal aspects of cost development for pharmacoeco-nomic studies. The objective is to help the participantbridge the gap between understanding pharma-coeconomic theory and the practice of developingcost estimates. Factors to consider when costingpharmacoeconomic analyses, such as perspective,data sources, data classification systems, developingresource use profiles, obtaining unit costs, and mak-ing cost adjustments will be presented. Examples ofissues encountered when identifying and extractingcost data will be discussed. This course is designedfor those with some experience with pharmacoeco-nomic analysis.

Clinical Assessment

INTRODUCTION TO PHARMACOEPIDEMIOLOGYACPE# 328-999-04-001-L04 SALON CFaculty: Adrian Levy PhD, Assistant Professor,University of British Columbia, Vancouver, BC,CanadaCourse description: Pharmacoepidemiology is theapplication of epidemiological knowledge and meth-ods to study the effects (both positive and negative)of drugs in human populations. Its purpose is todescribe and predict drug treatment in a definedtime, space, and population. This course will providean overview of the contribution of epidemiology tothe study of drug uses and effects. Risk assessmentmethodologies, and pharmacoepidemiologic studydesign strategies (observational, analytic, and inter-ventional studies) including their strengths and weak-nesses will be presented. A special consideration willbe given to the contribution of pharmacoepidemiolo-gy to outcomes research, and its relevance to deci-sion-making. This course is for those with no or littleexperience with pharmacoepidemiology.


I S P O R P R E - M E E T I N G S H O RT C O U R S E S

8

AFTERNOON COFFEE BREAK SPONSORED BY

Saturday, May 15th1:00PM-5:00PM Afternoon Short Courses


QUALITY OF LIFE / PATIENT-REPORTED OUTCOMESIN CLINICAL TRIALSACPE# 328-012-03-016-L04 SALON BFaculty: Bruce Crawford MA, MPH, Senior ProjectDirector/Manager US Operations, Mapi Values,Boston, MA, USA; Linda Abetz MA, ResearchDirector, Mapi Values, Bollington, UKCourse description: Practical methods for assessinghealth-related quality of life and patient reported out-comes (PRO) in clinical trials and health servicesresearch will be presented. Reliability, validity,responsiveness, item reduction, missing data, dataimputation, and issues of analysis and interpretationwill be discussed. New methods for development,validation and testing cross-cultural equivalencewill be presented (eg, Rasch and structural equa-tion modeling, simultaneous development). This course is designed for those with either littleor intermediate experience in health-related quali-ty-of-life assessment.

Economic Analysis

FINANCIAL IMPACT / COST OF ILLNESSACPE# 328-012-03-014-L04 SALON CFaculty: Josephine Mauskopf PhD, Division Director,Global Health Economics, RTI Health Solutions, RTIInternational, Research Triangle Park, NC, USA; C. Daniel Mullins PhD, Professor, University ofMaryland, School of Pharmacy, Baltimore, MD, USACourse Description: This will describe methods todetermine the cost-of-illness of a health conditionusing a "top-down" or "bottom-up" approach.Participants will also learn how to estimate theimpact of new health care technologies on disease-specific costs from different decision-maker perspec-tives. Actuarial methods using straight-line projec-tions and nonlinear trends will be described. Bothstatic and dynamic methods for estimating the budgetimpact of adding a new drug to a health plan formula-ry will also be presented. This course is designed forthose with some experience with pharmacoeconomicanalysis.

Clinical Assessment

RANDOMIZED CLINICAL TRIAL ANDOBSERVATIONAL/ NATURALISTIC STUDY DESIGN ACPE# 328-999-04-002-L04 SALON AFaculty: Adrian Levy PhD, Assistant Professor,University of British Columbia, Vancouver, BC,CanadaCourse description: This course will describe thedesign of randomized clinical trial and as well asobservational (naturalistic) clinical studies. Studydesign issues as well as a comparison of designs will

be discussed. Research problems commonly encoun-tered in health care settings as well as other issues,such as outcomes, population, setting, time frame,will be discussed. Examples using case studies willbe presented. This course is for those with little or noexperience in outcomes or clinical research.

S U N D AY, MAY 16TH8:00AM-5:00PM Full Day Short Courses

Clinical Assessment

RETROSPECTIVE DATABASE ANALYSIS: DATASOURCES AND METHODS (FULL-DAY COURSE)ACPE# 328-999-04-008-L04 SALON JFaculty: Lisa Stockwell-Morris PhD, RPh, IMSHealth, Plymouth Meeting, PA, USA; William H.Crown PhD, Ingenix Pharmaceutical Services,Auburndale, MA, USACourse Description: Large administrative claims data-bases provide a unique opportunity to examine retro-spectively the effects of drug use on clinical and eco-nomic outcomes in "real world" settings. This coursewill examine the characteristics of retrospectivedatabases and the statistical issues, which necessi-tates the use of multivariate methods. The ISPORChecklist for Retrospective Database Studies, a use-ful tool for assessing as well as conducting retro-spective studies will be discussed. This course willfocus on concepts and examples. This course willdescribe analytical approaches such as OLS, logistic,and Poisson regression, survival analysis, and theKaplan-Meier Sample Average (KMSA) method. Alsodiscussed will be the use of propensity scores, instru-mental variables, and nonparametric bootstrapping,as well as methods for selection of model covariatesand testing of model assumptions. Examples of pub-lished retrospective database studies will be dis-cussed. This course will assume participants haveknowledge of statistical methods and/or economet -rics and experience in the analysis of administrativeclaims databases.

MORNING COFFEE BREAK SPONSORED BY

Sunday, May 16th8:00AM-12:00PM Morning Short Courses


ADVANCED QUANTITATIVE METHODS FOR QUALITYOF LIFE / PATIENT-REPORTED OUTCOMES RESEARCHACPE# 328-999-04-005-L04 SALON HFaculty: John Ware PhD, CEO & Chief ScienceOfficer, Quality Metric Incorporated, Lincoln, RI, USA;Jakob B. Bjorner, MD, PhD, Deputy Chief ScienceOfficer, Quality Metric Incorporated, Lincoln, RI, USACourse Description: This course will describe classi-cal test theory, item response theory [theory andmodels used with modern" psychometric methods],computer-adaptive testing and analysis. Combining

multiple measures and scales and multiple measure-ment error [effect-indicator and cause-indicatormodels], reliability and latent variable analysis(exploratory factor analysis, principal componentsanalysis, principal factor analysis, and confirmatoryfactor analysis) will be described. This course isdesigned for those with experience with psychomet-ric measures.

Modeling

BAYESIAN ANALYSIS: OVERVIEWACPE# 328-012-03-012-L04 SALON AFaculty: Bryan Luce MBA, PhD, Senior ResearchLeader & CEO, MEDTAP International, Bethesda, MD,USA; Christopher S. Hollenbeak PhD, Surgery andHealth Evaluation Sciences, Penn State College ofMedicine, Hershey, PA, USA; Elisabeth Fenwick PhD,Lecturer, Department of Economics and RelatedStudies, University of York, York, UKCourse Description: This course is designed to pro-vide an overview of the Bayesian approach and itsapplications to health economics and outcomesresearch. The course will cover basic elements ofBayesian statistics, contrasting briefly with classical(frequentist) statistics and introduce available statisti -cal packages. This course is designed for those witha limited understanding of Bayesian statistical con-cepts. Modeling Part II is a suggested prerequisitefor this course.

Economic Analysis

INTRODUCTION TO PROBABILISTIC COST–EFFECTIVENESS MODELINGACPE# 328-999-04-16-LO4 SALON KFaculty: Andrew Briggs Dphil, Professor, HealthEconomics Research Centre, University of Oxford,Institute of Health Sciences Headington, Oxford, UK;Mark Sculpher MSc, PhD, P r o f e s s o r, University of Yo r k ,Centre for Health Economics, Heslington, York, UKCourse Description: This course will introduce theparticipant to statistical considerations that underliethe construction of cost-effectiveness models. Inparticular, we will review how standard statisticalprocedures (such as survival analysis, regressionmodels and meta-analysis) can be used to estimatethe parameters, together with associated distribu-tions for the construction of probabilistic models.Examples will be used throughout to illustrate theconcepts, and some practical spreadsheets will beavialable for download after the course. The focuswill be on understanding how to implement distribu-tions in a standard spreadsheet package rather thanusing a dedicated software programme or spread-sheet add-in. This course is designed for those withsome experience in cost-effectiveness modelling.

Clinical Assessment

META-ANALYSIS AND SYSTEMATIC LITERATUREREVIEWACPE# 328-012-03-018-L04 SALON CFaculty: Joseph C. Cappelleri PhD, Senior AssociateDirector, Pfizer Inc, Groton, CT, USACourse Description: Meta-analysis may be defined asthe statistical analysis of data from multiple studiesfor the purpose of synthesizing and summarizingresults, as well as for quantitatively evaluating


9

Continuing Education Credit Continuing Education credits for pharmacists will be provided by The University of Florida and Trinka MedicalPublications. Attendees can earn up to 16.0 hours (1.6 CEUs) for attending Issues Panels, Plenary Sessions, Workshops, and Podium Sessions at theAnnual Meeting, up to 4 hours (0.4 CEUs) for each half day short course, and up to 7.5 hours (0.75 CEUs) for each full day short course. TheUniversity of Florida and Trinka Medical Publications are approved by the Accreditation Council for Pharmacy Education as providers of continuingpharmaceutical education. Participants who attend the program and complete the evaluation forms can expect to receive their certificates within 4-6 weeks after the completion of the program.

sources of heterogeneity and bias. A systematic liter-ature review often includes meta-analysis andinvolves an explicit, detailed description of how areview was conducted. This course highlights andexpounds upon four key areas: 1) impetus for meta-analysis and systematic reviews; 2) basic steps toperform a quantitative systematic review; 3) statisti-cal methods of combining data; and 4) appraisal anduse of meta-analytic reports. The material is motivat-ed via applications in pharmacoeconomics, outcomesresearch, and clinical studies from the published lit-erature and hypothetical examples. Interactive exer -cises are part of the course. This course is designedfor those with little experience with meta-analysis.

Decision Analysis

INTRODUCTION TO DECISION ANALYSIS ACPE# 328-012-03-007-L04 SALON BFaculty: Mark Roberts MD, MPP, FACP, AssociateProfessor and Chief, Section of Decision Sciencesand Clinical Systems Modeling, University ofPittsburgh School of Medicine, Pittsburgh, PA, USA Course description: Decision analysis is a tool thatuses an explicit, quantitative structure to describeand analyze complex health care decisions. Thiscourse will provide an introduction to the principlesand practice of decision analysis. Upon completion ofthe course, participants will be able to evaluate theappropriateness of decision analysis in different set-tings, construct simple decision trees, understand thebasic mechanics of tree evaluation and sensitivityanalysis, and acquire skill in the interpretation of apublished decision analysis. Extension of basic tech-niques, such as cost-effectiveness analysis and theassessment of patient preferences will be briefly dis-cussed. Pen and paper exercises will be used to illus-trate these principles. This course is suitable forthose with little experience with decision analysis.

AFTERNOON COFFEE BREAK SPONSORED BY

Sunday, May 16th1:00PM-5:00PM Afternoon Short Courses

Pharmacoeconomics

ELEMENTS OF PHARMACEUTICAL PRICINGACPE# 328-012-03-009-L04 SALON HFaculty: Jack Mycka, President, Optimar StrategicConsulting LLC, Montclair, NJ, USA; RenatoDellamano PhD, President, ValueVector (Value AddedBusiness Strategies), Milan, ItalyCourse Description: This course is designed to cover

the elements of pharmaceutical pricing decisions. Itwill cover the issues, information and processesemployed and the role of pharmacoeconomics inhelping to shape pricing decisions. This course willbe interactive and is designed for those with someexperience in either pharmacoeconomics or pharma -ceutical pricing.


OLD AND NEW UTILITY MEASURES IN HEALTHECONOMICS AND OUTCOMES RESEARCHACPE# 328-012-03-008-L04 SALON FFaculty: F. Reed Johnson PhD, Senior Fellow, RTIHealth Solutions, Research Triangle Park, NC, USA; A. Brett Hauber PhD, Senior Economist, RTI HealthSolutions, Research Triangle Park, NC, USACourse Description: Course participants will learn theconceptual and empirical features of various health-utility measures and their relative advantages for dif-ferent health care decisions. Health utility measuresare often outcomes of interest in their own right. Inaddition, cost-utility analysis (CUA) and cost-benefitanalysis (CBA) are often used to evaluate new healthcare technologies. Both CUA and CBA are useful forinforming decision makers about the relative benefitsof an intervention to individual patients and to societyas a whole. There are different approaches to esti-mating benefit measures for comparison with treat-ment costs. CUA employs health-state utilities basedon cardinal utility theory to define quality-adjusted lifeyears (QALYs) for different health states. In contrast,CBA estimates take the form of ordinal utility valuesexpressed as money-equivalent values (often calledwillingness to pay). This course evaluates new meth-ods for bridging the gap between ordinal and cardinalutility measures. Newer methods allow analysts toestimate "super QALY" values using time or other non-monetary tradeoffs that do not require the restrictiveassumptions of conventional cardinal-utility methods.The course focuses particularly on how to derive util-ity estimates from CA surveys, including developingvalid and reliable tradeoff surveys and analyzing theresulting data. This course is designed for those withsome experience with psychometric measures.

Modeling

BAYESIAN ANALYSIS: APPLICATIONSACPE# 328-999-04-015-L04 SALON AFaculty: Bryan Luce MBA, PhD, Senior ResearchLeader & CEO, MEDTAP International, Bethesda, MD,USA; Christopher S. Hollenbeak PhD, Surgery andHealth Evaluation Sciences, Penn State College ofMedicine, Hershey, PA, USA; David Vanness PhD,Assistant Professor of Population Health Sciences,University of Wisconsin Medical School, Madison,WI, USA; Elisabeth Fenwick PhD, Lecturer,

Department of Economics and Related Studies,University of York, York, UKCourse Description: This course will focus on theBayesian "informative prior." Several examplevignettes of how a Bayesian analysis can be usedwithin outcomes modeling problems will be present-ed. Participants will learn how a Bayesian approachis different and why it is useful for their work andwhat tools are available to them. This course isdesigned for those with a limited understanding ofBayesian statistical concepts.

Economic Analysis

STATISTICAL CONSIDERATIONS IN ECONOMICEVALUATIONS ACPE# 328-999-04-014-L04 SALON KFaculty: John Cook PhD, Director, Merck ResearchLaboratories, Blue Bell, PA, USA; Joseph Heyse PhD,Executive Director, Biostatistics & Research DecisionSciences, Merck Research Laboratories, West Point,PA, USA; George W. Carides PhD, SeniorBiometrician, Merck, Blue Bell, PA, USACourse Description: This course will focus on the sta-tistical considerations of planning & analyzing studiesand interpreting the results, including comparisons oftypes of analyses used and discussing importantstudy design features for both clinical-economic tri-als and modeling studies based on available epidemi-ological and clinical data. Methods of statisticalanalysis for cost data and for estimating cost-effec-tiveness ratios will be thoroughly reviewed, makingextensive use of real-life examples and publishedstudies. This course is designed for those with expe-rience in conducting economic studies.

Decision Analysis

COMPUTER-ASSISTED DECISION ANALYSISAPPLICATIONSFaculty: Andrew Sheldon, Programmer and Trainer,TreeAge Software, Inc., Williamstown, MA, USAACPE# 328-999-04-003-L04 SALON GCourse description: This course is a hands-on intro-duction to the use of software in the creation andanalysis of cost-effectiveness decision models. Thebasics of cost-effectiveness decision making, build-ing and analyzing a simple decision tree will be dis-cussed. Markov modeling and Monte Carlo simulationwill be demonstrated. The participant must bring alaptop computer with Microsoft Windows 98 softwareor later onto which a special version of TreeAgeSoftware's software program will be loaded. Thiscourse is for those with no prior experience in build-ing decision trees. This course is suitable for thosewith little experience building decision trees.


10

Dear Colleagues,

As the members of the Program Planning Committee, we would like to take this opportunity to welcome you to Arlington for the 9th Annual International Meeting of the International Society forPharmacoeconomics and Outcomes Research.

This year's meeting is overshadowed by the premature death of our colleague and friend BernieO'Brien, on February 13, 2004. Bernie was the Program Chair for this meeting and, by rights, hiswords would have appeared in this space. We can try, however, to convey some of Bernie's thinking inplanning this meeting.

The theme for this meeting, chosen by Bernie, is “Health Care: Measuring Value and Managing Risk.”His choice of this theme reflected an international interest, in terms of health policy and researchmethods, in striking a balance between adopting promising new pharmaceutical interventions, andspreading the risk regarding their actual impact on population health and resource costs.

The plenary sessions that Bernie put together serve to develop this theme over the three days of ourmeeting. The opening plenary addresses US legislation concerning the Medicare Drug Benefits Planand the role of cost-effectiveness and outcomes research information for regulatory purposes. The sec-ond plenary discusses the international experience of using innovative risk-sharing techniques whennew pharmaceuticals are introduced to the health system. The final plenary concentrates on what, toBernie, is the $64,000 question: what are we willing to pay for a QALY?

This year the number of contributed workshops has been increased and, for the first time, contributedissues panels have been introduced. Together with the 64 contributed podium presentations and theposter presentations this meeting promises to be a truly stimulating event.

The program represents the culmination of another year of effort and preparation by many persons.Committee members volunteer their time to plan the program and key to their efforts are the energiesof the staff at ISPOR who manage the difficult and challenging task of organizing an internationalevent in an efficient and courteous fashion.

At this, the 9th Annual Meeting, ISPOR has emerged from a phase of rapid growth to achieve a criti-cal mass. Every year in May, individuals from around the world are eager to come to Arlington tolearn about the latest developments and thinking in pharmacoeconomics and outcomes research.ISPOR’s annual meeting is unique in that it provides a forum for individuals from industry, govern-ment and academia, as well as from different countries, to share perspectives.

Under Bern i e ’s leadership, our goal has been to create a meeting that is interesting, stimulating and onethat yields direct benefit to all attendees. A number of tributes are planned for Bernie during the courseof the meeting, but it is through the success of this meeting and the advancement of the science that heloved, that each of us can personally pay tribute to a valued and respected colleague and friend.

Adrian Levy PhD, Professor, Center for Health Evaluation and Outcome Sciences, St. Paul'sHospital, University of British Columbia Vancouver, CanadaISPOR Contributed Research Review Committee ChairISPOR 9th Annual International Meeting

Andrew Briggs Dphil, Professor, Health Economics Research Centre, University of Oxford, Institute of Health Sciences Headington, Oxford, UKIssue Panel & Contributed Workshop Co-ChairISPOR 9th Annual International Meeting

Mark Sculpher MSc, PhD, Professor, University of York, Centre for Health Economics, Heslington, York, UKIssue Panel & Contributed Workshop Co-ChairISPOR 9th Annual International Meeting

I n t e rnational Society for Pharmacoeconomics and Outcomes Researc h

ISP O R

I S P O R3100 Princeton Pike Building 3, Suite EL a w renceville, NJ 08648 USA Tel: 609-219-0773 Fax: 609-219-0774 email: info@ispor. o rg I n t e rnet: www. i s p o r. o rg

2003-2004 Board of Dire c t o r s

P re s i d e n tSean Sullivan PhDUniversity of Wa s h i n g t o ns d s u l l @ u . w a s h i n g t o n . e d u

P re s i d e n t - e l e c tLieven Annemans PhDH E D ML i e v e n . a n n e m a n s @ h e d m . b e

Past Pre s i d e n tPeter Davey MD, FRCPUniversity of Dundee and MEMOP e t e r @ m e m o . d u n d e e . a c . u k

D i re c t o r sKerstin (Chris) Bingefors PhDUppsala UniversityC h r i s . B i n g e f o r s @ f a rm a c i . u u . s e

D.S. (Pete) Fullerton RPh, PhDUniversity of Wa s h i n g t o nP e t e F u l @ m s n . c o m

Randel E. Richner BSN, MPHBoston Scientific Corp.r i c h n e r R @ b s c i . c o m

Mark Nuijten MD, MBAM E D TAP Intern a t i o n a ln u i j t e n @ m e d t a p . n l

M a rcus Wilson Pharm DHealth Core, Inc.m w i l s o n @ h e a l t h c o re . c o m

Tre a s u re rJean Paul Gagnon PhDAventis Pharm a c e u t i c a l sJ e a n . G a g n o n @ a v e n t i s . c o m

Executive Dire c t o rMarilyn Dix Smith RPh, PhDI S P O Rm d s m i t h @ i s p o r. o rg

11

Thomas Abbott PhD, MBA, Senior Director, Pharmaceutical Economics Merck & Co. Inc.,Whitehouse Station, NJ, USA

Jeonghoon Ahn PhD, Assistant Professor University of Southern California, Los Angeles, CA,USA

Lieven Annemans PhD, MSc, Mman, Director, HEDM, Meise, Belgium

Adam Atherley PhD, Health Economist, Centers for Disease Control, Atlanta, GA, USA

Mohan Bala, PhD, Associate Director, Centocor Inc., Malvern, PA, USA

*Rajesh Balkrishnan PhD, Associate Professor, University of Texas School of Public Health,Houston, TX, USA

Richard Barron MS, Manager, Health Economics, Allergan, Inc, Irvine, CA, USA

Lorne Basskin PharmD, President, Trinka Publications, Cooper City, FL, USA

Ramon Bautista MD, MBA, Assistant Professor of Neurology, University of FloridaHSC/Jacksonville, Jacksonville, FL, USA

Stephen Beard, Health Economist/Modeler, RTI Health Solutions, Manchester, UK

Timothy Bell, RTI Health Solutions, Research Triangle, NC, USA

Rami Ben-Joseph PhD, RPh, VP Operations, Health Process Management, Doylestown, PA, USA

Gilles Berdeaux MD, Health Economics Manager Laboratoires Alcon France, Rueil-MalmaisonCedex, France

Stephen J. Boccuzzi PhD, Executive Director, Merck & Company, Inc., West Point, PA, USA

Somali Misra Burgess PhD, PharMetrics, Inc., Watertown, MA, USA

Joseph C. Cappelleri PhD, Senior Associate Director, Pfizer Inc, Groton, CT, USA

Jean Carter PhD, PharmD, Assistant Professor, University of Montana, Missoula, MT, USA

Amit Chhabra MD, MPH, Research Associate, Harvard Clinical Research Institute, Boston, MA, USA

Steven Clause PharmD, Research Assistant Professor, Dept. of Pharmacy Practice, AlbanyCollege of Pharmacy, Albany, NY, USA

John Coombs PharmD, Outcomes Research Scientist, Pfizer, Ann Arbor, MI, USA

Bruce Crawford MA, MPH, Project Director, Mapi Values, Boston, MA, USA

Suellen Curkendall PhD, Principal, Healthcare Data Analysis, Vienna, VA, USA

Shelby D. Reed PhD, RPh, Assistant Research Professor, Duke Clinical Research Institute,Durham, NC, USA

Linda Davies MS, Reader and Director of Health Economics, University of Manchester,Manchester, UK

Mei-Sheng Duh, Vice President, Analysis Group/Economics, Boston, MA, USA

Thomas Einarson PhD, Associate Professor, Faculty of Pharmacy, University of Toronto, Toronto,Ontario, Canada

Jeffrey Ellis PharmD, MS, Outcomes Research Specialist, Cleveland Clinic Foundation,Cleveland, OH, USA

Lida Etemad MS, PharmD, Sr Research Analyst, Ingenix, Eden Prairie, MN, USA

Christopher Evans PhD, MPH, Senior Project Director, Mapi Values, Boston, MA, USA

Kevin Farmer PhD, Associate Professor, University of Oklahoma, Oklahoma City, OK, USA

Elisabeth Fenwick PhD, University of York, York, UK

Jack Fincham PhD, Dean, University of Kansas, Lawrence, KS, USA

Ellen Friedla PharmD, MPH, Clincal Director, Heritage Information Systems, Richmond, VA, USA

Yves M. Gagnon MSc, President, Occam Research & Consulting Inc, Vancouver, BC, Canada

Neil Goldfarb BA, ABD, Director of Research, Office of Health Policy, Thomas JeffersonUniversity, Philadelphia, PA, USA

Mugdha Gore PhD, BPharm, Principal Consultant, Avalon Health Solutions, Inc., Philadelphia,PA, USA

Dennis Grauer PhD, RPh, MS, Assistant Professor, The University of Kansas, Kansas City, KS, USA

J. Pierre Gregoire PhD, Director, Health Economics & Outcomes Research, Merck FrosstCanada & Co., Kirkland, QC, Canada

Jens Grueger PhD, Head of Health Economics Department, Novartis Pharmaceuticals AG, Basel,Switzerland

Cheryl Hankin PhD, Associate Director, Outcomes Research, McNeil Consumer and SpecialtyPharmaceuticals, San Jose, CA USA

A.Brett Hauber PhD, Senior Economist, RTI Health Solutions, Research Triangle, NC, USA

Daniel Huse MA, Director, MarketScan Studies, Medstat, Cambridge, MA, USA

Uchenna Iloeje MD, MPH, FACP, Associate Director – Outcomes, Bristol-Myers Squibb,Wallingford, CT, USA

Michael Iskedjian RPh, MSc, President, PharmIdeas Research & Consulting Inc., Oakville, ON,Canada

Joseph Jackson PhD, Group Director, Health Economic Policy and External Relations, Bristol-Myers Squibb, Princeton, NJ, USA

Ravishankar Jayadevappa PhD, Research Assistant Professor, University of Pennsylvania,Philadelphia, PA, USA

Program Planning Committee Chair: The late Bernie J. O’Brien PhD, Professor, Department of Clinical Epidemiology & Biostatistics, McMaster University, St. Joseph’s Hospital, Hamilton, Ontario, Canada

Issue Panels & Contributed Workshop Committee Co-Chairs: Andrew Briggs Dphil, Professor, Health Economics Research Centre, University of Oxford, Institute of Health Sciences Headington, Oxford, UK and

Mark Sculpher MSc, PhD, Professor, University of York, Centre for Health Economics, Heslington, York, UK

Contributed Research Review Committee Chair: Adrian Levy PhD, Professor, Center for Health Evaluation and Outcome Sciences, St. Paul's Hospital, University of British Columbia, Vancouver, Canada

Short Course Co-chairs: Lorne Basskin PharmD, President, Trinka Publications, Cooper City, FL, USA and Clinical Coordinator, North Shore Medical Center, Miami, FL, USA and

J. Jaime Caro MD, Scientific Director, Caro Research, Concord, MA, USA

Contributed Workshop Review Committee:Rajesh Balkrishnan PhD, MS, Associate Professor, University of Texas, School of Public Health, Houston, TX, USA; Lynda Bryant-Comstock, Manager, Environment and

Policy, GlaxoSmithKline, Research Triangle Park, NC, USA; Dong-Churl Suh MBA, PhD, Associate Professor, College of Pharmacy, Rutgers University, Piscataway, NJ, USA;Pennifer Erickson PhD, Co-founder, O.L.G.A., State College, PA, USA; Deborah Marshall PhD, Innovus Research Inc., Burlington, ON, Canada


ISPOR 9TH ANNUAL INTERNATIONAL MEETING PROGRAM COMMITTEES

Contributed Research Review Committee:

12

Sachin Kamal-Bahl Bpharm, MS, University of Maryland, Baltimore, MD, USA

Meredith Kilgore PhD, MSPH, Assistant Professor, UAB SOPH Health Care Organization &Policy, Birmingham, AL, USA

Nathan Kleinman PhD, Director of Analysis and Research, OCI, Cheyenne, WY, USA

Maria Koltowska-Haggstrom MD, Project Manager, Pharmacia AB, Stockholm, Sweden

Lincy Lal PhD, PharmD, Assistant Professor, Texas Southern University - College of Pharmacy,Houston, TX, USA

Deepa Lalla, Health Economist, Amgen, Inc., Thousand Oaks, CA, USA

Paul Langley PhD, USA International Manager, Health Economics, 3M Pharmaceuticals, St. Paul,MN, USA

Anandi Law PhD, Assistant Professor in Social Administration Sci., Western University of HealthSciences, Pomona, CA, USA

Shelah Leader PhD, Director, Pharmacoeconomics and Outcomes Research, Medimmune,Gaithersburg, MD, USA

Christopher Leibman PhD, Associate Director, Respiratory, AstraZeneca, Wilmington, DE, USA

Barbara Edelman Lewis PhD, MHA, Director, Health Economics and Outcomes Research,AstraZeneca, Worcester, MA, USA

Nick Lipskiy PhD, MBA, Director of Biostatistics, Surveillance Data Inc, Plymouth Meeting, PA, USA

Eva Lydick PhD, Lovelace Clinic Foundation, Albuquerque, NM, USA

Larry Lynd, McMaster University, Hamilton, ON, Canada

Neil MacKinnon PhD, RPh, Assistant Professor, Dalhousie University, Halifax, NS, Canada

Sunny Mahajan PhD, Director, GlaxoSmithKline, Research Triangle, NC, USA

Vittorio Maio PharmD, Thomas Jefferson University, Philadelphia, PA, USA

Susan Malecha, National Manager, Clinical Managers, Libertyville, IL, USA

William Marder PhD, Senior Vice President & General Manager, Medstat, Cambridge, MA, USA

Carlo Marra BSc, PharmD, FCSHP, University of British Columbia, Vancouver, BC, Canada

Wallace Marsh PhD, Assistant Professor, Nova Southeastern University, Ft. Lauderdale, FL, USA

Susan Mathias MPH, Vice President, Ovation Research Group, Highland Park, IL, USA

Josephine Mauskopf PhD, RTI Health Solutions, Research Triangle, NC, USA

Doreen McBride MBA, Research Associate, Institute of Social Medicine, Epidemiology andHealth Ecomonics, Berlin, Germany

Joseph Menzin PhD, President, Boston Health Economics, Inc., Waltham, MA, USA

Lamont Muchmore, Sr. Analyst, OCI, Cheyenne, WY, USA

Maureen Neary PhD, Director, Specialty Care Outcomes, Hoffmann-La Roche, Inc., Morristown,NJ, USA

Lars Nicklasson PhD, Pharmacoeconomics Manager, Novo Nordisk Pharmaceuticals, Inc.,Princeton, NJ, USA

Mark Nuijten PhD, MD, MBA, Director of European Business Development, MEDTAPInternational, Jisp, The Netherlands

Tursynbek Nurmagambetov MS, PhD, Economist, CDC, Atlanta, GA, USA

Judith O'Brien Rn. BSPA, Caro Research, Concord, MA, USA

Robert Ohsfeldt PhD, Professor, Dept. of Health Mgmt & Policy, University of Iowa, Iowa City, IA,USA

MerriKay Oleen-Burkey PhD, Director, Health Outcomes Research, Teva Neuroscience, Inc.,Kansas City, MO, USA

Mohamed Omar PhD, RPh, Outcomes Research Manager, Novartis PharmaceuticalsCorporation, East Hanover, NJ, USA

George Papadopoulos BSc, Director, Johnson & Johnson, Raritan, NJ, USA

Chris Pashos PhD, Vice Pres & Executive Director of HERQuLES, Abt Associates – HERQuLES,Cambridge, MA, USA

John E. Paul PhD, Global Head, Business Strategy and Development, RTI Health Solutions,Research Triangle, NC, USA

Andrew Peterson PharmD, Assistant Professor, University of the Sciences in Philadelphia,Philadelphia, PA, USA

James Piercy BSc, MSc, Project Director, MAPI Values, Macclesfield, Cheshire, UK

Andreas Pleil PhD, Director/Team Leader Worldwide Outcomes Researchomics, PfizerIncorporated, San Diego, CA, USA

Francoise Pradel PhD, Assistant Professor, University of Maryland, Baltimore, MD, USA

George Provenzano PhD, Senior Research Scientist, Battelle Memorial Institute, Arlington VA, USA

Eric Qiong Wu PhD, Associate, Analysis Group, Boston, MA, USA

Jeffrey Quon DC, FCCSC, MHSc, University of British Columbia, Vancouver, BC, Canada

Ateequr Rahman MBA, PhD, Assistant Professor, St. John's University, Jamaica, NY, USA

Rukmini Rajagopalan MBA, DrPH, Senior Manager, Outcomes Research, TakedaPharmaceuticals North America, Inc., Lincolnshire, IL, USA

Karen Rascati RPh, PhD, Professor, University of Texas, Austin, TX, USA

Aran Ratcliffe PhD, Senior Health Economist, AstraZeneca, Luton, Hertfordshire, UK

Prabashni Reddy RPh, BS, MS, PharmD, Lead Pharmacoeconomist, Abt Associates, Cambridge,MA, USA

Gene Reeder PhD, RPh, BS, MS, Professor, University of South Carolina, Columbia, SC, USA

Margaret Rothman PhD, Executive Director, Health Economics, Johnson and JohnsonPharmaceutical Research and Development, Raritan, NJ, USA

Marcia FT Rupnow PhD, Assistant Director, Outcomes Research, Janssen Pharmaceutica, Inc,Titusville, NJ, USA

Mason W. Russell MAPE, Director, Market Economics, Biogen, Inc., Cambridge, MA, USA

Nishan Sengupta PhD, Assistant Director, Abbott Labs, Abbott Park, IL, USA

Hemal Shah RPh, BS, PharmD, Director, Health Economics, Boehringer IngelheimPharmaceuticals, Inc., Ridgefield, CT, USA

Fadia Tohme Shaya PhD, MPH, Assistant Research Professor, University of Maryland School ofPharmacy, Baltimore, MD, USA

Judith Shinogle PhD, Assistant Professor, University of South Carolina, Columbia, SC, USA

Dean Smith PhD, Professor, University of Michigan, Ann Arbor, MI, USA

Dave Smith PhD, Investigator, Kaiser Permanente Center for Health Research, Portland, OR, USA

Harry Smolen MS, President, Medical Decision Modeling Inc., Indianapolis, IN, USA

Seema Sonnad PhD, Associate Professor, Dept of Surgery, University of Pennsylvania,Philadelphia, PA, USA

Bradley Stolshek PharmD, Manager, Inflammation, Amgen, Inc., Thousand Oaks, CA, USA

Erin Sullivan MPH, PhD, Senior Manager, Health Economics & Outcomes Research, BostonScientific Corporation, Natick, MA, USA

Kent Summers RPh, PhD , Research Scientist, Purdue University, West Lafayette, IN, USA

Sheryl Szeinbach PhD, RPh, BS, MS, Professor, Ohio State University, Columbus, OH, USA

Tammy Tengs ScD, Assistant Professor, University of California Irvine, Irvine, CA, USA

Simu Thomas PhD, Manager, Novartis, East Hanover, NJ, USA

George Torrance PhD, Professor Emeritus, McMaster University, VP, Innovus Research Inc.,Burlington, ON, Canada

F. Randy Vogenberg PhD, RPh, Vice President & National Pracitice Leader, Aon Health SystemEducation & Pharma Consulting, Wellesley, MA, USA

Samuel Wagner PhD, RPh, Senior Manager, Pfizer Inc., Cotton Grove, MN, USA

John H. Walker PhD, Assistant Professor, Brock University, St. Catherines, ON, Canada

Katrine Wallace MA, Manager, Health Economics & Outcomes Research, TAP Pharmaceuticals,Lake Forest, IL, USA

Peter Wong PhD, MBA, RPh, Vice-President, Clinical Effectiveness & PI, Good SamaritanHospital, Dayton, OH, USA

Chunliu Zhan MD, PhD, Senior Service Fellow, Agency for Healthcare Research & Quality,Rockville, MD, USA

Zhiyuan Zhou PhD, Sr. Scientist, Pfizer, Peapack, NJ, USA

*Assistant Chairperson, 9th Annual International Meeting Abstract Review Committee


13

I N T E R N ATIONAL SOCIETY

FOR PHARMACOECONOMICS

AND OUTCOMES RESEARCH

Mission Statement

The International Society for Pharmacoeconomics and Outcomes Research is an international organization promot-ing the science of pharmacoeconomics and health outcomes research. The International Society is organized to act as a scientific leader relevant to research in pharmacoeconomics, healthoutcomes assessment, and related issues of public policy.The International Society represents health care researchers and practitioners including pharmacists, physicians,economists, nursesand researches from academia, pharmaceutical industry, government, managed care, healthresearch organizations, and purchasers of healthcare. The mission of the International Society forPharmacoeconomics and Outcomes Research is to translate pharmacoeconomics and outcomes research into prac-tice to ensure that society allocates scarce healthcare resources wisely, fairly, and efficiently.

Objectives

The society serves the public interest by the following means:

• provides a forum to facilitate the interchange of scientific knowledge in pharmacoeconomics and patient healthoutcomes;

• facilitates and encourages communications among the research community, health care professionals, and otherresearch, regulatory, and educational groups, the communications media and the general public by educatingpublic and private agencies on the usefulness of research in pharmacoeconomic and patient outcomes assessment;

• acts as a resource in forming public policy relevant to the pharmacoeconomics, health care outcomes assessment,and related issues of public concern;

• promotes the science of pharmacoeconomics by providing services as may be appropriate to advance pharma-coeconomic and outcomes research and educational activities;

• represents the science of pharmacoeconomics and outcomes assessment before public and governmental bodiesby: a) seeking important issues concerning health care interventions as they relate to pharmacoeconomics andhealth care outcomes; b) making available the results of pharmacoeconomics analysis and health care outcomesstudies concerning these issues; c) developing scientifically-based input (evidence) for public policy decisions deal-ing with these issues; d) providing this evidence and data to governmental bodies and other public entities;

• provides recognition of individual achievement in the field of pharmacoeconomics and outcomes research; and

• fosters career growth and the development of individuals involved in pharmacoeconomic and outcomes researchand application of this research.

14

Annual Meeting Objectives Participants will be able to:

• Learn new pharmacoeconomic methodologiesand outcomes research techniques

• Improve the quality of their decision-makingby better utilization of pharmacoeconomicstudies

• Learn the latest about measuring quality of lifeand selecting appropriate survey instruments.

Abtracts Reference PageNumbersPage numbers to the left of program items referto the corresponding page for the abstract pub-lished in Value in Health Volume 7, Issue 3.

Continuing Education Credit For pharmacists (CPE): Continuingeducation credits for pharmacistswill be provided by The Universityof Florida and Trinka Publications.The University of Florida and

Trinka Publications designate this continuingpharmaceutical education activity for 16.0hours (1.60CEUs) for the Annual Meeting and 4hours (0.4CEUs) and 7.50 hours (0.75CEUs) foreach Short Course. The University of Floridaand Trinka Publications are approved by theAmerican Council of Pharmaceutical Educationas a provider of continuing pharmaceuticaleducation.

For physicians (CME): ISPOR provides docu-mentation for Physician-designated AmericanMedical Association (AMA) Physician’sRecognition Award Category 2 continuing med-ical education (CME) credit. This ISPOR 9thAnnual International Meeting program complieswith the AMA’s definition of CME, with AMAethical opinions on Gifts to Physicians fromIndustry and on Ethical Issues in CME.

Up to 16.0 hours (1.60CMEs) for the AnnualMeeting and 4 hours (0.4 CMEs) and 7.50 hours(0.75CMEs) for each Short Course can be desig-nated. ISPOR is not accredited by theAccreditation Council for Continuing MedicalEducation.

To receive continuing education credit, obtainthe Continuing Education Program SummaryBooklet at the ISPOR registration desk.Complete the information requested. Return theentire Continuing Education Program SummaryBooklet to the ISPOR registration desk at theend of the meeting. Your certificate will bemailed to you 4 to 6 weeks after the meeting.The fee for this service is $30.

Abstract Submission InformationIn 1999 there were 322 submissions (283research and 39 workshops) with 8.7% notaccepted. In 2000 there were 402 submissions(364 research and 38 workshops) with 15.9% notaccepted. In 2001 there were 440 submissions(408 research abstracts and 32 workshops) with14.3% not accepted. In 2002 there were 470submissions (439 research and 31 workshops)with 11.9% not accepted. In 2003 there were614 submissions (575 research and 39 work-shops) with 13.3% not accepted. In 2004 therewere 606 submissions (543 research, 47 work-shops, and 16 issue panels) with 11.4% notaccepted.

HandoutsHandouts for General Sessions will be madeavailable in the session room at the time ofpresentation. All remaining or additional hand -outs will be made available at the HandoutTable in the Registration area. All handouts forContributed Presentations (Podium, Poster andWorkshop) are the sole responsibility of thepresenting author(s). ISPOR requires allContributed Presenters to provide at least 100copies of their presentation for handouts perthe presentation instructions found on theISPOR web site at http://www.ispor.org/meet-ings/va0503/present_info.htm.

Poster PresentationsPoster presentations will be on view:

Session I: Monday, May 177:30 AM - 8:00 AM Set-up8:00 AM - 8:00 PM Poster Display Hours 6:00 PM - 7:00 PM Author Q&A Hour8:00 PM - 8:30 PM DismantleSession II: Tu e s d a y, May 187:30 AM - 8:00 AM Set-up 8:00 AM - 7:00 PM Poster Display Hours 5:00 PM - 6:00 PM Author Q&A Hour 7:00 PM - 7:30 PM Dismantle

Presenters are required to be with their postersduring the Author Presentation Hour. Seepages 30 to 51 for Contributed PosterPresentation titles and authors.

ExhibitsExhibits will be on view from 9:45AM, Monday,May 17th until 7:00PM, Tuesday, May 18th.Exhibitors will be at their booths during the fol-lowing times:

M o n d a y, May 179:45 - 10:15AM, 12:30 - 2:00PM, 3:00-3:15PM4:15 - 4:30PM, 6:00 - 8:00 PM

Tu e s d a y, May 189:00 - 9:15AM, 10:15-11:00AM, 12:30 - 1:30PM,2:30-2:45PM, 3:45 - 4:00PM, 5:00-7:00PM

ISPOR Professional RecruitmentAssistance Program Center

(PRAP)ISPOR provides an

opportunity for individuals seeking positionsand employers with available positions toarrange personal interviews during the AnnualMeeting. Candidates: bring 4 copies of yourresume or c.v. to the ISPOR PRAP Center in theAlexandria Room (Second floor). This service isfree to ISPOR members. For non-members, the fee is $135 ($30 for full-time students). PRAP Center Hours:Sunday, May 16, from 7:00AM to 6:00PMMonday, May 17, from from 7:00AM to 6:00PMTuesday, May 18, from from 7:00AM to 6:00PM

Meeting Program WarningPlease be advised that recording, by anymeans, of the Annual Meeting presentations isprohibited. The International Society forPharmacoeconomics and Outcomes Research(ISPOR) will strictly enforce its rights as theexclusive licensee of all publication and repro-duction rights to each presentation, and nopresentation, in whole or in part, may be repro-duced without the express written approvalfrom ISPOR.


ISPOR 9TH ANNUAL INTERNATIONAL MEETING KEY INFORMAT I O N

15

SATURDAY, MAY 15TH7:00AM-5:00PM REGISTRATION

8:00AM-5:00PM PRE-MEETING SHORT COURSES (FULL DAY)

8:00AM-12:00PM PRE-MEETING SHORT COURSES (MORNING SESSION)

1:00PM-5:00PM PRE-MEETING SHORT COURSES (AFTERNOON SESSION)

1:00PM-5:00PM STUDENT LEADERSHIP RETREAT

SUNDAY, MAY 16TH7:00AM-5:00PM REGISTRATION

7:00AM-6:00PM PRAP CENTER

8:00AM-5:00PM PRE-MEETING SHORT COURSE (FULL DAY)

8:00AM-12:00PM PRE-MEETING SHORT COURSES (MORNING SESSION)

1:00PM-5:00PM PRE-MEETING SHORT COURSES (AFTERNOON SESSION)

10:00AM-5:00PM ISPOR BOARD OF DIRECTORS MEETING

5:00PM-7:00PM BENEFIT/RISK: IN SEARCH OF THE PROPER BALANCE, A PRE-MEETING SYMPOSIUM

7:30PM-9:00PM STUDENT ICEBREAKER RECEPTION

MONDAY, MAY 17TH6:30AM-5:00PM REGISTRATION


8:00AM-8:30AM WELCOME & INTRODUCTION

8:30AM-9:45AM FIRST PLENARY SESSION

9:45AM-10:15AM EXHIBITS & POSTER PRESENTATIONS VIEWING - SESSION I

10:15AM-11:15AM CONTRIBUTED PODIUM PRESENTATIONS – SESSION ICARDIOVASCULAR DISEASES CANCER RESPIRATORY DISORDERS & INFECTIONS ARTHRITIS

11:15AM-11:30AM BREAK

11:30AM-12:30PM ISSUES PANEL – SESSION I (5 CONCURRENT)

12:30PM-2:00PM LUNCH, EXHIBITS & POSTER PRESENTATIONS VIEWING - SESSION I

2:00PM-3:00PM CONTRIBUTED WORKSHOPS – SESSION I (8 WORKSHOPS)W1 W2 W3 W4 W5 W6 W7 W8

2:00PM-4:00PM STUDENT MOCK INTERVIEW SESSION3:00PM-3:15PM BREAK

3:15PM-4:15PM CONTRIBUTED WORKSHOPS – SESSION II (8 WORKSHOPS)W9 W10 W11 W12 W13 W14 W15 W16

4:15PM-4:30PM BREAK

4:30PM-5:30PM ISPOR FORUMSSTUDENT FORUMCOMPLIANCE SPECIAL INTEREST GROUP FORUM–QOLRISK MANAGEMENT SPECIAL INTEREST GROUP FORUM–RCT-CEA


ISPOR 9TH ANNUAL INTERNATIONAL MEETING AT- A - G L A N C E

16


ISPOR 9TH ANNUAL INTERNATIONAL MEETING AT- A - G L A N C E

5:30PM-6:00PM ISPOR ANNUAL BUSINESS MEETING

6:00PM-8:00PM EXHIBITORS’ OPEN HOUSE RECEPTION & CONTRIBUTED POSTER PRESENTATION -SESSION I

TUESDAY, MAY 18TH6:30AM-5:00PM REGISTRATION


8:00AM-9:00AM CONTRIBUTED PODIUM PRESENTATIONS – SESSION IIH E A LTH CARE REIMBURSEMENT HEALTH CARE COST EVA L U ATION HEALTH CARE MODELING SCREENING

9:00AM-9:15AM BREAK

9:15AM-10:15AM ISSUES PANELS-SESSION II (4 CONCURRENT)

10:15AM-11:00AM EXHIBITS, POSTER PRESENTATIONS VIEWING -SESSION II

11:00AM-11:30AM INCOMING PRESIDENTIAL ADDRESSISPOR AWARDS PRESENTATIONS

11:30AM-12:30PM SECOND PLENARY SESSION

12:30PM-1:30PM LUNCH, EXHIBITS, POSTER PRESENTATIONS VIEWING - SESSION II

1:30PM-2:30PM CONTRIBUTED WORKSHOPS – SESSION III (8 WORKSHOPS)W17 W18 W19 W20 W21 W22 W23 W24

2:30PM- 2:45PM BREAK

2:45PM-3:45PM CONTRIBUTED WORKSHOPS – SESSION IV (8 WORKSHOPS)W25 W26 W27 W28 W29 W30 W31 W32

3:45PM-4:00PM BREAK

4:00PM-5:00PM ISPOR FORUMSMEDICAL DEVICE & DIAGNOSTICS COUNCIL FORUMMANAGED CARE_PBM SPECIAL INTEREST GROUP FORUMQUALITY OF LIFE FORUMVISION 2010 FORUM

5:00PM-7:00PM EXHIBITORS’ WINE & CHEESE RECEPTION & POSTER PRESENTATIONS VIEWING - SESSION II

WEDNESDAY, MAY 19TH6:30AM-12:00PM REGISTRATION

7:00AM-12:00PM CONTRIBUTED POSTER PRESENTATIONS VIEWING - SESSION II

8:00AM-9:00AM CONTRIBUTED PODIUM PRESENTATIONS – SESSION IIIPRESCRIBING STUDIES ADHERENCE/COMPLIANCE PHARMACOEPIDEMIOLOGY OUTCOMES & PREFERENCES

9:00AM - 9:15AM BREAK

9:15AM-10:15AM CONTRIBUTED PODIUM PRESENTATIONS – SESSION IVDIABETES MENTAL HEALTH NEUROLOGICAL DISORDERS/MIGRAINE HEALTH POLICY EVALUATION

10:15AM-10:45AM BREAK

10:45AM-11:15AM ISPOR CONTRIBUTED RESEARCH AWARDS PRESENTATION

11:15AM-12:30PM THIRD PLENARY SESSION

17

SCHEDULE OF EVENTSS AT U R D AY, MAY 15TH

8:00AM-5:00PM PRE-MEETING SHORT COURSES

1:00PM-5:00PM STUDENT LEADERSHIP RETREAT (BY INVITATION ONLY) SALON K

6:00PM – 8:00PM ISPOR SHORT COURSE INSTRUCTOR DINNER MEETING JACKSON

ISPOR STUDENT COUNCIL DINNER (MEET IN THE LOBBY)

S U N D AY, MAY 16TH8:00AM-5:00PM PRE-MEETING SHORT COURSES

10:00AM-5:00PM ISPOR BOARD OF DIRECTORS MEETING MCLEAN

5:00PM-7:00PM BENEFIT/RISK: IN SEARCH OF THE PROPER BALANCE SALON BCDEA Pre-Meeting Symposium Co-Sponsored by ISPOR and PhRMA Health Outcomes Committee

7:00PM-8:30PM ISPOR STUDENT CHAPTER FACULTY ADVISOR DINNER JEFFERSON

7:00PM-10:00PM MEDICATION COMPLIANCE SIG WORKING GROUP CHAIR DINNER MEETING MADISON

QUALITY OF LIFE SIG WORKING GROUP CHAIR DINNER MEETING LEE

ISPOR HEALTH SCIENCE COUNCIL DINNER MEETING MCLEAN

7:30PM-10:00PM VALUE IN HEALTH CO-EDITOR/MAB/BLACKWELL PUBLISHING DINNER MEETING MANASSAS

7:30PM-9:00PM STUDENT ICEBREAKER RECEPTION SALON H

8:00PM ISPOR BOARD OF DIRECTORS DINNER MT. VERNON

M O N D AY, MAY 17TH7:00AM-8:00AM NEW MEMBER WELCOME BREAKFAST (BY INVITATION ONLY) MCLEAN

PATIENT REGISTRIES…SAFETY SURVEILLANCE APPLICATIONS WORKING GROUP BREAKFAST JACKSON

PATIENT REGISTRIES…TECHNOLOGY WORKING GROUP BREAKFAST LEE

QUALITY OF LIFE…POPULATION HEALTH WORKING GROUP BREAKFAST JEFFERSON

QUALITY OF LIFE…CROSS-CULTURAL & TRANSLATIONAL ADAPTATION WORKING GROUP BREAKFAST M A D I S O N

7:30AM-8:00AM POSTER AUTHOR SET UP – SESSION I ARLINGTON BALLROOM

8:00AM-8:30 AM WELCOME & INTRODUCTION GRAND BALLROOMMark Sculpher MSc, PhD, Professor, University of York, Centre for Health Economics, Heslington, York, UK

IN MEMORIAM: BERNIE J. O'BRIEN PHD SEE PAGE 64Presented by: Michael Drummond PhD, Professor of Economics and Director, Centre for Health Economics, University of York, Heslington, York, UK

PRESIDENTIAL ADDRESSSean Sullivan PhD, 2003-2004 ISPOR President & Professor, University of Washington, Seattle, WA, USA

8:30AM-9:45 AM FIRST PLENARY SESSION GRAND BALLROOMMEDICARE DRUG BENEFIT & COST-EFFECTIVENESS: WHO PLAYS & WHO PAYS Moderator: Bryan Luce PhD, MBA, Chairman of the Board, MEDTAP International, Bethesda, MD, USASpeaker: Sean Tunis MD, MSc, Chief Medical Officer of CMS & Director, Office of Clinical Standards & Quality, Coverage and Analysis Group,Centers for Medicare and Medicaid Services, Baltimore, MD, USASpeaker: Jean Slutsky PA, MSPH, Acting Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality (AHRQ),Rockville, MD, USA

This plenary session will address US legislation concerning Medicare Drug Benefit Plan and the use of cost-effectiveness and outcomesresearch information in drug selection decisions. The role of the Agency for Health Care Research and Quality and the National Institutes ofHealth, as well as the Food and Drug Administration in providing and regulating this information will be discussed.


18

I SPOR 9TH ANNUAL INTERNATIONAL MEET ING PROGRAM

9:45AM-10:15 AM BREAK, EXHIBITS & CONTRIBUTED POSTER PRESENTATIONS VIEWING - SESSION I ARLINGTON BALLROOM

BREAK SPONSORED BY

10:15AM-11:15AM CONTRIBUTED PODIUM PRESENTATIONS – SESSION IPharmacoeconomics/health economic, quality-of-life, and outcomes research study results for the following diseases will be presented:

Cardiovascular Diseases SALON BCDEModerator: Deborah Marshall PhD, Assistant Professor, McMaster University and Innovus Research Inc., Hamilton, Ontario, Canada

pg 219 CV1 HEALTH PREFERENCES AFTER CABG OR PCI FOLLOWING AN ACUTE MYOCARDIAL INFARCTIONRadeva J, Reed S, Weinfurt K, Anstrom K, Velazquez E, Schulman K, Duke Clinical Research Institute, Durham, NC, USA

pg 219 CV2 CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS COMPARED TO OTHER NONSTEROIDAL ANTI-INFLAMMATORYAGENTS: AN OBSERVATIONAL STUDY OF A MEDICAID POPULATIONShaya FT, Blume SW, Blanchette CM, Mullins CD, Weir MR, University of Maryland, Baltimore, MD, USA

pg 219 CV3 THE USE OF A PROBABILISTIC DECISION MODEL TO ASSESS THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS IN ALTERNATIVE PATIENTSUB-GROUPSSculpher M, Hawkins NS1, 1University of York, York, UK

pg 220 CV4 LOWER CARDIOVASCULAR RISK ASSOCIATED WITH PIOGLITAZONE MONOTHERAPY COMPARED TO INSULIN MONOTHERAPY: A RETROSPEC-TIVE PROPENSITY SCORE MATCHED COHORT STUDYIyer S1, Xu Y1, Rosenson R2, Rajagopalan R1, 1Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA; 2Northwestern University,Feinberg School of Medicine, Chicago, IL, USA

Cancer SALON JKModerator: Diane Wild MSc, Partner, Oxford Outcomes, Headington, Oxford, UK

pg 220 CN1 THE STATE OF THE SCIENCE OF HRQOL ASSESSMENT IN CANCER: FINDINGS FROM THE CANCER OUTCOMES MEASUREMENT WORKING GROUPLipscomb J1, Gotay C2, Snyder C1, 1National Cancer Institute, Bethesda, MD, USA; 2Cancer Research Center of Hawaii, Honolulu, HI, USA

pg 220 CN2 COST-EFFECTIVENESS OF DIAGNOSTIC, STAGING, AND TREATMENT OPTIONS FOR MELANOMAChavez YE1, Lee WC 2, Botteman MF3, Pashos CL4, 1Abt Associates, Inc, Bethesda, MD, USA; 2Abt Associates Inc. - HERQuLES, Bethesda, MD,USA; 3Abt Associates Inc. - HERQuLES, Cambridge, MA, USA; 4Abt Associates Inc, Cambridge, MA, USA

pg 221 CN3 COST-EFFECTIVENESS OF ANASTROZOLE VS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREASTCANCER (EBC): A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVEBenedict Á1, Mansel on behalf of the ATAC Trialists' Group R2, 1MEDTAP International Inc, London, UK; 2University of Wales College of Medicine,Cardiff, UK

pg 221 CN4 COST-EFFECTIVENESS (CE) ANALYSIS OF INTERFERON-ALPHA IN HIGH-RISK MELANOMA PATIENTSDing M1, Xing Y2, Shih T2, Cox D1, Cantor S2, Cormier J2, 1Rice University, Houston, TX, USA; 2The University of Texas M.D. Anderson Cancer Center,Houston, TX, USA

Respiratory Disorders and Infections SALON ABModerator: Larry Lynd PhD, McMaster University, Hamilton, Ontario, Canada

pg 221 RI1 THE EFFECT OF PRESCRIPTION DRUG COVERAGE ON THE COST OF CARE FOR MEDICARE BENEFICIARIES WITH ASTHMAAtherly A, Williams S, Redd S, Centers for Disease Control, Atlanta, GA, USA

pg 222 RI2 THE EXCESS COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM A MANAGED-CARE PERSPECTIVE Boulanger L1, Marton JP2, Friedman M 1, Dixon D1, Menzin J1, 1Boston Health Economics, Inc, Waltham, MA, USA; 2Pfizer US Outcomes ResearchGroup, New York, NY, USA

pg 222 RI3 COST-EFFECTIVENESS OF INFLUENZA VACCINE IN 6-24 MONTH OLD CHILDRENWoolcott JC1, Marra F1, Brunham RC 2, 1BC Centre for Disease Control, Vancouver, BC, Canada; 2University of British Columbia Centre for DiseaseControl, Vancouver, BC, Canada

pg 222 RI4 AN ECONOMIC ANALYSIS OF RAPID TESTS AND ANTIVIRAL TREATMENTS FOR INFLUENZA IN CHILDRENProsser LA1, Uyeki TM 2, Bridges CB2, Rego VH1, Meltzer M2, Schwartz B2, Thompson WW 2, Fukuda K 2, Lieu TA1, 1Harvard Medical School andHarvard Pilgrim Health Care, Boston, MA, USA; 2CDC, Atlanta, GA, USA

Arthritis SALON FGHModerator: Carlo Marra BSc, PharmD, Head of Health Economics, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada

pg 223 AR1 ASSESSING THE COST-EFFECTIVENESS OF COX-2 SPECIFIC INHIBITORS FOR ARTHRITIS IN THE VETERANS HEALTH ADMINISTRATIONSchaefer M1, DeLattre M1, Gao X2, Stephens J2, Botteman M2, Morreale A 1, 1VA San Diego Health care System, San Diego, CA, USA; 2AbtAssociates Clinical Trials, Bethesda, MD, USA

pg 223 AR2 A COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL TREATMENTS FOR RHEUMATOID ARTHRITISChiou CF1, Wanke L2, Yu E2, Ofman J2, 1Zynx Health, A Cerner Company, Beverly Hills, CA, USA; 2Amgen, Inc, Thousand Oaks, CA, USA

pg 223 AR3 REVALIDATION OF THE ORIGINAL CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) INSTRUMENTChiou CF1, Sherbourne C2, Cornelio IL 3, Lubeck D3, Paulus H4, Dylan M 1, Weisman M5, 1Zynx Health, A Cerner Company, Beverly Hills, CA, USA;2RAND Corporation, Santa Monica, CA, USA; 3Amgen, Inc, Thousand Oaks, CA, USA; 4UCLA, Los Angeles, CA, USA; 5Cedars-Sinai Health System,Los Angeles, CA, USA

pg 224 AR4 THE DEVELOPMENT OF PROPENSITY SCORES FROM ADMINISTRATIVE DATABASES FOR THE ANALYSIS OF THE EFFECTIVENESS OF ANOSTEOARTHRITIS ACADEMIC DETAILING SERVICE ON PRESCRIBING BEHAVIOURGraham SD, Hartzema AG, University of Florida, Gainesville, FL, USA

19

I SPOR 9T H A NNUAL INTERNATIONAL MEET ING P ROGRAM

11:15AM-11:30AM BREAK ARLINGTON BALLROOM BREAK SPONSORED BY

11:30AM-12:30PM ISSUES PANELS – SESSION I (See page 53 for Issue Panel descriptions)EFFECTS OF SECTION 1013 “RESEARCH ON OUTCOMES OF HEALTHCARE ITEMS AND SERVICES” OF THE US MEDICARE MODERNIZATION ACTON OUTCOMES RESEARCH SALON CDEModerator: Jean Paul Gagnon PhD, Director Public Policy, Aventis Pharmaceuticals Inc., Bridgewater, NJ, USAPanelists: Jean R. Slutsky, PA, MSPH, Acting Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality (AHRQ),Rockville, MD, USA; Kathleen Lohr PhD, Co-Director, RTI-UNC Evidence-based Practice Center, Research Triangle Park, NC, USA; John SantosMD, Former Administrator, Office of Oregon Health Policy and Research, Portland, OR, USA

STRATIFIED COST-EFFECTIVENESS ANALYSIS: THE RISKS AND REWARDS OF LOOKING AT SUB-GROUPS SALON ABModerator: Henry Glick PhD, Health Economist, University of Pennsylvania, Division of Internal Medicine, Philadelphia, PA, USAPanelists: Jeffrey Hoch PhD, Assistant Professor, University of Western Ontario, Department of Epidemiology and Biostatistics, London, ON,Canada; Andrew Willan PhD, Professor, Department of Public Health Sciences, University of Toronto, Toronto, ON, Canada; Joseph Heyse PhD,Executive Director, Merck Research Laboratories, Biostatistics and Research Data Systems, West Point, PA, USA; John Cook PhD, HealthEconomics, Merck Research Laboratories, Blue Bell, PA, USA

COST ATTRIBUTION IN ECONOMIC EVALUATION: WHAT IS SIGNAL AND WHAT IS NOISE? SALON KModerator: Teresa Kauf PhD, Research Assistant Professor, Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Durham,NC, USAPanelists: Gerry Oster PhD, Vice President, Policy Analysis Inc. (PAI), Brookline, MA, USA; Daniel Polsky PhD, Research Associate Professor,General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA

INDUSTRY AND REGULATORY PERSPECTIVES ON TRANSLATING PATIENT-REPORTED OUTCOME MEASURES SALON FGHModerator: Joyce Cramer BS, Yale University, New Haven, CT, USAPanelists: Laurie Burke RPh, Director, Study Endpoints and Label Division, U.S. Food and Drug Administration, Rockville, MD, USA; Richard J.Willke PhD, Senior Director/Group Leader, Worldwide Outcomes Research, Pfizer Inc., Peapack, NJ, USA; Diane Wild MSc, Director, OxfordOutcomes, Cassington, Oxford, UK

RISK SHARING DEALS IN THE REAL WORLD: CAN WE AFFORD THEM AND DO THEY WORK? SALON JModerator: Charles Petrie PhD, Sr. Director/Team Leader, Outcomes Research Group, Pfizer Inc, Groton, CT, USAPanelists: Adrian Towse MA, Director, Office of Health Economics, London, UK; Maureen Mangotich MD, MPH, Medical Director, StateInitiatives, Pfizer Health Solutions, Santa Monica, CA, USA

12:30PM-2:00PM LUNCH, EXHIBITS & CONTRIBUTED POSTER PRESENTATIONS VIEWING - SESSION I GRAND OPENING ARLINGTON BALLROOMLUNCH SPONSORED BY

2:00PM-3:00 PM CONTRIBUTED WORKSHOPS – SESSION I (8 WORKSHOPS)Clinical study methodology issues including pharmacoepidemiology

pg 55* W1 PATIENT REPORTED OUTCOME AND RESOURCE USE DATA IN CLINICAL TRIALS: GOING BEYOND TREATMENT GROUP COMPARISONS SALON ABala MV1, Mauskopf JA2, 1Centocor, Inc, Malvern, PA, USA; 2Research Triangle Institute, Research Triangle Park, NC, USA

Compliance issues

pg 55* W2 PATIENT COMPLIANCE AND PERSISTENCE WITH PRESCRIBED MEDICATION: MEASUREMENT AND HEALTH ECONOMIC IMPACT SALON BKoncz TA1, Hughes D 2, Cleemput I 3, Annemans L4 for the Med Comp SIG, 1Semmelweis University, Budapest, Hungary; AARDEX, Zug, Switzerland;2University of Liverpool, Liverpool, UK; 3HEDM, Meise, Belgium; 4Ghent University, HEDM, Meise, Belgium

Cost study methodology issues

pg 55* W3 USE AND INTEGRATION OF FREELY AVAILABLE U.S. PUBLIC USE FILES TO ANSWER PHARMACOECONOMIC QUESTIONS: DECIPHERING THEALPHABET SOUP SALON CCisternas M, Noe L, Ovation Research Group, Highland Park, IL, USA

Formulary development research issues

pg 55* W4 MANAGED CARE DATA: TOOLS AND METRICS FOR FORMULARY DEVELOPMENT SALON FGShaya FT1, Mullins CD1, Wong W2, 1University of Maryland, Baltimore, MD, USA; 2CareFirst BlueCross BlueShield, Baltimore, MD, USA

Healthcare policy development issues using outcomes research

pg 56* W5 SYSTEMATIC REVIEWS OF COST-EFFECTIVENESS ANALYSES USING ELECTRONIC AND WEB-BASED REGISTRIES SALON HGreenberg D, Neumann PJ, Harvard School of Public Health, Boston, MA, USA

Preference-based studies methodology issues including utility studies

pg 56 W6 ADVANCES IN MAPPING HEALTH-RELATED QUALITY OF LIFE: AN EQ-5D INDEX BASED ON SF-36 DATA SALON JKind P1, McEwan P2, Currie CJ3, Dixon S4, 1Outcomes Research Group, York, UK; 2Cardiff University, Cardiff, Wales, UK; 3University of WalesCollege of Medicine, Cardiff, Wales, UK; 4Sheffield University, Sheffield, South Yorkshire, UK

Quality of life study methodology issues including patient reported outcomes

pg 56* W7 APPLYING ITEM RESPONSE THEORY MODELING FOR IMPROVING HEALTH OUTCOMES MEASUREMENT SALON DEReeve BB, National Cancer Institute, Bethesda, MD, USA

Risk assessment/risk management issues

pg 57* W8 THERAPEUTIC EXPANSION OF THE CLASSICAL Q-TWIST APPROACH SALON KSherrill B1, Irish W2, 1RTI Health Solutions, Research Triangle Park, NC, USA; 2RTI Health Solutions, Durham, NC, USA 20 * Program page number

I SPOR 9TH ANNUAL INTERNATIONAL MEET ING P ROGRAM

2:00PM-4:00PM ISPOR STUDENT MOCK INTERVIEW SESSION MCLEAN

3:00PM-3:15PM BREAK ARLINGTON BALLROOM BREAK SPONSORED BY

3:15PM-4:15PM CONTRIBUTED WORKSHOPS – SESSION II (8 WORKSHOPS)Clinical study methodology issues including pharmacoepidemiology

pg 57* W9 JOURNEY TOWARDS A TRUE EFFECT IN COHORT STUDIES: OBSTACLES, STATISTICAL TOOLS, AND “DIFFERENCE IN DIFFERENCE” ESTIMAT E SSALON ALee WC1, Pashos CL2, 1Abt Associates Inc, Bethesda, MD, USA; 2Abt Associates Inc, Cambridge, MA, USA

Compliance issues

pg 57* W10 METHODS IN COMPLIANCE EVALUATION: DETERMINING AND ANALYZING APPROPRIATE MEASURES SALON BNichol MB1, Gwadry-Sridhar F2, Nau DP3, Cramer JA4 for the Med Comp SIG, 1University of Southern California, Los Angeles, CA, USA; 2McMasterUniversity, Hamilton, ON, Canada; 3University of Michigan, Ann Arbor, MI, USA; 4Yale University, West Haven, CT, USA


pg 57* W11 AT THE FRONTIER: MAXIMZING THE VALUE OF CLAIMS DATA SALON CBirnbaum H1, Greenberg P2, 1Analysis Group, Boston, MA, USA; 2Analysis Group/Economics, Boston, MA, USA


pg 58* W12 THE FORMULARY DECISION PROCESS: WHAT KIND OF INFORMATION IS TRULY HELPFUL? SALON FGVan Den Bos J1, Mullins CD 2, 1Milliman USA, Denver, CO, USA; 2University of Maryland School of Pharmacy, Baltimore, MD, USA


pg 58* W13 THE USE OF DISCRETE EVENT SIMULATION TO ASSESS THE VALUE OF HEALTH CARE INTERVENTIONS SALON HCaro JJ1, Huybrechts KF1, Möller J2, 1Caro Research Institute, Concord, MA, USA; 2Caro Research Institute, Eslov, Sweden

Preference-based studies methodology issues including utility studies

pg 58* W14 INCORPORATING PREFERENCES INTO OUTCOME MEASURES FOR THE VALUATION OF GENETIC BASED SERVICES SALON JPayne K1, Jarrett J2, Davies LM1, 1Manchester University, Manchester, Gtr. Manchester, UK; 2University of East Anglia, Norwich, UK


pg 59* W15 SELECTING OUTCOME MEASURES FOR INTERVENTION STUDIES: MAXIMIZING USE OF WEB-BASED RESOURCES SALON DEBalkrishnan R1, Kelly PA2, 1University of Texas School of Public Health, Houston, TX, USA; 2Baylor College of Medicine and Houston Center forQuality of Care and Utilization Studies, Houston, TX, USA


pg 59* W16 CAPTURING THE VALUE OF PHARMACEUTICALS: THE ROLE OF OUTCOMES RESEARCH IN PRICING DECISIONS SALON KTierce JC1, LaPensee KT2, Wierz DJ3, Sugano DS4, 1ValueMedics Research, LLC, Arlington, VA, USA; 2Skylands Healthcare Consulting, LLC., for-merly of Cambridge Pharma Consultancy, Hampton, NJ, USA; 3Independent Consultant, formerly of Wyeth, Inc, Exton, PA, USA; 4Schering-PloughCorporation, Kenilworth, NJ, USA


4:30PM-5:30PM ISPOR FORUMSSTUDENT FORUM SALON AJOB SEARCH PROCESSES STUDENTS NEED TO ADOPT FOR ENTRY LEVEL POSITIONS IN HEALTH ECONOMICS AND OUTCOMES RESEARCHModerators: Zeba M. Khan PhD, RPh, Head Health Economics & Pricing CVM BF, Novartis Pharma AG, Global Marketing & Sales, Cardiovascularand Metabolism Business Franchise, Basel, Switzerland and Ritesh Kumar MS, University of Michigan, College of Pharmacy, Ann Arbor, MI, USASpeakers: Catherine Copley-Merriman MBA, MS, Director, Outcomes Research, Pfizer Inc, Ann Arbor, MI, USA; Randel Richner MPH, VicePresident, Federal Affairs, Reimbursement and Outcomes Planning, Boston Scientific Corporation, Natick, MA, USA; Mike Quinn, President,Quinn Associates, Jenkintown, PA, USA

4:30PM-5:30PM QUALITY OF LIFE SPECIAL INTEREST GROUP FORUM SALON B4:30PM-4:35PM EMERGING ISSUES IN PRO RESEARCH

This session will examine major applied research issues that are important for the development and use QoL and patient reported outcome(PRO) measures. The discussion will identify other areas that might also be added to a PRO/QoL research agenda and begin a dialog concerningISPOR’s role in furthering advances in applied PRO research.

Moderator: Pennifer Erickson PhD, Co-founder, O.L.G.A., State College, PA, USA

4:35PM-4:50PM INSTRUMENT DEVELOPMENT AND VALIDATION: HOW MUCH IS ENOUGH?Speaker: Margaret Rothman PhD, Executive Director, HE&P, PGSM, Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA

4:50PM-5:05PM THE MCID AND PRO RESEARCH: SHOULD WE DRAW A LINE IN THE SAND?Speaker: Nancy Kline Leidy PhD, President and CEO, MEDTAP International, Bethesda, MD, USA

5:05PM-5:15PM DISCUSSION OF CURRENT RESEARCH ISSUES: WHAT’S HOT? WHAT’S NOT?Speaker: Pennifer Erickson PhD, Co-founder, O.L.G.A., State College, PA, USA

5:15PM-5:30PM DISCUSSION

21

* Program page number


4:30PM-5:30PM ISPOR RCT-CEA FORUM SALON CISPOR TASK FORCE ON DEVELOPING STANDARDS FOR ECONOMIC ANALYSIS ALONGSIDE CLINICAL TRIALSCo-Chairs: Scott Ramsey, MD, PhD, Associate Member, Fred Hutchinson Cancer Research Center, Seattle, WA, USA andRichard Willke, PhD, Senior Director, Group Leader, Worldwide Outcomes Research, Pfizer, Inc., Bridgewater, NJ, USA Task Force Core Group Members: Andrew Briggs, Dphil, University of Oxford, Health Economics Research Centre, Institute of Health Sciences,Headington, Oxford, UK; Shelby Reed, PhD, Assistant Research Professor, Duke Clinical Research Institute, Durham, NC; Anita Chawla, PhD,Associate Director, Health Economics, Genentech, South San Francisco, CA; John Cook PhD, Director, Merck Research Laboratories,Biostatistics & Research Data Systems Vaccines, Blue Bell PA; Ruth Brown, MS, Director, MEDTAP International, London, UK,

4:30PM – 4:37PM INTRODUCTION & RATIONALE FOR STANDARDS IN ECONOMIC ANALYSIS ALONGSIDE CLINICAL TRIALS

4:37PM – 4:45PM TRIAL DESIGN ISSUES

4:45PM – 4:53PM CHOOSING DATA ELEMENTS

4:53PM – 5:00PM DATABASE DESIGN ISSUES

5:00PM – 5:08PM ANALYSIS OF DATA5:08PM – 5:15PM REPORTING THE RESULTS

5:15PM – 5:22PM RESEARCH AGENDA FOR METHODS AND REPORTING

5:25PM – 5:30PM QUESTIONS AND DISCUSSION

5:30PM-6:30PM ISPOR ANNUAL BUSINESS MEETING SALON DE5:30PM – 5:35 PM CALL TO ORDER: Sean Sullivan PhD, 2003-2004 ISPOR President5:35PM – 5:40 PM EXECUTIVE DIRECTOR’S REPORT: Marilyn Dix Smith PhD, ISPOR Executive Director5:40PM – 5:45 PM TREASURER’S REPORT: Jean Paul Gagnon PhD, ISPOR Tr e a s u r e r5:45PM – 5:50 PM AUDIT REPORT: Marcus Wilson PharmD, Chair, ISPOR Audit Committee5:50PM – 5:55 PM VALUE IN HEALTH EDITOR-IN-CHIEF REPORT: Josephine Mauskopf PhD, Value in Health Editor- i n - C h i e f5:55PM – 6:00 PM ISPOR CONNECTIONS EDITOR-IN-CHIEF REPORT: Steven E. Marx PharmD, MS6:00PM – 6:10 PM ISPOR COMMITTEE REPORTS

• Education Committee Report: Karen Rascati PhD, Education Committee Chair• Strategic Outreach Committee Report: Michael Drummond PhD, Strategic Outreach Committee Chair

6:10PM – 6:15 PM INSTALLATION OF THE 2004-2005 ISPOR OFFICERS: Sean Sullivan PhD, 2003-2004 ISPOR President6:15PM – 6:30 PM NEW BUSINESS: Sean Sullivan PhD, 2003-2004 ISPOR President

5:30PM-6:30PM CLINICAL PRACTICE SIG OPEN MEETING SALON H

5:30PM-6:30PM MEDICATION COMPLIANCE SIG OPEN MEETING SALON J

6:00PM-8:00PM EXHIBITORS’ OPEN HOUSE RECEPTION & CONTRIBUTED POSTER PRESENTATION – SESSION I A R L I N G TON BALLROOMRECEPTION SPONSORED BY

6:00PM-7:00PM CONTRIBUTED POSTER AUTHOR Q&A HOUR – SESSION I

8:00PM-8:30PM POSTER AUTHOR DISMANTLE – SESSION I

7:30PM-9:00PM VALUE IN HEALTH EDITORIAL ADVISORY BOARD DINNER MEETING MT. VERNONISPOR HEALTH CARE STRATEGY COUNCIL DINNER MEETING MCLEAN

7:45PM-10:00PM CLINICAL PRACTICE SIG WORKING GROUP CHAIR DINNER MEETING JACKSON

MANAGED CARE PBM SIG WORKING GROUP CHAIR DINNER MEETING FAIRFAX

PATIENT REGISTRIES SIG WORKING GROUP CHAIR DINNER MEETING MADISON

RISK MANAGEMENT SIG WORKING GROUP CHAIR DINNER MEETING LEE

LEARNING OUTCOMES TASK FORCE CORE GROUP DINNER MEETING JEFFERSON

RCT CEA TASK FORCE CORE GROUP DINNER MEETING MANASSAS

22


T U E S D AY, MAY 18TH7:00AM-8:00AM INSTITUTIONAL COUNCIL BREAKFAST SALON FG

MEDICAL COMPLIANCE SIG WORKING GROUPS BREAKFAST MEETING MCLEAN

CLINICAL PRACTICE SIG EDUCATION WORKING GROUP BREAKFAST MEETING MADISON

CLINICAL PRACTICE SIG LECTURE WORKING GROUP BREAKFAST MEETING JACKSON

CLINICAL PRACTICE CLINICIAN RESEARCH NETWORK WORKING GROUP BREAKFAST MEETING LEE

CLINICAL PRACTICE SIG PE/OR EVALUATION WORKING GROUP BREAKFAST MEETING JEFFERSON

PATIENT REGISTRIES SIG INTERNATIONAL APPLICATIONS WORKING GROUP BREAKFAST MEETING FAIRFAX

PATIENT REGISTRIES SIG ANALYTICAL APPROACHES WORKING GROUP BREAKFAST MEETING MANASSAS

PATIENT REGISTRIES SIG COMMERCIAL APPLICATIONS WORKING GROUP BREAKFAST MEETING MT. VERNON

7:30AM-8:00AM POSTER AUTHOR SET UP – SESSION II ARLINGTON BALLROOM

8:00AM-9:00AM CONTRIBUTED PODIUM PRESENTATIONS – SESSION II Research studies on the following topics will be discussed:

Health Care Reimbursement SALON CDEModerator: Marcus Wilson PharmD, President, Healthcore, Wilmington, DE, USA

pg 224 HR1 DO DRUG PRICES REFLECT VALUE? DO FORMULARY POLICIES?Neumann PJ, Lin PJ, Rosen AB, Greenberg D, Olchanski NV, Weinstein MC, Harvard School of Public Health, Boston, MA, USA

pg 224 HR2 DECISION-MAKER’S PERCEPTIONS OF ACCESS TO HIGH COST DRUGS (HCDS) IN PUBLIC HOSPITALS IN AUSTRALIAGallego G, Taylor S, Brien JAE, The University of Sydney, Sydney, NSW, Australia

pg 225 HR3 COMPARISON OF REIMBURSEMENT SYSTEMS OF VARIOUS COUNTRIES IN CENTRAL AND EASTERN EUROPE, AFRICA, AND MIDDLE EASTDavey P, Lees M, Makino K, Price N, Birinyi-Strachan L, M-TAG Pty Ltd, Chatswood, NSW, Australia

pg 225 HR4 IMPACT OF MEMBER COST-SHARING LEVELS ON POPULATION-BASED STATIN USE RATESMoore JM, Xiao JQ, Marks A, Caremark, Inc, Northbrook, IL, USA

Health Care Cost Evaluation SALON JKModerator: Andrew Briggs Dphil, Professor, Health Economics Research Centre, University of Oxford, Institute of Health Sciences Headington,Oxford, UK

pg225 CE1 THE EFFECT OF HAVING A PRIMARY CARE PROVIDER ON ASTHMA HEALTH CARE EXPENDITURE AND HEALTH CARE UTILIZATION Nurmagambetov T, Atherly A, Williams S, Redd S, Centers for Disease Control and Prevention, Atlanta, GA, USA

pg 226 CE2 PANEL ANALYSIS OF CENSORED MEDICAL COST DATABaser O1, Gardiner J2, Bradley C2, Yuce H2, Given C2, 1The MEDSTAT Group, Ann Arbor, MI, USA; 2Michigan State University, East Lansing, MI, USA

pg 226 CE3 THE COSTS OF ADJUVANT CHEMOTHERAPY IN EARLY STAGE BREAST CANCER PATIENTS: COMPARISON OF ATTRIBUTABLE COST ANDMICROCOSTING APPROACHESOestreicher N1, Veenstra D1, Linden H 2, McCune J2, Ramsey S 2, 1University of Washington, Seattle, WA, USA; 2University of Washington, FredHutchinson Cancer Research Center, Seattle, WA, USA

pg 226 CE4 6830 AN ACTUARIAL APPROACH TO ESTIMATING THE STREAM OF COSTS ASSOCIATED WITH BREAST AND COLORECTAL CANCERvan der Heijde MK, Milliman USA, Denver, CO, USA

Health Care Modeling SALON ABModerator: Elisabeth Fenwick PhD, Lecturer, Department of Economics and Related Studies, University of York, York, UK

pg 234 HM1 INDIVIDUALIZED PREDICTIVE DISEASE MODELING AS A TOOL TO IMPROVE EFFICACY AND EFFICIENCY OF DISEASE MANAGEMENT PRO-GRAMS FOR DIABETES MELLITUS Weber C, Woehl A, Schumacher A, Mast O Institute for Medical Informatics and Biostatistics, Basel, Switzerland

pg 227 HM2 MODELS IDENTIFYING VARIABLES INFLUENCING PHYSICIAN ADOPTION OF NEWLY LAUNCHED PHARMACEUTICALS IN THE UNITED STATESMayo KW, Glass H, Lee D, University of the Sciences in Philadelphia, Philadelphia, PA, USA

pg 227 HM3 PREDICTING PHARMACY COSTS USING HEALTH-RELATED QUALITY-OF-LIFE AND PHARMACY CLAIMS MEASURES IN ADULT ASTHMATICSMeyer C, Liberman J, Cooper D, Kalmanowicz J, Chaudry S, AdvancePCS, Hunt Valley, MD, USA

pg 227 HM4 HOW ROBUST IS COST-EFFECTIVENESS RATIO TO MISSING DATA IMPUTATION? ANALYSIS OF LONG-TERM CLINICAL TRIAL IN PARKINSONSDISEASENoyes K, Holloway RG, Dick AW, University of Rochester School of Medicine, Rochester, NY, USA

23

ISPOR 9T H A NNUAL INTERNATIONAL MEET ING P ROGRAM

Screening SALON HModerator: Adrian Levy PhD, Professor, Center for Health Evaluation and Outcome Sciences, St. Paul’s Hospital, University of British Columbia,Vancouver, Canada

pg 228 SC1 PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC) SCREENING STRATEGIESMarshall DA1, Marshall JK1, Phillips KA2, Johnson RF3, Thabane L1, Foster G1, O'Brien B1, 1McMaster University, Hamilton, ON, Canada; 2Universityof California San Francisco, San Francisco, CA, USA; 3Research Triangle Institute, NC, USA

pg 228 SC2 COST EFFECTIVENESS OF SCREENING AND STATIN THERAPY IN CLINICAL GUIDELINES FOR CARDIOVASCULAR PROPHYLAXISMilne RJ, Gamble GD, University of Auckland, Auckland, New Zealand

pg 228 SC3 FACTORS IMPACTING MAMMOGRAPHY SCREENING IN RURAL AND URBAN AREASKhan N, University of Illinois at Chicago, Chicago, IL, USA

pg 228 SC4 ECONOMIC EVALUATION OF SCREENING FOR THE A-ADDUCIN GENE VARIANT IN HYPERTENSIVE PATIENTSMeckley LM, Veenstra DL, University of Washington, Seattle, WA, USA

9:00AM–9:15AM BREAK ARLINGTON BALLROOM BREAK SPONSORED BY

9:15AM-10:15AM ISSUES PANELS-SESSION II (See page 54 for Issue Panel descriptions)THE IMPACT OF MEDICARE’S PRESCRIPTION DRUG LEGISLATION ON PHARMACOECONOMICS AND OUTCOMES RESEARCH SALON ABModerator: Peter Neumann ScD, Associate Professor of Policy and Decision Sciences, Harvard School of Public Health, Boston, MA, USA(researcher perspective)Panelists: Diane Simison PhD, Principal, PharmAnalysis Group, Inc., Alexandria, VA, USA (provisional perspective); Ronald J. Ozminkowski PhD,Director, Health and Productivity Management Research, Medstat, Ann Arbor, MI, USA (industry perspective)

THE VALUE OF POST-LAUNCH STUDIES- WHAT IS DESIRABLE VS. WHAT IS FEASIBLE? SALON CDEModerator: Adrian To w s e , Director, Office of Health Economics, London, UK Panelists: Michael Drummond DPhil, Director, Centre for Health Economics, York, UK (Research perspective); Andreas Laupacis MD, MSc,FRCPC, President & CEO, Institute for Clinical Evaluative Sciences, Toronto, ON, Canada (Agency perspective); Pete Fullerton PhD, Professor(Affiliate) University of Washington, WA, USA (Managed care perspective)

COST INFORMATION TREATMENT IN STATED PREFERENCE EXPERIMENTS- WHAT IS THE GOLD STANDARD? SALON JKModerator: Deborah Marshall PhD, Assistant Professor, McMaster University and Innovus Research Inc., Burlington, ON, CanadaPanelists: Reed Johnson PhD, Senior Fellow, Research Triangle Institute, Research Triangle Park, NC, USA; Kathryn Phillips PhD, AssociateProfessor, University of California, San Francisco, CA, USA

CAN WE BRIDGE TOO FAR? ISSUES IN MAPPING BETWEEN QUALITY-OF-LIFE INSTRUMENTS AND UTILITY SALON FGHModerator: Michael B. Nichol PhD, Associate Professor and Chair, University of Southern California, Los Angeles, CA, USAPanelists: Robert Kaplan PhD, Chair/Professor, University of California, San Diego, CA, USA; Christopher McCabe PhD, Depute Director, NICEDecision Support Unit, University of Sheffield, Sheffield, UK

10:15AM–11:00AM BREAK, EXHIBITS, CONTRIBUTED POSTER PRESENTATIONS VIEWING – SESSION II ARLINGTON BALLROOM BREAK SPONSORED BY

11:00AM-11:20AM AWARDS PRESENTATIONS GRAND BALLROOM

OPENING REMARKS GRAND BALLROOMSean Sullivan PhD, Professor, University of Washington, Seattle, WA, USA

PHRMA FOUNDATION 2004 RESEARCH STARTER GRANT AWARDS IN HEALTH OUTCOMESPresented by: Del Persinger, President and CEO of the Pharmaceutical Research Manufacturers Association Foundation, Washington DC, USA

AWARDEES:Suzi Levens MD, MS, Pennsylvania State University, College of Medicine, Department of Health Evaluation Sciences, Philadelphia, PA, USA, 2 yearsThomas G. Roberts MD, MSocSci, Harvard Medical School, Department of Hematology/Oncology, Concord, MA, USA, 2 yearsAngela Wisniewski PharmD, SUNY at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY, USA, 2 years

ISPOR STUDENT CHAPTER PRESIDENTS SERVICE AWARDS PRESENTATIONPresented by: Zeba Khan PhD, RPh, ISPOR Student Network Advisor and Head Health Economics and Pricing, Novartis Pharma AG, Basel,Switzerland

ISPOR SERVICE AWARDS PRESENTATION (See page 65 for ISPOR Service Awards Recipients)Presented by: Sean Sullivan PhD, Professor, University of Washington, Seattle, Washington, USA

ISPOR RESEARCH EXCELLENCE AWARDS & LIFETIME ACHEIVEMENT AWARD PRESENTATIONModerator: C. Daniel Mullins PhD, Chair ISPOR Awards Committee and Assistant Professor, University of Maryland, School of Pharmacy,Baltimore, MD, USA

24

I SPOR 9TH ANNUAL INTERNATIONAL MEET ING P ROGRAM

ISPOR RESEARCH EXCELLENCE AWARD FOR METHODOLOGY EXCELLENCEPresented by: John Brooks PhD, Chair, ISPORResearch Excellence Awards, Assistant Professor, University of Iowa, Iowa City, IA, USAAwardee: Andrew Briggs BA, MSc, DPhil, Professor, University of Oxford, Oxford, UK

“Missing…presumed at random: cost-analysis of incomplete data.” Health Economics 2003;12:377-92. (See page 66)

An economist by training, Andrew took an interest in health economics as an undergraduate and then took the York Masters programme inHealth Economics. Following a DPhil in Health Economics at the University of Oxford (Nuffield College) he was awarded a Training Fellowshipfrom the UK MRC to work on statistical issues in cost-effectiveness analysis and successfully completed an MSc Applied Statistics. Also as partof the award, he spent a sabbatical visit at the Centre for Evaluation of Medicines (CEM) at McMaster University working with Professors BernieO’Brien and Andy Willan, and he remains a research associate at CEM. A member of Oxford’s Health Economics Research Centre (under thedirectorship of Professor Alastair Gray) since 1996, Andrew currently holds a Public Health Career Scientist Award from the UK Department ofHealth.

Andrew’s research interests include both methodological issues in cost-effectiveness analysis and applications. His methodological interestsrevolve principally around statistical issues for economic appraisals conducted alongside clinical trials and the use of decision models for evalu-ating health care interventions. Applications include the cost-effectiveness of interventions in cardiovascular disease and diabetes, as well asthe use of alternative prostheses for total hip replacement and pharmaceutical treatment for respiratory disease.

He has acted as adviser to NICE in relation to its guidance to manufacturers, he serves on the UK Health Technology Assessment CommissioningBoard, and he as acted as consultant to the World Bank. He is on the editorial board of Medical Decision Making and is a co-editor of Value inHealth.

ISPOR RESEARCH EXCELLENCE AWARD FOR PRACTICAL APPLICATION EXCELLENCEPresented by: Joanna Seigel, ScD, Chair, ISPORResearch Excellence Awards, D i r e c t o r, Research Initiative in Clinical Economics, Agency forHealthcare Research & Quality, Rockville, MD, USA

Awardee: Emily R. Cox PhD, Director of Research, Express Scripts, Maryland Heights, MO, USA

“Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase2 inhibitors (COX-2s).” American Journal of Managed Care 2003;9:785-94. (See page 66)

In her position as Director of Research, Dr. Cox conducts research related to the impact of plan benefit design on utilization of pharmaceuticals,geriatric pharmacoepidemiology, pharmacoeconomic evaluation of drug therapy, and geographic variation in the use of prescription drugs. Shehas published extensively, and her research has been funded by numerous organizations, including a grant by The Robert Wood JohnsonFoundation evaluating the impact of capped prescription benefits on medication usage in Medicare populations. Previous to joining Express-Scripts, Dr. Cox held joint positions in the Colleges of Pharmacy and Medicine at the University of Arizona where her research focused on pre-scription use in geriatric populations.

ISPOR 2004 AVEDIS DONEBEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARDPresented by: Bryan Luce PhD, Chair of Avedis Donebedian Task Force and Chairman of the Board, MEDTAP International, Bethesda, MD, USA

Awardee: Michael F. Drummond PhD, Professor of Economics and Director, Centre for Health Economics, University of York, York, UK

Michael Drummond is Professor of Economics and Director of the Centre for Health Economics at the University of York, UK. He obtained his PhDfrom York in 1983, having previously obtained degrees in engineering and business administration.

Dr. Drummond’s main research interest is in the economic evaluation of health care programs and he has undertaken a wide range of empiricalstudies. In addition, he has written numerous ethodological papers and co-authored one of the main textbooks in the field. In addition to his aca-demic work, he has acted as consultant to the WHO and participated in numerous projects for the European Union. He is also Vice-President(European Operations) for Innovus, a contract research organization. He has served on numerous government committees in the UK, includingthe Medicines Commission and the National Institute for Clinical Excellence (NICE) Guidelines Advisory Committee.

11:20AM-11:30AM INCOMING PRESIDENTIAL ADDRESS Lieven Annemans PhD, MSc, Mman, 2004-2005 ISPOR President and Director, HEDM University of Ghent, Meise, Belgium

11:30AM-12:30PM SECOND PLENARY SESSION GRAND BALLROOMNEW DIRECTIONS IN RISK SHARING AND POST MARKETING ECONOMIC EVALUATIONModerator: Newell McElwee PharmD, MSPH, Vice President US Outcomes Research, Pfizer, Inc., New York, NY, USASpeaker: Andreas Laupacis MD, MSc, FRCPC, President & CEO and Senior Scientist, Institute for Clinical Evaluative Sciences, Toronto, Ontario,Canada Speaker: Monique Mrazek PhD, Health Economist, Europe and Central Asia, The World Bank, Washington DC, USASpeaker: Adrian Towse MA, Mphil, Director, Office of Health Economics, London, UK

This session will cover a review of international experience in risk sharing models and will also evaluate cost-effectiveness and shared risk ofMS drugs. Disease management and risk sharing in United States managed care will also be discussed.

12:30PM -1:30PM LUNCH, EXHIBITS, CONTRIBUTED POSTER PRESENTATIONS VIEWING - SESSION II GRAND OPENING ARLINGTON BALLROOM LUNCH SPONSORED BY

25


1:30PM-2:30PM CONTRIBUTED WORKSHOPS – SESSION III (8 WORKSHOPS)Clinical study methodology issues including pharmacoepidemiology

pg 59* W17 STATISTICAL ANALYSIS OF PATIENT REGISTRIES: METHODS FOR THE MOST EFFECTIVE USE OF OBSERVATIONAL DATA SALON DEPasta DJ, Miller DP, Ovation Research Group, Highland Park, IL, USA

Compliance issues

pg 60* W18 MEDICATION COMPLIANCE (ADHERENCE): ISSUES AND DEFINITIONS CONSENSUS WORKSHOP SALON FGCompliance SIG I&MDWG1, Wong P2, Fairchild C3, Clause S 4, Burrell A5, Cramer J 6 for the Med Comp SIG, 1ISPOR, ISPOR, NJ, USA; 2GoodSamaritan Hospital, Dayton, OH, USA; 3Bristol-Myers Squibb, Plainsboro, NJ, USA; 4Albany College of Pharmacy, Troy, NY, USA; 5Aventis,Bridgewater, NJ, USA; 6Yale University School of Medicine, West Haven, CT, USA


pg 60* W19 QUALITY AND VALIDATION STANDARDS IN HEALTHCARE MODELLING SALON CBeard S1, Davies L2, Payne K3, Earnshaw SR4, 1RTI Health Solutions, Manchester, UK; 2University of Manchester, Manchester, UK; 3ManchesterUniversity, Manchester, Gtr. Manchester, UK; 4RTI International, RTP, NC, USA


pg 60* W20 THE ART AND SCIENCE OF BUDGETARY IMPACT MODELING FOR FORMULARY SUBMISSIONS SALON ATaylor DC, Thompson D, Innovus Research, Inc, Medford, MA, USA, Healthcare policy development issues using outcomes research

Health Care Policy Development Issues Using Outcomes Research

pg 60* W21 IMPLICATIONS OF CANADA/US PARALLEL TRADE IN PRESCRIPTION DRUGS: A CANADIAN PERSPECTIVE SALON BPalmer WN, Palmer D'Angelo Consulting Inc, Ottawa, ON, Canada, Preference-based studies methodology issues including utility studies

Quality of Life Study Methodology Issues

pg 61* W22 QUALITY ADJUSTMENT USING AVERAGE UTILITIES: VIRTUE OR VICE? SALON HCaro JJ, Huybrechts KF, Caro Research Institute, Concord, MA, USA, Category: Quality of Life/Patient-Reported Outcomes

pg 61* W23 CHALLENGES IN DEVELOPING INSTRUMENTS TO SHOW THE VALUE OF NEW THERAPIES FOR SEVERE MENTAL ILLNESS SALON JRothman M1, Awad GA2, Revicki D3, Speight J4, 1Johnson & Johnson, Raritan, NJ, USA; 2River Regional Hospital, Toronto, Canada; 3MEDTAPInternational, Inc., Bethesda, MD, USA; 4Oxford Outcomes, Ltd., Cassington, Oxford, UK


pg 61* W24 RISK MANAGEMENT STRATEGIES USING PATIENT REGISTRIES SALON KTennis P1, Andrews E 1, Johnson FR2, 1RTI Health Solutions, RTP, NC, USA; 2Research Triangle Institute, Research Triangle Park, NC, USA


2:45PM-3:45PM CONTRIBUTED WORKSHOPS – SESSION IV (8 WORKSHOPS)Clinical study methodology issues including pharmacoepidemiology

pg 61* W25 HOW CAN HEALTH-RISK APPRAISAL DATA CONTRIBUTE TO CARDIOVASCULAR OUTCOMES RESEARCH? SALON AMenzin J1, Brown J1, Manocchia M2, 1Boston Health Economics, Inc, Waltham, MA, USA; 2Blue Cross And Blue Shield Of Rhode Island,Providence, RI, USA

Compliance issues

pg 62* W26 EDUCATION ISSUES IN MEDICATION ADHERENCE SALON DEAdamus AT1, Tran H2 for the Med Comp SIG, 1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; 2Lake Erie College ofOsteopathic Medicine, Erie, PA, USA

Clinical study methodology issues including pharmacoepidemiology

pg 62* W27 THE ROLE OF OUTCOMES RESEARCHERS IN DESIGNING PATIENT REGISTRIES: CREATING PROGRAMS TO MEET BROAD ORGANZIATIONALOBJECTIVES SALON CLarson LR1, Malamis P2, Gordon MJ1, Trotter JP1, 1Ovation Research Group, Highland Park, IL, USA; 2Galt Associates, Sterling, VA, USA


pg 62* W28 ASSESSMENT OF DATASOURCE OPTIONS FOR OUTCOMES RESEARCH AND FORMULATY DECISIONS SALON BBrixner DI1, Tabb K2, Stockdale B1, Holubkov R1, 1University of Utah, Salt Lake City, UT, USA; 2GE Medical Systems Information Technologies,Berkeley, CA, USA


pg 63* W29 DEVELOPING A STRATEGY FOR PROMOTING THE USE OF ECONOMIC EVALUATION IN HEALTH CARE DECISION MAKING IN LATIN AMERICASALON FGRovira J1, Bertozzi SM2, 1The World Bank, Washington, DC, USA; 2Instituto Nacional de Salud Publica, Cuernavaca, Morelos, Mexico


pg 63* W30 COLLECTING PATIENT-REPORTED OUTCOMES DATA OUTSIDE THE CLINICAL TRIAL PARADIGM SALON HMathias SD, Colwell HH, Matosian ML, Ovation Research Group, Highland Park, IL, USA

pg 63* W31 CANCER-SPECIFIC PATIENT-REPORTED OUTCOMES: DO THEY YIELD USEFUL INFORMATION? SALON JGondek K1, Kamath CC2, Copley-Merriman K3, 1Bayer Pharmaceuticals, West Haven, CT, USA; 2Mayo Clinic, Rochester, MN, USA; 3Pfizer, Inc, AnnArbor, MI, USA

26

* Program page number

I SPOR 9TH ANNUAL IN TERNATIONAL MEET ING PROGRAM


pg 63* W32 POTENTIAL ROLE OF PRO ASSESSMENTS IN RISK MANAGEMENT PROGRAMS SALON KMarquis P, Piault E, Mapi Values, Boston, MA, USA

3:45PM–4:00PM BREAK ARLINGTON BALLROOM BREAK SPONSORED BY

4:00PM–5:00PM ISPOR FORUMS

4:00PM–5:00PM VISION 2010 FORUM SALON DESpeaker: Gerry Oster PhD, Vice President, Policy Analysis Inc., Brookline, MA, USA; Marc Berger MD, Vice President, Outcomes Research andManagement, Merck & Co., Inc, West Point, PA, USAThe ISPOR Vision 2010 Committee was formed by the Board of Directors in May 2002 and charged with assisting the Board in plotting the futuredirection and activities of the Society. The Committee has completed its deliberations and recently delivered its final report to the Board. Duringthis session, members of the Committee will discuss the recommendations they have made to the Board concerning the future direction andactivities of ISPOR.

4:00PM–5:00PM MEDICAL DEVICE & DIAGNOSTICS COUNCIL FORUM SALON CPROS IN DEVICE EVALUATION: SCIENTIFIC AND REGULATORY CHALLENGES

4:00PM-4:10PM INTRODUCTION TO THE ISSUE – COMMON CHALLENGES, UNCOMMON SOLUTIONSModerator & Speaker: Nancy Kline Leidy PhD, President and CEO, MEDTAP International, Bethesda, MD, USAThe need to communicate value through rigorous scientific evidence common challenge to all areas of health care, including pharma & device,will be discussed.

4:10PM-4:25PM OVERVIEW OF PRO CHALLENGES – THE DEVICE INDUSTRY PERSPECTIVESpeaker: Randel Richner MPH, BSN, Vice President, Federal Affairs, Reimbursement and Outcomes Planning, Boston Scientific, Natick, MA, USAUnique challenges of the medical device industry will be presented.

4:25-4:45PM ACCUMULATION & PRESENTATION OF SCIENTIFIC EVIDENCE – REGULATORY PERSPECTIVESpeaker: Neal I. Muni, MD, MSPH, Medical Officer, FDA, Rockville, MD, USAMaking QOL claims for cardiovascular technologies - collaborative efforts between academia, industry, and the FDA…and more.

4:45PM-5:00PM PANEL DISCUSSION

5:00PM–6:00PM PATIENT REGISTRIES SIG OPEN MEETING SALON A

RISK MANAGEMENT SIG OPEN MEETING SALON B

5:00PM-7:00PM EXHIBITORS’ WINE & CHEESE RECEPTION & CONTRIBUTED POSTER PRESENTATIONS VIEWING – SESSION IIARLINGTON BALLROOM

5:00PM–6:00PM CONTRIBUTED POSTER AUTHOR PRESENTATION HOUR – SESSION II

7:00PM-7:30PM POSTER DISMANTLE – SESSION II

6:30PM-9:00PM ISPOR MEDICAL DEVICE & DIAGNOSTICS COUNCIL DINNER MEETING MCLEAN

7:00PM-9:00PM ISPOR CONNECTIONS EDITORIAL BOARD DINNER MEETING MANASSAS

W E D N E S D AY, MAY 19TH7:30AM POSTER PRESENTATIONS AWARD RECIPIENTS POSTED GRAND BALLROOM FOYER

8:00AM–9:00AM CONTRIBUTED PODIUM PRESENTATIONS – SESSION IIIResearch studies on the following topics will be presented:

Prescribing Studies SALON CModerator: Yen-Huei (Tony) Tarn PhD, Associate Professor and ISPOR F e l l o w, School of Pharmacy, National Defense Medical Center, Taipei, Ta i w a n

pg 229 RX1 CLAIM-BASED DRUG WASTAGE ESTIMATION: HOW HIDDEN REFILL BEHAVIOR CAN HELPXiao Q, Marks AS, Caremark Inc, Northbrook, IL, USA

pg 229 RX2 PREVALENCE AND CORRELATES OF POTENTIALLY INAPPROPRIATE PRESCRIBING AMONG THE AMBULATORY ELDERLY IN 2001Viswanathan H, Bharmal M, Thomas III J, Purdue University, West Lafayette, IN, USA

pg 229 RX3 EVALUATING CLINICAL AND FINANCIAL OUTCOMES ASSOCIATED WITH A RETROSPECTIVE DRUG UTILIZATION REVIEW PROGRAMLee KY, Zajack L, Berdovich S, Bertram C, Bundek N, Walgreens Health Initiatives, Deerfield, IL, USA

pg 230 RX4 A DYNAMIC MODEL OF BUDGET IMPACT ANALYSESHan S1, Shih YCT2, 1Rice University, Houston, TX, USA; 2The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

Adherence/Compliance SALON DEModerator: Femida Gwadry-Sridhar BSc, MSc, McMaster University, Hamilton, Ontario, Canada

pg 230 AC1 CAPTURING PATIENT-REPORTED COMPLIANCE DATA IN A NINE-COUNTRY PRODUCT REGISTRY USING MEMS CAP DEVICESSteffan P, Becker R, Sama P, Ovation Research Group, Highland Park, IL, USA 27


pg 230 AC2 COMPARING PATIENT-REPORTED MEDICATION COMPLIANCE WITH ELECTRONICALLY MONITORED MEDICATION COMPLIANCE IN A 12-MONTH INTERNATIONAL REGISTRYSteffan P, Becker R, Sama P, Ovation Research Group, Highland Park, IL, USA

pg 230 AC3 COMPARISION OF ADHERENCE TO ANTIHYPERTENSIVES IN A MANAGED CARE POPULATION.Naik RK1, Borrego ME1, Gupchup GV1, D'Angio R2, Sabrsula S3, 1University of New Mexico, Albuquerque, NM, USA; 2Pfizer Inc, Albuquerque, NM,USA; 3Firstcare MCO, Albuquerque, NM, USA

pg 231 AC4 CLINICAL AND ECONOMIC OUTCOMES OF NON-ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV Munakata J1, Benner JS1, Becker SL 2, Dezii CM3, Hazard EH1, Tierce JC1, 1ValueMedics Research, LLC, Arlington, VA, USA; 2Pacific HorizonMedical Group, Inc, San Francisco, CA, USA; 3Bristol-Myers Squibb, Plainsboro, NJ, USA

Pharmacoepidemiology SALON HModerator: Steven R. Erickson PharmD, Associate Professor, Department of Clinical, Sciences, University of Michigan College of Pharmacy, AnnArbor, MI, USA

pg 231 PE1 ASSESSING EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING: DATA FROM AN EFFECTIVENESS STUDY OF ANTIPSYCHOTICSFaries D1, Nyhuis A1, Tunis SL1, Hernan M2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Harvard School of Public Health, Boston, MA, USA

pg 232 PE2 USING HEALTH-RISK APPRAISAL DATA FOR ASSESSING PREDICTORS OF HYPERTENSION TREATMENTBrown JS1, Menzin J1, Manocchia M2, 1Boston Health Economics, Inc., Waltham, MA, USA; 2Blue Cross Blue Shield of Rhode Island, Providence, RI, USA

pg 232 PE3 COMORBIDITY INFLUENCE INDEXStockdale WA, Brixner DI, University of Utah, Salt Lake City, UT, USA

pg 232 PE4 AN AUTOMATED METHOD TO INFER MORBIDITY DESCRIPTIONS FROM PATIENT PHARMACY PROFILES Prasad BN, PD, Huang XPD, Ingenix, Eden Prairie, MN, USA

Outcomes & Preferences SALON FGModerator: Rajesh Balkrishnan PhD, Associate Professor, University of Texas School of Public Health, Houston, TX, US

pg 233 OP1 IS THE CURRENT METHOD OF VALUING HEALTH OUTCOMES IN COST-EFFECTIVENESS ANALYSIS VALID? O'Sullivan A1, Thompson D1, Weinstein M2, 1Innovus Research (US) Inc, Medford, MA, USA; 2Innovus Research Inc. and Harvard School of PublicHealth, Boston, MA, USA

pg 233 OP2 COMPARISON OF DISCRETE CHOICE EXPERIMENT (DCE) WITH VISUAL ANALOG SCALING (VAS) METHODS FOR ESTIMATING PREFERENCESFOR PHYSICAL DISABILITY STATESBanks JL1, Netten A2, Ryan M3, Watson V4, Salas M5, 1University of Kent at Canterbury, Lincoln, MA, USA; 2University of Kent at Canterbury,Canterbury, Kent, UK; 3University of Aberdeen, Aberdeen, UK; 4University of Aberdeen Medical School, Aberdeen, UK; 5Erasmus UniversityMedical School, Rotterdam, Netherlands

pg 233 OP3 UNDERSTANDING THE CHARACTERISTICS OF NON TRADERS IN TTO UTILITY ELICITATIONMiller LAN1, Mody R1, Singer ME 2, 1West Virginia University, Morgantown, WV, USA; 2Case Western Reserve University School of Medicine,Cleveland, OH, USA

pg 234 OP4 DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED USEFULNESS SCALE TO EVALUATE ANTIEPILEPTIC PHARMACOTHERAPY INPATIENTS WITH EPILEPSYBrown LM, Mulani P, Cifaldi M, Ashraf T, Abbott Laboratories, Abbott Park, IL, USA

9:00AM-9:15AM BREAK GRAND BALLROOM FOYER BREAK SPONSORED BY

9:15AM-10:15AM CONTRIBUTED PODIUM PRESENTATIONS – SESSION IVPharmacoeconomics/health economic, quality-of-life, and outcomes research study results for the following diseases will be presented:

Diabetes SALON CModerator: Joseph Menzin PhD, President, Boston Health Economics, Inc., Waltham, MA, USA

pg 234 DB1 THE IMPACT OF USING EITHER THE FRAMINGHAM OR THE UK PROSPECTIVE DIABETES STUDY RISK FORMULAE IN DIABETES HEALTH ECO-NOMICS MODELINGPalmer AJ1, Roze S 2, Lammert M3, Valentine WJ1, Nicklasson L4, 1CORE Center for Outcomes Research, Binningen/Basel, Baselland, Switzerland;2Novo Nordisk Pharmaceuticals Inc, Princeton, NJ, USA

pg 342 DB2 THE ECONOMIC BURDEN OF TYPE 2 DIABETES MANAGEMENT BY ETHNIC GROUP IN THE TEXAS MEDICAID POPULATIONLee WC1, Stephens JM 1, Tran KT1, Wang Q1, Dirani RG 2, Pashos CL 3, 1Abt Associates Inc, Bethesda, MD, USA; 2Glaxo Smith Kline, Philadelphia, PA;3Abt Associates Inc, Cambridge, MA, USA

pg 235 DB3 OUTCOMES ASSOCIATED WITH THE INTRODUCTION OF THIAZOLIDINEDIONE THERAPY IN ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLI-TUS: A RETROSPECTIVE DATA ANALYSISBalkrishnan R1, Rajagopalan R2, Camacho F3, Anderson R3, 1University of Texas School of Public Health, Houston, TX, USA; 2TakedaPharmaceuticals North America, Inc, Lincolnshire, IL, USA; 3Wake Forest University School of Medicine, Winston-Salem, NC, USA

pg 235 DB4 DRIVERS OF TREATMENT PREFERENCE AMONG INDIVIDUALS WITH TYPE-2 DIABETESMcHorney C1, Hayes RP2, Bowman L2, Myers J3, 1Indiana University School of Medicine, Regenstrief Institute for Health Care, Roudebush VAMedical Center, Indianapolis, IN, USA; 2Eli Lilly & Company, Indianapolis, IN, USA; 3Roudebush VA Medical Center, Indianapolis, IN, USA

Mental Health SALON H Moderator: Kerstin (Chris) Bingefors MSc, PhD, Associate Professor, Research Director, Biomedical Centre, Uppsala University, Dept ofPharmacy, Uppsala, Sweden

28

ISPOR 9TH A NNUAL INTERNATIONAL MEET ING P ROGRAM

pg 235 MH1 AN ECONOMIC ANALYSIS OF ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIALui G1, Sun S1, Christensen D1, Zhao Z2, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2Eli Lilly and Company, Indianapolis, IN, USA

pg 236 MH2 IMPACT OF OPEN ACCESS TO ATYPICAL ANTIPSYCHOTICS IN CALIFORNIA MEDICAIDAhn J, McCombs JS, University of Southern California, Los Angeles, CA, USA

pg 236 MH3 COST-EFFECTIVENESS OF METHYLPHENIDATE OROS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): AN EVALUATION FROM THEPERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)Schlander M, University of Witten/Herdecke & University of Applied Sciences Ludwigshafen, Ludwigshafen am Rhein, Germany

pg 236 MH4 ASSESSMENT OF HEALTH STATE UTILITIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN USING PARENT-BASED STAN-DARD GAMBLE SCORESSecnik K1, Cottrell S2, Matza L3, Edgell E4, Aristides M5, Tilden D2, Burridge J5, Mannix S 6, 1Eli Lilly and Company, Indianapolis, IN, USA; 2M-TAG PtyLtd., London, England; 3MEDTAP International, Bethesda, MD, USA; 4Lilly Research Centre, Windlesham, UK; 5M-TAG Limited, London, UK; 6MED-TAP International, Inc, Bethesda, MD, USA

Neurological Disorders/Migraine SALON DEModerator: Mark Sculpher MSc, PhD, Professor, University of York, Center for Health Economics, York, UK

pg 237 ND1 ESTIMATING COST-EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS USING NET BENEFITREGRESSION MODEL METHODSBrown MG1, Hoch JS2, MacKinnon-Cameron D1, 1Dalhousie University, Halifax, NS, Canada; 2University of Western Ontario, London, ON, Canada

pg 237 ND2 COST-EFFECTIVENESS OF MIGRAINE PREVENTION: RESULTS FROM A MODEL OF TOPIRAMATE TREATMENTBrown J1, Papadopoulos G 2, Neumann P3, Friedman M1, Menzin J1, 1Boston Health Economics, Inc, Waltham, MA, USA; 2Johnson & JohnsonPharmaceutical Services, Raritan, NJ, USA; 3Harvard School of Public Health, Boston, MA, USA

pg 237 ND3 MEDICAL SERVICES UTILIZATION FOR PATIENTS WITH PARKINSON’S DISEASE IN A STATE MEDICAID PROGRAMKamat S, Smith MJ, West Virginia University, Morgantown, WV, USA

pg 238 ND4 BURDEN OF ILLNESS IN ALZHEIMER’S DISEASE IN THE UKLivingston G1, Katona C2, Roch B3, 1University College London, London, UK; 2University of Kent at Canterbury, Kent, UK; 3H. Lundbeck A/S, Paris, France

Health Policy Evaluation SALON FGModerator: John Woolcott MA, Health Economist, BC Centre for Disease Control, Vancouver, British Columbia, Canada

pg 238 HP1 EVALUATION OF GENERIC DISPENSING INCENTIVE PROGRAM (GDIP)Hong SH, University of Arkansas for Medical Sciences, Little Rock, AR, USA

pg 313 HP2 THE EFFECT OF MEDICAID COVERAGE DECISIONS ON NON-SEDATING ANTIHISTAMINE UTILIZATION AND SPENDING FOLLOWING OVER-THE-COUNTER AVAILABILITY OF LORATADINEHansen RA, Trygstad TK, University of North Carolina - Chapel Hill, Chapel Hill, NC, USA

pg 238 HP3 EFFECT OF COPAY INCREASE ON FOUR MEASURES OF COMPLIANCE: A NATURAL EXPERIMENTMeissner B, Shinogle J, Kozma C, Shah M, Franklin M, University of South Carolina, Columbia, SC, USA

pg 239 HP4 CHALLENGES FOR EXAMINING THE ECONOMICS OF PHARMACOGENOMICSPhillips KA, Van Bebber SL, Veenstra DL, University of California San Francisco, San Francisco, CA, USA

10:15AM–10:45AM BREAK GRAND BALLROOM FOYER BREAK SPONSORED BY

10:45AM-11:00AM OPENING REMARKSSean Sullivan PhD, Professor, University of Washington, Seattle, WA, USA

ISPOR CONTRIBUTED RESEARCH AWARDS PRESENTATION GRAND BALLROOMModerator: C. Daniel Mullins PhD, Chair ISPOR Awards Committee and Assistant Professor, University of Maryland, School of Pharmacy,Baltimore, MD, USA

ISPOR BEST CONTRIBUTED POSTER PRESENTATIONGENERAL - NEW INVESTIGATOR - STUDENT (up to 3 awards in each category)Presented by: Les Noe RPh, MPA, ISPOR Contributed Poster Awards Task Force Chair and Vice President, Ovation Research Group, HighlandPark, IL, USA

ISPOR BEST CONTRIBUTED PODIUM PRESENTATIONGENERAL - NEW INVESTIGATOR - STUDENT (up to 3 awards in each category)Presented by: Ya-Chen Tina Shih MS, PhD, ISPOR Contributed Podium Awards Task Force Chair and Associate Professor, M.D. Anderson CancerCenter, Houston, TX, USA

11:00AM-12:30PM THIRD PLENARY SESSION GRAND BALLROOMTHE $64,000 QUESTION: WHAT ARE WE WILLING TO PAY FOR A QALY?Moderator: Peter Neumann ScD, Associate Professor of Policy and Decision Sciences, Harvard School of Public Health, Boston, MA, USASpeaker: James Hammitt PhD, Professor of Economics & Decision Sciences, Harvard School of Public Health, Boston, MA, USASpeaker: Reed Johnson PhD, Principal Economist and Senior Fellow, RTI – Health Solutions, Research Triangle Park, NC USASpeaker: Cam Donaldson MSc, PhD, Professor of Health Economics, University of Newcastle upon Tyne, Newcastle, UK

This plenary session addresses the willingness to pay for a QALY, new OMB guidance on QALYs and whether or not QALYs should be monetized.This session will also take a look at the research agenda for WTP and QALYs.

29

30

Does your next study have too many tasks for you to do?• Determine your research objectives• Find the right database or design a survey• Review the relevant literature• Write the protocol• Design the statistical analyses• Analyze the data• Write up the methods and results• Develop posters and presentations• Write the manuscript• Navigate the publication submission process

Healthcare Data Analysis can help you with any of these tasks.

Healthcare Data Analysis is a consulting company specializing in retrospective pharmacoeconomic and pharmacoepi-demiologic studies and in the design and analysis of patient registries.

For information, please contact Suellen Curkendall at 703-319-2155 [email protected] or visit the web site.

www.healthcaredataanalysis.com


ARTHRITIS

ARTHRITIS-Clinical Outcomes Studies

pg240 PAR1 RHEUMATOID ARTHRITIS IMPACT OF DISEASE AND DRUG THERAPYFranic DM1, Kotzan J1, Fagan SC 1, Grauer D2, 1The University of Georgia, Athens, GA, USA; 2The University of Kansas, Kansas City, KS, USA

pg240 PAR2 INFLIXIMAB DOSING PATTERNS IN RHEUMATOLOGY PRACTICESHendricks D, Callegari P, Ziskind M, Centocor Inc, Malvern, PA, USA

ARTHRITIS-Cost Studies

pg240 PAR3 ECONOMIC EVALUATION OF SELF-INJECTION VS AMBULATORY CARE OF ANTI-RHEUMATOID BIOLOGICS (ETANERCEPT) IN JAPANIgarashi A1, Fukuda T1, Tsutani K1, Miyasaka N2, 1University of Tokyo, Bunkyo, Tokyo, Japan; 2Tokyo Medical and Dental University, Tokyo, Bunkyo-ku,Japan

pg241 PAR4 COST-EFFECTIVENESS OF TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS AS FIRST-LINE AGENTS IN RHEUMATOID ARTHRITIS Spalding JR, Hay JW, University of Southern California, Los Angeles, CA, USA

pg241 PAR5 COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRATM) IN THE TREATMENT OF US PATIENTS WITH RHEUMATOID ARTHRITIS (RA)Bansback N1, Brennan A1, Sengupta N2, 1University of Sheffield, Sheffield, South Yorkshire, UK; 2Abbott Laboratories, Abbott Park, IL, USA

pg241 PAR6 COST-EFFECTIVENESS OF TREATMENT STRATEGIES FOR RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATEPatel VD, Hay J, University of Southern California, Los Angeles, CA, USA

ARTHRITIS-Quality Of Life/Patient-Reported Outcomes/Patient Preference Studies

pg242 PAR7 ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG OSTEOARTHRITIC PATIENTSGandra SR, Lawrence LW, The University of Louisiana at Monroe, Monroe, LA, USA

pg242 PAR8 THE RELATIONSHIP BETWEEN GASTROINTESTINAL SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE IN KOREAN PATIENTS WITH RHEUMATICDISEASESBae SC1, Kim S2, Uhm WS1, 1Hanyang University, Seoul, South Korea; 2Pochon CHA University, SeongNam, South Korea

pg242 PAR9 HEALTH RELATED QUALITY OF LIFE OF CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS PATIENTS RECEIVING FENTANYL TRANSDERMAL SYSTEMHamed A1, Huang YH1, Lee A 1, Miller DR1, Ren SX1, Iqbal U1, Vallow S2, Schein J2, Kazis L1, 1Boston University, Boston, MA, USA; 2Janssen PharmaceuticaProducts, Titusville, NJ, USA

pg243 PAR10 IMPROVING THE SENSITIVITY OF PHYSICAL FUNCTION MEASURES IN RHEUMATOID ARTHRITIS: USE OF ITEM RESPONSE THEORY IN PATIENTSTREATED WITH ABATACEPT (CTLA4IG)Martin M1, Emery P2, Kosinski M1, Ware J1, Li T3, Williams R4, Maclean R3, Bjorner J1, 1Quality Metric, Inc, Lincoln, RI, USA; 2University of Leeds, Leeds, UK;3Bristol-Myers Squibb, Princeton, NJ, USA; 4Bristol-Myers Squibb, Brussels, Belgium

pg243 PAR11 REVALIDATION OF THE CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) SHORT FORM INSTRUMENTChiou CF1, Sherbourne C2, Cornelio IL 3, Lubeck D 3, Paulus H4, Dylan M 1, Weisman M5, 1Zynx Health, A Cerner Company, Beverly Hills, CA, USA; 2RANDCorporation, Santa Monica, CA, USA; 3Amgen, Inc, Thousand Oaks, CA, USA; 4University of California, Los Angeles, CA, USA; 5Cedars-Sinai HealthSystem, Los Angeles, CA, USA

pg243 PAR12 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR VIOXX® AS A TREATMENT FOR OSTEOARTHRITIS RELATIVE TO NSAIDSTilden D1, Mernagh P2, FitzGerald P2, Adams J 2, Mark S3, van Bavel J 3, Davey P4, 1M-TAG Pty Ltd., London, UK; 2M-TAG Pty Ltd Australia, Chatswood West,NSW, Australia; 3Merck Sharpe and Dohme, Granville, NSW, Australia; 4Medical Technology Assessment Group, Chatswood West, NSW, Australia

pg244 PAR13 BURDEN OF OSTEOARTHRITIS AND ITS TREATMENT ON PATIENTSChang J1, Kauf T2, Mahajan S2, Reed S3, Friedman J2, Omar M1, Kahler K1, Schulman K2, 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;2Duke University, Durham, NC, USA; 3Duke Clinical Research Institute, Durham, NC, USA

pg244 PAR14 CONTRIBUTION OF PAIN, SITE OF PAIN AND NUMBER OF JOINTS AFFECTED ON PRODUCTIVITY LOSS AMONG WORKERS AND NON-WORKERS WITHOSTEOARTHRITIS Mahajan S1, Kauf T 1, Chang J2, Omar M2, Kahler K2, Schulman K1, 1Duke University, Durham, NC, USA; 2Novartis Pharmaceuticals Corporation, EastHanover, NJ, USA

pg244 PAR15 ETHNIC VARIATIONS IN PREFERENCE FOR TOTAL KNEE REPLACEMENT IN PATIENTS WITH OSTEOARTHRITISSuarez-Almazor M1, Souchek J 1, Kelly PA2, Byrne M3, Richardson M 1, Pak C2, 1Baylor College of Medicine and Houston Center for Quality of Care &Utilization Studies, Houston, TX, USA; 2Baylor College of Medicine and Houston Center for Quality of Care and Utilization Studies, Houston, TX, USA;3University of Pittsburgh, Pittsburgh, PA, USA

pg245 PAR16 TRENDS IN THE USE OF PATIENT REPORTED OUTCOMES IN OSTEOARTHRITIS CLINICAL TRIALS AND SUBSEQUENT PRODUCT LABELSStafkey DR1, Coombs JH 2, 1University of Michigan/ Pfizer, Ann Arbor, MI, USA; 2Pfizer Inc, Ann Arbor, MI, USA

pg245 PAR17 CHARACTERIZATION OF THE TREATMENT OF RHEUMATOID ARTHRITIS FOR PATIENTS PRESCRIBED TUMOR NECROSIS FACTOR-ALPHA INHIBITORSStockl K1, Jarrar M1, Tandon N2, 1Prescription Solutions, Costa Mesa, CA, USA; 2Centocor, Inc, Malvern, PA, USA

POSTER PRESENTATIONS – SESSION I

31

I SPOR 9TH ANNUAL INTERNAT IONAL MEET ING POSTER PRES ENTAT I O N S

ARTHRITIS-Health Policy Studies

pg245 PAR18 RACIAL DISPARITIES IN PRESCRIBING OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS OVER OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTSIN A MEDICAID MANAGED CARE POPULATIONShaya FT, Blume SW, Blanchette CM, Mullins CD, University of Maryland, Baltimore, MD, USA

CANCER

CANCER-Clinical Outcomes Studies

pg246 PCN1 EPOETIN ALFA AND DARBEPOETIN ALFA ANEMIA TREATMENT OUTCOMES IN CANCER PATIENTS FROM A VA PERSPECTIVE Papatheofanis FJ1, Fastenau JM2, Chiang T1, Piech CT 2, 1Aequitas, Carlsbad, CA, USA; 2Ortho Biotech Products, LP, Bridgewater, NJ, USA

pg246 PCN2 IMPACT OF CHEMOTHERAPY- INDUCED DIARRHEA ON MANAGEMENT PATTERNS AND RESOURCE UTILIZATION AMONG CANCER PATIENTS: RESULTSFROM A MULTI-SITE STUDYArnold R1, Gabrail N2, Raut M3, Kim R1, Sung J3, Gause D3, Zhou Y1, 1Pharmacon International, Inc, New York, NY, USA; 2Nashat Y. Gabrail, Canton, OH, USA;3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

pg246 PCN3 POTENTIAL IMPACT OF WANING OF VACCINE-INDUCED IMMUNITY AGAINST HUMAN PAPILLOMAVIRUS 16/18Goldie S1, Kohli M2, Grima D2, Weinstein M1, Wright T3, Bosch F4, Franco E5, 1Harvard School of Public Health, Boston, MA, USA; 2Innovus Research Inc,Burlington, ON, Canada; 3Columbia University, New York, NY, USA; 4Institut Catala D'Oncologia, Barcelona, Spain; 5McGill University, Montreal, QC, Canada

pg246 PCN4 TECHNOLOGY ADVANCES AND TREATMENT PATTERN VARIATIONS IN ONCOLOGY: EVIDENCE FROM USE OF CPT-11 IN ELDERLY METASTATIC COL-ORECTAL CANCER PATIENTSShih YCT, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

pg247 PCN5 ANALYSIS OF OVER 2,400 MODERN PHASE I CANCER TRIALS: COMPOSITION, OUTCOMES, AND USE OF SURROGATE ENDPOINTSRoberts TG1, Goulart BH1, Stallings SC2, Squitieri L2, Chabner BA1, Finkelstein SN2, Clark JW1, 1Massachusetts General Hospital, Boston, MA, USA;2Massachusetts Institute of Technology, Cambridge, MA, USA

pg247 PCN6 FACTORS INFLUENCING PHYSICIAN RECOMMENDATION FOR IMATINIB MESYLATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML)PATIENTSIyer SS, Doucette WR, University of Iowa, Iowa City, IA, USA

CANCER-Cost Studies

pg247 PCN7 TRENDS IN CHEMOTHERAPY USE, OUTCOMES, AND COST FOR PATIENTS WITH ADVANCED NONSMALL LUNG CANCER: EVIDENCE FROM SEER-MEDICARERamsey SD,Etzioni RD, Howlader N, Abullarade J, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

pg248 PCN8 OUTCOMES AND COSTS OF SURROGATE END-POINTS (SES) AND BIOMARKERS IN PHASE I ONCOLOGY CLINICAL TRIALSGoulart BHL, Roberts TG, Liu Y, Clark JW, Massachusetts General Hospital, Boston, MA, USA

pg248 PCN9 COST EFFECTIVENESS OF ADDING BISPHOSPHONATES TO THE NON-SURGICAL ANDROGEN DEPRIVATION THERAPY FOR FRACTURE REDUCTION INPATIENTS WITH NON-METASTATIC PROSTATE CANCERPhatak HM, Thomas III J, Purdue University, West Lafayette, IN, USA

pg248 PCN10 THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY (MAL-PDT) FOR BASAL CELL CARCINOMA Orme ME, Howard P, Heron Evidence Development, Letchworth, Herts, UK

pg249 PCN11 C O S T-EFFECTIVENESS ANALYSIS OF DOSE-DENSE CHEMOTHERAPY WITH FILGRASTIM AS POSTOPERATIVE ADJUVANT TREATMENT OF BREAST CANCERYu AP, Hay JW, University of Southern California, Los Angeles, CA, USA

pg249 PCN12 ECONOMIC BURDEN OF PANCREATIC CANCER AND TREATMENT FAILUREChang S1, Long S1, Kutikova L2, Bowman L2, Crown WH 3, 1Medstat, Washington, DC, USA; 2Eli Lilly and Company, Indianapolis, IN, USA; 3The MEDSTATGroup, Cambridge, MA, USA

pg249 PCN13 AN ECONOMIC ANALYSIS OF RADIATION VERSUS RADIATION PLUS GOSERELIN IN THE TREATMENT OF LOCALLY ADVANCED PROSTATE CANCERTaylor MD, University of Florida, Gainesville, FL, USA

pg250 PCN15 DIRECT MEDICAL COSTS OF MANAGING TOXICITIES RELATED TO TAXANE THERAPY FOR METASTATIC BREAST CANCER IN THE UNITED STATESBramley TJ, Vishalpura TT, Nightengale BS, Applied Health Outcomes, Palm Harbor, FL, USA

pg250 PCN16 ECONOMIC BURDEN OF PROSTATE CANCER AMONG HOSPITALIZED PATIENTSAtkins E, Xiao H, Florida Agricultural & Mechanical University, Tallahassee, FL, USA

pg251 PCN17 THE HEALTH CARE COST OF SMOKING IN CANADAPetit P1, Cremieux P 2, Ouellette P3, 1Groupe d’analyse, inc, Montreal, QC, Canada; 2Analysis Group, Boston, MA, USA; 3Universite’ du Quebec a Montreal,Montreal, QC, Canada

pg251 PCN18 COST ANALYSIS OF LUNG CANCER TREATMENT IN TAIWANYang CH1, Wang YJ2, Chang CJ1, 1National Taiwan University Hospital, Taipei, Taiwan, 2ProTech Pharmaceuticals Corporation, Taipei, Taiwan

pg251 PCN19 THE COST-EFFECTIVENESS ANALYSIS RECOMBINANT HUMAN ERYTHROPOIETIN GROWTH FACTORS VS. TRANSFUSION IN CHEMOTHERAPY CANCERPATIENTSTonnu IQ, Hay J, USC School of Pharmacy, Los Angeles, CA, USA

pg251 PCN20 PRELIMINARY ECONOMIC ANALYSIS OF THE AMERICAN CANCER SOCIETY GUIDELINES FOR MAMMOGRAPHY SCREENING IN AVERAGE-RISKWOMEN UNDER 70 YEARS OF AGEZammit D, Hay J, University of Southern California, Los Angeles, CA, USA

PCN33 WEEKLY EPOETIN ALFA (EPO QW) FOR CHEMOTHERAPY-RELATED ANEMIA IS COST-EFFECTIVE COMPARED TO DARBEPOETIN ALFA ADMINISTEREDBY EVERY 2-WEEK (DARB Q2W) OR FRONT LOADING (DARB FL) SCHEDULES Rosberg J1, Duh M1, Cremieux P1, McKenzie S2, Fastenau JM2, Piech CT 2, 1Analysis Group, Bridgewater, NJ, USA; 2Ortho Biotech Products, LP,Bridgewater, NJ, USA

32

CANCER-Quality Of Life/Patient Preferences

pg252 PCN21 SHORT-TERM PSYCHOSOCIAL COUNSELING FOR PATIENTS WITH NEWLY-DIAGNOSED PROSTATE CANCERSadetsky N1, Kneier A1, Latini DM 1, Knight S2, Loi J1, Carroll PR1, 1University of California, San Francisco, CA, USA; 2San Francisco VA Medical Center, SanFrancisco, CA, USA

pg252 PCN22 THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE CORE QUESTIONNAIRE (EORTC QLQ-C30): VALIDA-TION OF ENGLISH VERSION IN SINGAPOREXie F, Luo N, Li S, National University of Singapore, Singapore, Singapore

pg252 PCN23 XEROSTOMIA SYMPTOMS: A NEWLY DEVELOPED PATIENT REPORTED OUTCOMES QUESTIONNAIREColwell HH1, Pritchard ML 1, Hill JC1, Sneeringer RK 1, Miller DP 1, Calhoun EA2, 1Ovation Research Group, Highland Park, IL, USA; 2Northwestern University,Chicago, IL, USA

pg252 PCN24 QUALITY OF LIFE OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS IN A PUBLIC VS. PRIVATE SETTING Jayadevappa R, Chhatre S, Fomberstein K, Johnson KJ, Rosner A, Bloom BS, Malkowicz SB, University of Pennsylvania, Philadelphia, PA, USA

pg253 PCN25 CASE-MATCHED CONTROLLED STUDY SHOWS MEN PREFER PROSTATE BRACHYTHERAPY TO CONFORMAL RADIATION THERAPYKulkarni S1, Hanlon A1, Konski A2, Pollack A2, Horwitz E2, Raysor S1, Bruner DW1, 1Fox Chase Cancer Center, Cheltenham, PA, USA; 2Fox Chase CancerCenter, Philadelphia, PA, USA

pg253 PCN26 ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION USING A REPEATED MEASURES DESIGNFranic DM1, Gafni A 2, 1The University of Georgia, Athens, GA, USA; 2McMaster University, Hamilton, ON, Canada

CANCER-Health Policy Studies

pg254 PCN27 THE BREAST CANCER SCREENING RATES OF GEORGIA MEDICAID RECIPIENTS Chen H, Kotzan JA, Martin BC, 1The University of Georgia, Athens, GA, USA

CANCER-Methods

pg254 PCN28 GAPS IN COLORECTAL CANCER OUTCOMES RESEARCHYe X1, Schommer JC 1, Castellanos JW1, Sanchez LD 1, Wagner S2, 1University of Minnesota, Minneapolis, MN, USA; 2Pfizer Corporation, New York, NY, USA

pg254 PCN29 MEASURING CHEMOTHERAPY EFFECTIVENESS IN NATURALISTIC SETTINGS: THE THREE FACES OF RELATIVE DOSE INTENSITYKilgore KM, Zdanis MR, Cetus Group, LLC, Timonium, MD, USA

pg255 PCN30 USING THE DIFFERENCE IN DIFFERENCE METHOD TO UNDERSTAND OUTCOMES IN PROSTATE CANCERLee WC1, Pashos CL2, Brandman J3, Wang Q1, Botteman M 1, 1Abt Associates Inc, Bethesda, MD, USA; 2Abt Associates Inc, Cambridge, MA, USA; 3NovartisPharmaceutical, Florham Park, NJ, USA

pg255 PCN31 WEIGHT OR NOT TO WEIGHT?Baser O1, Given C2, 1The MEDSTAT Group, Ann Arbor, MI, USA; 2Michigan State University, East Lansing, MI, USA

pg255 PCN32 CENSORED MEDICAL COST ESTIMATIONBaser O1, Gardiner J2, Bradley C2, Given C2, 1The MEDSTAT Group, Ann Arbor, MI, USA; 2Michigan State University, East Lansing, MI, USA

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE-Clinical Outcomes Studies

pg256 PCO1 SMOKING BEHAVIOR AMONG COPD PATIENTS, SASKATCHEWAN CANADACurkendall SM1, Goehring E2, Stang MR3, de Luise C4, Lanes S5, Jones JK6, 1Health care Data Analysis, Vienna, VA, USA; 2The Deggge Group, Arlington, VA,USA; 3Saskatchewan Health, Saskatchewan, Canada; 4Pfizer, Inc, Cambridge, MA, USA; 5Boehringer-Ingelheim Pharmaceuticals, Inc., Ingeheim,Germany; 6The Degge Group, Ltd, Arlington, VA, USA

pg256 PCO2 IMPACT OF ANEMIA ON HOSPITALIZATION AND MORTALITY IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ANDCHRONIC KIDNEY DISEASEColey KC, Saul MI, Kirisci L, Smith RB, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA

CHRONIC OBSTRUCTIVE PULMONARY DISEASE-Cost Studies

pg256 PCO3 ESTIMATING COST-EFFECTIVENESS OF INHALED CORTICOSTEROIDS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THEPRESENCE OF MISSING DATAGagnon YM1, Briggs AH2, Levy AR3, Spencer S4, Bale G5, Spencer MD 6, Burge PS5, 1Occam Research & Consulting Inc, Vancouver, BC, Canada; 2Universityof Oxford, Oxford, UK; 3University of British Columbia, Vancouver, BC, Canada; 4St. George's Hospital Medical School, London, UK; 5BirminghamHeartlands Hospital, Birmingham, UK; 6GlaxoSmithKline Global Health Outcomes, Greenford, UK

pg257 PCO4 EPISODES OF RESPIRATORY CARE FOR MANAGED CARE PATIENTS WITH COPD: ASSESSING THE ECONOMIC BURDENBrown J1, Marton JP 2, Friedman M1, Chace M1, Menzin J1, 1Boston Health Economics, Inc, Waltham, MA, USA; 2Pfizer, US Outcomes Research Group,New York, NY, USA

pg257 PCO5 ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A STATE HEALTH INSURANCE PROGRAMJoshi AV1, Madhavan SS 2, Ambegaonkar AJ3, Smith M2, Scott V2, Dedhia H2, 1West Virginia University / Pfizer Inc, Morgantown, WV, USA; 2West VirginiaUniversity, Morgantown, WV, USA; 3Pfizer Inc, New York, NY, USA

CHRONIC OBSTRUCTIVE PULMONARY DISEASE-Quality Of Life Studies

pg257 PCO6 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC RESPIRATORY DISEASE Joshi AV1, Madhavan SS 2, Ambegaonkar AJ3, Smith M2, Scott V2, Dedhia H2, 1West Virginia University / Pfizer Inc, Morgantown, WV, USA; 2West VirginiaUniversity, Morgantown, WV, USA; 3Pfizer Inc, New York, NY, USA

I SPOR 9TH ANNUAL INTERNAT IONAL MEET ING POSTER PRESENTAT I O N S

33

EAR/EYE/SKIN DISEASES OR DISORDERS

EAR/EYE/SKIN DISEASES OR DISORDERS-Clinical Outcomes Studies

pg258 PES1 PATIENTS’ PERSISTENCE AND ADHERENCE WITH GLAUCOMA THERAPY: A LONGITUDINAL RETROSPECTIVE DATABASE ANALYSIS OF OPHTHALMICLIPIDSWalt J1, Kline SEJ2, Carlson A3, Trygstad GJ3, Ravelo A1, 1Allergan, Irvine, CA, USA; 2IMS Health, Plymouth Meeting, PA, USA; 3Data IntelligenceConsultants LLC, Eden Prairie, MN, USA

pg258 PES2 MEDICATION ADHERENCE RATES AND DISEASE SEVERITY CHANGES IN PSORIASISBalkrishnan R1, Carroll CL2, Camacho F2, Feldman S2, 1University of Texas School of Public Health, Houston, TX, USA; 2Wake Forest University School ofMedicine, Winston-Salem, NC, USA

pg258 PES3 PRIOR AUTHORIZATION OF TOPICAL RETINOIDS NEEDED? EVIDENCE FROM OUTPATIENT US NATIONAL PRACTICE DATABalkrishnan R1, Shenolikar R1, Sansbury JC2, Feldman S2, 1University of Texas School of Public Health, Houston, TX, USA; 2Wake Forest University Schoolof Medicine, Winston-Salem, NC, USA

EAR/EYE/SKIN DISEASES OR DISORDERS-Cost Studies

pg259 PES4 COST-UTILITY OF COCHLEAR IMPLANTS A SOCIETAL PERSPECTIVE ANALYSISBarlev A, Hay JW, University of Southern California, Los Angeles, CA, USA

pg259 PES5 THE COST-EFFECTIVENESS OF OTOTOPICAL CIPROFLOXACIN AND DEXAMETHASONE VERSUS OTOTOPICAL OFLOXACIN FOR THE TREATMENT OFOTORRHEA IN PATIENTS WITH TYMPANOSTOMY TUBESRoland P1, Waycaster C2, 1University of Texas Southwestern Medical Center, Dallas, TX, USA; 2Alcon Labs Inc, Fort Worth, TX, USA

pg259 PES6 PATIENT-REPORTED IMPACT OF AGE-RELATED MACULAR DEGENERATIONSchmier JK1, Halpern MT1, Covert D2, 1Exponent, Alexandria, VA, USA; 2Alcon Labs, Forth Worth, TX, USA

pg259 PES7 A COST-EFFECTIVENESS ANALYSIS OF TREATING OPEN ANGLE GLAUCOMA Malone DC1, Ward S2, Gesser K3, 1University of Arizona, Tucson, AZ, USA; 2Royal Danish School of Pharmacy, Copenhagen, Denmark; 3The Royal DanishSchool of Pharmacy, Copenhagen, Denmark

pg260 PES8 ECONOMIC RESOURCES UTILIZED IN A COHORT OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD)Sharma S1, Dugar A2, Bakal J1, Brown G 3, Shah G4, 1Queen's University, Kingston, ON, Canada; 2Pfizer Global Pharmaceuticals, Pfizer, Inc, New York, NY,USA; 3Wills Eye Hospital, Philadelphia, PA, USA; 4Barnes Retina Institute, St. Louis, MO, USA

pg260 PES9 ELIGIBILITY, UTILIZATION, AND COSTS IN A CALIFORNIA MEDICAID LUPUS POPULATIONNichol MB1, Knight TK1, Shi S1, Wallace DJ2, Weisman MH3, 1University of Southern California, Los Angeles, CA, USA; 2University of California, Los Angeles,CA, USA; 3Cedars-Sinai Hospital, Los Angeles, CA, USA

pg260 PES10 THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY (MAL-PDT) FOR DIFFICULT TO TREAT ACTINIC KERATOSESOrme ME, Howard P, Heron Evidence Development, Letchworth, Herts, UK

pg261 PES11 A COST COMPARISON OF TOPICAL 5% FLUOROURACIL VS. CRYOSURGERY FOR THE TREATMENT OF ACTINIC KERATOSISKnoth RL1, Cyprien L1, Cunningham R2, Kirk M2, 1Prescription Solutions, Costa Mesa, CA, USA; 2Valeant Pharmaceuticals International, Costa Mesa, CA, USA

pg261 PES12 ESTIMATE OF DIRECT MEDICAL COSTS ASSOCIATED WITH THE USE OF CONVENTIONAL SYSTEMIC AGENTS IN THE TREATMENT OF MODERATE TOSEVERE PSORIASISFeldman S1, Taylor DC2, Russell MW3, 1Wake Forest University School of Medicine, Winston-Salem, NC, USA; 2Innovus Research Inc, Medford, MA, USA;3Biogen Idec, Inc, Cambridge, MA, USA

pg261 PES13 FACTORS AFFECTING HEALTH CARE EXPENDITURES AMONG PATIENTS WITH DERMATOPHYTOSISDastani H1, Gause D2, Raut M2, 1The University of Texas at Austin, Austin, TX, USA, 2Novartis Pharmaceuticals Corp, East Hanover, NJ, USA

pg262 PES14 MEDICATION AND HEALTH CARE SERVICE UTILIZATION RELATED TO DEPRESSIVE SYMPTOMS IN OLDER ADULTS WITH PSORIASISKulkarni A1, Balkrishnan R1, Camacho F2, Anderson R2, Feldman S2, 1University of Texas School of Public Health, Houston, TX, USA; 2Wake Forest UniversitySchool of Medicine, Winston-Salem, NC, USA

EAR/EYE/SKIN DISEASES OR DISORDERS-Quality Of Life Studies

pg262 PES15 A COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD) WITH MONOCULAR VERSUS BILATERALDISEASEDugar A1, Sharma S2, Blair J2, Bakal J 2, 1Pfizer Global Pharmaceuticals, Pfizer, Inc, New York, NY, USA; 2Queen's University, Kingston, ON, Canada

pg262 PES16 VALIDATION OF A NEW SELF-ASSESSMENT QUESTIONNAIRE AND THE SKINDEX-29 QUALITY OF LIFE (QOL) INSTRUMENT FOR CHRONIC HAND DER-MATITIS (CHHD): A PILOT STUDYFowler J1, Ghosh A2, Duh MS2, Raut M3, Reynolds J2, Thorn D3, Den E2, Chang J3, 1University of Louisville, Lousville, KY, USA; 2Analysis Group, Boston, MA,USA; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

pg263 PES17 IMPROVED HEALTH-RELATED QUALITY OF LIFE FOLLOWING SUSTAINED REDUCTIONS IN ANTI DS-DNA ANTIBODYS [ÁDSDNA AB] IN PATIENTS WITHSYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AFTER TREATMENT WITH LJP394 Crawford B1, Strand V2, 1Mapi Values, Boston, MA, USA; 2Stanford University School of Medicine, Palo Alto, CA, USA

EARS/EYES/SKIN-Health Policy Studies

pg263 PES18 THE IMPACT OF THE SYSTEM TO MANAGE ACCUTANE-RELATED TERATOGENICITYTM (SMARTTM) RISK MANAGEMENT PROGRAM ON ISOTRETINOINPRESCRIBING TRENDSMendelsohn AB1, Governale LA 2, 1FDA & CDC, Rockville, MD, USA; 2FDA, Rockville, MD, USA

I SPOR 9TH ANNUAL INTERNAT IO NAL MEET ING POSTER PRESENTAT I O N S

34

MENTAL HEALTH

MENTAL HEALTH-Clinical Outcomes Studies

pg263 PMH1 EFFECT OF ZIPRASIDONE INITIAL DOSING ON DISCONTINUATION IN SCHIZOPHRENIAHarrison DJ1, Joyce AT2, Ollendorf DA2, Loebel A1, Warrington L1, 1Pfizer Inc, New York, NY, USA; 2PharMetrics Inc, Watertown, MA, USA

pg263 PMH2 GAPS IN ANTIPSYCHOTIC MEDICATION AND RISK OF HOSPITALIZATION FOR THE TREATMENT OF SCHIZOPHRENIA IN MANAGED CARE SETTINGSKozma C1, Locklear J2, Weiden PJ3, 1College of Pharmacy, University of South Carolina, Columbia, SC, USA; 2Janssen Pharmaceutica Products, L.P,Titusville, NJ, USA; 3SUNY Downstate Medical Center, Brooklyn, NY, USA

pg264 PMH3 FACTORS ASSOCIATED WITH SECOND-GENERATION ANTIPSYCHOITC USE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PATIENTS WITH SCHIZOPHRENIAChen L, McCombs J, University of Southern California, Los Angeles, CA, USA

pg264 PMH4 ATYPICAL ANTIPSYCHOTIC TREATMENT ADHERENCE AND PERSISTENCE IN A STATE MEDICAID PROGRAMZhao Z1, Damler RM2, Jackson EA2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Milliman USA, Indianapolis, IN, USA

pg265 PMH6 ANTIPSYCHOTIC TREATMENT AND DIABETES IN A PRIVATELY INSURED POPULATION Zhao Z, Loosbrock D, Cooper L, Eli Lilly and Company, Indianapolis, IN, USA

pg265 PMH7 TREATMENT AND ECONOMIC OUTCOMES IN PEDIATRIC INPATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICSFlanders S1, Pandina G1, Rupnow M1, Jensik S 2, 1Janssen Pharmaceutica Products, L.P, Titusville, NJ, USA; 2Mental Health Outcomes, Inc., Lewisville, TX,USA

pg265 PMH8 SWITCHING & DISCONTINUATION OF SERTRALINE, PAROXETINE AND CITALOPRAM THERAPYWang J1, Mullins CD 1, Shaya F1, Meng F1, Harrison D 2, 1University of Maryland, Baltimore, MD, USA; 2Pfizer, Inc, New York, NY, USA

pg266 PMH9 ANALYSIS OF ANTIDEPRESSANT MEDICATION UTILIZATION AND ADHERENCE OF MANAGED CARE PATIENTS ENROLLED IN A MEDICATION ADHER-ENCE PROGRAMCockerham TR1, Ara SB 2, Waugh WJ1, 1WellPoint Pharmacy Management, West Hills, CA, USA; 2Health Net, Woodland Hills, CA, USA

pg 266 PMH10 PEDIATRIC ANTIDEPRESSANT PRESCRIPTION PATTERNSCossrow N, Von Allmen H, Henderson SC, Luce J, Yoder S, Morris LS, IMS Health, Plymouth Meeting, PA, USA

pg266 PMH11 ANTIDEPRESSANT USE AND RISK OF SUICIDE ATTEMPT IN ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDERValuck RJ1, Libby AM1, Sills MR 1, Allen RR2, Giese AA 1, 1University of Colorado Health Sciences Center, Denver, CO, USA; 2Peak Statistical Services, Inc

pg267 PMH12 THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIDEPRESSANT THERAPY IN MAJOR DEPRESSIVE DISORDEREarnshaw S1, Krishnan A2, Hogue S2, Williams J3, 1RTI-Health Solutions, RTP, NC, USA; 2GlaxoSmithKline, RTP, NC, USA; 3Duke University, Durham, NC, USA

pg267 PMH13 USING PATIENT REPORTED OUTCOMES (PROS) TO DETERMINE DEPRESSION AND ANXIETY POPULATIONS IN FOUR COUNTRIESEdmondson M, Mills D, Consumer Health Sciences, Princeton, NJ, USA

pg267 PMH14 CANADIAN NETWORK FOR BIPOLAR DISORDER (CAN-BD): FREQUENCY OF RELAPSE IN AN OBSERVATIONAL STUDY.Yatham LN1, Silverstone P2, Baruch P 3, Gorman C4, Leblanc J5, Ferrazzi S6, 1University of British Columbia, Vancouver, BC, Canada; 2University of Alberta,Edmonton, AB, Canada; 3Universite de Laval, Laval, QC, Canada; 4University of Calgary, Calgary, AB, Canada; 5Hopital du Sacre-Coeur, Montreal, QC,Canada; 6Janssen-Ortho Inc, Toronto, ON, Canada

pg267 PMH15 FACTORS ASSOCIATED WITH SECOND-GENERATION ANITPSYCHOTICS IN THE CALIFORNIA MEDICAID (MEDI-CAL) PATIENTS WITH BIPOLAR DISORDERSPark J, McCombs J, University of Southern California, Los Angeles, CA, USA

pg268 PMH16 OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER: DETERMINANTS OF CHANGE IN SEVERITY OF BIPOLAR ILLNESSRATINGSBrown E1, Ahmed S2, Schuh L2, Baker RW2, 1Eli Lilly and Company, Nederland, CO, USA; 2Eli Lilly and Company, Indianapolis, IN, USA

pg268 PMH17 ANTIDEPRESSANT MONOTHERAPY AND OUTCOMES FOR PATIENTS WITH BIPOLAR DISORDERFu AZ, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

pg268 PMH18 THE EFFECTS OF OPEN ACCESS ON DRUG THERAPY OUTCOMES FOR PATIENTS WITH BIPOLAR DISORDER IN THE CALIFORNIA MEDICAID (MEDI-CAL)PROGRAMNarayan S, McCombs J, University of Southern California, Los Angeles, CA, USA

pg269 PMH19 ESCITALOPRAM IN THE TREATMENT OF KLEPTOMANIAAboujaoude E, Gamel N, Koran L, Stanford University School of Medicine, Stanford, CA, USA

MENTAL HEALTH-Cost Studies

pg269 PMH20 RISK OF REHOSPITALIZATION: OLANZAPINE VERSUS QUETIAPINEWang PF1, Zhao Z2, Cooper LM2, Gaylord B1, Gutierrez B 1, 1Premier, Inc, Charlotte, NC, USA; 2Eli Lilly and Company, Indianapolis, IN, USA

pg269 PMH21 RELATIONSHIP BETWEEN QUETIAPINE DOSE AND LEVELS OF MENTAL HEALTH RESOURCE USE AMONG PATIENTS WITH SCHIZOPHRENIA OR BIPO-LAR DISORDERGianfrancesco F1, Wang RH2, Pesa J2, 1HECON Associates, Inc, Montgomery Village, MD, USA; 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

pg270 PMH22 CONVENTIONAL ANTIPSYCHOTICS CAN BE COST EFFECTIVE FOR BROADLY DEFINED TREATMENT RESISTANT OR INTOLERANT SCHIZOPHRENIADavies L, Lewis S, Hay Hurst K, University of Manchester, Manchester, UK

pg270 PMH23 COST-EFFECTIVENESS EVALUATION OF LONG-ACTING RISPERIDONE INJECTIONEdwards N1, Rupnow M2, Pashos CL1, Botteman MF1, Locklear J2, Diamond R3, 1Abt Associates Inc. - HERQuLES, Cambridge, MA, USA; 2JanssenPharmaceutica Products, LP, Titusville, NJ, USA; 3Department of Mental Health, Madison, WI, USA

I SPOR 9TH ANNUAL INTERNAT IONAL MEET ING POST ER PRESENTAT I O N S

35

pg270 PMH24 UTILIZATION ANALYSIS OF HEALTH CARE RESOURCES FOR PATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICSLiu G1, Sun S1, Christensen DB1, Zhao Z 2, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2Eli Lilly and Company, Indianapolis, IN, USA

pg271 PMH25 A RETROSPECTIVE COMPARISON OF THE COST-EFFECTIVENESS OF OLANZAPINE FOR THE TREATMENT OF SCHIZOPHRENIA IN SELECTED NON-OECDCOUNTRIESDavey P, Price N, Lees M, Birinyi-Strachan L, Makino K, Mudge M, M-TAG Pty Ltd, Chatswood, NSW, Australia

pg271 PMH26 OUT-OF-POCKET DRUG EXPENDITURES AND PATTERNS OF DEPRESSION IN THE ELDERLY: A 5-YEAR POPULATION-BASED STUDYDalal M, Pickard AS, Lin SJ, University of Illinois at Chicago, Chicago, IL, USA

pg271 PMH27 DIRECT HEALTH CARE COST OF DEPRESSIVE DISORDERS IN THE UNITED STATES: A PATIENT TIME PROFILEBirnbaum H1, Greenberg P1, Kessler R2, Moyneur É3, Lowe S1, Leong S1, Mallett D4, 1Analysis Group, Boston, MA, USA; 2Harvard University, Boston, MA,USA; 3Analysis Group, Montreal, QC, Canada; 4Ingenix, New Haven, CT, USA

pg272 PMH28 COST-EFFECTIVENESS OF INTERVENTIONS TO IMPROVE PATIENT MEDICATON COMPLIANCE IN MAJOR DEPRESSIVE DISORDERSetyawan J,Hay JW, Nichol MB, University of Southern California, Los Angeles, CA, USA

pg272 PMH29 COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS CITALOPRAM IN THE TREATMENT OF SEVERE DEPRESSION IN AUSTRIAHemels ME1, Kasper S2, Walter E3, Einarson T4, 1H. Lundbeck A/S, Paris, France; 2University of Vienna, Vienna, Austria; 3IPF - Institute forPharmacoeconomic Research, Vienna, Austria; 4University of Toronto, Toronto, Canada

pg272 PMH31 COST AND COMORBIDITIES ASSOCIATED WITH BIPOLAR DISORDERParece A1, Wu E1, Birnbaum H1, Greenberg P 1, Huang Z1, Victor T2, Kessler R3, 1Analysis Group/Economics, Boston, MA, USA; 2AstraZenecaPharmaceuticals LP, Wilmington, DE, USA; 3Harvard University, Boston, MA, USA

pg273 PMH32 COMPARISON OF BIPOLAR DISORDER-RELATED COSTS AMONG PATIENTS WITH AND WITHOUT COMORBID DIABETESHarley C1, Li H 2, L'Italien G2, Hirschfeld R3, Walker A4, Carson W 5, 1Ingenix, Eden Prairie, MN, USA; 2Bristol-Myers Squibb, Wallingford, CT, USA; 3Universityof Texas Medical Branch, Galveston, TX, USA; 4Ingenix, Auburndale, MA, USA; 5Otsuka America Pharmaceutical, Inc, Princeton, NJ, USA

pg273 PMH33 DRUG TREATMENT PATTERNS OF BIPOLAR DISORDER AND ASSOCIATED COSTSWu E1, Birnbaum H1, Greenberg P1, Kessler R 2, Huang Z1, Victor T3, Parece A1, 1Analysis Group / Economics, Boston, MA, USA; 2Harvard University, Boston,MA, USA; 3AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

pg273 PMH34 COST-EFFECTIVENESS OF OLANZAPINE VERSUS LITHIUM FOR THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER IN AUSTRALIAPrice N1, Davey P1, Mudge M1, Fitzgerald B2, Rajan N2, Montgomery B2, 1M-TAG Pty Ltd, Chatswood, NSW, Australia; 2Eli Lilly Australia Pty Ltd, West Ryde,NSW, Australia

pg274 PMH35 SERVICE UTILIZATION AND COSTS FOR BIPOLAR DEPRESSIONdeLay N1, Ciaglia M2, Viswanathan S3, 1Eli Lilly and Company, Indianapolis, IN, USA; 2ZS Associates, Evanston, IL, USA; 3ZS Associates, Boston, MA, USA

pg274 PMH36 THE COSTS OF POLY-PHARMACY, NON-DRUG TREATMENT, NUMBER OF DRUGS AND SWITCHING FOR BIPOLAR DISORDERdeLay N1, Stensland MD1, Viswanathan S2, Ciaglia M3, 1Eli Lilly and Company, Indianapolis, IN, USA; 2ZS Associates, Boston, MA, USA; 3ZS Associates,Evanston, IL, USA

pg274 PMH37 COST CONSEQUENCE ASSOCIATED WITH DIFFERENT INITIAL MOOD STABILIZERS FOR NEWLY TREATED PATIENTS WITH BIPOLAR DISORDERSGuo JJ1, Keck PE 2, Jang R1, Li H3, Carson W4, 1University of Cincinnati, Cincinnati, OH, USA; 2University of Cincinnati Medical Center, Cincinnati, OH, USA;3Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, USA; 4Otsuka America Pharmaceutical, Inc, Princeton, NJ, USA

pg275 PMH38 EPILEPSY PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: PREVALENCE AND COST OF CAREMarynchenko M1, Secnik K 2, Allen AJ2, Birnbaum H 1, Dunn D3, 1Analysis Group, Boston, MA, USA; 2Eli Lilly and Company, Indianapolis, IN, USA; 3IndianaUniversity Purdue University of Indianapolis, Indianapolis, IN, USA

pg275 PMH40 COST-EFFECTIVENESS OF RITALINTM VERSUS ADDERALLTM FOR FIRST-LINE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)IN CHILDRENNarayan S1, Hay J2, 1University of Southern California, Los Angeles, CA, USA; 2USC School of Pharmacy, Los Angeles, CA, USA

pg276 PMH41 SUICIDE ATTEMPTS BY THE ELDERLY: HOSPITAL RESOURCE USE AND COSTSO'Brien J, Pitoniak-Morse C, Caro JJ, Caro Research Institute, Concord, MA, USA

MENTAL HEALTH-Quality Of Life/Utility/Patient Reported Outcomes Studies

pg276 PMH42 CORRELATIONS BETWEEN PSYCHOPATHOLOGY AND HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN SCHIZOPHRENIA. RESULTS FROMTHE SQUARE STUDYKarokis A1, Yfantopoulos J2, Christodoulopoulou A1, Papagiannopoulou V2, Gourzis F3, Lavrentzou E4, Lymberaki G5, Yfantis A5, Kallinis C6, Gamvroula K7,Kafantari A7, Mavreas V8, 1AstraZeneca SA, Athens, Greece; 2University of Athens, Greece; 3University of Patras, Patras, Greece; 4University Hospital ofIoannina, Ioannina, Greece; 5Psychiatric Hospital of Tripoli, Tripoli, Greece; 6”G.Papanikolaou” General Hospital, Athens, Greece; 7University PsychiatricClinic, “Papageorgiou” General Hospital, Athens, Greece; 8University of Ioannina, Ioannina, Greece

pg276 PMH43 DIFFERENTIAL IMPACT OF OLANZAPINE AND RISPERIDONE ON SEXUAL DYSFUNCTION AND ITS POTENTIAL IMPLICATIONSAscher-Svanum H, Zhu B, Faries D, Jiang Q, Kinon BJ, Eli Lilly and Company, Indianapolis, IN, USA

pg277 PMH44 REMISSION OF PSYCHOTIC SYMPTOMS AND LONG-TERM FUNCTIONAL OUTCOMES IN THE TREATMENT OF SCHIZOPHRENIA IN USUAL CAREAscher-Svanum H1, Zhu B 1, Faries D1, Jiang Q 1, Rosenheck RA2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Yale University School of Medicine, WestHaven, CT, USA

pg277 PMH45 MAPPING UTILITY SCORES FROM THE EQ-5D AND SF-6D ONTO THE SCHIZOPHRENIA QUALITY OF LIFE SCALEClayson DJ1, Briggs A2, Sculpher M3, De Hert M4, 1Oxford Outcomes Ltd, Oxford, Oxon, UK; 2University of Oxford, Oxford, UK; 3University of York, York, NorthYorkshire, UK; 4University Centrum V.Z.W, Centrum, Belgium

pg277 PMH46 IMPROVEMENTS IN COGNITIVE DEFICITS ARE ASSOCIATED WITH IMPROVED FUNCTIONAL OUTCOMES: RESULTS FROM A LONGITUDINAL OBSERVA-TIONAL STUDY OF SCHIZOPHRENIA PATIENTSAscher-Svanum H, Zhu B, Faries D, Jiang Q, Shi L, Eli Lilly and Company, Indianapolis, IN, USA

ISPOR 9TH ANNUAL INTERNAT IONAL MEET ING POSTER PRESENTAT I O N S

36

pg278 PMH47 WEIGHT GAIN AND IMPROVEMENT IN PSYCHOPATHOLOGY DURING TREATMENT OF SCHIZOPHRENIA WITH ANTIPSYCHOTICS AND WITH PLACEBOAscher-Svanum H, Stensland MD, Kinon BJ, Tollefson GD, Eli Lilly and Company, Indianapolis, IN, USA

pg278 PMH48 ASSESSMENT OF THE IMPACT OF QUETIAPINE TREATMENT ON PSYCHOPATHOLOGY, HEALTH RELATED QUALITY OF LIFE AND DISABILITY INPATIENTS WITH SCHIZOPHRENIA IN GREECE. THE SQUARE STUDYChristodoulopoulou A1, Yfantopoulos J2, Karokis A1, Papagiannopoulou V2, Karavatos A3, Gourzis F4, Mouzas O5, Panagoutsos P6, Tzanakaki M7, Stathakis I8,Mavreas V9, 1AstraZeneca SA, Athens, Greece; 2University of Athens, Athens, Greece; 3University Psychiatric Clinic, “Papageorgiou” General Hospital,Athens, Greece; 4University of Patras, Patras, Greece; 5University Hospital of Larissa, Larissa, Greece; 6Psychiatric Hospital of Tripoli, Tripoli, Greece;7Psychiatric Hospital of Hania, Hania, Greece; 8”G.Papanikolaou” General Hospital, Athens, Greece; 9University of Ioannina, Ioannina, Greece

pg278 PMH49 USING CLIENT AND STAFF STRUCTURED INPUT IN FORMATTING THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP) SURVEYBarr J, Schumacher G, Ohman SM, Quimby C, Northeastern University, Boston, MA, USA

pg 279 PMH50 THE ROLE OF ANTIPARKINSONIAN AGENTS IN SELF-REPORTED COGNITIVE IMPAIRMENT AND AKATHISIA DURING THE LONG-TERM TREATMENT OFSCHIZOPHRENIAAscher-Svanum H, Zhu B, Faries D, Jiang Q, Eli Lilly and Company, Indianapolis, IN, USA

pg279 PMH52 IMPROVEMENT IN QUALITY-OF-LIFE WITH RISPERIDONE AUGMENTATION IN TREATMENT-RESISTANT DEPRESSIONWalling D1, Rupnow M2, Canuso C2, Gharabawi G 2, Turkoz I2, Rapaport M3, 1CNS Network, Garden Grove, CA, USA; 2Janssen Pharmaceutica Products, L.P,Titusville, NJ, USA; 3Cedars-Sinai Medical Center, Los Angeles, CA, USA

pg279 PMH53 HOSPITALIZATION RATES DURING COMBINATION THERAPY WITH ATYPICAL ANTIPSYCHOTICS IN BIPOLAR DISORDERLazarus A1, Lage MJ2, Pesa JA2, 1AstraZeneca, Wilmington, DE, USA; 2AstraZeneca LP, Wilmington, DE, USA

pg280 PMH54 WORK LOSS ASSOCIATED WITH BIPOLAR DISORDERSasane R1, de Lissovoy G2, Matza LS2, Mauskopf JA3, Pesa JA1, 1AstraZeneca LP, Wilmington, DE, USA; 2MEDTAP International, Bethesda, MD, USA;3Research Triangle Institute, Research Triangle Park, NC, USA

pg280 PMH55 CHILD HEALTH ILLNESS PROFILE AS A QUALITY OF LIFE MEASURE OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDERSecnik K1, Matza L2, Mannix S2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2MEDTAP International, Bethesda, MD, USA

MENTAL HEALTH-Health Policy Studies

pg280 PMH56 MENTAL HEALTH SERVICES AND DRUG UTILIZATION PATTERNS FOR STUDENTS WITH MENTAL ILLNESSES IN SCHOOL-BASED HEALTH CENTERSGuo JJ1, Jang R1, Cluxton RJ 1, Keller K2, 1University of Cincinnati, Cincinnati, OH, USA; 2Health Foundation of Greater Cincinnati, Cincinnati, OH, USA

pg281 PMH57 THE EFFECT OF BEHAVIORAL CARVE-OUTS ON PHARMACEUTICAL USE AND EXPENDITURESMark TL, Coffey R, Medstat, Washington, DC, USA

pg281 PMH58 THE RELATIONSHIP BETWEEN MENTAL DISTRESS, HEALTH RISKS AND HEALTH CARE COSTS FROM THE MANAGED CARE HEALTH RISK ASSESSMENTDATABASEManocchia M1, Brown J2, Finkelstein J3, 1Blue Cross and Blue Shield of Rhode Island, Providence, RI, USA; 2Boston Health Economics, Inc., Waltham, MA,USA; 3Brown University, Providence, RI, USA

pg281 PMH59 ANTIPSYCHOTIC ADHERENCE AMONG CENTRAL TEXAS VETERANSYang M1, Barner J1, Worchel J2, 1University of Texas at Austin, Austin, TX, USA; 2Veterans Administration, Austin, TX, USA

pg282 PMH60 ANALYSIS OF LONGITUDINAL CLAIMS DATA TO EXAMINE FIRST AND SECOND-LINE USE OF PEMOLINE (CYLERT®)Morrato E1, Staffa J2, 1Johns Hopkins University Bloomberg School of Public Health (FDA student project), Baltimore, MD, USA; 2Food and DrugAdministration, Rockville, MD, USA

pg282 PMH61 TRENDS IN ANTIPSYCHOTIC PRESCRIBING TO CHILDREN AND ADOLESCENTS: 1996 TO 2001Patel NC1, Crismon ML1, Hoagwood K2, Johnsrud M1, Rascati K1, Wilson JP1, 1The University of Texas at Austin, Austin, TX, USA; 2Columbia University, NewYork, NY, USA

pg282 PMH62 HOSPITAL UTILIZATION FOLLOWING AN OPEN ACCESS POLICY FOR ATYPICAL ANTIPSYCHOTIC MEDICATIONS FOR PATIENTS WITH SCHIZOPHRENIAO'Reilly DJ, Parfrey PS, Memorial University of Newfoundland, St. John's, NF, Canada

pg283 PMH63 TREND AND GEOGRAPHIC VARIATIONS IN THE LENGTH OF STAY FOR SCHIZOPHRENIA IN THE UNITED STATESSun SX1, Liu G1, Luo X2, Fu AZ1, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2Duke University Medical Center, Durham, NC, USA

pg283 PMH64 MISDIAGNOSIS OF BIPOLAR DISORDER AS UNIPOLAR DEPRESSION: Stensland MD1, deLay N1, Ciaglia M2, Viswanathan S3, 1Eli Lilly and Company, Indianapolis, IN, USA; 2ZS Associates, Evanston, IL, USA; 3ZS Associates,Boston, MA, USA

pg283 PMH65 SECOND SSRIS SWITCHING AND DISCONTINUATION AFTER FLUOXETINE INITIAL THERAPYShaya F1, Mullins CD1, Meng F 1, Wang J1, Harrison D 2, 1University of Maryland, Baltimore, MD, USA; 2Pfizer, Inc, New York, NY, USA

pg283 PMH66 COMPARISON OF FIRST REFILL RATES AMONG BRANDED SSRI USERSMullins CD1, Shaya F1, Meng F1, Wang J1, Bron M2, 1University of Maryland, Baltimore, MD, USA; 2Pfizer, Inc, New York, NY, USA

pg284 PMH67 DEPRESSION DIAGNOSIS IN PRIMARY CARE VISITS NOT FOR MENTAL HEALTH REASONS Singer ME, Propper VH, Case Western Reserve University, Cleveland, OH, USA

pg284 PMH68 TRENDS IN PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR: 1992-2002Cooper L, Zhao Z, Zhu B, Eli Lilly and Company, Indianapolis, IN, USA

pg284 PMH69 PATTERNS OF PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR DISORDERZhu B, Zhao Z, Cooper L, Eli Lilly and Company, Indianapolis, IN, USA

pg284 PMH70 PHARMACOLOGIC TREATMENT PATTERNS FOR BIPOLAR DISORDERdeLay N1, Stensland MD1, Viswanathan S2, Ciaglia M3, 1Eli Lilly and Company, Indianapolis, IN, USA; 2ZS Associates, Boston, MA, USA; 3ZS Associates,Evanston, IL, USA

I SPOR 9TH ANNUAL INTERNAT IONAL MEET ING POSTER PRES ENTAT I O N S

37

pg285 PMH71 WHEN BIPOLAR DISORDER IS BEING IDENTIFIED: PHASE OF DISORDER, PROVIDER SPECIALTY, FACILITY TYPE, AND RESOURCE UTILIZATION SUR-ROUNDING THE INITIAL BIPOLAR DIAGNOSIS IN CLINICAL PRACTICE.Stensland MD1, deLay N1, Viswanathan S2, Ciaglia M3, 1Eli Lilly and Company, Indianapolis, IN, USA; 2ZS Associates, Boston, MA, USA; 3ZS Associates,Evanston, IL, USA

pg285 PMH72 MEDICATION PRESCRIBING PATTERNS FOR PATIENTS WITH BIPOLAR DEPRESSIONdeLay N1, Viswanathan S2, Ciaglia M3, Stensland MD1, Zhao Z1, Vedarajan G3, 1Eli Lilly and Company, Indianapolis, IN, USA; 2ZS Associates, Boston, MA,USA; 3ZS Associates, Evanston, IL, USA

MENTAL HEALTH-Methods

pg285 PMH73 DEPRESSION IN THE GENERAL POPULATION AND AFTER STROKE: A PSYCHOMETRIC COMPARISON USING THE CES-D SCALEPickard AS1, Dalal M1, Bushnell DM2, 1University of Illinois at Chicago, Chicago, IL, USA; 2Health Research Associates, Inc, Mountlake Terrace, WA, USA

pg286 PMH74 COMPARING PSYCHOMETRIC PROPERTIES OF SELF- VERSUS INTERVIEWER-RATED INSTRUMENTS USED IN CLINICAL TRIALS FOR PATIENTS WITHANXIETY DISORDERSLau DT1, Cappelleri JC2, Morlock R2, Feltner D2, 1Pfizer - University of Michigan, Ann Arbor, MI, USA; 2Pfizer, Inc., Groton, CT, USA

pg286 PMH75 DEVELOPMENT OF A PATIENT-REPORTED INSTRUMENT TO ASSESS THE FUNCTIONAL STATUS OF PATIENTS WITH BIPOLAR DISORDERFehnel SE1, Victor T2, Manjunath R1, Sechrest L3, Haynes S4, Strawkoski S5, Goldberg J6, Cramer J7, Mullen J 2, Suppes T8, 1RTI Health Solutions, ResearchTriangle Park, NC, USA; 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA; 3University of Arizonia, Tucson, AZ, USA; 4University of Hawaii at Manoa,Oahu, HI, USA; 5University of Cincinnati College of Medicine, Cincinnati, OH, USA; 6Cornell University, New York, NY, USA; 7Yale University School ofMedicine, West Haven, CT, USA; 8University of Texas Medical Center, Dallas, TX, USA

pg286 PMH76 A COMPREHENSIVE RETROSPECTIVE STUDY OF ASSOCIATIONS BETWEEN DIABETES AND TREATMENT WITH RISPERIDONE, OLANZAPINE, QUETIAP-INE, AND CONVENTIONAL ANTIPSYCHOTICSGianfrancesco F, Wang RH, HECON Associates, Inc, Montgomery Village, MD, USA

pg287 PMH77 ORDERING EFFECTS IN CROSSOVER STUDIES OF PHOTOTHERAPY: IMPLICATIONS FOR PSYCHOLOGICAL INTERVENTIONSChapell R, Tregear S, Turkelson C, ECRI, Plymouth Meeting, PA, USA

pg287 PMH79 STATISTICALLY DETERMINING TREATMENT OF CHOICE FOR INDIVIDUAL PATIENTS WITH SCHIZOPHRENIAVan Brunt DL1, Gibson PJ 2, Liu-Seifert H1, Obenchain RL 1, Ahmed S1, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Health & Hospital Corporation of MarionCounty, Indianapolis, IN, USA

NEUROLOGICAL/GENETIC DISORDERS (Migraine, Alzheimer’s, Parkinson’s, MS, Epilepsy, Brain Injury, Hunter Syndrome, Insomnia)

NEUROLOGICAL/GENETIC DISORDERS-Clinical Outcomes Studies

pg288 PNL1 HOW COGNITIVE FUNCTION AFFECTS ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ALZHEIMER’S DISEASE Treglia M1, Bushmakin A2, Siddiqi S2, Cappelleri J 1, 1Pfizer Inc, Groton, CT, USA; 2Pfizer Global Research and Development, Groton, CT, USA

pg288 PNL2 OXCARBAZEPINE REDUCES HOSPITALISATIONS FOR EPILEPTIC SEIZURES AND RELATED SYMPTOMS IN THE NETHERLANDS: A PHARMO STUDYErkens JA1, Panneman MJ1, Snyder EH 2, Herings RMC1, 1PHARMO Institute, Utrecht, The Netherlands; 2Novartis Pharmaceuticals, East Hanover, NJ, USA

NEUROLOGICAL/GENETIC DISORDERS-Cost Studies

pg288 PNL3 PREDICTORS OF LOST PRODUCTIVITY AMONG EMPLOYEES WITH MIGRAINE HEADACHES IN A MEDICAL GROUP SETTING: IMPLICATIONS FOR WORK-SITE DISEASE MANAGEMENT PROGRAMS Borok G1, Ershoff D2, Maurer R3, Webb D3, Pesa J4, 1AstraZeneca, Encino, CA, USA; 2AstraZeneca, Tarzana, CA, USA; 3St. Joseph Heritage Health Care, LaMirada, CA, USA; 4AstraZeneca, Wilmington, DE, USA

pg289 PNL4 IMPACT OF MIGRAINE AND NON-MIGRAINE HEADACHES ON EMPLOYEE PRODUCTIVITY IN A MEDICAL GROUP SETTING Maurer R1, Borok G2, Ershoff D3, Webb D1, Ross T4, 1St. Joseph Heritage Health care, La Mirada, CA, USA; 2AstraZeneca, Encino, CA, USA; 3AstraZeneca,Tarzana, CA, USA; 4AstraZeneca, Newport Beach, CA, USA

pg289 PNL5 COST- EFFECTIVENESS ANALYSIS OF RIZATRIPTAN AND SUMATRIPTAN VERSUS CAFERGOT IN THE ACUTE TREATMENT OF MIGRAINE Zhang L1, Hay J 2, 1University of Southern California, Los Angeles, CA, USA; 2USC School of Pharmacy, Los Angeles, CA, USA

pg289 PNL6 COMPARISON OF CLINICAL EFFICACY AND COST-EFFECTIVENESS BETWEEN ELETRIPTAN 40 MG AND SUMATRIPTAN 100 MG IN THE ACUTE TREAT-MENT OF MIGRAINEHealey PJ, Dugar A, Weis K, Pfizer Global Pharmaceuticals, Pfizer, Inc, New York, NY, USA

pg289 PNL7 A RETROSPECTIVE CLAIMS ANALYSIS OF THE DIRECT COSTS OF MIGRAINE AND ITS COMORBID CONDITIONS IN TAIWAN Lin CW, Lee CT, Bureau of National Health Insurance, Kao-Ping Branch, Kaohsiung City, Taiwan

pg290 PNL8 TRIPTANS IN THE ACUTE TREATMENT OF MIGRAINE: COST-EFFECTIVENESS ANALYSIS BASED ON NUMBER NEEDED TO TREAT AND DOSES NEEDEDTO TREATDugar A, Healey PJ, Weis K, Pfizer Global Pharmaceuticals, Pfizer, Inc, New York, NY, USA

pg290 PNL9 COST EFFECTIVENESS ANALYSIS OF INTERFERON BETA-1A (AVONEX®) IN PRE-CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS)Iskedjian M1, Walker J1, Gray T2, Vicente C1, Einarson T3, Gehshan A4, 1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada; 2St. Michael’sHospital, University of Toronto, Toronto, ON, Canada; 3University of Toronto, Toronto, ON, Canada; 4Biogen Idec Canada Inc, Mississauga, ON, Canada

pg290 PNL10 COST-EFFECTIVENESS OF SCREENING FOR NEUTRALIZING ANTIBODIES TO INTERFERON BETAS IN THE TREATMENT OF MULTIPLE SCLEROSISMunschauer F1, Rich S2, Huse D3, 1Jacobs Neurological Institute, Buffalo, NY, USA; 2University of Michigan, Ann Arbor, MI, USA; 3The MEDSTAT Group,Cambridge, MA, USA

I SPO R 9TH ANNUAL INTERNAT IONAL MEET ING POSTER PRESENTAT I O N S

38

pg291 PNL11 HEALTH CARE COSTS FOR FLORIDA MEDICAID RECIPIENTS WITH MULTIPLE SCLEROSIS Boulanger L, Friedman M, Dixon D, Menzin J, Boston Health Economics, Inc, Waltham, MA, USA

pg291 PNL12 COST UTILITY ANALYSIS OF INTERFERON BETA-1A (AVONEX®) IN PRE-CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS)Iskedjian M1, Walker J1, Gray T2, Vicente C1, Einarson T3, Gehshan A4, 1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada; 2St. Michael’sHospital, University of Toronto, Toronto, ON, Canada; 3University of Toronto, Toronto, ON, Canada; 4Biogen Idec Canada Inc, Mississauga, ON, Canada

pg291 PNL13 A COMPARATIVE COST ANALYSIS OF VASCULAR DEMENTIA VERSUS ALZHEIMER'S DISEASE IN TAIWANLin CW, Lee CT, Bureau of National Health Insurance, Kao-Ping Branch, Kaohsiung City, Taiwan

pg292 PNL14 HEALTH CARE UTILIZATION AND EXPENDITURES AMONG MEDICAID PATIENTS WITH PARKINSON'S DISEASEOrsini LS1, Kennedy S2, Castelli-Haley J 3, Huse DM1, 1The MEDSTAT Group, Inc, Cambridge, MA, USA; 2The Medstat Group, Santa Barbara, CA, USA; 3TevaNeuroscience, Kansas City, MO, USA

pg292 PNL15 AN ECONOMIC ANALYSIS OF CALCIUM CHANNEL BLOCKERS FOR ACUTE TRAUMATIC BRAIN INJURYSchiller KC, University of Florida, Gainesville, FL, USA

NEUROLOGICAL/GENETIC DISORDERS-Quality of Life Studies

pg292 PNL16 FACTORS THAT DETERMINE EMPLOYABILITY IN EPILEPSY PATIENTS: A PILOT STUDYBautista RED, Wludyka P, University of Florida HSC, Jacksonville, FL, USA

pg293 PNL17 VALIDATION OF THE CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE (CHAQ) IN HUNTER SYNDROME Tran KT1, Gold KF1, Stephens JM 1, Kimura A2, Muenzer J3, Singh G4, 1Abt Associates Inc, Bethesda, MD, USA; 2Transkaryotic Therapies Inc, Cambridge,MA, USA; 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 4Stanford University, Palo Alto, CA, USA

pg293 PNL18 DEVELOPMENT AND PILOT TESTING OF THE HUNTER SYNDROME-FUNCTIONAL OUTCOMES FOR CLINICAL UNDERSTANDING SCALE (HS-FOCUS): ANINSTRUMENT TO ASSESS FUNCTIONAL HEALTH IN HUNTER SYNDROMETran KT1, Stephens JM1, Gold KF 1, Kimura A2, Pashos C3, Muenzer J 4, 1Abt Associates Inc, Bethesda, MD, USA; 2Transkaryotic Therapies Inc, Cambridge,MA, USA; 3Abt Associates Inc, Cambridge, MA, USA; 4University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

pg293 PNL19 VALIDATION OF THE HUNTER SYNDROME-FUNCTIONAL OUTCOMES FOR CLINICAL UNDERSTANDING SCALE (HS-FOCUS)Tran KT1, Gold KF1, Stephens JM 1, Kimura A2, Pashos CL3, Muenzer J4, 1Abt Associates Inc, Bethesda, MD, USA; 2Transkaryotic Therapies Inc, Cambridge,MA, USA; 3Abt Associates Inc, Cambridge, MA, USA; 4University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

NEUROLOGICAL/GENETIC DISORDERS-Health Policy Studies

pg294 PNL20 UTILIZATION OF IMMUNOMODULATORY DRUG THERAPIES IN MULTIPLE SCLEROSIS (MS) IN NOVA SCOTIA, CANADA 1998-2003Sketris IS1, Hicks V 1, Lummis H2, Brown M 1, 1Dalhousie University, Halifax, NS, Canada; 2Capital District Health Authority, Halifax, NS, Canada

pg294 PNL21 INSOMNIA IN A NATIONAL AMBULATORY CARE SETTING 2001Stafkey DR1, Morlock R2, 1University of Michigan/ Pfizer, Ann Arbor, MI, USA; 2Pfizer, Inc, Ann Arbor, MI, USA

NEUROLOGICAL/GENETIC DISORDERS-Methods

pg294 PNL22 THE SENSITIVITY OF COST-EFFECTIVENESS ESTIMATES IN MULTIPLE SCLEROSIS TO INTERNATIONAL DIFFERENCES IN NATURAL HISTORY: SWEDENVERSUS NOVA SCOTIA, CANADASkedgel CD, Brown MG, MacKinnon-Cameron D, Dalhousie University, Halifax, NS, Canada

pg295 PNL23 PROBABILISTIC SENSITIVITY ANALYSIS OF A COST-EFFECTIVENESS MODEL FOR TRIPTANS (5-HT AGONISTS)Livengood KB, Ambegaonkar AJ, Pfizer Inc, New York, NY, USA

pg295 PNL24 DEVELOPING A COMPUTER ALGORITHM TO IDENTIFY EPILEPSY CASES IN MANAGED CARE ORGANIZATIONS AND ESTIMATE PREVALENCE, INCIDENCE,AND MORTALITY Nelson LS1, Gunter MJ1, Robinson S 1, Holden EW2, 1Lovelace Clinic Foundation, Albuquerque, NM, USA; 2ORC Macro, Atlanta, GA

OSTEOPOROSIS

OSTEOPOROSIS-Clinical Outcomes Studies

pg295 POS1 THE INFLUENCE OF BONE MINERAL DENSITY TESTING ON THE INITIATION OF AN OSTEOPOROSIS-RELATED PHARMACOTHERAPY: A POPULATION-BASED ANALYSISCaetano PA, Metge CJ, Leslie WD, University of Manitoba, Winnipeg, MB, Canada

pg296 POS2 DIFFERENCES BETWEEN DOCTOR AND PATIENT RECALL OF EVENTS IN AND INVESTIGATIONS FOR OSTEOPOROSIS IN FIVE COUNTRIESPiercy J1, Tompkins R2, Kay S 2, Karavali M2, 1Adelphi Group, Macclesfield, Cheshire, UK; 2Adelphi Group Products, Macclesfield, Cheshire, UK

OSTEOPOROSIS-Cost Studies

pg296 POS3 HEALTH CARE UTILIZATION AND EXPENDITURES: A STUDY OF SEVERE OSTEOPOROSISOrsini LS1, Long S2, Pantos B3, Wang S1, Rousculp M3, 1The Medstat Group, Inc, Cambridge, MA, USA; 2Medstat, Washington, DC, USA; 3Eli Lilly,Indianapolis, IN, USA

pg296 POS4 COST-EFFECTIVENESS OF LONG-TERM HORMONE REPLACEMENT THERAPY (ESTROGEN PLUS PROGESTIN) IN HEALTHY POSTMENOPAUSAL WOMENFOR OSTEOPOROSIS PREVENTIONYu YF, Hay JW, Yu AP, University of Southern California, Los Angeles, CA, USA

pg297 POS5 ECONOMIC EVALUATION OF SHORT-TERM NON-VERTEBRAL FRACTURE-RELATED COSTS AMONG OSTEOPOROSIS TREATMENTSOhsfeldt RL1, Borisov NN2, Sheer RL2, Lindsay R3, 1College of Public Health, University of Iowa, Iowa City, IA, USA; 2Procter and Gamble Pharmaceuticals,Mason, OH, USA; 3Regional Bone Center, Helen Hayes Hospital, Stony Point, NY, USA

I SPO R 9TH ANNUAL INTERNAT IO NAL MEET ING POSTER PRESENTAT I O N S

39

pg297 POS6 TERIPARATIDE VERSUS BISPHOSPHONATES IN HIGH RISK OSTEOPOROSIS PATIENTS: A DECISION MODEL ANALYSISHendley YG1, DeLattre ML2, Schaefer MG3, Boggie DT2, Tuey C2, 1University of the Pacific, La Jolla, CA, USA; 2VA San Diego Health Care System, SanDiego, CA, USA; 3Kansas City VA Medical Center, Kansas City, MO, USA

pg297 POS7 COST-EFFECTIVENESS OF TERIPARATIDE (FORTEO) IN THE PREVENTION OF OSTEOPOROTIC FRACTURES AMONG MEN AND POSTMENOPAUSALWOMEN IN AUSTRALIAGraham-Clarke PL1, Lees M2, Wolthers T1, Thiebaud D1, Price N 2, 1Eli Lilly, Australia, West Ryde, NSW, Australia; 2M-TAG Pty Ltd, Chatswood, NSW,Australia

PAIN

PAIN-Clinical Outcomes Studies

pg298 PPN1 ANTICIPATED PAIN PRIOR TO SURGERY COMPARED TO ACTUAL PAIN IN PATIENTS UNDERGOING OUTPATIENT ARTHROSCOPIC KNEE PROCEDURESLee WC1, Barlas S2, Gold K 1, Ma L2, Duong P2, Madoo L1, Reddy P 3, Pashos C3, 1Abt Associates Inc. - HERQuLES, Bethesda, MD, USA; 2Merck & Co. Inc,West Point, PA, USA; 3Abt Associates Inc. - HERQuLES, Cambridge, MA, USA

PAIN-Cost Studies

pg298 PPN2 THE DIRECT AND INDIRECT ECONOMIC IMPACT OF PAIN AND ITS COMPARISON WITH THREE OF THE TOP FIVE MOST COSTLY DISEASESTrivedi DN, Grossman PR, Purdue Pharma L.P, Stamford, CT, USA

pg298 PPN3 AN EVALUATION OF THE DIRECT COSTS OF ADVERSE GI EVENTS ASSOCIATED WITH THE USE OF NSAIDS IN THE UNITED STATESArant TW1, Sullivan PW2, 1University of Adelaide School of Medicine (Australia) and The George Washington University, Carlsbad, CA, USA; 2University ofColorado School of Pharmacy, Denver, CO, USA

pg298 PPN4 EXAMINATION OF TOTAL HEALTH CARE EXPENDITURES FOR PATIENTS ON LONG ACTING OPIOID MEDICATIONS FOR THE TREATMENT OF CHRONICPAIN IN A MEDICAID POPULATIONHawkins K1, Grossman P2, Orsini LS3, Ozminkowski RJ1, Baser O 1, 1The MEDSTAT Group, Inc, Ann Arbor, MI, USA; 2Purdue Pharma L.P; 3The MedstatGroup, Inc, Cambridge, MA, USA

pg299 PPN5 AN OPIATE RENEWAL CLINIC: A COST EFFECTIVE APPROACH TO REDUCING UNSCHEDULED PATIENT VISITSSampson JM, Goldenson AC, Swanson SA, VA Medical Center, Gainesville, FL, USA

PAIN-Quality Of Life Studies

pg299 PPN6 RELATIONSHIP BETWEEN PAIN AND PERCEIVED HEALTH STATUS IN OLDER PERSONS WITH POST-HERPETIC NEURALGIAOster G1, Dukes E2, Edelsberg J1, Cleary P 3, 1Policy Analysis Inc., Brookline, MA, USA; 2Pfizer Inc, New York, NY, USA; 3Harvard Medical School, Boston,MA, USA

PAIN-Health Policy Studies

pg299 PPN7 TRENDS IN MEDICAL USE AND ABUSE OF SUSTAINED-RELEASE OPIOID ANALGESICS: A REVISITNovak S1, Nemeth WC 2, Lawson KA1, 1University of Texas at Austin, Austin, TX, USA; 2Texas Worker's Compensation Commission, Austin, TX, USA

pg300 PPN8 PATTERNS AND TRENDS IN OPIOID USE AMONG INDIVIDUALS WITH BACK PAIN IN THE UNITED STATESLuo X, Pietrobon R, Hey L, Duke University Medical Center, Durham, NC, USA

pg300 PPN9 PRESCRIPTION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND MUSCLE RELAXANTS FOR BACK PAIN IN THE UNITED STATESLuo X, Pietrobon R, Curtis L, Hey L, Duke University Medical Center, Durham, NC, USA

METHODS

METHODS-Cost Related Studies

pg300 PMD1 COMPARISON OF GENERALIZED LINEAR MODELS AND ORDINARY LEAST-SQUARES REGRESSION FOR COST ESTIMATIONOllendorf DA, Pedan A, PharMetrics Inc, Watertown, MA, USA

pg301 PMD2 MONTE-CARLO VALIDATION OF DELTA-K METHOD FOR SAMPLE-SIZE CALCULATION IN A COST-EFFECTIVENESS TRIALNakajo K, Cai L, Kamae I, Nakahara N, Aino H, Inoue H, Washio K, Yanagisawa S, Kobe University, Kobe, Japan

pg301 PMD3 INCREMENTAL COST EFFECTIVENESS RATIOS AND CONFIDENCE INTERVALS -- RELATIONSHIP OF CALCULATIONS WITH NNT VERSUS BOOTSTRAPMETHODSMcGhan W1, Peterson A1, Kulkarni S2, Kamble S1, Shetty N1, 1University of the Sciences, Philadelphia, PA, USA; 2Fox Chase Cancer Center, Cheltenham,PA, USA

pg301 PMD4 ISHIKAWA CAUSE AND EFFECT DIAGRAMS: A USEFUL TOOL IN DESIGNING ECONOMIC ANALYSESSalvador CG1, Goldfarb N2, 1Jefferson Medical College, Philadelphia, PA, USA; 2Thomas Jefferson University, Philadelphia, PA, USA

pg302 PMD5 TRACING THE DIFFUSION OF COST-UTILITY ANALYSIS AS AN INNOVATIONSonnad SS1, Greenberg D2, Rosen AB2, Olchanski NV2, Chapman R2, Neumann PJ2, 1University of Pennsylvania, Philadelphia, PA, USA; 2Harvard School ofPublic Health, Boston, MA, USA

pg302 PMD6 RESOURCE COSTING IN CLINICAL TRIALSPolsky D1, Henk HJ2, Glick HA1, 1University of Pennsylvania, Philadelphia, PA, USA; 2University of Wisconsin, Madison, WI, USA

pg302 PMD7 REGRESSION-BASED STATISTICAL MODEL AND PROPENSITY SCORE METHODS FOR THE EVALUATION OF COST-EFFECTIVENESS STUDIESBoye M1, Kim S 2, 1Pfizer, Inc, Ann Arbor, MI, USA; 2Ohio University, Athens, OH, USA

I SPOR 9TH ANNUAL INTERNAT IONAL MEET ING POST ER PRESENTAT I O N S

40

pg302 PMD8 HAZARD ISOBARS: A NEW, POLICY-ORIENTED TOOL FOR INTEGRATING INFORMATION FROM COX PROPORTIONAL HAZARD MODELS INTO COST-EFFECTIVENESS SIMULATIONSGold KF, Abt Associates Inc, Bethesda, MD, USA

pg303 PMD9 AGGREGATING COST DATA FROM MULTICENTER CLINICAL TRIALS: AN INCREMENTAL COST-EFFECTIVENESS ELASTICITY APPROACHTano BD1, Stanford RH 2, Pathak DS1, 1Ohio State University Medical Center, Columbus, OH, USA; 2GlaxoSmithKline, Research Triangle Park, NC, USA

pg303 PMD10 TESTING AND CORRECTING NON-RANDOM SELECTION BIAS: AN APPLICATION TO CENSORED MEDICAL COSTBaser O1, Bradley C2, Gardiner J2, Given C2, 1The MEDSTAT Group, Ann Arbor, MI, USA; 2Michigan State University, East Lansing, MI, USA

pg303 PMD11 CHOOSING AMONG DIFFERENT TYPES OF BOOTSTRAPPING METHODSBaser O1, Crown W2, 1The MEDSTAT Group, Ann Arbor, MI, USA; 2The Medstat Group, Inc, Cambridge, MA, USA

METHODS-Compliance Studies

pg304 PMD12 MEDICATION COMPLIANCE AND CONCOMITANT THERAPYLevin RJ1, Sikka R2, Aubert RE 1, 1Medco Health Solutions, Franklin Lakes, NJ, USA; 2Boston City Hospital, Jamaica Plain, MA, USA

pg304 PMD13 ADHERENCE INDEX: A NEW AND IMPROVED APPROACH TO MEASURE MEDICATION COMPLIANCEChaikledkaew U, Marks AS, Caremark Inc, Northbrook, IL, USA

pg304 PMD14 STUDYING COMPLIANCE WITH MEDICATION IN CHRONIC ILLNESSES USING ADMINISTRATIVE DATA: INTRACTABLE CALENDAR TRENDS?Caro JJ1, Ishak KJ2, Huybrechts KF1, Naujoks C3, 1Caro Research Institute, Concord, MA, USA; 2Caro Research Institute, Dorval, QC, Canada; 3NovartisPharma AG, Basel, Switzerland

METHODS-Quality Of Life/Patient-Reported Outcomes/Utility Studies

pg305 PMD15 RELIABILITY AND VALIDITY OF THE EQ-5D SELF-REPORT QUESTIONNAIRE IN TAIWAN POPULATIONChang TJ, Tarn YH, National Defense Medical Center, Taipei, Taiwan

pg305 PMD16 INVESTIGATING THE CEILING EFFECT IN THE EUROQOL IN THE U.S GENERAL POPULATIONBharmal M, Thomas III J, Purdue University, West Lafayette, IN, USA

pg305 PMD17 USING AN ARTIFICIAL NEURAL NETWORK TO PREDICT UTILITY SCORES FROM SF-36 DATAMcEwan P1, Kind P2, Dixon S3, Currie CJ4, 1Cardiff University, Cardiff, Wales, UK; 2Outcomes Research Group, York, UK; 3Sheffield University, Sheffield,South Yorkshire, UK; 4University of Wales College of Medicine, Cardiff, Wales, UK

pg305 PMD18 REAL-LIFE PATIENT REPORTED OUTCOMES: DATA MINING OF CONSUMER SPONTANEOUS REPORTS FOR TWO STATINSReynolds M, Ross S, Fahrbach K, Frame D, James K, Metaworks, Inc, Medford, MA, USA

pg306 PMD19 TRAINING REGULATORY AGENCIES IN PRO EVALUATION: THE WORKMATS EXPERIENCEAcquadro C1, Lobo-Luppi L1, Chassany O 2, 1Mapi Research Institute, Lyon, France; 2Hôpital Saint-Louis, Paris, France

pg306 PMD20 PRO INSTRUMENT DEVELOPMENT FOR RARE DISORDERS: A FOCUS-ED APPROACHGold KF1, Tran KT1, Stephens JM 1, Kimura A2, 1Abt Associates Inc, Bethesda, MD, USA; 2Transkaryotic Therapies Inc, Cambridge, MA, USA

METHODS-Patient Preference Studies

pg306 PMD21 A DESCRIPTIVE ANALYSIS TO INVESTIGATE THE DIFFERENCES BETWEEN TRADERS AND NON-TRADERS IN TIME TRADE OFFMiller LAN, Mody R, West Virginia University, Morgantown, WV, USA

pg307 PMD22 PATIENT PREFERENCES FOR COMPUTER ASSISTED DATA COLLECTION AT THE CLINICAL INTERFACE Shaya FT1, Finkelstein J 2, Arora M2, Samant N 1, Scharf S3, 1University of Maryland, Center on Drugs and Public Policy, Baltimore, MD, USA; 2University ofMaryland, Chronic Disease Informatics Group, Baltimore, MD, USA; 3University of Maryland, Division of Pulmonary and Critical Care, Baltimore, MD, USA

pg307 PMD23 WHAT IS THE VALUE OF SOCIAL VALUES? THE USELESSNESS OF ASSESSING HEALTH-RELATED QUALITY OF LIFE THROUGH PREFERENCE MEASURES Prieto L, Sacristán JA, Lilly, SA, Alcobendas, Madrid, Spain

pg307 PMD24 EXPECTED VALUE OF SYMMETRY OF INFORMATION: A FRAMEWORK FOR ASSESSING THE POTENTIAL VALUE OF INDIVIDUALIZING CARE BASED ONPATIENT PREFERENCESBasu A, Meltzer D, University of Chicago, Chicago, IL, USA

pg308 PMD25 ELICITING WILLINGNESS TO PAY WITHIN THE HEALTH SECTOR WITHOUT BIASBlumenschein K1, Blomquist G2, Johannesson M3, Horn N4, Freeman P 5, 1University of Kentucky College of Pharmacy and Martin School of Public Policyand Administration, Lexington, KY, USA; 2University of Kentucky, Lexington, KY, USA; 3Stockholm School of Economics, Stockholm, Sweden; 4AmericanPharmacy Services Corporation, Frankfort, KY, USA; 5American Pharmacy Services Corporation, Frankfort, KY, USA

METHODS-Database/Productivity/Risk Management Studies

pg308 PMD26 UTILIZATION OF COMPLEMENTARY DATA SOURCES TO DEVELOP INDICATION ALLOCATIONSMorris L, Von Allmen H, Margolis J, IMS Health, Plymouth Meeting, PA, USA

pg308 PMD27 THE APPLICATION OF TWO PRODUCTIVITY INSTRUMENTS AT A LARGE EMPLOYEROzminkowski RJ1, Goetzel RG2, Chang S2, Long S2, Lerner D3, 1The MEDSTAT Group, Inc, Ann Arbor, MI, USA; 2Medstat, Washington, DC, USA; 3The HealthInstitute, Tufts New England Medical Center, Boston, MA, USA

pg309 PMD28 USING A WEB-PANEL TO AID DEFINITION OF A TARGET PATIENT POPULATION TO ASSIST RISK MANAGEMENTEaton SC1, Cook SF 2, Andrews EB1, Hollis KA1, Ameen VZ2, Fehnel S1, 1RTI Health Solutions, Research Triangle Park, NC, USA; 2GlaxoSmithKline, Inc,Research Triangle Park, NC, USA

I SPOR 9TH ANNUAL INTERNAT IO NAL MEET ING POSTER PRESENTAT I O N S

41

ASTHMA/ALLERGY (including ARDS)

ASTHMA/ALLERGY-Clinical Outcomes Studies

pg309 PAA1 MEASURING THE IMPACT OF AN ASTHMA DISEASE MANAGEMENT INTERVENTION ON PHARMACY AND IN-PATIENT SERVICE UTILIZATION IN AMANAGED CARE SETTINGPatel VD1, Weingarten J2, Wedemeyer D2, Ershoff D 3, Horwitz K1, 1University of Southern California, Los Angeles, CA, USA; 2Care 1st Health Plan, Alhambra,CA, USA; 3AstraZeneca, Encino, CA, USA

pg309 PAA2 THE PREVALENCE OF INAPPROPRIATE USE OF SHORT-ACTING ASTHMA MEDICATION Hong SH, University of Arkansas for Medical Sciences, Little Rock, AR, USA

pg310 PAA3 WEB-ENABLED ASTHMA APPLICATION FOR PERSONALIZED MEDICAL COMMUNICATION WITHIN A MULTI-GROUP PRACTICE SETTINGArnold RJ1, Kaniecki DJ1, Rosen J2, 1Pharmacon International, Inc, New York, NY, USA; 2ProHealth Physicians, Bristol, CT, USA

pg310 PAA4 INHALED SALMETEROL UTILIZATION AND ASTHMA PATIENT OUTCOMES IN A GROUP-MODEL MANAGED CARE ORGANIZATIONPlauschinat CA1, Browne B 1, Godley P1, Weldon DR2, 1Scott & White Memorial Hospital, Temple, TX, USA; 2Scott & White Clinic in College Station, CollegeStation, TX, USA

ASTHMA/ALLERGY-Cost Studies

pg310 PAA5 LOCAL ADVERSE EVENT RATES AND COSTS ASSOCIATED WITH INHALED CORTICOSTEROIDS USEChow W1, Concetta C1, Szwarcberg J1, Lee D2, Patton M2, Haberman M2, Goldberg G2, Broderick W2, 1Aventis Pharmaceuticals, Bridgewater, NJ, USA;2Constella Health Strategies, Durham, NC, USA

pg311 PAA6 RACIAL DIFFERENCES IN PHARMACOTHERAPY AND HEALTH CARE EXPENDITURES FOR THE TREATMENT OF ASTHMA IN A MEDICAID POPULATIONHawkins K1, Stanford RH2, Orsini LS 3, Ozminkowski RJ1, Jiang C4, 1The MEDSTAT Group, Inc, Ann Arbor, MI, USA; 2GlaxoSmithKline, Research TrianglePark, NC, USA; 3The MEDSTAT Group, Inc, Cambridge, MA, USA; 4The MEDSTAT Group, Inc, Santa Barbara, CA, USA

pg311 PAA7 HEALTH CARE EXPENDITURES OF PATIENTS WITH COMORBID ALLERGIC RHINITIS AND ASTHMAChang S1, Long S 1, Leahy M2, Crown WH3, 1Medstat, Washington, DC, USA; 2Aventis Pharmaceutical, Bridgewater, NJ, USA; 3The MEDSTAT Group,Cambridge, MA, USA

pg311 PAA8 THE EFFECT OF HAVING A PRIMARY CARE PROVIDER ON ASTHMA HEALTH CARE EXPENDITURE AND HEALTH CARE UTILIZATIONNurmagambetov T, Atherly A, Williams S, Redd S, Centers for Disease Control and Prevention, Atlanta, GA, USA

pg311 PAA9 ASTHMA-RELATED HEALTH CARE SERVICES UTILIZATION BY AFRICAN-AMERICANS IN A MEDICAID POPULATIONPawar VS, Smith MJ, West Virginia University, Morgantown, WV, USA

pg312 PAA10 BUDGET IMPACT ANALYSIS: COMBINATION FLUTICASONE AND SALMETEROL FOR ASTHMAMauskopf J1, Shih T2, Baker T3, Borker R4, Stanford R4, Jhingran P 4, 1RTI Health Solutions, Research Triangle Park, NC, USA; 2The University of Texas M.D.Anderson Cancer Center, Houston, TX, USA; 3MEDTAP, Bethesda, MD, USA; 4GlaxoSmithKline, Research Triangle Park, NC, USA

pg312 PAA11 EFFECTIVENESS AND COST-BENEFIT OF LEUKOTRIENE MODIFIERS IN ADULTS WITH ASTHMA IN THE OHIO MEDICAID POPULATIONHeaton PC, Guo JJ, Jang R, Cluxton RJ, University of Cincinnati, Cincinnati, OH, USA

pg312 PAA12 RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN COST/VISITS) BEFORE AND AFTER INTRODUCTION OF THE NEW TREATMENT GUIDELINES INASTHMA (1997) AND ODDS OF BEING ON APPROPRIATE ASTHMA THERAPY USING MULTIVARIATE LOGISTIC REGRESSIONMehta R, Cady P, Idaho State University, Salt Lake City, UT, USA

pg313 PAA13 COSTS FOR ASTHMA-RELATED MEDICAL SERVICES AND PRESCRIPTION MEDICATIONS IN A STATE MEDICAID PROGRAMD'Souza A, Smith M, West Virginia University, Morgantown, WV, USA

pg313 PAA14 THE EFFECT OF MEDICAID COVERAGE DECISIONS ON NON-SEDATING ANTIHISTAMINE UTILIZATION AND SPENDING FOLLOWING OVER-THE-COUNTER AVAILABILITY OF LORATADINEHansen RA, Trygstad TK, University of North Carolina - Chapel Hill, Chapel Hill, NC, USA

PAA21 AFFECT OF PAYMENT SOURCES ON THE DIAGNOSTIC TESTS PRESCRIBING FOR PEDIATRIC ASTHMARahman A, St. John's University, Jamaica, NY, USA

ASTHMA/ALLERGY-Quality Of Life/Adherence/Patient Preferences

pg313 PAA15 INVESTIGATION OF THE DETERMINANTS OF ADHERENCE IN ASTHMA USING Q METHODOLOGYButler MG1, Schumock GT 2, Wilken L2, Jaffe HA2, Mrtek R2, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 2University of Illinois atChicago, Chicago, IL, USA

pg314 PAA16 PREDICTORS OF SELF-REPORTED ADHERENCE IN PATIENTS WITH ASTHMADe Smet BD, Erickson SR, Kirking DM, University of Michigan, Ann Arbor, MI, USA

pg314 PAA17 THE ASSOCIATION BETWEEN ADHERENCE, ASTHMA CONTROL, GENERIC AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN ASTHMAFranic DM1, Larry A1, Oyelowo O1, Grauer D 2, 1University of Georgia, Athens, GA, USA; 2The University of Kansas, Kansas City, KS, USA

pg314 PAA18 THE ASSOCIATION BETWEEN MEASURES OF HEALTH STATE UTILITIES, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA.Franic DM, Aull L, Oyelowo O, The University of Georgia, Athens, GA, USA

pg315 PAA19 CONSUMER SATISFACTION WITH ASTHMA TREATMENT – WHAT MATTERS?Prütz C1, Karlsson G 1, Ovanfors A2, Pilman E3, Brun J1, Westlund A4, 1AstraZeneca Sweden, Södertälje, Sweden; 2CFI Group, Stockholm, Sweden; 3StatenaPrimary Care Centre, Helsingborg, Sweden; 4Stockholm School of Economics, Stockholm, Sweden

ISPOR 9TH ANNUAL INTERNAT IONAL MEET ING POSTER PRESENTAT I O N S

POSTER PRESENTAT IONS – SESSION I I

42

pg315 PAA20 PREFERENCE SCORES FROM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) PATIENTSSakthong P1, Gross CR1, Treesak C2, 1University of Minnesota, Minneapolis, MN, USA; 2Srinakharinwirot University, Nakhornnayok, Thailand

BLOOD RELATED STUDIES

BLOOD RELATED STUDIES-Cost Studies

pg315 PBR1 THE ECONOMIC BURDEN OF ANEMIA IN AN INSURED POPULATIONWade SW1, Knight K1, Wilson A1, Dubois R 1, Goodnough LT2, Nissenson AR 3, 1Zynx Health, Beverly Hills, CA, USA; 2National Anemia Action Council andWashington University, St. Louis, MO, USA; 3National Anemia Action Council and David Geffen School of Medicine, Los Angeles, CA, USA

BLOOD RELATED STUDIES-Quality of Life Studies

pg316 PBR3 THE HEALTH-RELATED QUALITY OF LIFE EXPERIENCES OF YOUNG ADULTS WITH SICKLE CELL DISEASE: A QUALITATIVE ASSESSMENTMehta SR, Mayhew DY, De Leon JM, Hartzema AG, Lottenberg R, University of Florida, Gainesville, FL, USA

BLOOD RELATED STUDIES-Health Policy Studies

pg316 PBR4 BLOOD DONATION IN THE 21ST CENTURY: MOTIVATION AMIDST CRISISGabriel Z, Richard L, Heron Evidence Development, Letchworth, Herts, UK

BLOOD RELATED STUDIES-Methods

pg317 PBR5 GREATER AREA UNDER THE HEMOGLOBIN CHANGE CURVE DURING EPOETIN ALFA TREATMENT IS ASSOCIATED WITH IMPROVED PATIENT OUTCOMES Lefebvre P1, Fastenau JM2, Duh MS1, Cremieux P 1, McKenzie RS2, Piech CT2, 1Analysis Group, Inc, Boston, MA, USA; 2Ortho Biotech Products, LP,Bridgewater, NJ, USA

pg317 PBR6 REPORT FROM THE FIRST MULTIDISCIPLINARY COST OF BLOOD CONSENSUS (COBCON) WORKING GROUP TO ESTABLISH STANDARD METHODOLOGYBroder M1, for the COBCON Working Group (SABM) 2, Aledort LM3, Busch MP 4, Custer B 4, Fergusson DA5, Goodnough LT6, Hendler RS7, Hofmann A8, KleinHG9, Louie JE10, Page PL 11, Sazama K12, Shander A 13, Shulman IA14, Spence RK 15, Sullivan MT16, Thurer RL17, 1Zynx Health, A Cerner Company, Beverly Hills,CA, USA; 2Society for the Advancement of Blood Management, Englewood, NJ, USA; 3Mount Sinai School of Medicine, New York, NY, USA; 4ThePacific/Blood Systems, Inc., San Francisco, CA, USA; 5University of Ottawa Centre for Transfusion Research, Ottowa, ON, Canada; 6Washington UniversitySchool of Medicine, St. Louis, MO, USA; 7Tenet Health Systems, Dallas, TX, USA; 8SABM-Austria, Vienna, Austria; 9Warren G. Magnuson Clinical Center,Bethesda, MD, USA; 10New York Blood Center, New York, NY, USA; 11American Red Cross, Washington, D.C., USA; 12University of Texas MD AndersonCancer Center, Houston, TX, USA; 13Mount Sinai School of Medicine and Englewood Hospital and Medical Center, Englewood, NJ, USA; 14Keck School ofMedicine of the University of Southern California, Los Angels, CA, USA; 15St. Agnes Heatlh Care; 16National Blood Data Resource Center, Baltimore, MD,USA; 17Harvard Medical School and Beth Israel Medical Center, Boston, MA, USA

CARDIOVASCULAR DISEASE (including Obesity)

CARDIOVASCULAR DISEASE-Clinical Outcomes Studies

pg 318 PCV1 ZIPRASIDONE VS OLANZAPINE: CONTRASTS IN CHD RISKLeaderer M, Harrison DJ, Loebel A, Murray S, Pfizer Inc, New York, NY, USA

pg318 PCV2 COMBINED LIPID GOAL ATTAINMENT IN THE MANAGED CARE SETTINGSarawate C1, Bullano MF1, Cziraky MJ1, Willey VJ 1, Schrader BJ2, Charland SL 2, Stanek EJ2, 1Health Core, Inc, Newark, DE, USA; 2Kos Pharmaceuticals,Inc, Weston, FL, USA

pg318 PCV3 USING HEALTH-RISK APPRAISAL DATA FOR ASSESSING PREDICTORS OF HYPERTENSION TREATMENTBrown JS1, Menzin J1, Manocchia M2, 1Boston Health Economics, Inc, Waltham, MA, USA; 2Blue Cross Blue Shield of Rhode Island, Providence, RI, USA

pg319 PCV5 PREDICTORS OF ADHERENCE WITH CONCOMITANT ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPYChapman RH1, Benner JS1, Petrilla AA1, Tierce JC1, Battleman DS2, Schwartz JS3, 1ValueMedics Research, LLC, Arlington, VA, USA; 2Pfizer Inc, New York,NY, USA; 3University of Pennsylvania, Philadelphia, PA, USA

pg319 PCV6 ANALYZING RISK OF BLEEDING IN ADMINISTERING LOW MOLECULAR WEIGHT HEPARINS AND/OR ASPIRIN TO ORTHOPEDIC PATIENTSVin H1, Vogenberg FR2, 1University of Illinois, Chicago, IL, USA; 2Aon Consulting Co, Wellesley, MA, USA

pg320 PCV8 WARFARIN ANTICOAGULATION AND OUTCOMES IN ATRIAL FIBRILLATION PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSISReynolds MW1, Nalysnyk L1, Fahrbach K1, Hauch O2, Wygant G2, Estok R1, Frame D1, Cella C 1, Scheye R 1, Ross S1, 1Metaworks, Inc, Medford, MA, USA;2AstraZeneca, L.P, Wilmington, DE, USA

pg320 PCV9 LIPID MANAGEMENT AND FACTORS AFFECTING GOAL ATTAINMENT IN LATIN AMERICAMeaney E1, Armaganijan D 2, Ruiz A3, Ramos A4, Alemao E5, Yin D5, 11o. Octubre Hospital, Mexico City, Mexico; 2Instituto Dante Pazzanese de Cardiologia,Sao Paulo, Brazil; 3Universidad Pontificia, Bogotá, Colombia; 4Innoval, Mexico City, Mexico; 5Merck & Co, Whitehouse Station, NJ, USA

pg320 PCV10 THE IMPACT OF ADEQUATE MONITORING OF LIPID LEVELS IN PATIENTS HAVING ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS IN A LOCALPUBLIC HOSPITAL IN HONG KONGLee VW1, Chan WK 2, Lee KK1, 1The Chinese University of Hong Kong, Shatin, Hong Kong, China; 2United Christian Hospital, Kwun Tong, Hong Kong, China

pg321 PCV11 EVALUATING CLINICAL OUTCOMES FOR SUBJECTS THAT ARE NEWLY INITIATED ON HMG-COA REDUCTASE INHIBITORS IN A NATURALISTIC ENVI-RONMENT USING LONGITUDINAL DESIGNAl-Zakwani I1, Bullano MF1, Willey VJ1, Cziraky MJ1, Hoffman L 2, 1Health Core, Inc, Newark, DE, USA; 2Blue Cross and Blue Shield of Florida, Jacksonville,FL, USA

pg321 PCV12 UTILIZATION PATTERNS OF HYPERTENSION THERAPIES AMONG PATIENTS INITIATING ANGIOTENSION II RECEPTOR ANTAGONIST THERAPYYoung CH1, Zhang K 1, Poret AW2, 1AdvancePCS, Hunt Valley, MD, USA; 2Boehringer Ingelheim Pharmaceuticals, Inc., Ingelheim, Germany


43

pg321 PCV13 RECENT EVIDENCE SURROUNDING THE EFFICACY OF PROTECTED CAROTID ANGIOPLASTY WITH STENTS Burton K, University of Toronto, Toronto, ON, Canada

pg322 PCV14 A COMPARISON OF THE RISK OF ADVERSE THROMBOEMBOLIC AND BLEEDING EVENTS BETWEEN SUBJECTS TREATED AND NOT TREATED WITHWARFARINRiedel A1, Hauch O2, Harley C1, Nelson M 1, Wygant G2, Reynolds M2, 1Ingenix, Eden Prairie, MN, USA; 2AstraZeneca, L.P, Wilmington, DE, USA

CARDIOVASCULAR DISEASE-Cost Studies

pg322 PCV15 ECONOMIC EVALUATION OF GLYCOPROTEIN IIB/IIIA ANTAGONISTS IN DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PER-CUTANEOUS CORONARY INTERVENTIONS WITH STENTINGMittmann N1, Brown A2, Seung SJ1, Noorani H2, Mensinkai S2, Cohen E 3, Risebrough N3, Oh P4, Tang Z2, 1HOPE Research Centre, Toronto, ON, Canada;2Canadian Coordinating Office For Health Technology Assessment (CCOHTA), Ottowa, ON, Canada; 3Sunnybrook & Women's College Health SciencesCentre, Toronto, ON, Canada; 4Toronto Rehabilitation Institute (Rumsey Centre), Toronto, ON, Canada

pg322 PCV16 DIFFERENCES IN RESOURCE UTILIZATION IN POST-MI PATIENTS WITH AND WITHOUT HEART FAILUREArondekar BV1, Basu A2, Manning WG 2, Walton SM1, 1University of Illinois at Chicago, Chicago, IL, USA; 2University of Chicago, Chicago, IL, USA

pg323 PCV17 A COST-UTILITY ANALYSIS OF LOSARTAN VERSUS ATENOLOL IN THE TREATMENT OF MILD TO MODERATE HYPERTENSIONAnis AH1, Sun H1, Singh S2, Woolcott J3, Nosyk B2, 1University of British Columbia, Vancouver, BC, Canada; 2Canadian HIV Trials Network, Vancouver, BC,Canada; 3BC Centre for Disease Control, Vancouver, BC, Canada

pg323 PCV18 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, AND SIMVASTATINBenner JS1, Smith TW1, Klingman D1, Tierce JC1, Mullins CD2, Pethick N3, O'Donnell J3, 1ValueMedics Research, LLC, Arlington, VA, USA; 2University ofMaryland, Baltimore, MD, USA; 3Astrazeneca LP, Wilmington, DE, USA

pg323 PCV19 GENDER AND STATIN THERAPY COST AND EFFICACY Larsen TL, Smith DG, University of Michigan, Ann Arbor, MI, USA

pg324 PCV20 RATES OF HYPERTENSION-RELATED MEDICAL AND PRESCRIPTION UTILIZATION AND COSTS IN A STATE MEDICAID POPULATIONMody RR, Smith MJ, West Virginia University, Morgantown, WV, USA

pg324 PCV21 PREVALENCE AND COST IMPLICATIONS OF POTENTIAL INTERACTIONS WITH STATIN MEDICATIONS IN A MANAGED CARE POPULATIONEtemad LR1, Fairchild C2, Waldeck R2, 1Ingenix, Eden Prairie, MN, USA; 2Bristol-Myers Squibb, Princeton, NJ, USA

pg324 PCV22 COST AND COMORBIDITIES ASSOCIATED WITH ATRIAL FIBRILLATION IN DIFFERENT AGE GROUPSWu EQ, Birnbaum H, Milena M, Analysis Group Inc, Boston, MA, USA

pg325 PCV23 HEALTH CARE AND DRUG UTILIZATION PATTERNS IN PATIENTS RECEIVING LONG TERM THIENOPYRIDINE THERAPYMcCollam PL1, Lage M2, Bowman L 1, 1Eli Lilly and Company, Indianapolis, IN, USA; 2HealthMetrics Outcomes Research, Groton, CT, USA

pg325 PCV24 7309 HEALTH CARE RESOURCE UTILIZATION BY PATIENTS WITH ESSENTIAL HYPERTENSIONNair RR,Bollu VK, Blake SG, The University of Louisiana at Monroe, Monroe, LA, USA

pg325 PCV25 TOBACCO COST-EFFECTIVENESS ANALYSES AND THE PAYER: IS THE SHORT TERM LONG OVERDUE? Reed KE, Wieck SG, Tengs TO, Milliman USA, Denver, CO, USA

pg325 PCV26 MEDICARE EXPENDITURES IN RELATION TO FUNCTIONAL HEALTH STATUS POST-STROKE FOR A NATIONALLY-REPRESENTATIVE SAMPLE OFMEDICARE BENEFICIARIES FROM 1996 TO 2000Singhal PK, Stuart B, Menis M, Kamal-Bahl S, University of Maryland, Baltimore, MD, USA

pg326 PCV27 HOSPITALIZATION COSTS AND LENGTH OF STAY IN POST-MI PATIENTS WITH HEART FAILUREArondekar BV1, Basu A2, Walton SM1, Akhras K3, 1University of Illinois at Chicago, Chicago, IL, USA; 2University of Chicago, Chicago, IL, USA; 3Pfizer Inc,Skokie, IL, USA

pg326 PCV28 AN ARB COST-EFFECTIVENESS MODEL IN TREATING MILD-TO-MODERATE HYPERTENSIONSmolen HJ1, Klein RW1, Ohsfeldt RL2, Poret AW3, Weinberger MH4, 1Medical Decision Modeling Inc, Indianapolis, IN, USA; 2University of Iowa, Iowa City,IA, USA; 3Boehringer Ingelheim Pharmaceuticals, Inc., Ingelheim, Germany; 4Indiana University, Indianapolis, IN, USA

pg326 PCV29 COST EFFECTIVENESS ANALYSIS OF THERAPY MODIFICATION AFTER FAILING STATIN TREATMENTGrauer DW1, Franic DM2, Sullins G1, 1The University of Kansas, Kansas City, KS, USA; 2The University of Georgia, Athens, GA, USA

pg327 PCV31 ECONOMIC ANALYSIS OF AMIODARONE, ATRIAL SEPTAL PACING, AMIODARONE PLUS ATRIAL SEPTAL PACING VERSUS STANDARD OF CARE TO PRE-VENT ATRIAL FIBRILLATION AFTER OPEN-HEART SURGERYReddy P1, Kalus J2, Caron MF2, Horowitz S2, Karapanos A3, Coleman CI3, Kluger J2, White CM3, 1Abt Associates Clinical Trials, Cambridge, MA, USA;2Hartford Hospital, Hartford, CT, USA; 3University of Connecticut, Storrs, CT, USA

pg328 PCV33 COST ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM FOR ANTI-OBESITY THERAPY IN A MEDICAID POPULATIONGrauer DW, Karpinski TA, The University of Kansas, Kansas City, KS, USA

CARDIOVASCULAR DISEASE-Quality Of Life/Patient Preference/Adherence Studies

pg328 PCV34 QUALITY OF LIFE FROM THE MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE FOLLOWING AORTIC VALVE REPLACEMENT SURGERYSonnad SS1, Lee B1, Pagani FD2, Bolling SF2, Deeb GM2, 1University of Pennsylvania, Philadelphia, PA, USA; 2University of Michigan, Ann Arbor, MI, USA

pg328 PCV35 VALIDATION OF THE EQ-5D QUESTIONNAIRE IN PATIENTS WITH A HISTORY OF ACUTE CORONARY SYNDROMEEllis JJ1, Eagle KA2, Kline-Rogers EM2, Rogers B2, Erickson SR2, 1Cleveland Clinic Foundation, Cleveland, OH, USA; 2University of Michigan, Ann Arbor, MI, USA

pg329 PCV36 THE IMPACT OF ACEI RELATED COUGH: A SURVEY OF AUSTRALIAN PATIENTSAdams J1, Le Reun C2, Heavey M 2, Burke M2, Flowers M3, Germanos P4, Lindsay P 5, Noble P6, Webb K7, Davey P1, 1M-TAG, Chatswood, NSW, Australia;2Bristol-Myers Squibb Australia, Nobel Park, Vic, Australia; 3Astra-Zeneca Australia, North Ryde, NSW, Australia; 4Boehringer-Ingelheim Pty Ltd, NorthRyde, NSW, Australia; 5GlaxoSmithKline, Boronia, Vic, Australia; 6Solvay Pharmaceuticals, Pymble, NSW, Australia; 7Sanofi-Synthelabo, North Ryde, NSW,Australia


44

pg329 PCV37 HEALTH-RELATED QUALITY OF LIFE OF PATIENTS MAKING AN ATTEMPT AT SMOKING CESSATIONErickson SR, Thomas LA, Blitz SG, University of Michigan, Ann Arbor, MI, USA

pg329 PCV38 HEALTH-RELATED QUALITY OF LIFE IN AN ACUTE CORONARY SYNDROME POPULATION IS AFFECTED BY DEPRESSION TREATMENT ADEQUACYEllis JJ1, Eagle KA2, Kline-Rogers EM2, Rogers B2, Erickson SR2, 1Cleveland Clinic Foundation, Cleveland, OH, USA; 2University of Michigan, Ann Arbor, MI, USA

pg330 PCV39 HEALTH STATUS IN HIGH-RISK PATIENTS UNDERGOING NONCARDIAC VASCULAR SURGERY IN THE UNITED STATESSheikh S1, Haider S1, Joseph C C1, Lee WC2, Gold K 2, Stephens J2, Fleisher LA3, 1Pfizer Inc, Groton, CT, USA; 2Abt Associates Inc, Bethesda, MD, USA;3University of Pennsylvania Medical Center, Philadelphia, PA, USA

pg330 PCV40 ASSESSMENT OF THE QUALITY OF DRUG TREATMENT IN CORONARY ARTERY DISEASE USING QUALITY INDICATORSSzalayova A, Dubrava M, Comenius University, Bratislava, Slovak Republic

pg330 PCV41 MEDICATION POSSESSION RATIOS FOR PATIENTS WITH CALCIUM CHANNEL BLOCKERS AND/OR STATINSNichol MB1, Shi S1, Knight TK1, Livengood K2, Ambegaonkar AJ2, 1University of Southern California, Los Angeles, CA, USA; 2Pfizer Inc, New York, NY, USA

pg330 PCV42 PERSISTENCE AND ADHERENCE TO STATIN THERAPY IN A MANAGED CARE SETTINGQuach C1, Nichol MB2, Chen L1, Patel BV1, Berenbeim D1, 1MedImpact Health Care Systems Inc, San Diego, CA, USA; 2University of Southern California, LosAngeles, CA, USA

pg331 PCV43 EVALUATION OF THE ASSOCIATION BETWEEN HEALTH-RELATED UTILITY AND OBESITY IN HOSPITAL TREATED SUBJECTS Currie CJ1, Dixon S2, Morrissey M3, Farina C4, Peters JR5, McEwan P6, 1University of Wales College of Medicine, Cardiff, Wales, UK; 2Sheffield University,Sheffield, South Yorkshire, UK; 3Cardiff Research Consortium, Cardiff, Wales, UK; 4Roche Ltd, Welwyn Garden City, Hertfordsire, UK; 5University Hospital ofWales, Cardiff, Wales, UK; 6Cardiff University, Cardiff, Wales, UK

pg331 PCV44 BMI, SELF-REPORTED COMORBIDITIES, AGE, AND GENDER DO NOT EXPLAIN COUNTRY-SPECIFIC DIFFERENCES IN OBESITY- R E L ATED QUALITY OF LIFEHayes RP, Bowman L, Eli Lilly & Company, Indianapolis, IN, USA

CARDIOVASCULAR DISEASE-Health Policy Studies

pg332 PCV46 EXPLORATION OF HIGHLY ELEVATED CREATININE KINASE RESULTS AND ASSOCIATED CHOLESTEROL THERAPY IN A LARGE COMMERCIAL HEALTHPLANHarley C1, Kempf J 2, Nelson M1, Riedel A1, 1Ingenix, Eden Prairie, MN, USA; 2AstraZeneca LP, Wilmington, DE, USA

pg332 PCV47 THE NATIONAL ANTICOAGULATION BENCHMARK AND OUTCOMES REPORT (NABOR™): EVIDENCE OF A SIGNIFICANT DIFFERENCE BETWEEN GUIDE-LINES AND ACTUAL PRACTICE Shillington A1, Tapson V2, Hyers T3, Becker R2, Colgan K1, 1EPI-Q, Inc, Oakbrook Terrace, IL, USA; 2Duke University Medical Center, Durham, NC, USA;3CARE Clinical Research, St. Louis, MO, USA

pg332 PCV48 OBESITY AMONG HIGH SCHOOL STUDENT AND CONTRIBUTING FACTORSWilliams BD, Xiao H, Florida Agricultural & Mechanical University, Tallahassee, FL, USA

pg333 PCV49 DOES THE RATE OF MEDICARE MANAGED-CARE PENETRATION AFFECT AVAILABILITY OF RESOURCES FOR HEART FAILURE TREATMENT?Masselink LE1, Friedman JY1, Whellan DJ2, Schulman KA 1, 1Duke Clinical Research Institute, Durham, NC, USA; 2Duke University Medical Center, Durham,NC, USA

pg333 PCV50 GASTRIC BYPASS SURGERY – AN OVERVIEWMisra S, Rush University Medical Center, Chicago, IL, USA

pg333 PCV51 RETROSPECTIVE EVALUATION OF UTILIZATION PATTERNS OF BETA-BLOCKER THERAPY IN CONGESTIVE HEART FAILURE PATIENTS IN A MANAGEDCARE ENVIRONMENTThaker DJ, Godley PJ, Browne BA, Rohack J, Houck P, Scott & White, Temple, TX, USA

pg334 PCV52 IMPACT OF MARKET FORCES ON STATIN PERSISTENCE PATTERNS IN A CALIFORNIA MEDICAID POPULATIONNichol MB1, Shi S1, Knight TK1, Popovian R2, Morita R2, 1University of Southern California, Los Angeles, CA, USA; 2Pfizer, Inc, New York, NY, USA

pg334 PCV53 IMPACT OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) ON PHYSICIAN PRESCRIBINGPATTERNS AND PATIENT UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONSLiu X, Yu W, Yokoyama K, WellPoint Pharmacy Management, West Hills, CA, USA

pg334 PCV54 IMPACT OF THE NATIONAL SERVICE FRAMEWORK (NSF) FOR CORONARY ARTERY DISEASE (CAD) ON PHYSICIAN COMPLIANCE OF PRESCRIBINGASPIRIN AND STATINS FOR SECONDARY PREVENTION IN THE UNITED KINGDOM (UK) Pradhan A1, Ray S2, Cislo P2, 1Bristol Myers Squibb, London, UK; 2Bristol Myers Squibb, Wallingford, CT, USA

pg335 PCV55 DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERCHOLESTEROLAEMIAO'Regan CP1, Lister SP2, Marchant NJ 1, 1Pfizer UK Limited, Walton on the Hill, UK; 2Compufile Limited, Woking, UK

pg335 PCV56 DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERTENSIONO'Regan CP1, Lister SP2, Marchant NJ 1, 1Pfizer UK Limited, Walton on the Hill, UK; 2Compufile Limited, Woking, UK

pg335 PCV57 ASSOCIATION BETWEEN INSURANCE COVERAGE AND OUTCOMES FOR INDIVIDUALS HOSPITALIZED FOR NONHEMORRHAGIC STROKEOkafor MC, Thomas III J, Purdue University, West Lafayette, IN, USA

pg335 PCV58 USE OF GPIIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH DRUG-ELUTING STENTSYoung J, Foster D, Heller S, Solucient, LLC, Ann Arbor, MI, USA

pg336 PCV59 CLINICAL PHARMACIST INVOLVMENT IN COMMUNITY ANTICOAGULATION CONTROLGuy-Alfandary S, Raz M, Timkin N, Triki N, Katz M, Maccabi Healthcare Services, Azur, Israel

pg336 PCV60 DISORDERS OF LIPOID METABOLISM: LIKELIHOOD OF PRESCRIPTION THERAPYHess GP, Lipskiy N, Surveillance Data, Plymouth Meeting, PA, USA

I SPOR 9T H ANNUAL INTERNAT IONAL MEET ING POSTER PRES ENTAT I O N S

45

DIABETES (including Parathyroid Disease)

DIABETES-Clinical Outcomes Studies

pg336 PDB1 LOWER INCIDENCE OF MICROVASCULAR EVENTS ASSOCIATED WITH PIOGLITAZONE MONOTHERAPY THAN INSULIN MONOTHERAPY IN PATIENTSWITH TYPE 2 DIABETES: A RETROSPECTIVE PROPENSITY SCORE MATCHED COHORT ANALYSIS.Rajagopalan R1, Xu Y1, Rosenson R2, 1Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA; 2Northwestern University, Feinberg School ofMedicine, Chicago, IL, USA

pg337 PDB2 COMPARISON OF PIOGLITAZONE WITH OTHER ANTIDIABETIC DRUGS FOR ASSOCIATED INCIDENCE OF LIVER FAILURE: NO EVIDENCE OF INCREASEDLIVER FAILURE WITH PIOGLITAZONE Rajagopalan R, Iyer S, Perez A, Takeda Pharmaceuticals North America Inc, Lincolnshire, IL, USA

pg337 PDB3 EVALUATION OF PHARMACIST INTERVENTIONS IN DIABETIC PATIENTS FROM RURAL COMMUNITY HEALTH CENTERSPinto S, Segal R, Winterstein A, Annis L, Robinson D, Yates D, Pederson L, Willis M, University of Florida, Gainesville, FL, USA

pg337 PDB4 PARTICIPATION IN HOME-BASED A1C TESTING IN CAREPATTERNS® PROGRAM FOR DIABETES Berger J, Low D, Hu L, Stine N, Caremark, Northbrook, IL, USA

pg338 PDB5 SELF-MONITORING OF BLOOD GLUCOSE AMONG VETERANS WITH DIABETES MANAGED ON ORAL THERAPY Wen L1, Parchman M2, Linn W1, Lee S1, 1Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, TX, USA; 2University of TexasHealth Science Center at San Antonio, San Antonio, TX, USA

pg338 PDB6 GENDER DISPARITY IN THE MANAGEMENT OF DYSLIPIDEMIA AMONG TYPE 2 DIABETES PATIENTS IN A MANAGED-CARE SETTINGMallya UG, Nau DP, University of Michigan, Ann Arbor, MI, USA

pg338 PDB7 ALTERNATIVE ANTIPSYCHOTIC TREATMENT AND RISK OF DIABETES: RESULTS FROM NC MEDICAID POPULATIONSun SX, Liu GG, Christensen DB, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

pg339 PDB8 THE ROLE OF INTRAOPERATIVE PARATHYROID HORMONE MONITORING FOR PARATHYROID HYPERPLASIAMisra S, Weber KJ, Wilhelm, SM, Prinz RA, Rush University Medical Center, Chicago, IL, USA

DIABETES-Cost studies

pg339 PDB9 POTENTIAL MEDICAL COST REDUCTION DUE TO DECREASES IN A1C RESULTING FROM PHARMACIST DIABETES EDUCATON AND MEDICATION REC-OMMENDATIONS IN A COMMUNITY SETTINGGunderson SM, Lee KY, Duvel AH, Luce DF, Walgreens Health Initiatives, Deerfield, IL, USA

pg339 PDB10 UTILIZATION PATTERNS OF DRUGS AND HEALTH CARE SERVICES AMONG RECIPIENTS WITH DIABETES IN A MEDICAID POPULATIONSundaram M, Smith MJ, West Virginia University, Morgantown, WV, USA

pg340 PDB11 DIFFERENCES IN HYPOGLYCEMIA EVENT RATES AND ASSOCIATED COST-CONSEQUENCE IN PATIENTS INITIATED ON LONG-ACTING AND INTERMEDI-ATE-ACTING INSULIN PRODUCTSBullano MF1, Al-Zakwani I1, Barron JJ 1, Menditto L2, Willey VJ 1, 1Health Core, Newark, DE, USA; 2Aventis Pharmaceuticals, Inc, Parsippany, NJ, USA

pg340 PDB12 ESTIMATING THE REDUCTION IN LONG TERM COMPLICATION AND COSTS OF COMPLICATIONS IN TYPE 1 DIABETES BY REDUCED A1C LEVELS DUETO MORE FREQUENT BLOOD GLUCOSE MONITORINGNicklasson L1, Palmer A2, Roze S2, 1Novo Nordisk Pharmaceuticals Inc, Princeton, NJ, USA; 2CORE Center for Outcomes Research, Basel, Switzerland

pg340 PDB13 PHARMACY AND MEDICAL RESOURCE UTILIZATION AMONG INITIAL METFORMIN AND THIAZOLIDINEDIONE PATIENTSShaya FT1, Shin JY1, Mullins CD1, Foster S2, Fatodu H2, 1University of Maryland, Baltimore, MD, USA; 2Johns Hopkins Health Care LLC, Glen Burnie, MD, USA

pg340 PDB14 PROPENSITY SCORE METHODS FOR REDUCING BIAS IN THE COMPARISON OF COSTS AND UTILIZATION BETWEEN INSULIN LISPRO AND REGULARINSULINChen K1, Chang E1, Summers K2, Obenchain R3, Yu-Isenberg K1, Sun P3, 1Prescription Solutions, Cost Mesa, CA, USA; 2Purdue University, West Lafayette,IN, USA; 3Eli Lilly and Company, Indianapolis, IN, USA

pg341 PDB15 TOTAL CHOLESTEROL, HDL CHOLESTEROL AND HBA1C AFFECT QUALITY-ADJUSTED LIFE YEARS AND HOSPITAL COSTS FOR PATIENTS WITH TYPE 2DIABETES IN THE UNITED KINGDOM – THE CARDIFF DIABETES COST UTILITY MODELMcEwan P1, Peters JR2, Morrissey M3, Bergenheim K4, Currie CJ3, 1Cardiff University, Cardiff, Wales, UK; 2University Hospital of Wales, Cardiff, Wales, UK;3Cardiff Research Consortium, Cardiff, Wales, UK; 4AstraZeneca R&D Mölndal, Mölndal, Sweden

pg341 PDB16 THE ECONOMIC AND HEALTH OUTCOMES OF USING DIFFERENT INSULIN DELIVERY DEVICES IN A MANAGED CARE ENVIRONMENTLiu X, Yu W, Yokoyama K, WellPoint Pharmacy Management, West Hills, CA, USA

pg341 PDB17 RETIREE TYPE 2 DIABETES HEALTH CARE COSTS FOR A SELF-INSURED TELECOMMUNICATIONS COMPANYErwin G1, Rajagopalan R 2, Astuto J3, Wilson P 4, Schaneman J5, Kleinman N 5, 1Omnicare, Inc, King of Prussia, PA, USA; 2Takeda Pharmaceuticals NorthAmerica, Lincolnshire, IL, USA; 3Verizon Communications, Alpharetta, GA, USA; 4Associates & Wilson, Rosemont, PA, USA; 5Options & Choices, Inc,Cheyenne, WY, USA

pg342 PDB18 INCREASED HEALTH EXPENDITURES AMONG DIABETES PATIENTS ON INSULIN WITH HYPOGLYCEMIAOrsini LS1, Rhoads G2, Wang S1, Zhang Q3, Crown W1, 1The Medstat Group, Inc, Cambridge, MA, USA; 2University of Medicine and Dentistry of New Jersey,Piscataway, NJ, USA; 3Aventis Pharmaceuticals, Bridgewater, NJ, USA

pg342 PDB19 THE ECONOMIC BURDEN OF TYPE 2 DIABETES MANAGEMENT BY ETHNIC GROUP IN THE TEXAS MEDICAID POPULATIONLee WC1, Stephens JM 1, Tran KT1, Wang Q1, Dirani RG 2, Pashos CL3, 1Abt Associates Inc, Bethesda, MD, USA; 2GlaxoSmithKline, Philadelphia, PA, USA;3Abt Associates Inc, Cambridge, MA, USA

pg342 PDB20 COST-EFFECTIVENESS OF DULOXETINE VERSUS ROUTINE TREATMENT FOR PAINFUL DIABETIC NEUROPATHY IN A RANDOMIZED TRIAL FROM A SOCI-ETAL PROSPECTIVEWu E1, Birnbaum H 1, Mareva M1, Le TK2, Rosen A2, Robinson R2, Corey-Lisle P2, 1Analysis Group Inc, Boston, MA, USA; 2Eli Lilly and Company, Indianapolis,IN, USA


46

DIABETES-Quality Of Life/Patient Preference Studies

pg343 PDB21 THE IMPACT OF COMMON DIABETIC COMPLICATIONS ON QUALITY OF LIFEHolmes JW1, Hemmett L 1, New JP2, Vaughan N3, Sharplin P4, Marchant N5, 1Beaufort International, London, UK; 2Hope Hospital, Salford, UK; 3Royal SussexCounty Hospital, Brighton, UK; 4Aventis Pharma UK, West Malling, Kent, UK; 5Pfizer Ltd, Sandwich, Kent, UK

pg343 PDB22 THE VALUE TO HIGH-RISK PATIENTS OF PREVENTING A CASE OF DIABETESJohnson FR, Manjunath R, Hoerger TJ, Research Triangle Institute, Research Triangle Park, NC, USA

pg343 PDB23 IS PSYCHOLOGICAL GENERAL WELL-BEING AN IMPORTANT PATIENT-REPORTED OUTCOME FOR THE EVALUATION OF DIABETES DRUG THERAPY?Hayes RP, Bowman L, Eli Lilly & Company, Indianapolis, IN, USA

pg344 PDB24 COMPARE USABILITY OF TWO TYPES OF DISPOSABLE PEN (FLEXPEN VERSUS HUMALOG PEN) CONTAINING RAPID-ACTING INSULIN ANALOGUESAsakura T1, Seino H1, Nicklasson L2, 1Ohta Nishinouchi Hospital, Fukushima, Japan; 2Novo Nordisk Pharmaceuticals Inc, Princeton, NJ, USA

pg344 PDB25 PAIN SEVERITY AFFECTS PERCEIVED HEALTH STATUS IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHYGore M1, Brandenburg N2, Hoffman D1, Tai KS1, 1Avalon Health Solutions, Philadelphia, PA, USA; 2Pfizer Global Pharmaceuticals, New York, NY, USA

pg344 PDB26 PREFERENCE, EFFICACY, SAFETY AND ACTUAL USE OF BLOOD GLUCOSE (BG) MONITORING WITH INDUO® VS SYRINGE AND SEPARATE METER INSUBJECTS WITH TYPE 1 DIABETESBode B1, Shelmet J 2, Gooch B3, Hassman D4, Lyness W5, Nicklasson L5, Schneider S6, 1Atlanta Diabetes Associates, Atlanta, GA, USA; 2Novo Nordisk,Lawrenceville, NJ, USA; 3Melbourne Internal Medicine Associates, Melbourne, FL, USA; 4Comprehensive Clinical Research, Berlin, NJ, USA; 5NovoNordisk Pharmaceuticals Inc, Princeton, NJ, USA; 6Robert Wood Johnson Medical School, New Brunswick, NJ, USA

DIABETES-Health Policy Studies

pg345 PDB27 HOSPITALIZATIONS WITHIN THE VA AMONG VETERANS WITH DIABETES Wen L1, Parchman M2, Linn W1, 1Audie L. Murphy Division, South Texas Veterans Health Care System, San Antonio, TX, USA; 2University of Texas HealthScience Center at San Antonio, San Antonio, TX, USA

DIABETES-Methods

pg345 PDB28 GLYCEMIC CONTROL AS A CLINICAL OUTCOME VARIABLE: THE IMPACT OF NON-STANDARDIZED MEASURES Kavookjian J, West Virginia University School of Pharmacy, Morgantown, WV, USA

pg346 PDB29 VALIDATION OF THE DIABETES RESOURCE CONSUMPTION INDEX (DRCI): A RISK ADJUSTMENT TOOL FOR PREDICTING HEALTH CARE RESOURCE USEAND COSTSJoish VN1, Malone DC 2, Wendel C3, Mohler MJ 3, 1University of Utah, Salt Lake City, UT, USA; 2University of Arizona, Tucson, AZ, USA; 3Southern Arizona VAHealth Care System, Tucson, AZ, USA

pg346 PDB30 DEVELOPMENT OF A DIABETES RESOURCE CONSUMPTION INDEX (DRCI) USING VETERANS HEALTH ADMINISTRATION DATAJoish VN1, Malone DC2, Wendel C3, Mohler MJ3, 1University of Utah, Salt Lake City, UT, USA; 2University of Arizona, Tucson, AZ, USA; 3Southern Arizona VAHealth Care System, Tucson, AZ, USA

GI DISEASES/DISORDERS

GI DISEASES/DISORDERS-Clinical Outcomes Studies

pg346 PGI1 GASTROINTESTINAL ADVERSE EVENTS FROM NON STEROIDAL ANTI-INFLAMMATORY DRUGS: RELATIONSHIPS BETWEEN RISK ASSESSMENT, VET-ERANS AFFAIRS PRESCRIBING GUIDELINES, AND HOSPITALIZATION COSTSNetravali SS1, Raisch DW1, Harris CL2, 1Department of Veterans Affairs, Albuquerque, NM, USA; 2VA Cooperative Studies Program, Albuquerque, NM, USA

pg346 PGI2 A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF TOTAL AND PARTIAL LAPAROSCOPIC FUNDOPLICATION FOR THE TREATMENT OF GORD.Boler A1, Howard P2, 1Heron Evidence Development, Letchworth, Hertfordshire, UK; 2Heron Evidence Development, Letchworth, Herts, UK

GI DISEASES/DISORDERS-Cost Studies

pg347 PGI3 COST-UTILITY ANALYSIS COMPARING ESOMEPRAZOLE WITH THE ORO-DISPERSIBLE FORMULATION OF LANSOPRAZOLE IN THE INITIAL TREATMENTOF REFLUX OESOPHAGITISPlumb J, Edwards S, AstraZeneca UK Ltd, Luton, Bedfordshire, UK

pg347 PGI4 INPATIENT COSTS OF LIVER CIRRHOSIS IN THE UNITED STATES: A RETROSPECTIVE CLAIMS DATA ANALYSIS, 1993-2001Billah K, Goldstein S, Bower W, Margolis H, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA

pg347 PGI5 COST-EFFECTIVENESS OF TREATING ADULTS WITH CHRONIC HEPATITIS C (CHC) AND PERSISTENTLY NORMAL ALANINE AMINOTRANSFERASE(PNALT) WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS)Hornberger J1, Farci P2, Prati D3, Zuezem S4, Patel KK5, Green J5, 1Stanford University & Acumen, LLC, Burlingame, CA, USA; 2Università di Cagliari, Cagliari, TN,Italy; 3IRCCS Ospedale Maggiore, Milan, Italy; 4Saarland University Hospital, Homburg/Saar, Germany; 5Hoffmann-La Roche Inc, Nutley, NJ, USA

pg348 PGI6 ECONOMIC BURDEN OF GERD AND PUD IN AN EMPLOYED POPULATIONJoish VN1, Donaldson G1, Stockdale WA1, Oderda G1, Brixner DI1, Sasane R2, Joshua-Gotlib S2, Crawley JA2, 1University Of Utah, Salt Lake City, UT, USA;2AstraZeneca LP, Wilmington, DE, USA

pg348 PGI7 FECAL LACTOFERRIN ASSAY FOR THE INITIAL DIAGNOSTIC APPROACH TO SYMPTOMATIC PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS: ACOST-EFFECTIVENESS ANALYSIS Ellis JJ, Parsi MA, Lashner BA, Cleveland Clinic Foundation, Cleveland, OH, USA

pg348 PGI8 A PHARMACOECONOMIC ASSESSMENT OF THE BENEFITS AND COSTS OF MANAGING IMMUNOSUPPRESSION IN POST-LIVER TRANSPLANTPATIENTS: A UNIVERSITY HOSPITAL PERSPECTIVEStolpman NM1, Valuck RJ2, Lezotte D2, Malone DC3, Glazner J 2, Everson GT2, 1University of Colorado Hospital, Denver, CO, USA; 2University of ColoradoHealth Sciences Center, Denver, CO, USA; 3University of Arizona, Tucson, AZ, USA


47

GI DISEASES/DISORDERS-Quality of Life

pg349 PGI9 RESPONSIVENESS TO CHANGE AND ENGLISH LANGUAGE VALIDATION OF THE WPAI-GERD QUESTIONNAIRE - RESULTS FROM A CANADIAN STUDYWahlqvist P1, Guyatt G2, Armstrong D2, Austin P2, Barkun A3, Chiba N2, degl'Innocenti A1, El-Dika S4, Fallone C3, Heels-Ansdell D2, Tanser L5, Veldhuyzen vanZanten S6, Wiklund I1, Schünemann H4, 1AstraZeneca R&D Mölndal, Mölndal, Sweden; 2McMaster University, Hamilton, ON, Canada; 3McGill UniversityHealth Centre, Montreal, QC, Canada; 4University at Buffalo, Buffalo, NY, USA; 5AstraZeneca Canada, Mississauga, ON, Canada; 6Dalhousie University,Halifax, NS, Canada

pg349 PGI10 WORK LOSS AND ACTIVITY IMPAIRMENT DUE TO INFLAMMATORY BOWEL DISEASEWeston C1, Sikirica V1, Pizzi L1, Goldfarb N1, Morretti D2, Cobb N1, Howell J 1, Infantolino A2, DiMarino A 2, Cohen S2, 1Jefferson Medical College, Philadelphia,PA, USA; 2Thomas Jefferson University, Philadelphia, PA, USA

GI DISEASES/DISORDERS-Health Policy Studies

pg350 PGI11 RETROSPECTIVE ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM USING COX-2 INHIBITORS IN A MANAGED CARE POPULATIONBarlev A1, Yu W2, Johnson K 1, 1University of Southern California, Los Angeles, CA, USA; 2WellPoint Pharmacy Management, West Hills, CA, USA

GI DISEASES/DISORDERS-Methods

pg350 PGI12 EVALUATING THE GERD SYMPTOM AND MEDICATION QUESTIONNAIRE (GERD-SMQ) IN A CLINICAL TRIALHowell JB1, Reyes EB2, Dylan M2, Wade SW2, Dodd SL1, DeLemos BP1, 1Janssen Pharmaceutica, Inc, Titusville, NJ, USA; 2Zynx Health, Beverly Hills, CA, USA

INFECTIONS

INFECTIONS-Clinical Outcomes Studies

pg350 PIN1 OUTCOMES OF AN INTERACTIVE VOICE RESPONSE (IVR) REMINDER SYSTEM TO PROMOTE MANAGED CARE ORGANIZATION (MCO) MEMBERS'ATTAINMENT OF INFLUENZA IMMUNIZATION Sikirica V1, Crawford A1, Goldfarb N1, Nash D1, Popiel R2, Patel M2, Wang C2, Chu J2, 1Department of Health Policy, Jefferson Medical College, Philadelphia,PA, USA; 2Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA

pg351 PIN2 RETREATMENT RATES OF ACUTE OTITIS MEDIA IN PATIENTS WITH TYMPANOSTOMY TUBES WITHIN THE LOUISIANA MEDICAID PROGRAMBlake S1, Waycaster C2, Kothari S1, Myers E1, Humble L 1, Bollu V1, 1ULM School of Pharmacy, Monroe, LA, USA; 2Alcon Labs Inc, Fort Worth, TX, USA

pg351 PIN3 OUTCOMES FOLLOWING THE USE OF AZITHROMYCIN OR CLARITHROMYCIN FOR RESPIRATORY TRACT INFECTIONS IN A MEDICAID POPULATION Boulanger L1, Harnett J2, Dixon D1, Menzin J1, Wilson J 2, 1Boston Health Economics, Inc, Waltham, MA, USA; 2Pfizer, Inc, New York, NY, USA

pg351 PIN4 EXAMINATION OF HEPATITIS C IN THE LOUISIANA MEDICAID POPULATIONDalal A, Blake S, University of Louisiana at Monroe, Monroe, LA, USA

pg352 PIN5 A META-ANALYSIS OF THREE-DAY AZITHROMYCIN THERAPY VERSUS LONGER COURSES OF COMPARATOR ANTIBIOTICS IN ACUTE SINUSITISHarnett J, Enuha S, Xuan J, Cappelleri J, Pfizer, Inc, New York, NY, USA

pg352 PIN7 CHANGES IN HIV ANTIVIRAL PHENOTYPIC DRUG RESISTANCE DURING THE HAART ERAHess GP, Nelson C, Seiders J, Surveillance Data, Plymouth Meeting, PA, USA

pg352 PIN8 AN EVIDENCE BASED PROPOSAL TO MODIFY PRESCRIBING PATTERNS: THE CASE OF METRONIDAZOL USED WHEN INTESTINAL AMOEBIASIS ISS U S P E C T E DMedecigo-Micete C, Garduno-Espinosa J, Constantino-Casas P, Gomez-Delgado A, Munoz-Hernandez O, Mexican Institute for Social Security, MexicoCity, Mexico

pg353 PIN9 VARIABILITY IN THE USE OF HIV PHENOTYPIC TESTING BY SPECIALTY OF PRACTITIONERHess GP, Nelson C, Lipskiy N, Surveillance Data, Plymouth Meeting, PA, USA

pg353 PIN10 OFF-LABEL USE OF PIPERACILLIN/TAZOBACTAM (ZOSYN®) IN A PEDIATRIC UNIT Thaker DJ1, Wilson JP 2, Browne BA1, Godley PJ1, 1Scott & White Health Plan, Temple, TX, USA; 2University of Texas, Austin, TX, USA

pg353 PIN11 TESTING AND TREATMENT OF HEPATITIS C IN THE LOUISIANA MEDICAID POPULATIONBlake SG, Dalal A, Leader WG, The University of Louisiana at Monroe School of Pharmacy, Monroe, LA, USA

INFECTIONS-Cost Studies

pg354 PIN12 COST-EFFECTIVENESS OF INTRAVENOUS IMMUNOGLOBULIN MANUFACTURED FROM CHROMOTOGRAPHY-CAPRYLATE VS. SOLVENT-DETERGENTMETHODS IN PERSONS WITH PRIMARY IMMUNODEFICIENCY DISEASEMahadevia PJ1, Strell J2, Kunaprayoon D1, Gelfand E3, 1MEDTAP International, Bethesda, MD, USA; 2Bayer Health Care, Biological Products Division, LLC,West Haven, CT, USA; 3National Jewish Medical and Research Center, Denver, CO, USA

pg354 PIN13 AN ECONOMIC AND CLINICAL ASSESSMENT OF FIRST-LINE MONOTHERAPY IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA WITHINMANAGED CARESkrepnek GH, Armstrong EP, Malone DC, Ramachandran S, University of Arizona, Tucson, AZ, USA

pg354 PIN14 ECONOMIC COST STRUCTURE OF SEVERE SEPSIS MANAGEMENT Patel AB1, Jang R2, Imhoff T 3, Wuestefeld N3, Mueller PJ3, 1Xavier University, New Orleans, LA, USA; 2University of Cincinnati, Cincinnati, OH, USA; 3GoodSamaritan Hospital, Cincinnati, OH, USA

pg355 PIN15 THE COST OF TREATMENT FAILURE IN ACUTE BACTERIAL MAXILLARY SINUSITISThompson D1, Amorosi SL1, Taylor DC1, Stokes M1, Asche C 2, Hadley J3, Ferguson BJ4, 1Innovus Research, Inc, Medford, MA, USA; 2AventisPharmaceuticals, Bridgewood, NJ, USA; 3University Otolaryngology Associates, Montgomery, AL, USA; 4University ENT Specialists, Inc., Pittsburgh, PA, USA

pg355 PIN16 COST-EFFECTIVENESS OF FOUR ANTIMICROBIAL REGIMENS IN PATIENTS ADMITTED TO THE MEDICAL FLOOR WITH CLASS IV OR V COMMUNITY-ACQUIRED PNEUMONIAFrei CR, Burgess DS, The University of Texas at Austin & The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA


48

pg355 PIN17 COST-EFFECTIVENESS MODELING OF TREATMENT APPROACHES TO HEPATITIS C: A MANAGED CARE PERSPECTIVEKlaskala W1, Shaya FT2, Mullins CD2, Law AW1, Pettit K1, 1Roche Laboratories, Nutley, NJ, USA; 2University of Maryland School of Pharmacy, Baltimore,MD, USA

pg356 PIN18 DIRECT TREATMENT COSTS OF TINEA CAPITIS AMONG THE UNITED STATES PRIVATELY INSURED POPULATIONSuh DC1, Raut M2, Chang J 2, Shin H1, Gause D2, Tavakkol A2, 1Rutgers University, Piscataway, NJ, USA; 2Novartis Pharmaceuticals Corporation, EastHanover, NJ, USA

pg356 PIN20 BURDEN OF ILLNESS OF BACTERIAL CELLULITIS AND ERYSIPELAS OF THE LEG IN THE NETHERLANDSGoettsch WG, Panneman MJ, Herings RMC, PHARMO Institute, Utrecht, The Netherlands

pg357 PIN21 COMPARISON OF 30-DAY DIRECT MEDICAL COSTS OF AZITHROMYCIN AND LEVOFLOXACIN FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA Matchar DB1, Samsa GP1, Harnett J2, Wilson J2, 1Duke University, Durham, NC, USA; 2Pfizer, Inc, New York, NY, USA

pg357 PIN22 HOSPITAL UTILIZATION TRENDS OF HIV DISEASE IN THE UNITED STATES, 1993 TO 2001Zhang HF, Rajiv M, Ciuryla VT, Wyeth Research, Collegeville, PA, USA

pg357 PIN23 CLINICAL AND ECONOMIC IMPACT OF HERD IMMUNITY ASSOCIATED WITH HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADAFord MW1, Wang ECY1, Ciuryla V2, 1Wyeth Canada, Markham, ON, Canada; 2Wyeth Research, Philadelphia, PA, USA

pg357 PIN24 ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE SETTINGS FOR PATIENTS DIAGNOSED WITH INFLUENZA, 1997-2001Ciesla G1, Stoddard J2, Leader S1, 1MedImmune, Inc, Gaithersburg, MD, USA; 2MedImmune Vaccines, Inc, Gaithersburg, MD, USA

pg358 PIN25 COSTS AND OUTCOMES OF EXTENDED-RELEASE CLARITHROMYCIN FOR LOWER RESPIRATORY TRACT INFECTIONSHalpern MT1, Cifaldi M2, Schmier JK1, 1Exponent, Alexandria, VA, USA; 2Abbott Laboratories, Abbott Park, IL, USA

pg358 PIN26 MENINGOCOCCAL VACCINE IN PORTUGAL - A COST-EFFECTIVENESS ANALYSISGouveia M1, Borges M2, Tavares L2, Portugal R2, 1Universidade Católica Portuguesa, Lisbon, Portugal; 2Faculdade de Medicina da Universidade de Lisboa,Lisboa, Portugal

pg358 PIN27 THE IMPACT OF PHYSICIAN PROFILING ON ANTIBIOTIC COST AND UTILIZATION. Ramos K1, Teng DG1, Ara SB2, Tam JY1, Keeling F 2, Finch MJ 1, 1Health Net, Oakland, CA, USA; 2Health Net, Woodland Hills, CA, USA

pg359 PIN28 MEDICOECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF INFANTILE BRONCHIOLITIS IN FRANCEVainchtock A1, Trichard M2, Chaufferin G2, Duru G 3, Nicoloyannis N4, Stagnara J5, 1GYD Institut Groupe IMS Health, Lyon, France; 2BOIRON Laboratories,Sainte-Foy-Lès-Lyon, France; 3Claude Bernard University, Villeurbanne, France; 4Lyon 2 University, Bron, France; 5Paediatrician, Lyon, France

pg359 PIN29 THE ECONOMIC EVALUATION OF INFLUENZA VACCINATION IN THE ELDERLY POPULATION: A MODEL BASED ON BAYESIAN NETWORKSBaio G1, Pammolli F1, Baldo V2, Trivello R2, 1University of Florence, Florence, Italy; 2University of Padua, Padua, Italy

pg359 PIN30 OBSERVATIONAL STUDY ON THE “REAL LIFE” PRACTICE AND COST OF ANTIBIOTIC (AB) MEDICATION IN PNEUMOCOCCAL PNEUMONIA PATIENTS:PARENTERAL VERSUS STEP DOWN THERAPY (SDT)Verplanken P1, Van Wilder P2, 1IMS Health Belgium, Brussels, Belgium; 2S.M.A.R.T, Zaventem, Belgium

INFECTIONS-Quality of Life Studies

pg360 PIN31 SUBSTITUTION TO LOPINAVIR/RITONAVIR (LPV/R) IS ASSOCIATED WITH IMPROVED PATIENT-REPORTED FATIGUE IN HIV+ PATIENTS EXPERIENCINGSIDE EFFECTS RELATED TO THEIR PROTEASE INHIBITOR (PI)/NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)Luo MP, Shen Y, Rode R, McMillan F, Tressler R, Ashraf T, Abbott Laboratories, Abbott Park, IL, USA

INFECTIONS-Health Policy Studies

pg360 PIN32 ACUTE SINUSITIS IN MANAGED CARE: ANTIBIOTIC TREATMENT AND OUTCOMESSinger ME1, Jaffe DH 2, Coyte PC3, Asche CV4, 1Case Western Reserve University, Cleveland, OH, USA; 2Hebrew University, Cleveland, OH, USA; 3Universityof Toronto, Toronto, ON, Canada; 4Aventis Pharma, Bridgewater, NJ, USA

pg360 PIN33 UTILIZATION PATTERNS OF MEDICAL SERVICES AND PRESCRIPTION DRUGS FOR THE TREATMENT OF TINEA CAPITISSuh DC1, Raut M2, Chang J2, Valiyeva E1, Tavakkol A2, Vo L1, 1Rutgers University, Piscataway, NJ, USA; 2Novartis Pharmaceuticals Corporation, EastHanover, NJ, USA

pg361 PIN34 THE USE OF ANTIBIOTICS TO TREAT ACUTE UPPER RESPIRATORY TRACT INFECTIONS IN A STATE MEDICAID POPULATIONCoffindaffer JW1, Smith MJ 2, 1West Virginia University School of Pharmacy, Morgantown, WV, USA; 2West Virginia University, Morgantown, WV, USA

MEN’S HEALTH

MEN’S HEALTH-Clinical Outcomes Studies

pg361 PSD1 A SELF-ADMINISTERED SCREENER FOR MALE ERECTILE DISFUNCTION: THE SPANISH VERSION OF THE LIFE-SATISFACTION CHECK LIST “LISAT 8”.Rejas J1, Gil A2, Martínez EM3, Díaz E4, San Isidro C5, Carrasco P2, 1Health Outcomes Research, Medical Unit, Pfizer SA, Alcobendas, Madrid, Spain; 2ReyJuan Carlos University, Alcorcón, Madrid, Spain; 3Pfizer Medical Unit, Alcobendas, Madrid, Spain; 4Primary Care Health Center Mendiguchía Garriche,Leganés, Madrid, Spain; 5Health Center, Inocencio Jiménez, Zaragoza, Spain

pg361 PSD2 ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION (ADSD) IN EUROPE: A PRELIMINARY INVESTIGATIONWilliams VSL1, Fehnel SE1, Hogue SL2, 1RTI-Health Solutions, Research Triangle Park, NC, USA; 2GlaxoSmithKline, Research Triangle Park, NC, USA

MEN’S HEALTH-Cost Studies

pg362 PSD3 TOTAL HEALTH CARE COSTS FOR BENIGN PROSTATIC HYPERPLASIA PATIENTS ON ALPHA1-BLOCKER TREATMENT IN A MANAGED CARE SETTINGGirts TK1, Meyer JW2, Shah H1, 1Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA; 2Ingenix, Eden Prairie, MN, USA

I SPOR 9TH ANNUAL INTERNAT IONAL MEET ING POSTER PRESENTAT I O N S

49

URINARY/KIDNEY DISEASES/DISORDERS

URINARY/KIDNEY DISEASES/DISORDERS-Clinical Outcomes Studies

pg362 PUK1 REACHING TARGET HEMATOCRITS WITH EPOETIN: IS THE INFERENCE OF A SURVIVAL BENEFIT VALID? Zhang Y1, Thamer M1, Stefanik K1, Scharfstein D2, Kaufman J3, Cotter D1, 1Medical Technology and Practice Patterns Institute, Bethesda, MD, USA; 2J o h n sHopkins University, Baltimore, MD, USA; 3Boston VA Medical Center, Boston MA, USA

URINARY/KIDNEY DISEASES/DISORDERS-Cost Studies

pg363 PUK2 A COST COMPARISON ANALYSIS OF TWO CLINICALLY UROSELECTIVE ALPHA BLOCKERS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIABotteman MF1, Lowe FC2, Naslund M3, Sollano J 4, Pashos C5, Litwin M6, 1Abt Associates Inc, Bethesda, MD, USA; 2St. Luke’s Roosevelt Hospital, New York,NY, USA; 3University of Maryland Hospital, Baltimore, MD, USA; 4Sanofi-Synthelabo, Inc, New York, NY, USA; 5Abt Associates Inc, Cambridge, MA, USA;6University of California, Los Angeles, Los Angeles, CA, USA

pg363 PUK3 DITROPAN XL PROVIDES SUPERIOR OUTCOMES AND LOWER COSTS COMPARED TO DETROL LAEl-Hadi W1, Getsios D2, Feng W3, Duchesne I4, Dubois D5, Caro JJ6, 1Caro Research Institute, Dorval, QC, Canada; 2Caro Research Institute, HammondsPlains, NS, Canada; 3Johnson & Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA; 4Janssen Pharmaceutica N.V, Beerse, Belgium; 5Johnson &Johnson Pharmaceutical Services, L.L.C, Beerse, Belgium; 6Caro Research Institute, Concord, MA, USA

pg363 PUK4 OVERACTIVE BLADDER: AN UNDERESTIMATED AND GROWING DISEASE BURDENCalvert NW1, Irwin DE2, Kopp Z3, Dooley JA4, 1Fourth Hurdle Consulting Ltd, London, UK; 2University of North Carolina, Chapel Hill, NC, USA; 3Pfizer, NewYork, NY, USA; 4Pfizer, Surrey, UK

pg364 PUK5 THE COST-EFFECTIVENESS OF SIROLIMUS WITH CYCLOSPORIN WITHDRAWAL VERSUS LOW DOSE SIROLIMUS AND CONTINUED CYCLOSPORINWHEN INITIATED WITHIN FOUR MONTHS OF RENAL TRANSPLANTATIONGordois A1, Mudge M1, Davey P1, Aldridge G1, Nobes M2, Lees M1, Toohey M2, 1M-TAG Pty Ltd, Chatswood, NSW, Australia; 2Wyeth Australia Pty Ltd,Baulkham Hills, NSW, Australia

pg364 PUK6 THE RELATIONSHIP BETWEEN COST OF CARE AND COMORBIDITY IN CHRONIC KIDNEY DISEASESmith DH1, Nichols G1, Gullion C1, Keith D 2, 1Kaiser Permanente Center for Health Research, Portland, OR, USA; 2McGill University, Montreal, Quebec,Canada

pg364 PUK7 A COST EVA L U ATION OF CYCLOPHOSPHAMIDE PLUS PREDNISONE VERSUS AZATHIOPRINE PLUS PREDNISONE FOR TREATMENT OF LUPUS NEPHRITISTelfair T, University of Florida, Gainesville, FL, USA

pg365 PUK8 COST-EFFECTIVENESS ANALYSIS OF THE TREATMENT OF URINARY TRACT INFECTIONS IN A COLLEGE-AGE POPULATIONKachur SG, Hiendlmayr K, University of Rhode Island, Kingston, RI, USA

pg365 PUK9 ECONOMIC IMPACT OF EPOETIN ALFA (EPO) TREATMENT AMONG NON-DIALYSIS CHRONIC KIDNEY DISEASE (NDCKD) PATIENTS WITH ANEMIADuh MS1, Boyce SP1, Mody SH 2, Piech CT2, 1Analysis Group, Inc, Boston, MA, USA; 2Ortho Biotech Products, LP, Bridgewater, NJ, USA

URINARY/KIDNEY DISEASES/DISORDERS-Quality of Life Studies

pg365 PUK10 USING CONJOINT ANALYSIS TO EXAMINE PATIENT QUALITY OF LIFE AND PRESCRIPTION INSURANCE COVERAGE PREFERENCES IN THE MANAGE-MENT OF OVERACTIVE BLADDERHarpe SE1, Szeinbach SL1, Corey R2, 1The Ohio State University, Columbus, OH, USA; 2Philadelphia College of Pharmacy, Philadelphia, PA, USA

URINARY/KIDNEY DISEASES/DISORDERS-Health Policy Studies

pg366 PUK11 PATIENT PERSISTENCY WITH MEDICATIONS FOR OVERACTIVE BLADDERChui MA1, Williamson T2, Arciniega J3, Thompson C2, Benecke H3, 1Midwestern College of Pharmacy, Glendale, AZ, USA; 2Yamanouchi America, Paramus,NJ, USA; 3NDCHealth, Yardley, PA, USA

URINARY/KIDNEY DISEASES/DISORDERS-Methods

pg366 PUK12 PROSPECTIVE URINARY INCONTINENCE RESEARCH (PURE): DESCRIPTION OF STUDY, RATIONAL, DESIGN AND METHODOLOGY Papanicolaou S1, Castro R2, Espuna-Pons M3, Hampel C4, Hunskaar S5, Monz B6, Samsioe G 7, Voss S1, Wagg A8, Sykes DP9, 1Eli Lilly & Co, Surrey, UK;2Boehringer Ingelheim, Ingelheim, Germany; 3University Hospital of Barcelona, Spain; 4Johannes Gutenberg University, Mainz, Germany; 5University ofBergen, Norway; 6Boehringer-Ingelheim, Ridgefield, CT, USA; 7Lunds University Hospital, Lund, Sweden; 8University College Hospital, London, UK; 9Eli Lillyand Company, Windlesham, UK

pg366 PUK13 VALIDATION OF AUTOMATED DATABASE ALGORITHMS TO IDENTIFY HOSPITAL-ACQUIRED ACUTE RENAL FAILURE Winterstein AG, Weiner ID, Johns TE, Hatton RC, University of Florida, Gainesville, FL, USA

HEALTH POLICY

HEALTH POLICY-Handguns, Fireworks & Poisons

pg367 PHP1 A COST MINIMIZATION ANALYSIS OF FOMEPIZOLE VERSUS ETHANOL WITH OR WITHOUT HEMODIALYSIS IN THE ACUTE MANAGEMENT OFMETHANOL OR ETHYLENE-GLYCOL POISONINGCastanier J1, Lamarsalle L1, Zinai A2, Lambert C2, Guardiola J2, 1GYD Institut IMS Health, Lyon, France; 2OPI, Dardilly, France

pg367 PHP2 HOSPITALIZATIONS FOR INJURIES FROM FIREWORKS: RESOURCE USE AND COSTSO'Brien J1, Pitoniak-Morse C1, Jacobs L2, 1Caro Research Institute, Concord, MA, USA; 2University of Connecticut School of Medicine, Farmington, CT, USA

pg367 PHP3 HANDGUN INJURIES TO CHILDREN AND TEENS RESULTING IN HOSPITALIZATION: CIRCUMSTANCES, RESOURCE USE AND COSTSO'Brien J1, Pitoniak-Morse C1, Jacobs L2, 1Caro Research Institute, Concord, MA, USA; 2University of Connecticut School of Medicine, Farmington, CT, USA


50


HEALTH POLICY-Burden Of Illness Studies

pg368 PHP4 BURDEN OF ILLNESS FOR EMPLOYEES WITH PAINFUL CONDITIONSWhite AG1, Birnbaum HG 1, Mareva MN1, Henckler AE 1, Seifelden R2, Grossman P 2, 1Analysis Group, Boston, MA, USA; 2Purdue Pharma L.P, Stamford, CT,USA

pg368 PHP5 EVALUATING THE COSTS OF DISEASES IMPUTABLE TO STRESS AT WORKBéjean S, Sultan Taïeb H, Wolff N, University of Burgundy, Dijon, France

pg368 PHP6 THE SOCIOECONOMIC COST OF DISEASES DUE TO SMOKING IN KOREAJung YH, Ko S, Korea Institute for Health and Social Affairs, Seoul, South Korea

pg368 PHP7 THE SOCIOECONOMIC COST OF DISEASES IN KOREAJung YH, Ko S, Korea Institute for Health and Social Affairs, Seoul, South Korea

HEALTH POLICY-Health Care Decision Studies

pg369 PHP8 PEER PRESSURE IN HEALTH CARELo JC, The Institute of Economics, Academia Sinica, Taiwan, Taipei, Taiwan

pg369 PHP9 RELATIONSHIP BETWEEN PATIENT-REPORTED READINESS, SELF-MANAGEMENT BEHAVIOR, AND HEALTH STATUS IN MANAGED-CARE PATIENTSWITH CHRONIC CONDITIONSSankaranarayanan J, Mason HL, Purdue University, West Lafayette, IN, USA

HEALTH POLICY-Health Care Cost Studies

pg369 PHP10 EQUITY IN THE NATIONAL HEALTH INSURANCE DURING ECONOMIC RECESSION: MISSION IMPOSSIBLE?Lai MS1, Lan CF2, Huang SM3, Liang LY2, 1National Taiwan University, Taipei, Taiwan; 2National Yang-Ming University, Taipei, Taiwan; 3Department of Health,Taipei, Taiwan

pg370 PHP11 ESTIMATING THE ABILITY-TO-PAY FOR HEALTH CARE EXPENDITURES RISING FASTER THAN GDP: AN INTERNATIONAL PERSPECTIVE COMPARINGTHE USA AND GERMANYSchlander M1, Schwarz O2, Thielscher C 3, 1University of Witten/Herdecke & University of Applied Sciences Ludwigshafen, Ludwigshafen am Rhein,Germany; 2University of Cooperative Education Mannheim, Mannheim, Germany; 3University of Witten/Herdecke, Niederkassel, Germany

pg370 PHP12 FACTORS AFFECTING CONSUMER VIEWS REGARDING GENERIC DRUG SUBSTITUTION PRACTICES: AN EFFECTIVE TOOL TO MANAGE HEALTH CARECOSTBhosle MJ, Sansgiry SS, University of Houston, Houston, TX, USA

pg370 PHP13 WHO BENEFITS FROM OVER-THE-COUNTER (OTC) MEDICATION COVERAGE IN A STATE MEDICAID PROGRAM?Johnsrud MT, Shepherd M, Anantharaman R, Shah S, Doan QD, Dastani H, Parthan A, The University of Texas at Austin, Austin, TX, USA

pg370 PHP14 ADDITION OF PHARMACY COST DATA IMPROVES PERFORMANCE OF THE ADJUSTED CLINICAL GROUPS PREDICTIVE MODEL FOR TOTAL HEALTH CARECOSTS OVERALL AND WITHIN DISEASE SPECIFIC GROUPSPowers CA, Meyer C, Pierson P, Vaziri B, AdvancePCS, Hunt Valley, MD, USA

pg371 PHP15 INCLUDING CARER UTILITY IN ECONOMIC EVALUATIONS: A PRELIMINARY ANALYSIS OF THE IMPLICATIONS FOR FUNDING THRESHOLDSDixon S1, McEwan P2, Currie CJ3, 1Sheffield University, Sheffield, South Yorkshire, UK; 2Cardiff University, Cardiff, Wales, UK; 3University of Wales Collegeof Medicine, Cardiff, Wales, UK

pg371 PHP16 FAMILIES, FRIENDS AND COST-EFFECTIVENESS ANALYSISBasu A, Meltzer D, University of Chicago, Chicago, IL, USA

HEALTH POLICY-Drug Prescribing, Reimbursement & Cost Studies

pg372 PHP17 RECENT TRENDS IN INPATIENT DRUG COSTS: 2000 - 2002Foster DA, Solucient, LLC, Ann Arbor, MI, USA

pg372 PHP18 PREVALENCE OF DRUG-RELATED PROBLEMS AMONGST HOSPITALISED PATIENTS ON POLYPHARMACY IN SINGAPOREKoh Y1, Fatimah MK2, Li SC1, 1National University of Singapore, Department of Pharmacy, Singapore; 2Alexandra Hospital, Singapore

pg372 PHP19 COMPARING THE COSTS OF MAIL ORDER AND RETAIL PHARMACYCarroll NV1, Brusilovsky I2, York B2, Oscar R2, 1Virginia Commonwealth University, Richmond, VA, USA; 2Rx-EOB, Richmond, VA, USA

pg372 PHP20 FACTORS THAT INFLUENCE PRESCRIBING DECISIONSBlackburn JC1, Park HY1, Nutescu EA1, Walton SM1, Finley JM2, Lewis RK2, Schumock GT1, 1University of Illinois at Chicago, Chicago, IL, USA; 2MercyResource Management Inc, Naperville, IL, USA

pg373 PHP22 TRENDS IN APPROVALS BY THE PHARMACEUTICAL BENEFITS ADVISORY COMMITTEEWonder M1, Neville AM2, Parsons R2, 1Novartis Pharmaceuticals Australia Pty Ltd, North Ryde, New South Wales, Australia; 2Pretium (Health EconomicConsultants), Sydney, NSW, Australia

pg373 PHP23 PHARMACEUTICAL PRESCRIPTION: COSTS AND FACTORS OF INFLUENCE Akremi J, Laboratory THEMA (Economic Theory, Modelling and Applications),University Paris X, Paris, Nanterre Cedex, France

pg374 PHP24 QUALITY OF DECISION-MAKING BY THE PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) AND THE IMPACT ON OUTCOMESNeville AM, Lloyd JM, Pretium (Health Economic Consultants), Sydney, NSW, Australia

pg374 PHP25 ASSESSMENT OF THE IMPACT OF ‘ACADEMIC DETAILING’ IN PROMOTING COST-EFFECTIVE GENERIC DRUG PRESCRIPTION AMONG AMBULATORYCARE PHYSICIANS IN WEST VIRGINIARoy S, Roy AN, Madhavan S, Bochna K, Kavookjian J, Susman T, Joseph F, Hodges B, West Virginia University, Morgantown, WV, USA

pg374 PHP26 CCOHTA GUIDELINES FOR THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: CANADA 2004Brady BK, Amin M, Mensinkai S, CCOHTA, Ottawa, ON, Canada

51


pg374 PHP27 INFLATION: PRESCRIPTION DRUG MARKET BASKET DEFINITION AND THEIR IMPACTHutchins DS, Mitrany DM, Caremark, Scottsdale, AZ, USA

HEALTH POLICY-Patient Satisfaction Studies

pg375 PHP28 PATIENT SATISFACTION - PATIENT EDUCATION INTERFACEMisra S, Hargreaves MB, Blundy JM, Rush University Medical Center, Chicago, IL, USA

pg375 PHP29 CONSUMER SATISFACTION WITH HEALTH PLANS AND DRUG BENEFIT MANAGEMENT STRATEGIESSansgiry SS, Sikri S, Kawatkar A, University of Houston, Houston, TX, USA

pg375 PHP30 PATIENT SATISFACTION WITH HEALTH CARE SERVICES: IDENTIFYING VOIDSSansgiry SS, Jayawant SS, Bhosle MJ, University of Houston, Houston, TX, USA

HEALTH POLICY-Older Patient Studies

pg376 PHP32 HEALTH-RELATED QUALITY OF LIFE AND HEALTH PREFERENCE AS PREDICTORS OF MORTALITY AMONG OLDER PEOPLE AT VETERAN HOMELai KL1, Kao S 2, 1Institute of Life Science, National Defense Medical Center, Taipei, Taiwan; 2School of Public Health, National Defense Medical Center,Taipei, Taiwan

pg377 PHP33 FACTORS ASSOCIATED WITH TTO UTILITY CHANGES AMONG OLDER PEOPLE AT VETERAN HOMELai KL1, Kao S 2, 1Institute of Life Science, National Defense Medical Center, Taipei, Taiwan; 2School of Public Health, National Defense Medical Center,Taipei, Taiwan

pg377 PHP34 EXPLICIT INDICATORS TO MEASURE PREVENTABLE DRUG-RELATED MORBIDITY IN AN ELDERLY POPULATIONFaris RJ, University of Tennessee, Memphis, TN, USA

pg377 PHP35 JUDGMENT RULES IN OLDER ADULTS' EVALUATIONS OF DRUG BENEFIT PLANSCline RR, Gupta K, University of Minnesota, Minneapolis, MN, USA

pg377 PHP36 PRESCRIPTION DRUG UTILIZATION PATTERNS AND CHARACTERISTICS FOR A MEDICARE POPULATION IN MANAGED CAREYokoyama KK, Yu W, WellPoint Pharmacy Management, West Hills, CA, USA

HEALTH POLICY-Consumer Advertising

pg378 PHP38 AN ASSESSMENT OF THE EFFECT OF DEMOGRAPHICAL AND SOCIOPSYCHOLOGICAL FACTORS ON INDIVIDUAL RESPONSE TO DIRECT-TO-CONSUMERADVERTISING OF PRESCRIPTION DRUGSMakin C1, Murawski M2, 1Purdue University, Louisville, KY, USA; 2Purdue University, West Lafayette, IN, USA

HEALTH POLICY-Pharmaceutical Industry Issues

pg378 PHP39 STOCK MARKET VALUATION AND FIRM-LEVEL DETERMINANTS OF INNOVATIVE ACTIVITY IN THE PHARMACEUTICAL INDUSTRYSkrepnek GH1, Lawson KA2, 1University of Arizona, Tucson, AZ, USA; 2University of Texas at Austin, Austin, TX, USA

pg379 PHP40 POST-LAUNCH STUDIES – WHAT IS DESIRABLE, WHAT IS FEASIBLE?Mason A1, Drummond MF1, Towse A2, 1University of York, York, UK; 2Office of Health Economics, London, UK

pg379 PHP41 PARALLEL TRADE OF PHARMACEUTICALS AS A COST-CONTAINMENT MEASURE- ANALYSIS OF THE ISRAELI EXPERIENCEEldar-Lissai A1, Shvarts S 2, Goldberg A2, Shani S2, 1University of Rochester, Rochester, NY, USA; 2Ben-Gurion University of the Negev, Israel

pg379 PHP42 METHODS FOR “GO/NO-GO” MODELING OF COMPOUNDS IN THE DEVELOPMENT PIPELINEThompson D1, O'Sullivan A1, Weinstein M2, 1Innovus Research, Inc, Medford, MA, USA; 2Innovus Research Inc. and Harvard School of Public Health,Boston, MA, USA

pg380 PHP43 THE IMPACT OF PRICE CONTROLS ON PHARMACEUTICAL R&D INVESTMENTAbbott TA, Abbott Consulting, North Wales, PA, USA

52

EFFECT OF SECTION 1013 “RESEARCH ON OUTCOMES OFHEALTH CARE ITEMS AND SERVICES” OF THE US MEDICAREMODERNIZATION ACT ON OUTCOMES RESEARCHMODERATOR: Jean Paul Gagnon PhD, Director Public Policy, AventisPharmaceuticals Inc., Bridgewater, NJ, USA

PANELISTS: Jean R. Slutsky PA, MSPH, Acting Director, Center for Outcomes andEvidence, Agency for Healthcare Research and Quality (AHRQ), Rockville, MD,USA; Kathleen Lohr PhD, Co-Director, RTI-UNC Evidence-based Practice Center,Research Triangle Park, NC, USA; John Santos MD, Former Administrator, Office ofOregon Health Policy and Research, Portland, OR, USA

PURPOSE: Three perspectives (AHRQ, Evidence-based Practice Center [EPC] , anda health policy analyst) will be presented to address issues relating to Section 1013(Research on Outcomes of Health Care Items and Services) of the US MedicarePrescription Drug, Improvement and Modernization bill and outcomes research.Panelists will address questions that include what AHRQ will do to address its newMedicare program charge, how the EPCs will be involved, how successful havethey been, how the EPCs relate to the discipline of health outcomes research, whatimpact they will have on the process of assessing health care technology, and howhave they been used in decision-making.

OVERVIEW: Evidence-based practice and outcomes research have gained broadacceptance among academics, health care providers, policy makers, and patientsalike over the past few years. With the passage of the new Medicare bill withSection 1013 (Research on Outcomes of Health Care Items and Services) it is rea-sonable to consider the potential changes in store for the pharmaceutical industry,patients, payers and decisionmakers. Since 1997 AHRQ has supported EPCs to con-duct systematic reviews of a wide range of clinical and health policy topics. Healthcare decisionmakers use these reports to construct clinical practice guidelines andquality measures, to make coverage decisions, and to design future research agen-das. The new Medicare bill calls for AHRQ to conduct and support research tomeet the priorities and requests for scientific evidence and information that willimprove the quality, effectiveness, and efficiency of health care delivered to the eld-e r l y. Specifically, the bill calls for AHRQ to determine the outcomes, comparativeclinical effectiveness, and appropriateness of health care items and services includ-ing prescription drugs. This session looks at ways that AHRQ generally, its EPC pro-gram specifically, and related entities might respond to the Section 1013 charges.

STRATIFIED COST-EFFECTIVENESS ANALYSIS: THE RISKS ANDREWARD OF LOOKING AT SUB-GROUPSMODERATOR: Henry Glick PhD, Health Economist, University of Pennsylvania,Division of Internal Medicine, Philadelphia, PA, USA

PANELISTS: Jeffrey Hoch PhD, Assistant Professor, University of Western Ontario,Department of Epidemiology and Biostatistics, London, ON, Canada; Andrew WillanPhD, Professor, Department of Public Health Sciences, University of Toronto,Toronto, ON, Canada; Joseph Heyse PhD, Executive Director, Merck ResearchLaboratories, Biostatistics and Research Data Systems, West Point, PA, USA; JohnCook PhD, Health Economics, Merck Research Laboratories, Blue Bell, PA, USA

PURPOSE: The most common result from an economic evaluation is a pooledanalysis for a potentially heterogeneous population (e.g., one that includes peopleof different ages, genders, levels of disease severity, one that includes people whomay be treated in different health care settings, and one that includes people whomay be treated in different parts of the world). This panel will explore the strengthsand weaknesses of three analytic approaches for the evaluation of whether such

pooled economic results in trials are applicable to subgroups in the trial.

OVERVIEW: The speakers will outline three approaches to the evaluation of therepresentativeness of pooled economic results in the analysis of patient-level data:net monetary benefit regression (Hoch); empirical Bayes shrinkage estimation(Willan); and the assessment of qualitative and quantitative interaction(Cook/Heyse). The interactive discussion between the audience and participantswill focus on synergies between the methods as well as their differences.

COST ATTRIBUTION IN ECONOMIC EVALUATION: WHAT IS SIGNAL AND WHAT IS NOISE? MODERATOR : Teresa Kauf PhD, Research Assistant Professor, Center for Clinicaland Genetic Economics, Duke Clinical Research Institute, Durham, NC, USA

PANELISTS: Gerry Oster PhD, Vice President, Policy Analysis Inc. (PAI), Brookline,MA, USA; Daniel Polsky PhD, Research Associate Professor, General InternalMedicine, University of Pennsylvania, Philadelphia, PA, USA

PURPOSE: The intent of this Issues Panel is to discuss the pros and cons of study-ing total medical costs versus disease- or intervention-related costs in economicevaluations.

OVERVIEW: Limiting the inclusion of costs in economic evaluation to disease- orintervention-specific components increases the opportunity for analysts to detectimportant treatment differences (increased signal through decreased noise). On theother hand, others argue that difficulties with classifying costs as ‘related’ and‘unrelated’ require consideration of all costs in economic evaluations at theexpense of increased variance (decreased ability to detect signal throughincreased noise). The panelists in this session will present contrasting views oncost attribution in economic evaluation. An interactive discussion between theaudience and participants will focus on valid and reliable methods of cost attribu-tion in the context of the 'noise versus signal' debate.

INDUSTRY AND REGULATORY PERSPECTIVES ON TRANSLATINGPATIENT REPORTED OUTCOME MEASURESMODERATOR: Joyce Cramer BS, Associate Research Scientist, Yale University,New Haven, CT, USA

PANELISTS: Laurie Burke RPh, Director, Study Endpoints and Label Division, U.S.Food and Drug Administration, Rockville, MD, USA; Richard J. Willke PhD, SeniorDirector/Group Leader, Worldwide Outcomes Research, Pfizer Inc., Peapack, NJ,USA; Diane Wild MSc, Director, Oxford Outcomes, Cassington, Oxford, UK

PURPOSE: During this session an industry perspective and a regulatory perspectivewill be presented to compare different approaches to translation and cultural vali-dation of patient reported outcomes measures (PROs) instruments prior to their usein clinical trials, as well as consideration of the costs and potential benefits ofthese approaches, including their implications for bias and precision of results.

OVERVIEW: Various methods for translation and cultural adaptation have been pro-posed recently to ensure that the meaning of the original PRO instrument will bethe same in all translations. While setting standards for producing translations,encouraging homogeneity of translation processes, and facilitating use existingtranslations, these procedures have the potential to impede trial implementation byincreasing the time and budget required for including PRO endpoints. The panelistsand audience will discuss what degree of stringency in the proposed methodologyadds to the quality of the instrument.


ISSUE PA N E L S

53

THE IMPACT OF MEDICARE’S PRESCRIPTION DRUG LEGISLATIONON PHARMACOECONOMICS AND OUTCOMES RESEARCH MODERATOR: Peter Neumann ScD, Associate Professor of Policy and DecisionSciences, Harvard School of Public Health, Boston, MA, USA (researcher perspective)

PANELISTS: Diane Simison PhD, Principal, PharmAnalysis Group, Inc., Alexandria,VA, USA (provisional perspective); Ronald J. Ozminkowski PhD, Director, Healthand Productivity Management Research, Medstat, Ann Arbor, MI, USA (industryperspective)

PURPOSE: To explore how the recently enacted Medicare Modernization Act(MMA) will impact the funding and performance of pharmacoeconomics and out-comes research.

OVERVIEW: Panelists will examine the impact and relevance of MMA provisions onpharmacoeconomic and health outcomes research. Key discussion topics willinclude: existing Medicare data and data needs for the future; how to analyze theinpatient, outpatient, and pharmaceutical experience for beneficiaries with aselected number of high-cost medical conditions; the financial impact of the “donuthole” in coverage, and the laws impact on self-administered Part B drugs, use offormularies, the Medication Management Program, competitive bidding for drugsand biologics, and new technologies for hospitals.

THE VALUE OF POST-LAUNCH STUDIES – WHAT IS DESIRABLE VS. WHAT IS FEASIBLE?MODERATOR: Adrian Towse, Director, Office of Health Economics, London, UK

PANELISTS: Michael Drummond DPhil, Director, Centre for Health Economics, York,UK (research perspective); Andreas Laupacis MD, MSc, FRCPC, President & CEO,Institute for Clinical Evaluative Sciences, Toronto, ON, Canada (agency perspec-tive); Pete Fullerton PhD, Professor (Affiliate) University of Washington, WA, USA(managed care perspective)

PURPOSE: During this issue panel, 3 perspectives (managed care, health technolo-gy assessment, and researcher) will be presented to compare and contrast what isdesirable versus what is feasible for post-launch pharmacoeconomics and out-comes studies.

OVERVIEW: Although the main emphasis of pharmacoeconomics and outcomesresearch is likely to remain on the pre-launch phase, there is increasing interest inconducting studies post-launch. Many payers are interested in the cost-effective-ness of the drug in regular clinical practice and there are examples of researchpartnerships between manufacturers and managed care groups. Also, agenciesdetermining guidelines for the reimbursement or use of drugs (e.g. NICE in the UK)are increasingly specifying the types of further research that will help them whenthey come to revise their guidance in the future. These include additional clinicalstudies, observational studies and research into the impact of new drugs on qualityof life. The panel will discuss the types of study requirements that are currentlybeing specified by agencies and the practical and methodological problems in car-rying them out.

COST INFORMATION TREATMENT IN STATED PREFERENCE EXPERIMENTS – WHAT IS THE GOLD STANDARD?MODERATOR: Deborah Marshall PhD, Assistant Professor, McMaster Universityand Innovus Research Inc, Burlington, ON, Canada

PANELISTS: Reed Johnson PhD, Senior Fellow, Research Triangle Institute,Research Triangle Park, NC, USA; Kathryn Phillips PhD, Associate Professor,University of California, San Francisco, CA, USA

PURPOSE: To examine controversies in alternative approaches to informationtreatment in stated preference experiments and propose ‘best practice’ criteria.

OVERVIEW: In the real world, we observe actual behaviours that are based onindividuals’ preferences. In stated preference studies (either contingent valuation

or conjoint analysis), we can control and standardize the information provided torespondents, but this naively assumes that our description will prevent individualsfrom ‘recoding’ the information and interpreting it based on their own experiences.On the other hand, it has been shown in examining the value of mortality risks thatpeople can be trained to appropriately interpret changes in small fractions, but thisjeopardizes the generalizability of the results to any representative sample of thepopulation.

Similarly, stated preference studies are often used to estimate the marginal utilityof money and measure benefits using willingness-to-pay. However, estimates ofthe marginal utility of income are only valid if respondents accept cost levels asincome-constrained, out-of-pocket expenses of obtaining the desired scenario. Dorespondents interpret stated preference questions in this way? There is currentlylittle empirical evidence on how cost information is perceived and thus no goldstandard on how stated preference studies should present such information.

This debate will centre on how much preparation and information should be provid-ed to respondents so that the responses represent the preferences of the individu-als in the sample, but also represent a response within some standardized contextthat is generalizable. The panelists will elucidate the pros and cons of alternativeapproaches, including options for presenting cost information, and propose ‘bestpractice’ criteria.

CAN WE BRIDGE TOO FAR? ISSUES IN MAPPING BETWEENQUALITY-OF-LIFE INSTRUMENTS AND UTILITYMODERATOR: Michael B. Nichol PhD, Associate Professor and Chair, University ofSouthern California, Los Angeles, CA, USA

PANELISTS: Robert Kaplan PhD, Chair/Professor, University of California, SanDiego, San Diego, CA, USA; Christopher McCabe PhD, Depute Director, NICEDecision Support Unit, University of Sheffield, Sheffield, UK

PURPOSE: This issues panel will explore the use of mapping methods for derivingutility scores for cost-effectiveness research.

OVERVIEW: Researchers have been increasingly interested in the use of mappingmethods to expand the availability of utility scores for CEA.

Panelists will address such issues as: reliability and validity of mapping proce-dures; sensitivity to change of mapping procedures; comparison to gold standards,such as direct elicitation; and the importance of differences in the utility estimatingprocedure from a CEA perspective.

RISK SHARING DEALS IN THE REAL WORLD: CAN WE AFFORDTHEM AND DO THEY WORK? MODERATOR: Charles Petrie PhD, Sr. Director/Team Leader, Outcomes ResearchGroup, Pfizer Inc, Groton, CT, USA

PANELISTS: Adrian Towse MA, Director, Office of Health Economics, London, UK;Maureen Mangotich MD, MPH, Medical Director, State Initiatives, Pfizer HealthSolutions, Santa Monica, CA, USA

PURPOSE: To illustrate and discuss basic components of two current, real worldexamples of risk sharing arrangements involving a pharmaceutical manufacturerand a health care payer.

OVERVIEW: For a variety of reasons, health care delivery systems and payers ofhealth care are increasingly reluctant to carry all the risk for the medicines, proce-dures, and services they offer given that pricing and utilization can be unpre-dictable and difficult to control. Consequently, health care financing arrangementsdesigned to share the risk, manage budgetary volatility, and align payer andprovider incentives are finding application. Panelists will present and discuss tworisk share arrangements: the Pfizer-Florida Medicaid Disease ManagementProgram and the NHS Multiple Sclerosis Program.

I SP OR 9TH ANNUAL INTERNAT IONAL MEETING ISSUES PA N E L S

54

WORKSHOP PRESENTAT I O N S

CLINICAL STUDY METHODOLOGY ISSUES INCLUDING PHARMACOEPIDEMIOLOGY

W1 PATIENT REPORTED OUTCOME AND RESOURCE USE DATA IN CLINICAL TRI-ALS: GOING BEYOND TREATMENT GROUP COMPARISONS Bala MV1, Mauskopf JA2, 1Centocor, Inc, Malvern, PA, USA; 2Research TriangleInstitute, Research Triangle Park, NC, USA Learning Objectives: The objective of this workshop will be to discuss poten-tial uses of patient reported outcome (PRO) and resource use data collectedin clinical trials, beyond comparing treatment groups.Who Would Benefit: Researchers involved in the analysis and disseminationof PRO or resource use data from clinical trials.

Workshop Description: Collection of PRO and resource use data alongsidelate-phase clinical trials is becoming increasingly common. These data areprimarily used to examine the difference between treatment groups. Howeverthe constraints imposed by the design of the trial and sample size often limitthe utility of the data for this purpose. In this workshop we will explore alter-nate uses of PRO and resource use data collected alongside clinical trialsincluding: 1) describing the unmet need in the target patient population; 2)examining the association between disease severity and patient well beingand function; 3) establishing the value of improvements in clinical parameters;4) validating measures and estimating minimum clinically meaningful improve-ments; and 5) estimating the cost and utility associated with health states formodeling purposes. We demonstrate using actual clinical trial data howexploring all these uses allows one to derive maximal value from these data.We will conclude with an interactive discussion regarding other potentialuses of such data.

COMPLIANCE ISSUES

W2 PATIENT COMPLIANCE AND PERSISTENCE WITH PRESCRIBED MEDICATION:MEASUREMENT AND HEALTH ECONOMIC IMPACTKoncz TA1, Hughes D2, Cleemput I 3, Annemans L4 for the Med Comp SIG,1Semmelweis University, Budapest, Hungary; AARDEX, Zug, Switzerland;2University of Liverpool, Liverpool, UK; 3HEDM, Meise, Belgium; 4GhentUniversity, HEDM, Meise, Belgium Learning Objectives: Participants will learn about: 1) the advantages and limi-tations of various methodologies to measure compliance in clinical trials andpractice and the analysis of these data for maximum explanatory power, rela-tive to outcomes; 2) case studies on the health economic impact of variablecompliance with prescribed drug regimens; 3) appropriate modelling strate-gies to represent various patterns of non-compliance in pharmaco-economicevaluations. Who Would Benefit: Health care services researchers, policy-makers, andpayers concerned with medication compliance issues as well as outcomesresearchers interested in improving methods to incorporate non-complianceinto economic evaluations.

Workshop Description: There is agreement among stakeholders in healthcare that a large minority of patients are partially or poorly compliant withprescribed drug dosing regimens. However, varying definitions and methodsof measurement limit our capability to quantify the effect of variable compli-ance on outcomes, and to evaluate its health economic impact. Achieving theworkshop objectives necessitates that current methods used to measurecompliance be reviewed, highlighting their strengths and weaknesses, alongwith the kind of analytic procedures they support to interpret compliance data

relative to outcomes. Second, we will consider the economic impact of med-ication non-compliance by applying the conventional “cost of non-compli-ance” approach and another approach potentially more meaningful to deci-sion makers, i.e. that of examining the impact of non-compliance on the cost-effectiveness of pharmaceuticals. Careful attention will be given to assessingthe role non-compliance plays in the distinction between efficacy and effec-tiveness. Examples will be drawn from our own research and published litera-ture. Lastly, we will consider how data on medication non-compliance can beintegrated into cost-effectiveness modelling. Participants will be encouragedto comment on presented methods, data, and interpretation. We will concludewith a discussion on how guidelines for economic evaluations could beextended to allow for non-compliance.

COST STUDY METHODOLOGY ISSUES

W3 USE AND INTEGRATION OF FREELY AVAILABLE U.S. PUBLIC USE FILES TOANSWER PHARMACOECONOMIC QUESTIONS: DECIPHERING THE ALPHA -BET SOUPCisternas M, Noe L, Ovation Research Group, Highland Park, IL, USA Learning Objectives: Participants will 1) learn about the various public usefile (PUF) data sources available in the United States for pharmacoeconomicresearch; 2) evaluate PUFs for creating prevalence, resource utilization, andcost estimates; 3) identify which PUF sources are available and appropriate toanswer disease-specific questions; and 4) learn how to integrate thesesources into pharmacoeconomic studies.Who Would Benefit: Individuals in health economics, outcomes research,marketing, and academic departments interested in utilizing publicly availabledata as primary or secondary sources for pharmacoeconomic research.Workshop Description: Public use files can be valuable data sources for con-ducting pharmacoeconomic research. Databases include information basedon patient surveys, medical records, outpatient visits, and inpatient stays, andcan represent various patient groups and settings such as Medicare,Medicaid, VA, long-term care, elderly patients, pediatric patients, and more.Information can be used to develop research hypotheses, as well as to helpestablish the incidence and prevalence of a disease, treatment patterns,resource utilization, productivity and work loss, costs, and variables for sensi-tivity analysis. While many pharmacoeconomic studies can be strengthenedthrough the analysis of PUF data, others, such as cost of illness studies, canbe based solely on such data. This workshop will begin with a guided discus-sion concerning the questions that can be answered through PUF data. Wewill describe the various PUF databases available to answer these questions,along with brief examples of their use from the authors’ own work and otherpublished articles. The pitfalls of using PUF data and how to mitigate themwill also be discussed, and finally, guidelines for combining estimates fromvarious sources into a single study will be described. Materials summarizingthe various data sources, as well as URLs for data download or purchasefrom federal agencies will be provided.

FORMULARY DEVELOPMENT RESEARCH ISSUES

W4 MANAGED CARE DATA: TOOLS AND METRICS FOR FORMULARYDEVELOPMENTShaya FT1, Mullins CD1, Wong W2, 1University of Maryland, Baltimore, MD,USA; 2CareFirst BlueCross BlueShield, Baltimore, MD, USA Learning Objectives: This workshop will demonstrate the strengths of man-aged care claims databases used for formulary development. The aim of theworkshop is to provide practical tools to manage and analyze claims data andinterpret results used for the cost-effectiveness, value and clinical claimsconsidered by formulary committees.


WORKSHOPS - SESSION I

55

Who Would Benefit: Stakeholders, decision-makers, researchers and dataanalysts who have an interest in formulary selection and decision-making.Health care/regulatory professionals who practice in settings of managedcare, hospitals, the pharmaceutical industry, consulting, data management,research or academia. Workshop Description: There has been a growing interest in looking at man-aged care administrative claims databases - which are designed to processbilling claims - to support clinical and cost-effectiveness arguments used indeveloping formularies. This hands-on workshop will examine practicalissues and characteristics of managed care databases, and will outline theirstrengths and mention their limitations in answering research questions andsupporting value claims. With active participation from the audience, we willpropose novel tools to develop medical and prescription data queries,addressing data mining, cleaning and operationalization challenges.Participants will be guided in methods to merge and match medical and pre-scription claims, and will identify validity issues related to properly specifyingthe data fields (e.g. primary, secondary and tertiary diagnoses, or billedcharges versus paid charges etc ..). We will outline bias and confoundingconcerns, and demonstrate tools to handle them in retrospective claims data,as compared to prospective data. We will propose measures to handle miss-ing data, duplicate data, and data integrity, in the context of patient confiden-tiality, HIPAA and IRB regulations. Participants will use a case study to inter-pret the answers to questions of value statement, cost-effectiveness, risk pro-jection, compliance modeling and budget impact. We will assess bias, com-paring and contrasting with the clinical trial design. By the end of the work-shop, the participants will be able to apply the tools for research geared atformulary development.

HEALTH CARE POLICY DEVELOPMENT ISSUES USING OUTCOMESRESEARCH

W5 SYSTEMATIC REVIEWS OF COST-EFFECTIVENESS ANALYSES USING ELEC-TRONIC AND WEB-BASED REGISTRIES Greenberg D, Neumann PJ, Harvard School of Public Health, Boston, MA, USALearning Objectives: The objectives of this workshop are to familiarize partic-ipants with various comprehensive electronic sources of economic evalua-tions. Participants will learn the potential applications and limitations of thesesources; discuss the current practice and the main methods used in cost-effectiveness studies, and changes in CEA practice over time. We will alsoidentify the “under-studied” areas of cost-utility and CEA in clinical medicinethat will need future attention. Participants will then individually complete aseries of web searches of studies of their interest, and explore cost-effective-ness ratios and utility weights for different health states. The workshop willconclude by discussing the documented lack of standard in this field and thepotential barriers for using cost-effectiveness data for coverage and reim-bursement decision-making. Who Would Benefit: Outcome researchers (both in academia and pharma-ceutical and medical device industry) involved in economic evaluation ofhealth interventions, those interested in conducting reviews of CEAs, publichealth department officials, and medical directors at different levels of health-care systems making, reimbursement and resource allocation decisions.Workshop Description: Cost-effectiveness analysis (CEA) has become a pop-ular technique to support resource allocation decisions, and the number ofCEAs published has been increasing steadily in recent years. Due to thegrowing importance of these studies, several efforts to create comprehensiveelectronic or web-based sources (e.g., National Health Service EconomicEvaluation Database-NHSEED, the Health Economic Evaluation Database-HEED, and the Harvard School of Public Health Cost-Effectiveness AnalysisRegistry), summarizing data from economic evaluations, have been made.Although many similarities exist, the focus of these databases and the type ofinformation presented vary. The objectives of this workshop are to familiarizeparticipants with various comprehensive electronic sources of economicevaluations. Participants will learn the potential applications and limitations ofthese sources; discuss the current practice and the main methods used incost-effectiveness studies, and changes in CEA practice over time. We willalso identify the “under-studied” areas of cost-utility and CEA in clinical medi-

cine that will need future attention. Participants will then individually com-plete a series of web searches of studies of their interest, and explore cost-effectiveness ratios and utility weights for different health states. The workshopwill conclude by discussing the documented lack of standard in this field andthe potential barriers for using cost-effectiveness data for coverage and reim-bursement decision-making.

PREFERENCE-BASED STUDIES METHODOLOGY ISSUES INCLUDING UTILITY STUDIES

W6 ADVANCES IN MAPPING HEALTH-RELATED QUALITY OF LIFE: AN EQ-5DINDEX BASED ON SF-36 DATAKind P1, McEwan P2, Currie CJ 3, Dixon S4, 1Outcomes Research Group, York,UK; 2Cardiff University, Cardiff, Wales, UK; 3University of Wales College ofMedicine, Cardiff, Wales, UK; 4Sheffield University, Sheffield, South Yorkshire,UK Learning Objectives: To present current methods of mapping alternativemeasures of health-related quality of life. To discuss the potential benefits ofnew and more advanced modelling techniqes. To provide examples of theapplication of these techniques in mapping SF-36 onto EQ-5D.Who Would Benefit: Those concerned with the analysis of health-relatedquality of life data for use in cost effectiveness analysis and specifically thosewith access to SF-36 who require a single-index preference-weighted sum-mary score.Workshop Description: Single index values are required for use in cost-utilityanalysis. Where profile measures such as SF-36 have been used in clinicaltrials it can be extremely difficult to recover useful data for applications thatrequire a preference-weighted summary measure. One option, where utilityestimates are not directly available, is to predict such values using mappingmethods. This workshop will present examples based on both hospital andnon-hospital data to highlight and contrast issues surrounding the mapping ofSF-36 data to EQ-5D. The first data set, the Health Outcomes Data Repository(HODaR), contains SF-36 and EQ-5D data on more than 25,000 hospital in-patients alongside targeted disease-specific measures. The second data set,Health Survey for England, contains SF-36 and EQ-5D data on some 16,000adults drawn from a representative sample of the general population. Theworkshop will demonstrate the extent to which the EQ-5D domains and utilityscores can be predicted from SF-36 data. Results based on mapping usingstandard regression techniques will be demonstrated and compared withresults obtained using more sophisticated methods based on flexible, non-lin-ear models such as neural networks and classification and regression trees(CART). The benefits of indirect mapping to sub-domain scores rather thansingle utility score will be demonstrated. Improvement in these methods hasmany applications particularly where utility estimates are absent from costly,large-scale clinical trials.

QUALITY OF LIFE STUDY METHODOLOGY ISSUES INCLUDINGPATIENT REPORTED OUTCOMES

W7 APPLYING ITEM RESPONSE THEORY MODELING FOR IMPROVING HEALTHOUTCOMES MEASUREMENTReeve BB, National Cancer Institute, Bethesda, MD, USA Learning Objectives: Participants will learn: 1) the basic concepts and meth-ods of item response theory; 2) what differentiates traditional and modernmeasurement theory; and 3) potential applications of item response theorymodeling for health outcomes measurement.Who Would Benefit: Health outcomes researchers with interest in scaledevelopment or evaluation.Workshop Description: There is a great need in health outcomes research todevelop instruments that accurately measure a person’s health status withminimal response burden. This need for psychometrically sound and clinicallymeaningful measures calls for better analytical tools beyond the methodsavailable from traditional measurement theory. Applications of item responsetheory (IRT) modeling have increased considerably because of its utility forinstrument development and evaluation, assessment of measurement equiva-

ISPOR 9TH A NNUAL INTERN ATIONAL MEET IN G WORKSHOP PRESEN TAT I O N S

56

lence, instrument linking, and computerized adaptive testing. IRT models therelationship, in probabilistic terms, between a person’s response to a surveyquestion and their standing on a health construct such as fatigue or depres-sion. This one hour workshop will discuss the basics of IRT models and appli-cations of these models to improve health outcomes measurement.Illustrations will be used throughout the presentation that focuses on measur-ing key health-related quality of life domains in breast cancer survivors.

RISK ASSESSMENT/RISK MANAGEMENT ISSUES

W8 THERAPEUTIC EXPANSION OF THE CLASSICAL Q-TWIST APPROACHSherrill B1, Irish W2, 1RTI Health Solutions, Research Triangle Park, NC, USA;2RTI Health Solutions, Durham, NC, USA Learning Objectives: To provide enough understanding of the Q-TWiSTmethodology to evaluate treatment differences on successive health statessuch that researchers can consider it for applications in therapeutic areasnot traditionally served with this approach. Who Would Benefit: Health care decision-makers, outcomes researchers andpharmacoeconomists who are responsible for assessing the relative benefitof time-related treatment effects and balancing treatment advantages againstthe risks of adverse events. Workshop Description: Increasingly, researchers are called upon to weighthe clinical and/or quality-of-life benefit of treatments for chronic conditionsagainst the risk of adverse events. Typically, treatment differences in efficacyand safety from clinical trials are evaluated separately. The Q-TWiST method-ology represents a unique analytical opportunity to simultaneously evaluateboth the quantity and quality of successive health states. Q-TWiST stands forQuality-adjusted Time Without Symptoms or Toxicity and was originally devel-oped for oncology studies. Kaplan-Meier analyses are used to estimate timespent in clinically different health states, usually toxicity, symptom-free periodand disease relapse. These states are weighted with utility scores to repre-sent relative value to the patient then summed to provide a Q-TWiST score.Treatments may then be compared for their overall effect on the patient expe-rience with this single measure that encompasses adverse events, time todisease progression or clinical improvement, and relapse or sustainedresponse. We will provide an overview of the analytical approach and demon-strate how the Q-TWiST methodology can be extended to more than threehealth states. The guided interactive part of the workshop will use a casestudy in depression, a non-traditional area for Q-TWiST analyses. Participantswill discuss interpretation of results and determine when Q-TWiST is applica-ble. They will outline the pros and cons of Q-TWiST compared to other meas-ures. They will then be invited to brainstorm applications of the Q-TWiSTapproach in additional therapeutic areas, such as Alzheimer’s Disease.


W9 JOURNEY TOWARDS A TRUE EFFECT IN COHORT STUDIES: OBSTACLES,STATISTICAL TOOLS, AND “DIFFERENCE IN DIFFERENCE” ESTIMATES Lee WC1, Pashos CL2, 1Abt Associates Inc, Bethesda, MD, USA; 2AbtAssociates Inc, Cambridge, MA, USA Learning Objectives: The goal of this workshop is to provide participants with1) a basic understanding of what the difficulties and obstacles are in estimat-ing a meaningful, unbiased effect in cohort studies; 2) statistical tools andstudy designs that can be used to address these challenges; 3) an approachknown as the “difference in difference” econometric method; and 4) exam-ples using the Medicare Public Use Files (PUF), that track the care and costsof a 5% random sample of Medicare beneficiaries. Who Would Benefit: Researchers interested in designing a rigorous cohortstudy enhanced by econometric tools.Workshop Description: Retrospective cohort studies are fraught with numer-ous potential sources of bias that make it difficult to ascertain the differential

impact of a medical intervention on patient outcomes. These potential pitfallsinclude differing length of survival time between groups, censored data,ignored reverse causality, selection bias, improper selection of the controlgroup and model misspecifications. This workshop will provide stepwiseapproaches to deal with these potential pitfalls. Relevant statistical strategiessuch as stratification, matching, and various econometric tools (e.g., logisticregression and Cox proportional hazards model) will be discussed.Throughout the workshop, participants will be given opportunities to studyactual examples, to identify problems, and to offer and review suggestions forstatistical tools to remedy or reduce these problems. Particular attention willbe brought to the “difference in difference” method, a tool more commonlyused in the field of health economics but which has been underutilized in epi-demiological cohort outcome studies. In this regard, emphasis will be placedon understanding: 1) how a cohort study design can be translated into a “dif-ference in difference” econometric equation to adjust for imbalances thatmay remain even after matching, and 2) how the “difference in difference”estimates will complement or enhance a cohort study design.

COMPLIANCE ISSUES

W10 METHODS IN COMPLIANCE EVALUATION: DETERMINING AND ANALYZINGAPPROPRIATE MEASURESNichol MB1, Gwadry-Sridhar F2, Nau DP3, Cramer JA4 for the Med Comp SIG,1University of Southern California, Los Angeles, CA, USA; 2McMasterUniversity, Hamilton, ON, Canada; 3University of Michigan, Ann Arbor, MI,USA; 4Yale University, West Haven, CT, USALearning Objectives: This workshop is designed to elicit participation by theaudience in the derivation of appropriate measures of medication complianceand evaluation of those measures in a variety of settings and diseases. Who Would Benefit: Researchers, practitioners, and policy makers interestedin the field of compliance would benefit from the discussion at this workshopWorkshop Description: Compliance with medications has become an increas-ingly important area of research as policy makers have perceived the extentand effect of the problem. Unfortunately, there are no standards in the fieldfor such concepts as the definition of key compliance measures (such as cat-egorical or continuous rates), duration of observation, outcome measures ofinterest, and the measurement of multiple medications within an observation-al profile. There are also issues with the analytic methods used in determiningimportant statistical and clinical differences between medications and otherinterventions (such as violation of observational independence, historical bias,and measurement bias). Specific problems associated with retrospective data-base analyses will also be considered, including methods for controlling selec-tion, assumptions regarding distributional normality, and approached for defin-ing continuous use. Three members of the ISPOR SIG Analysis StandardsWorking Group will initiate the discussion of these issues by providing a briefdescription of alternative solutions to the analytic problems. Where possible,the discussion leaders will provide examples of methods that could alleviateanalytic obstacles. Workshop participants will be encouraged to explore thestrengths and weaknesses of the alternative approaches.


W11 AT THE FRONTIER: MAXIMZING THE VALUE OF CLAIMS DATABirnbaum H1, Greenberg P2, 1Analysis Group, Boston, MA, USA; 2AnalysisGroup/Economics, Boston, MA, USA Learning Objectives: Participants will explore innovative claims data analysismethodologies regarding pharmacoeconomic outcomes analysis. The pur-pose is for participants to gain useful insights regarding analysis of adminis-trative claims data bases containing a variety of components including med-ical, prescription drug, disability, and workers compensation claims, as wellas sick leave and at-work productivity measures. Who Would Benefit: Outcomes researchers and research sponsors who areinterested in designing and analyzing claims data studies regarding cost of ill-ness and impact of treatment issues.

I SPOR 9TH ANNUAL INTERNAT IONAL MEET ING WORKSHOP PRESENTAT I O N S

WORKSHOPS - SESS ION I I

57

Workshop Description: At the Frontier: Maximizing the Value of Claims DataAssessing at-work productivity loss associated with the use of pharmaceuticals.Disease-specific examples will be discussed concerning each of the following cat-egories: • Assessment of the relationship between direct and indirect costs • Examination of the clinical content of claims data for use in economic analysisincluding attention to proxies that can inform severity of illness adjustments • Adjustments for comorbidities • Analysis of the economic impact on caregivers ofdependents’ illness experience • Estimates of the lifetime costs of illness identifica-tion of patient outcomes over time. The diseases that will be discussed couldinclude: • Attention deficit hyperactivity disorder • Bipolar depressive disorder •Cancer • Major depression • Diabetes • Osteoporosis • Respiratory infections •Rheumatoid arthritis • Treatment resistant depression. The participants will be invit-ed to translate findings into inferences and interpretations. The workshop will con-clude by discussing how these approaches can be adapted to the actual needs ofaudience participants.


W12 THE FORMULARY DECISION PROCESS: WHAT KIND OF INFORMATION ISTRULY HELPFUL?Van Den Bos J1, Mullins CD 2, 1Milliman USA, Denver, CO, USA; 2University ofMaryland, School of Pharmacy, Baltimore, MD, USA Learning Objectives: Participants will learn: 1) about the formulary decisionprocess, based on a review of the literature and on observational study; 2)where decision-makers are not being served; and 3) changes that canimprove the transfer of information to decision-makers from both an academ-ic and an actuarial perspective.Who Would Benefit: Researchers and their sponsors whose intended audi-ence is MCO formulary decision-makers, and formulary decision-makers.Workshop Description: A recent report of the ISPOR Task Force on the Use ofPharmacoeconomic/Health Economic Information in Health Care DecisionMaking found, unfortunately, that pharmacoeconomic research is not widelyused by MCOs. Reasons for this include: the absence of total budget impactanalysis, lack of transparency in methods, and models that are not specific toan MCO’s covered population. This workshop is designed to: a) examine theworkings of formulary decision-making groups; b) pinpoint where the needs ofthese groups are not being met; and c) suggest changes that would makepharmacoeconomic information more useful to MCOs. We will begin with areview of the literature on P&T Committees, with special focus on their use ofpharmacoeconomic information. We will supplement this with informationgleaned from direct observation of P&T Committee meetings and decision-makers. Then we will examine features of economic research that cause P&TCommittees to place low value on pharmacoeconomic findings. We will con-clude by discussing changes that would make economic research more use-ful to P&T Committees, such as methodological and reporting improvements.Suggestions will also include an actuarial perspective on the elements ofgood budget impact modeling, such as consideration of the payer (e.g. com-mercial, Medicare), benefit design, demographic characteristics, treatmentpatterns, condition incidence and prevalence, the rate at which the drug willenter the system, medical cost offsets, and degree of medical management.


W13 THE USE OF DISCRETE EVENT SIMULATION TO ASSESS THE VALUE OFHEALTH CARE INTERVENTIONSCaro JJ1, Huybrechts KF1, Möller J2, 1Caro Research Institute, Concord, MA,USA; 2Caro Research Institute, Eslov, Sweden Learning Objectives: To demonstrate that discrete event simulation is a ver-satile, worthwhile technology for current outcomes research problems.Who Would Benefit: Health care decision makers, policy makers andresearchers who are responsible for conducting, evaluating and utilizinghealth economic analyses.

Workshop Description: It is by now well accepted that a model of the diseaseand its management is required to estimate the value of most health careinterventions. Economic models have typically been structured and analyzedusing decision trees or Markov models, despite recognition of the major limi-tations of these techniques. In this workshop, a much more natural, less limit-ing technique is presented. Although the approach — discrete event simula-tion (DES) — has a long trajectory in operations research, it has to date beenrarely employed in medicine. Through interactive group exercises using anexample of a typical problem in valuing a health care intervention, we willillustrate how the needs of decision makers translate to technical require-ments for the models and how these can be met with the new technique vis avis traditional modeling approaches. The key elements — entities and theirattributes, events, the simulation clock, resources and queues, and computa-tional algorithms — will be presented, and the process for implementing themodels will be illustrated using available software. A DES represents thecourse of disease very naturally with few restrictions. Neither mutually exclu-sive branches nor states are required, nor is the cycle fixed. All relevantaspects are incorporated explicitly and efficiently. Flexibility in handling per-spectives and carrying out sensitivity analyses, including structural varia-tions, is incorporated and the entire model can be presented very transpar-ently. We propose that DES should be the method of choice in carrying outhealth care evaluations, particularly those aimed at informing policy makersand at estimating the budget impact of an intervention.

PREFERENCE-BASED STUDIES METHODOLOGY ISSUES INCLUDING UTILITY STUDIES

W14 INCORPORATING PREFERENCES INTO OUTCOME MEASURES FOR THE VALU-ATION OF GENETIC BASED SERVICESPayne K1, Jarrett J2, Davies LM1, 1Manchester University, Manchester, Gtr.Manchester, UK; 2University of East Anglia, Norwich, UK Learning Objectives: Participants will learn about 1) outcome measures cur-rently used to evaluate genetic services; 2) the need for and qualitative andquantitative methods to develop tools to measure and value, genetic services. Who Would Benefit: Researchers and decision-makers responsible for thedevelopment, application and interpretation of outcome measures in the eval-uation of genetic based services.Workshop Description: Unlike conventional medicine, genetic care typicallydoes not have a direct effect on the prevention, amelioration or cure of dis-ease symptoms, but affect other aspects of people’s life-choices and wellbeing (e.g. decision about whether to marry or have children). Standardmeasures of health status and health related quality of life are unlikely to beadequate for the evaluation of genetic services. The nature of the key attrib-utes to include in an array of tools to measure and value genetic services ispoorly understood. This workshop will introduce participants to 1) the limita-tions of current outcome measures, and 2) an overview of qualitative andquantitative methods to develop instruments to measure and value the(dis)benefits of genetic services. Using a case study of a genetic counsellingservice, participants will be asked to form a focus group, and under guidancefrom the presenters, critique an existing outcome measure. Participants willthen identify the factors they feel are important in the delivery and outcomesof this service. The presenters will then demonstrate how these factors canbe used to generate attributes and levels to use in the design of a stated pref-erence tool (discrete choice experiment). The workshop will conclude by dis-cussing how the development of stated preference instruments could betaken forward to provide robust measures to inform decision-making.

I SPOR 9TH ANNUAL INTERN ATION AL MEET ING WORKSHOP PRESENTAT I O N S

58


W15 SELECTING OUTCOME MEASURES FOR INTERVENTION STUDIES: MAXIMIZ-ING USE OF WEB-BASED RESOURCESBalkrishnan R1, Kelly PA2, 1University of Texas School of Public Health,Houston, TX, USA; 2Baylor College of Medicine and Houston Center for Qualityof Care and Utilization Studies, Houston, TX, USA Learning Objectives: Participants will learn: 1) utilization of web-basedresources to identify appropriate outcome measures for intervention studies;2) develop an understanding of the outcomes framework and aspects of psychometrics that will assist in selection of appropriate measures; and 3) develop a complete understanding of freely available and newly introducedweb resources such as the METRIC that have been developed to assistresearchers with outcome measure selection. Who Would Benefit: Applied health services researchers with little back-ground or training in health psychometrics and evaluation of patient centeredoutcomes, researchers involved in intervention studies, and graduate stu-dents interested in outcomes evaluation.

Workshop Description: Many applied health services researchers with limit-ed background and training in health psychometrics or outcomes evaluationare faced with the dilemma of choosing appropriate patient-centered out-come measures for intervention studies. This workshop provides suchresearchers the basic tools needed to appropriately and efficiently selectsuch measures making maximum use of available web-based resourcesavailable for this purpose. The workshop will begin with a detailed descriptionof the outcomes evaluation framework in intervention research delineatingthe role of premeditating factors, treatment, and short and long-term out-comes. This will be followed by delineation of key types of generic and condi-tion-specific outcome measures, as well as discussion of issues in develop-ment and application of these measures, using examples from the presentersown recent research. This will be followed by a brief discussion of pertinenthealth psychometric issues such as reliability and validity measurement, aswell as practical administration issues. A detailed hands-on demonstration ofweb-based databases such as the METRIC will follow, where the participantswill be able to understand how knowledge of this basic outcome measureselection-related information can be used to identify the appropriate outcomemeasure for their intervention study. Finally a brief self-evaluative exercisewill be provided to participants.


W16 CAPTURING THE VALUE OF PHARMACEUTICALS: THE ROLE OF OUTCOMESRESEARCH IN PRICING DECISIONSTierce JC1, LaPensee KT2, Wierz DJ3, Sugano DS 4 , 1ValueMedics Research,LLC, Arlington, VA, USA; 2Skylands Healthcare Consulting, LLC., formerly ofCambridge Pharma Consultancy, Hampton, NJ, USA; 3Independent Consultant,formerly of Wyeth, Inc, Exton, PA, USA; 4Schering-Plough Corporation,Kenilworth, NJ, USA Learning Objectives: This workshop helps outcomes researchers assume anactive role in pharmaceutical pricing. At the conclusion, attendees will under-stand the principals for integrating pricing and reimbursement with outcomesresearch and health economics to determine, demonstrate and capture prod-uct value. Who Would Benefit: This session is for those engaged in pricing, reimburse-ment, outcomes research and health economics. Anyone with an interest inintegrating these disciplines will benefit.

Workshop Description: As medical technologies cost more to develop andlaunch, health budgets are receiving greater scrutiny for the value for moneyof each component. While outcomes researchers traditionally assess value ofpharmaceuticals, they rarely apply their skills to product pricing. However,outcomes researchers involved in drug development know the most aboutproduct value. This sets up a disconnect—or worse, a “train wreck”—between business planning, expectations, and the value that can be credibly

demonstrated. Capturing product value within today’s global market is mosteffectively accomplished by applying the skills of outcomes research andhealth economics to pricing and reimbursement throughout the productdevelopment and commercialization processes. In this workshop, attendeeswill learn pricing strategies from the perspective of a) value determination,including market assessment, reimbursement and product/portfolio revenueand profit forecasts; b) value demonstration, including studies, informationconsiderations, models and pricing research; and c) value capture, includingoutcomes research in value-based pricing research and the development of aproduct pricing strategy, qualitative and quantitative techniques in value-based pricing research, market segment differences and dynamics in pricingand reimbursement and applying the knowledge gained through participatingin that process to reimbursement applications and contracting negotiationswith payers. The workshop format will include case studies where partici-pants will discuss the appropriate application of outcomes research to pric-ing decisions. Attendees will also have the opportunity to ask questions andshare experiences with integrating these disciplines.

CLINICAL STUDY METHODOLOGY ISSUES INCLUDING PHARMA-COEPIDEMIOLOGY

W17 STATISTICAL ANALYSIS OF PATIENT REGISTRIES: METHODS FOR THE MOSTEFFECTIVE USE OF OBSERVATIONAL DATAPasta DJ, Miller DP, Ovation Research Group, Highland Park, IL, USA Learning Objectives: Observational outcomes studies, or registries, present anovel way of collecting naturalistic outcomes data associated with a particu-lar disease or product. This workshop reviews the primary types of data col-lected in registries and the procedural and methodological challenges facedwhen analyzing those data. Who Would Benefit: This workshop is intended for individuals who want tolearn more about the methods of analyzing registry data. Individuals responsi-ble for design and implementation of registries would also benefit from thisworkshop.Workshop Description: Procedural Challenges: Analysis of observationalstudies has different challenges than analysis of randomized clinical trials.Obtaining accurate data on practice patterns, resource utilization, andpatient-reported outcomes requires a naturalistic study design. As a result,treatment groups will not be randomized, sites who do not regularly performcertain diagnostic tests may have a great deal of missing data, and unexpect-ed practice patterns are almost guaranteed. From a procedural standpoint,this means that a certain amount of directed exploratory analysis is usuallynecessary before a comprehensive analysis plan can be developed. Theworkshop provides concrete steps for meeting this procedural challengethrough a process of successive refinement of the analytical approach.Methodological Challenges: The fact that the analysis of observational datatends to be less driven by a priori hypotheses leads to some specific method-ological challenges. The absence of pre-specified hypotheses does not meanthat the analysis is strictly descriptive; comparisons can still be made amonggroups even though those groups probably have not been pre-defined or ran-domized. However, there are special statistical techniques that need to beused to account for the likely differences between groups. Patients undergo-ing the various treatments or no treatment are likely to differ in material waysfrom each other. The workshop compares several statistical approaches toovercoming this problem, including matching, using propensity scores, andadjusting using covariates.

I SPOR 9TH ANNUAL INTERNATION AL MEET ING WORKSHOP PRESENTAT I O N S

WORKSHOPS - SESS ION I I I

59

COMPLIANCE ISSUES

W18 MEDICATION COMPLIANCE (ADHERENCE): ISSUES AND DEFINITIONS CON-SENSUS WORKSHOPCompliance SIG I&MDWG1, Wong P2, Fairchild C3, Clause S 4, Burrell A5,Cramer J6 for the Med Comp SIG, 1ISPOR, ISPOR, NJ, USA; 2Good SamaritanHospital, Dayton, OH, USA; 3Bristol-Myers Squibb, Plainsboro, NJ, USA;4Albany College of Pharmacy, Troy, NY, USA; 5Aventis, Bridgewater, NJ, USA;6Yale University School of Medicine, West Haven, CT, USA Learning Objectives: The objectives of the workshop are 1) to evaluate theapplicability of the definitions in various practice settings; 2) to identify issuesrelated to these proposed definitions in conducting and evaluating research;3) to gather opinions for the further refinement of these definitions; and 4) tobuild consensus among ISPOR members for the early adoption of these defi-nitions.Who Would Benefit: Researchers, clinical practitioners, academicians andresearch sponsors that are interested in medication compliance research andclinical practice.

Workshop Description: In 2003, the International Society ofPharmacoeconomics and Outcomes Research (ISPOR) chartered aMedication Compliance Special Interest Group (SIG) to provide ISPOR mem-bers with a forum for discussing issues related to medication compliance(adherence) and treatment persistence. In addition, ISPOR anticipates thatthis SIG will stimulate research and evaluation on issues related to medica-tion compliance, treatment persistence, and implications for health outcomes.Five working groups were created to reach the SIG’s objectives. These work-ing groups are: 1) Issues & Methods Definition; 2) Analyses Standards; 3)Bibliography; 4) Education; and 5) Economics of Medication Compliance. Thisworkshop is organized by the Issues and Methods Definition Working group.At this workshop, the working group members will provide background infor-mation regarding the derivation of the definitions and comparisons with simi-lar definitions in the global medical literature. Participants will engage insmall group discussions which will focus on issues with the application ofproposed definitions. Examples include use in acute and chronic diseases, inclinical practice, in clinical research, in health policy, as well as variousmeasurement tools (e.g., electronic medical records, electronic monitors, pillcounts, serum levels, patient adherence questionnaires, etc). Finally, the smallgroups will present their recommendations to all the participants for discus-sion. Key issues raised in 2003 will be addressed and recommendations gen-erated from this workshop will be published at the ISPOR SIG website.


W19 QUALITY AND VALIDATION STANDARDS IN HEALTH CARE MODELLINGBeard S1, Davies L2, Payne K3, Earnshaw SR4, 1RTI Health Solutions,Manchester, UK; 2University of Manchester, Manchester, UK; 3ManchesterUniversity, Manchester, Gtr. Manchester, UK; 4RTI International, RTP, NC, USA Learning Objectives: Participants will learn methods and practical steps toimprove the validity and quality of health care decision models and improveadherence to published guidance on health care modelling standards.

Who Would Benefit: Health care decision makers and analysts involved incommissioning, developing and analysing or applying the results of computerbased decision models to evaluate new and existing health care technolo-gies.Workshop Description: Decision modelling is an increasingly important andfrequent approach in establishing the relative economic value and likelybudgetary impact of new and existing healthcare technologies. The rationalefor a model approach requires that clinical and resource cost data from morethan 1 source are synthesised. The process of building the model to representthe clinical decision process also utilises data and opinion from a number ofsources and perspectives. These factors lead to variation in the assumptionsand biases that underpin the model structure and data selection, quality ofdata and overall quality of the model that is difficult to assess and interpret. Anumber of guidance statements have been published in recent years, aimedat providing a common reference point to assess the quality of such models.

This workshop will summarise the key common elements of available guid-ance, then split into 4 facilitator led work groups to highlight practical steps toidentify and minimise the impact of implicit biases, maximise the accuracy ofthe model structure and data, identify and quantify structural and data drivenuncertainty and thereby attempt to optimize overall model quality. A numberof model scenarios will be used to stimulate these discussions. The groupswill reconvene to discuss and summarise the key messages to improve modelquality and obstacles to the implementation of these guidelines. This willinclude presentation of practical examples illustrating different approaches.


W20 THE ART AND SCIENCE OF BUDGETARY IMPACT MODELING FOR FORMULA-RY SUBMISSIONSTaylor DC, Thompson D, Innovus Research, Inc, Medford, MA, USA Learning Objectives: To share tips and techniques for building scientificallyrigorous budgetary impact models while maintaining transparency and auser-friendly interface.Who Would Benefit: Applied researchers or research sponsors interested inincluding budgetary impact models in dossiers for formulary submissions, aswell as potential end users of such models.Workshop Description: Budgetary impact models (BIM) are increasingly usedin formulary submissions to help decision-makers assess the potential finan-cial implications of adding a new therapy to their formulary. These modelsmust incorporate complex marketplace dynamics such as product substitu-tion effects and the potential for market expansion, but need to be flexibleenough for users to modify the model parameters to fit their own institution’spopulation, practice patterns, and costs. The art of creating a successful BIMlies in making it transparent enough so that the user can understand all of theunderlying assumptions and calculations, simple enough to be used with littleor no training, yet complex enough to capture the cost and science of the dis-ease and its treatment options in a world with and without the treatment beingevaluated. This workshop will draw on the presenters’ experience in balancingthese sometimes conflicting objectives in a BIM. In true workshop fashion,participants will be asked to share their experiences on a variety of relevantissues, including population selection, event rates, treatment regimens, andcost determination. Discussions will also focus on how methodologic andinterface design decisions may affect the accuracy, usability, and perceptionof the model. Particular attention will be paid to the implications of incorporat-ing the element of time into a BIM, including the need to estimate screeningcosts, discount rates, discontinuation rates, and plan turnover rates.


W21 IMPLICATIONS OF CANADA/US PARALLEL TRADE IN PRESCRIPTION DRUGS:A CANADIAN PERSPECTIVEPalmer WN, Palmer D'Angelo Consulting Inc, Ottawa, ON, Canada Learning Objectives: To provide an understanding of Canada/US cross bordertrade, the factors contributing to lower Canadian prices, implications forCanadian pricing and reimbursement and the outlook for parallel trade inNorth America.Who Would Benefit: Health Policy Analysts, Pricing Managers,Reimbursement Managers

Workshop Description: The growth of Canadian internet pharmacies and thedebate over the importation into the United States of lower-priced Canadianprescription drugs raises questions of why Canadian drug prices are lowerthan those in the United States and if these lower prices can be sustainedinto the future. In Canada both the public and private sectors play an impor-tant role in pharmaceutical reimbursement although it is government policiesthat have limited drug prices since 1987. This workshop is designed to assistdecision makers understand Canada’s pricing and reimbursement environ-ment and the impact the cross border trade issues are having on Canadiandrug prices. We will discuss the role of the Patented Medicines Prices

I SPOR 9TH A NNUAL INTERN ATION AL MEET ING WORKSHOP PRESEN TAT I O N S

60

Review Board (PMPRB), which regulates prices of patented medicines, illus-trate pharmaceutical price trends and international price comparisons, anddescribe the impact of government policies on prices. We will explain provin-cial reimbursement programs and outline the role and growing importance ofpharmaco-economics and outcomes research in light of increasing drugprices. Parallel trade (internet pharmacies, re-importation legislation) with theUnited States has resulted in upward pressure on Canadian drug prices aswell as new distribution arrangements targeted at limiting supplies toCanadian pharmacies. Recently, Canadian pharmaceutical manufacturershave challenged decade old price regulations and Canadian prescription drugprices have begun moving closer to US prices. In light of these and relateddevelopments, the workshop will consider the outlook for parallel trade inNorth America and the implications on pricing and reimbursement in Canada.The workshop will encourage discussion and debate on the desirability ofparallel trade and what measure if any policy makers in Canada and theUnited States should implement to encourage or discourage cross bordertrade in prescription drugs.

PREFERENCE-BASED STUDIES METHODOLOGY ISSUES INCLUDINGUTILITY STUDIES

W22 QUALITY ADJUSTMENT USING AVERAGE UTILITIES: VIRTUE OR VICE?Caro JJ, Huybrechts KF, Caro Research Institute, Concord, MA, USA Learning Objectives: To examine the basis for using average utilities in cost-effectiveness analysis, its appropriateness and its potential impact on deci-sion-making.Who Would Benefit: Health care decision makers, policy makers andresearchers who are responsible for conducting, evaluating and utilizingcost-utility analyses.Workshop Description: A major challenge in economic analyses has been tofind a way to aggregate the disparate health effects into a single measurethat can be used comparatively and can be combined with the costs into asingle criterion of economic efficiency. The most prominent contender for asolution to this problem has been the construct of quality adjusted life years(QALY). Survival is quality adjusted using weights attached to each of the pos-sible health states. These weights have been estimated as the averageobtained from patients (or their surrogates), health professionals or the gen-eral public (or by expert opinion!). There are major problems with this use ofaverage weights. A fundamental issue is that it demands an absolute scaleacross all possible outcomes — an impossible task. More importantly, even ifthis flaw is ignored, average values mask potentially large individual varia-tions, both cardinal (different people value health states differently) and ordi-nal (disagreement in terms of ranking). Ignoring the heterogeneity may distortthe health effects to such an extent that they misrepresent the value of someoutcomes and thus impair optimal decision-making, as will be shown using anexample. Throughout the workshop, the theoretical concepts, beginning withthe sound original approach to individual decision-making, will be illustratedby means of interactive group exercises and views of the participants will bevigorously elicited. Recommendations for improved application of these con-cepts will be made.

QUALITY OF LIFE/PATIENT-REPORTED OUTCOMES

W23 CHALLENGES IN DEVELOPING INSTRUMENTS TO SHOW THE VALUE OFNEW THERAPIES FOR SEVERE MENTAL ILLNESSRothman M1, Awad GA2, Revicki D3, Speight J4, 1Johnson & Johnson, Raritan,NJ, USA; 2River Regional Hospital, Toronto, Canada; 3MEDTAP International,Inc., Bethesda, MD, USA; 4Oxford Outcomes, Ltd., Cassington, Oxford, UKLearning Objectives: Participants will gain a greater understanding of thecomplexities of measuring outcomes in clinical trials of new therapies forsevere mental illness. Participants will have the opportunity to participate indiscussion of a research agenda to address these issues.Who Would Benefit: Health outcomes researchers in academia, industry andgovernment interested in assessing outcomes in severe mental illness.Workshop Description: This workshop is presented by health outcomes

researchers with extensive experience in the development of outcome meas-ures used to assess new therapies. There is increasing recognition of theimportance of understanding the patient perception of new therapies formany conditions and findings based on this experience are accepted forapproval and promotion of products. However, there remain challenges toobtaining credible evidence from persons with severe mental illness that isacceptable to regulatory authorities and clinicians. Examples of these chal-lenges include determining when a respond or a proxy may provide reliabledata, identification of an appropriate baseline, outcome specificity and evalu-ating outcomes in multiple.


W24 RISK MANAGEMENT STRATEGIES USING PATIENT REGISTRIESTennis P1, Andrews E1, Johnson FR2, 1RTI Health Solutions, RTP, NC, USA;2Research Triangle Institute, Research Triangle Park, NC, USA Learning Objectives: The objective of this workshop is to demonstrate theutility of patient registries as an integral part of a risk management strategythroughout drug development. We will discuss methodologic and regulatoryissues which arise in performing such registries and utilize an audience par-ticipation exercise to illustrate these issues. Who Would Benefit: This workshop is useful for people who wish to learn 1)how information from registries contribute to an effective product strategy; 2)how to evaluate elements of risk management programs (RMPs); and 3) howpatient-reported outcomes contribute.Workshop Description: Focus on risk management throughout drug develop-ment has resulted in closer monitoring of the risk/benefit profiles during thepre-approval phase; and at times, therapies may only be approved with RiskManagement Programs (RMPs) requiring education, focused prescribing, orother mandatory elements. This focus on risk management has generatedinterest in registries of patients with specific diseases and post-approval reg-istries of patients using a therapy. Disease registries can identify the contextfor safety signals and facilitate rapid response to a shifting product profileduring the pre- and post-approval phases. Post-approval therapy registriescan generate data to assess whether elements of a RMP are achieving theirgoals, including whether patients receive and perceive information as intend-ed, whether they utilize medications as prescribed, and whether intendedtypes of patients receive the therapy. Therapy registries can also evaluate thecharacteristics of patients who most benefit from therapy. Included statedpreference surveys of patients quantify their value trade-offs between clinicalbenefits and risks. Follow-up assessments can be used to assess patients’perceptions of the impact of therapy (in therapy registries) or disease (in dis-ease registries). Responses from clinicians and patients permit the integrationof clinical data and patient-reported outcomes.

CLINICAL STUDY METHODOLOGY ISSUES INCLUDING PHARMA-COEPIDEMIOLOGY

W25 HOW CAN HEALTH-RISK APPRAISAL DATA CONTRIBUTE TO CARDIOVASCU-LAR OUTCOMES RESEARCH? Menzin J1, Brown J1, Manocchia M2, 1Boston Health Economics, Inc, Waltham,MA, USA; 2Blue Cross And Blue Shield Of Rhode Island, Providence, RI, USA Learning Objectives: The objective of this workshop is to review the use ofhealth-risk appraisals (HRAs) in health promotion, and describe how thesedata may supplement administrative claims in conducting outcomes researchfor cardiovascular disease. Who Would Benefit: Persons involved in research using administrative claimsdata or cardiovascular outcomes research would benefit from this workshop.

Workshop Description: Cardiovascular disease is an active area for out-comes research. Administrative claims data, sometimes supplemented byclinical laboratory results, are often used to assess prevalence, treatmentpractices, and costs related to cardiovascular risk factors such as hyperlipi-demia, hypertension, and diabetes. However, current data sources often lackkey measures of cardiovascular risk, including smoking status, blood pres-sure, body mass index, and family history of heart disease. These measures

ISPOR 9T H A NNUAL INTERN ATIONAL MEET IN G WORKS HOP PRESEN TAT I O N S

61

and others are available through HRAs. In this workshop, we will outline therole of HRAs in health promotion and their usefulness as a tool in outcomesresearch. We will describe the process by which HRAs are linked to adminis-trative claims data, and carefully appraise the advantages and limitations ofthe combined data source. Published examples and case studies will illus-trate the use of linked HRA-claims data to examine cardiovascular treatmentpractices and associated costs of care.

COMPLIANCE ISSUES

W26 EDUCATION ISSUES IN MEDICATION ADHERENCEAdamus AT1, Tran H2 for the Med Comp SIG, 1University of Texas M.D.Anderson Cancer Center, Houston, TX, USA; 2Lake Erie College of OsteopathicMedicine, Erie, PA, USA Learning Objectives: Formulate a plan of action to increase the rate of med-ication adherence by engaging participants in a discussion of the salient fac-tors associated with medication adherence education and research. Theobjectives are to: 1) identify factors thought to lead to medication non-adherence; 2) appreciate the underlying reasons associated with these factors; 3) know why these factors and underlying reasons are important toadherence education. Who Would Benefit: Anyone interested in 1) promoting patient medicationadherence; 2) educating the public about medication adherence; 3) develop-ing or integrating a curriculum centered around patient medication adher-ence; and 4) those responsible for teaching health professionals.Workshop Description: There is wide variation in the research on medicationadherence making study comparisons and a single educational focus difficult.The development of educational content requires a different level of knowl-edge be delivered to different groups depending on their level of need. For cli-nicians, practical strategies to increase medication adherence should beexpounded upon while researchers and educators may need more exposureto the measurement and analysis of medication adherence. The goal of theworkshop will be to formulate a plan of action to increase the rate of patientmedication adherence by discussing educational content and target groups.The workshop will begin with an overview of the most researched and pre-vailing factors thought to lead to medication non-adherence (e.g. poor com-munication), underlying causes (e.g. literacy and perception) identified inmedication adherence research, and the impact of non-adherence. Workshopfacilitators will then present selected target groups who would benefit fromeducation on adherence issues. Participants will be given these target groupsas topics to discuss in small groups. The goal of small groups will be to 1) brainstorm a plan of action to educate their assigned target group, and 2) identify the most salient educational content for their selected target group.Participants will then present the consensus for their topics to the entiregroup.


W27 THE ROLE OF OUTCOMES RESEARCHERS IN DESIGNING PATIENT REGISTRIES: CREATING PROGRAMS TO MEET BROAD ORGANIZATIONALOBJECTIVESLarson LR1, Malamis P2, Gordon MJ1, Trotter JP1, 1Ovation Research Group,Highland Park, IL, USA; 2Galt Associates, Sterling, VA, USA Learning Objectives: Participants will gain an understanding of: 1) registrystrategy and design principles; 2) trends in regulatory requirements for post-marketing safety-surveillance registries; and 3) opportunities for integratingoutcomes measures within these programs.Who Would Benefit: Outcomes researchers interested in exploring the designand application of patient registries to meet outcomes, commercial, and safe-ty-surveillance objectives. Those with responsibility for implementing peri-approval programs to meet the growing demand for integratedcommercial/risk management/outcomes data would also benefit.

Workshop Description: Growing demands from regulators, including the FDAand the EMEA, as well as from global commercial markets, to better docu-ment the real-world effects of new and marketed products are contributing tothe necessity for – and proliferation of – patient registries. When designedappropriately, these registries represent a valuable new tool allowing out-comes researchers to collaboratively and efficiently meet a broad range oforganizational objectives. While the responsibility for initiating a patient reg-istry has traditionally fallen to marketing, clinical, or medical affairs, outcomesresearch groups are increasingly involved in these programs. Patient reg-istries offer outcomes researchers an opportunity to create and accessunique datasets. On a broader scale, patient registries can address a widerange of objectives - from developing a competitive differentiation strategybased on safety and effectiveness, to meeting post-launch regulatory commit-ments (including risk-management demands), to supporting a new product’smarket entry and acceptance. Outcomes researchers can play a prominentrole in directing the design and direction of these important programs. Thisinteractive workshop will review registry strategy and design, including a dis-cussion of approaches to incorporating both safety and outcomes measureswithin an integrated program. Global regulatory and risk-management trendswill also be discussed, highlighting the potential value of these programsthroughout the sponsor organization.


W28 ASSESSMENT OF DATASOURCE OPTIONS FOR OUTCOMES RESEARCH ANDFORMULATY DECISIONSBrixner DI1, Tabb K2, Stockdale B1, Holubkov R1, 1University of Utah, Salt LakeCity, UT, USA; 2GE Medical Systems Information Technologies, Berkeley, CA,USA Learning Objectives: Participants will learn 1) to describe the types of dataavailable from various sources; 2) compare and contrast the value of thesedata sources in conducting outcomes research; 3) determine which datasetsbest answer what type of research question; and 4) describe how data fromeach source can define new product value for formulary decisionsWho Would Benefit: Individuals involved in the conduct or evaluation of out-comes research studies deciding which type of database can best answerspecific research questions and decision makers deciding where to go forinformation in defining value for new products coming to market.Workshop Description: Various types of datasets will be described includingpatient registries, public sector databases, clinical trail and observationalstudy datasets, retrospective claims and electronic medical record databas-es. Each of these sources provides varying degrees of information that is use-ful in the conduct of outcomes research and in the context of formulary deci-sion making. Patient registries and public sector databases such as theNational Health and Examination Survey (NHANES) provide information on thecurrent statistics for a particular disease state. Datasets from clinical trailsand observational studies can provide information to project the potentialimpact of a new product once available in the marketplace. Claims databasesare derived from various sources where there are paid reimbursements formedical services, including managed care datasets. These sources may pro-vide accurate information on drug utilization, however few of these databasesprovide information on outcome measures such as laboratory values, bloodpressures or body weight. An electronic medical record can provide exten-sive data in these areas. The advantages and limitations of each type ofdataset will be discussed both for outcomes research and formulary decisionmaking. Assessment of which type of datasource to use for different types ofresearch or value questions will be explored through the presentation of twooutcomes research scenarios where the audience will assist in decidingwhich type of datasource would best answer the questions.

I SPOR 9T H A NNUAL INTERNATIONAL MEET IN G WORKS HOP PRESEN TAT I O N S

62


W29 DEVELOPING A STRATEGY FOR PROMOTING THE USE OF ECONOMIC EVALU-ATION IN HEALTH CARE DECISION MAKING IN LATIN AMERICA Rovira J1, Bertozzi SM2, 1The World Bank, Washington, DC, USA; 2InstitutoNacional de Salud Publica, Cuernavaca, Morelos, Mexico Learning Objectives: To review preliminary evidence and discuss the beststrategies for increasing the application of economic evaluation to actualdecision making in the health sectorWho Would Benefit: Health care decision makers as well as researchersinterested in ensuring the practical application of economic analyses

Workshop Description: In many countries there is a clear disconnectbetween the analytical work of economic evaluation researchers and thedecision-making processes. Although the former are able of producing workof acceptable and high quality, decision makers seem to ignore this work ineveryday decisions. The workshop will present the experience of an initiativeaimed at bridging that gap in nine LA countries: Argentina, Brazil, Colombia,Cuba, Mexico, Nicaragua, Peru, Uruguay and Venezuela. The key aspects ofthe strategy were that will be presented are: An assessment of the situationof economic evaluation in each country based on a review of the studies andliterature on the topic and an identification of the human and institutionalresources available. An analysis of the decision making process and the iden-tification of the potential users of economic evaluations, as well as someanalyses carried out in order to eliciting the knowledge and attitudes of thesedecision makers in relation to economic evaluation tools. The strategyincludes the development and dissemination of standard user friendly tools –a software program for economic evaluation and cost databases – that mightreduce the cost of carrying out the studies and to increase their transparencyand credibility to non expert users. The previous analyses allowed to identifythe main bottlenecks that limit a more widespread use of economic evalua-tions at country level and to define strategies at national level aimed at over-coming the existing obstacles. Workshop participants are expected to providea critical feedback to the proposed strategy and to share similar experiencesaimed at improving the use of tools by decision makers. The work has beenthe result of a collaborative activity of two projects: NEVALAT “ThematicNetwork on the Economic Evaluation of Health Programmes and itsApplication to Decision Making in Latin American Countries” and the REDBOBADILLA.


W30 COLLECTING PATIENT-REPORTED OUTCOMES DATA OUTSIDE THE CLINICALTRIAL PARADIGMMathias SD, Colwell HH, Matosian ML, Ovation Research Group, HighlandPark, IL, USA Learning Objectives: There are distinct benefits of collecting PROs withinnon-clinical trial (“real world”) study designs. Without disrupting patient care,real world studies can be designed to provide data on the cost and outcomesunder usual care conditions. Participants will gain an understanding of recentadvances which have resulted in the use of innovative approaches in the col-lection of PRO data. Who Would Benefit: The workshop is intended for individuals from pharma-ceutical, biotech, and device companies as well as academic researchersresponsible for the design and conduct of late phase, real world outcomesstudies, including disease and product registries.

Workshop Description: Real world, late phase studies offer many advantagesover clinical trials for the collection of outcomes data. These include theirincreased external validity, reduced burden on both investigators and sub-jects, the use of more relevant comparators, and the lack of protocol-mandat-ed visits and procedures. Thus without disrupting patient care, real worldstudies can be designed to provide data on the cost and outcomes underusual care conditions. Recently, technological advances have resulted in themore frequent use of electronic data collection (EDC) methods for the collec-tion of PRO data. This workshop will highlight many of the available options

for the collection of PRO data and will address relative strengths and weak-nesses of these innovative approaches. Several case studies will be present-ed which incorporate these new advances in late phase studies. Audienceparticipation will be encouraged through an activity that uses a case study toreview and recommend an approach for the collection of PRO data.


W31 CANCER-SPECIFIC PATIENT REPORTED OUTCOMES: DO THEY YIELD USEFULINFORMATION?Gondek K1, Kamath CC2, Copley-Merriman K3, 1Bayer Pharmaceuticals, WestHaven, Connecticut, USA; 2Mayo Clinic, Rochester, Minnesota USA; 3Pfizer,Inc, Ann Arbor, Michigan Learning Objectives: The participants of this workshop will gain an under-standing of the challenges faced in collecting and analyzing patient reportedoutcomes in cancer. Insight regarding changes necessary to demonstratethe value of patient reported outcomes in cancer.Who Would Benefit: Health outcomes researchers in academia, industry,government or regulatory bodies. Decision-makers at all levels of clinicalpractice.Workshop Description: The potential utility of patient-reported outcomes incancer has been called into question (e.g., the Goodwin & Gantz paper). Themany factors responsible for this include unreasonable expectations, old con-ceptual foundations as well as poor methodological and statistical rigor. Theconcept of a clinically significant difference in outcomes is emerging as anaid to clinical decision making and in design of clinical trials. This couldpotentially contribute to greater utility of these outcomes. But is this anotherattention-grabber or a concept that holds genuine promise? What will it taketo ensure better use of patient-reported outcomes in the clinical care ofpatients? What will it take to ensure better assessment of patient-reportedoutcomes in clinical trials?


W32 POTENTIAL ROLE OF PRO ASSESSMENTS IN RISK MAMANGEMENT PROGRAMSMarquis P, Piault E, Mapi Values, Boston, MA, USA Learning Objectives: To understand the potential role of patient reported out-comes (PRO) in risk management and more specifically to determine 1) whenPRO should be evaluated in a clinical development to support the meaningful-ness of the drug efficacy, and 2) how the use of PROs will contribute to betterassess the benefit in real life for risk management programs. Who Would Benefit: Outcomes researchers involved in the clinical develop-ment and marketing activities, regulatory affair managers. Workshop Description: The creation of the Study Endpoint and LabelDevelopment group (FDA/CDER/OND) and its interaction with the review divi-sions demonstrates the acceptance of PRO as important endpoints, and alsoemphasizes the need for quality. Recently, FDA has put a lot of focus on riskmanagement (concept paper, rule for safety reporting requirements). Riskmanagement concentrates mainly on safety issues and little room is given tothe evaluation of the treatment benefit. Therefore, regulators are in need formore meaningful endpoints demonstrating the drug benefit particularly from apatient perspective that will complete the data from traditional “objective”endpoints. Indeed the role of PRO in the new risk management paradigm hasto be better defined. During the workshop, the emphasis will be put on practi-cal considerations when implementing risk management programs (role ofPRO in light of the type of pivotal endpoints, characterization of severity lev-els, identification of responders…) and strategies will be proposed. Successstories (i.e., Lotronex, Accutane) will be discussed. The workshop will helpPRO researchers and regulatory affair managers to better determine the rele-vant PRO endpoints needed to support drug approval and design efficient riskmanagement program. This would finally contribute to support the availabilityof those products where the benefit as perceived by the patients is worth therisk of the treatment.

I SPOR 9TH ANNUAL INTERNATIONAL MEET IN G WORKS HOP PRESEN TAT I O N S

63

I N M E M O R I A M

Bernard J. O’Brien BA, MSc, PhD1959-2004DirectorProgram for Assessment of Technology in Health (PATH)Hamilton, Ontario, Canada

Bernie J. O’Brien BA, MSc, PhD was Director of PATH and Associate Directorof the Centre for Evaluation of Medicines at St. Joseph’s Hospital inHamilton, Ontario. A graduate of the University of York (BA, MSc) andBrunel University (PhD) in London, he was also a Professor in the Departmentof Clinical Epidemiology and Biostatistics, McMaster University.

Dr. O’Brien was also Director, Clinical Effectiveness Research of the FatherSean O’Sullivan Research Centre and an Associate of the Centre for HealthEconomics and Policy Analysis, McMaster University. Previously, he heldother appointments in the Department of Clinical Epidemiology andBiostatistics at McMaster, and the Health Economics Research Group, BrunelUniversity, London, United Kingdom.

He was an outstanding researcher in the field of economic evaluation, whopublished more than 150 books, articles and papers. His particular fieldsof expertise were economic analysis alongside clinical trials, decision ana-lytic modelling, health output measurement and valuation, and statisticalanalysis in economic evaluation. He published several landmark articles andwas a recipient of ISPOR Research Excellence Award for Methodology in2002. He was also a co-author of the textbook, Methods for the EconomicEvaluation of Health Care Programmes, published in 1997.

Dr. O’Brien was an enthusiastic teacher with a special skill for communicat-ing health economics concepts in an understandable way. His other mainpassion was for the development of young investigators and many membersof ISPOR benefited from his mentorship and encouragement.

64

ISPOR SERVICE AWA R D E E S

HEALTH CARE COST, QUALITY, AND OUTCOMES:ISPOR BOOK OF TERMS CO-EDITORSKerstin (Chris) Bingefors MSc, PhDAssociate Pro f e s s o r, Uppsala University, Dept of Pharm a c y, Pharmacoepidemiology &PE, Biomedical Center, Uppsala, Sweden

M a rc Berger MDVice President, Outcomes Research &Management, Merck & Company, Inc., We s tPoint, PA, USA

Edwin Hedblom Pharm DGlobal Health Economics Manager, MedicalDivision, 3M, St. Paul, MN, USA

Chris Pashos PhDVice President & Executive Director ofP h a rmacoeconomics & Outcomes Research, A b tAssociates Clinical Trials, Cambridge, MA, USA

G e o rge To rrance PhDVice President, McMaster University andInnovus Research Inc., Burlington, Ontario, Canada

Marilyn Dix Smith RPh, PhDExecutive Dire c t o r, ISPOR, Lawrenceville, NJ, USA

STUDENT NETWORK CHAIRRitesh Kumar BS Pharm, MSDoctoral Candidate, University of Michigan,College of Pharm a c y, Ann Arbor, MI, USA

AUBURN UNIVERSITY - ISPOR STUDENT CHAPTER PRESIDENTNikhil Khandelwal BS Pharm, MSDoctoral Student

FLORIDA A&M UNIVERSITY - ISPOR STUDENT CHAPTER PRESIDENTBenita D. Williams BSM a s t e r’s Candidate

OHIO STATE UNIVERSITY - ISPOR STUDENT CHAPTER PRESIDENTSpencer Harper Pharm D

RUTGERS UNIVERSITY - ISPOR STUDENT CHAPTER PRESIDENTConcetta Crivera Pharm DM a s t e r’s Candidate

UNIVERSITY OF ARIZONA - ISPOR STUDENT CHAPTER PRESIDENTD u rgesh D. Bhandary BSPharm, MSP re-Doctoral Fellow

UNIVERSITY OF FLORIDA - ISPOR STUDENT CHAPTER PRESIDENTDionne Mayhew MPHDoctoral Student

UNIVERSITY OF HOUSTON - ISPOR STUDENT CHAPTER PRESIDENTMonali Bhosle BSM a s t e r’s Candidate

UNIVERSITY OF LOUISIANA AT MONROE - ISPORSTUDENT CHAPTER PRESIDENTL a rry Humble BS PharmDoctoral Student

UNIVERSITY OF MARYLAND - ISPOR STUDENT CHAPTER PRESIDENTPrasun Subedi BS

UNIVERSITY OF MICHIGAN - ISPOR STUDENT CHAPTER PRESIDENTMathew C. Garber BS Pharm, Pharm DMA in Economics, Doctoral Student

UNIVERSITY OF MINNESOTA - ISPOR STUDENT CHAPTER PRESIDENTShuchita Agarwal BS Pharm, MBADoctoral Candidate

UNIVERSITY OF NEW MEXICO - ISPOR STUDENT CHAPTER PRESIDENTRupali Naik BS Pharm, MBAMaster's Candidate

UNIVERSITY OF RHODE ISLAND - ISPOR STUDENT CHAPTER PRESIDENTG reg Low BS Pharm, MSDoctoral Student

UNIVERSITY OF SOUTH CAROLINA - ISPOR STUDENT CHAPTER PRESIDENTBrian Meissner Pharm DDoctoral Student

UNIVERSITY OF SOUTHERN CALIFORNIA - ISPOR STUDENT CHAPTER PRESIDENTVaishali Patel Pharm DM a s t e r’s Candidate

UNIVERSITY OF TENNESSEE - ISPOR STUDENT CHAPTER PRESIDENTC a m e ron James BA P h a rm DDoctoral student

UNIVERSITY OF TEXAS - ISPOR STUDENT CHAPTER PRESIDENTHoma B. Dastani BS Pharm, MSDoctoral Candidate

UNIVERSITY OF TOLEDO - ISPOR STUDENT CHAPTER PRESIDENTJason Lundy BAEconomics and Political Science, GraduateS t u d e n t

VIRGINIA COMMONWEALTH UNIVERSITY – CHAPTER PRESIDENTAnuprita Patklar MS Pharm

UNIVERSITY OF TORONTO -ISPOR STUDENT CHAPTER PRESIDENTColin Vicente BSc (Hons)M a s t e r’s Candidate

WEST VIRGINIA UNIVERSITY - ISPOR STUDENT CHAPTER PRESIDENTAshish V. Joshi BS Pharm, MSPfizer Fellow/ Doctoral Candidate

UNIVERSITY OF DUNDEE - ISPOR STUDENT CHAPTER PRESIDENTBenjamin D. Ofori BS Pharm, MSc, MRPharm SDoctoral Student/Research Training Fellow

UNIVERSITY OF UTAH – CHAPTER PRESIDENTMei-Jen Ho Pharm D

UNIVERSITY OF GEORGIA – CHAPTER PRESIDENTHua Chen MS

UNIVERSITY OF ILLINOIS AT CHICAGO- CHAPTERPRESIDENTHayley Park BSc, Pharm D

PRESIDENT (2002-2003) Peter Davey MD, FRCP

Head of Pharmacoeconomics, University ofDundee, Dept. of Clinical Pharm a c o l o g y,

Ninewells Hospital & Medical School, Dundee, Scotland

DIRECTOR (2002-2004) Kerstin (Chris) Bingefors MSc, PhD

Associate Pro f e s s o r, Research Dire c t o r,Biomedical Centre, Uppsala U n i v e r s i t y,

Dept of Pharm a c y ; P h a rmacoepidemiology & PE,Uppsala, Sweden

DIRECTOR (2002-2004) D.S. (Pete) Fullerton PhD

P rofessor (Affiliate), University of Washington,

Seattle, WA, USA

ISPOR DISTINGUISHED SERVICE AWARDS

ISPOR 2003 – 2004 BOARD OF DIRECTORS SERVICE AWARDS

DIRECTOR (2002-2004) Mark Nuijten PhD, MD, MBA

D i rector of European Business Development, M E D TAP International, The Netherlands

TREASURER (2001-2004) Jean Paul Gagnon PhD

D i re c t o r, Public Policy, Aventis Pharmaceuticals Inc., B r i d g e w a t e r, NJ, USA

I SPOR 9 TH ANNUA L INT ERNATIONAL MEETING

65

2004 ISPOR RESEARCH EXCELLENCE AWA R D S

I SPOR 9TH ANN UAL INTERNATIONAL MEETING

METHODOLOGY EXCELLENCEAndrew BriggsBriggs A. Missing . . . Presumed at Random: Cost-Analysis of Incomplete Data.Health Economics 2003;12:377-92.

A B S T R A C T: To verify the gastro p rotective agent (GPA) rate assumption used in cost-

e ffectiveness models for cyclo-oxygenase 2 inhibitors (COX-2s) and to re-estimate model

outcomes using GPA rates from actual practice. Prescription and medical claims data obtained from January 1,

1999, through May 31, 2001, from a large pre f e rred provider organization in the Midwest, were used to

estimate GPA rates within 3 groups of patients aged at least 18 years who were new to nonselective

n o n s t e roidal anti-inflammatory drugs (NSAIDs) and COX-2 therapy: all new NSAID users, new NSAID users with

a diagnosis of rheumatoid arthritis (RA) or osteoarthritis (OA), and a matched cohort of new NSAID users. Of

the more than 319,000 members with at least 1 day of eligibility, 1900 met the study inclusion criteria for new

NSAID users, 289 had a diagnosis of OA or RA, and 1232 were included in the matched cohort. Gastro p ro t e c t i v e

agent estimates for nonselective NSAID and COX-2 users were consistent across all 3 samples (all new NSAID

users, new NSAID users with a diagnosis of OA or RA, and the matched cohort), with COX-2 GPA rates of 22%,

21%, and 20%, and nonselective NSAID GPA rates of 15%, 15%, and 18%, re s p e c t i v e l y. Re-estimation of the

c o s t - e ffectiveness model increased the cost per year of life saved for COX-2s from $18,614 to more than

$100,000. Contrary to COX-2 cost-effectiveness model assumptions, the rate of GPA use is positive and

m a rginally higher among COX-2 users than among nonselective NSAID users. These findings call into question

the use of expert opinion in estimating practice pattern model inputs prior to a product's use in clinical

practice. A re-evaluation of COX-2 cost-effectiveness models is warr a n t e d .

A B S T R A C T: When collecting patient-level re s o u rce use data for statistical analysis, for

some patients and in some categories of re s o u rce use, the re q u i red count will not be

o b s e rved. Although this problem must arise in most re p o rted economic evaluations

containing patient-level data, it is rare for authors to detail how the problem was overcome. Statistical packages

may default to handling missing data through a so-called ‘complete case analysis’, while some recent cost-

analyses have appeared to favour an ‘available case’ approach. Both of these methods are problematic: complete

case analysis is inefficient and is likely to be biased; available case analysis, by employing diff e rent numbers of

o b s e rvations for each re s o u rce use item, generates sever problems for standard statistical inference. Instead we

e x p l o re imputation methods for generating ‘replacement’ values for missing data that will permit complete case

analysis using the whole data set and we illustrate these methods using two data sets that had incomplete

re s o u rce use information.

PRACTICAL APPLICATIONEmily CoxCox ER. Verification of a Decision Analytic Model Assumption Using R e a l - World Practice Data: Implications for the Cost Effectiveness of Blue PrintCyclo-Oxygenase 2 Inhibitors (COX-2s). American Journal of Managed Care2 0 0 3 ; 9 : 7 8 5 - 9 4

66

ISPOR President Sean D. Sullivan RPh, PhD e a rned his PhD in HealthEconomics and Policy from the University ofC a l i f o rnia, Berkeley, an MS in Pharm a c yAdministration from the University of Texas, and a BSin Pharmacy from Oregon State University. Hecompleted an AHRQ sponsored fellowship in Health

Policy at the University of California San Francisco Institute for HealthPolicies Studies. He directs the Pharmaceutical Outcomes Research andPolicy Program at the University of Washington. He serves as principalinvestigator or co-investigator on numerous health services re s e a rch andp h a rmaceutical costs and outcomes assessment grants and contracts andhas published more than 150 papers, book chapters and books. He is aco-editor of Value in Health and serves on the editorial boards ofP h a rmacoEconomics, Pharm a c o t h e r a p y, and Journal of Managed CareP h a rm a c y. His current re s e a rch interests include the evaluation ofeconomic and health outcomes of interventions for re s p i r a t o ry disord e r s ,end-stage renal disease, hepatitis, cardiovascular disease, and mentalhealth disord e r s .

ISPOR President-Elect Lieven Annemans PhD is a health economist, Dire c t o rof the independent re s e a rch organisation HEDM(Health Economics and Disease Management) sinceM a rch 1997, Professor of Health Economics at theMedical Faculty and Pharmacoepidemiology at the

P h a rmaceutical Faculty at Ghent University since Febru a ry 2001. He isalso Chairman of the Flemish Health Council, an advisory board to theMinister of Public Health. Before starting HEDM and becoming aP ro f e s s o r, he has worked for several years in the pharmaceutical Industryin market re s e a rch and health economic functions.

Since working as a re s e a rc h e r, he has experience in health economicevaluations in 16 diff e rent countries, various therapeutic areas, includingalcoholism, Alzheimer’s disease, antibiotherapy, arthritis, asthma andCOPD, BPH, burns, diff e rent types of cancer, depression, schizophre n i a ,diabetes, fungal infections, viral infections, diff e rent derm a t o l o g i c a lconditions, cardiovascular diseases, gastro - e n t e reologic disord e r s ,muskulo-skeletal disorders, Parkinson’s disease, vaccination againstd i ff e rent diseases, severe sepsis, and transplantation.

His educational re c o rd includes a Master’s degree in Physical Education, aM a s t e r’s degree in Management from Brussels Free University, a Degre ein Commercial Engineering from the Solvay School of BusinessEconomics, a degree in Health Economics from the University ofAntwerp, and a PhD in Economics from Brussels Free University. His maini n t e rests are decision and epidemiological models, early new technologyassessment, re t rospective/ prospective economic evaluations, andwillingness to pay assessments. Lieven Annemans is fluent in Dutch,English and French and has good practical knowledge of German andS p a n i s h .

P L E N A RY SPEAKER BIOGRAPHICAL INFORMAT I O N

I S P O R PRESIDENT AND PRESIDENT-ELECT BIOSUMMARY

ISPOR 9T H ANNUAL INTERNAT IONAL MEET ING B IOGRA PHICAL INFORMAT I O N

Cam Donaldson MSc, PhD holds the HealthFoundation Chair in Health Economics at theUniversity of Newcastle upon Tyne, where he isjointly-appointed to the School of Population &Health Sciences and the Business School. During2003-4, he is a Public Service Fellow in the ESRC’sAdvanced Institute of Management Research (AIM).

C a m ’s main re s e a rch interests are in: measuring and valuing the benefitsof health care, financing and organization of health care, economicevaluation (such as cost effectiveness and cost benefit analyses) ofvarious health care interventions, and using economics in health carepriority setting.

He is currently principle or co-investigator on several projects fundedf rom competitive provincial and national sourc e s .

F rom 1998 until August 2002, Cam held the Svare Chair in HealthEconomics at the University of Calgary, where he was a CanadianInstitutes of Health Research (CIHR) Senior Investigator and Albert aHeritage Senior Scholar. Cam has been a professor at the University ofA b e rdeen in the UK, from where he obtained his PhD in Economics, andhas also worked at Universities of York, Newcastle upon Tyne (1984-8)and Sydney and has been a visiting professor at the Centre for HealthEconomics and Policy Analysis at McMaster University in Ontario.

Cam is a member of the Health Services and Public Health Researc hB o a rd of the Medical Research Council and sits on the Nort h u m b e r l a n dand Tyne & Wear Health Authority Modernisation Commission. He is amember of the Governing Board of the International Health Economics

Association, is joint coordinator of the Cochrane CollaborationEconomics Methods Group, is on the editorial boards of HealthEconomics and Health Policy and is an advisory editor for Social Scienceand Medicine.

James K. Hammitt PhD is Professor of Economicsand Decision Sciences at the Harv a rd School of PublicHealth and Director of the Harv a rd Center for RiskAnalysis. His re s e a rch includes investigation andcomparison of the theoretical pro p e rties of methodsfor valuing health risk, including willingness to payand health-adjusted life years, as well as empiricalestimation in developed and developing countries.

F. Reed Johnson PhD is Principal Economist andSenior Fellow at Research Triangle Institute. He isAdjunct Professor of Public Policy at the University ofN o rth Carolina at Chapel Hill and is a member of theU.S. Environmental Protection Agency's ScienceA d v i s o ry Board. Dr. Johnson received his Ph.D.d e g ree in economics from the State University of

New York, Stony Brook in 1974. He has served on the economicsfaculties of Illinois State University, Simon Fraser University, theStockholm School of Economics, the University of Stockholm, LinköpingU n i v e r s i t y, and the U.S. Naval Academy. He previously worked as aneconomist in the Office of Policy Analysis, U.S. Department of theI n t e r i o r, and in the Office of Policy, Planning, and Evaluation, U.S.E n v i ronmental Protection Agency. From 1994 to 2001 he was Vi c e

67

P resident for Research and Development at Triangle Economic Researc h .He has been awarded a Brookings Economic Policy Fellowship and twoFulbright fellowships.

As a staff member in the U.S. Environmental Protection Agency’se n v i ronmental economics re s e a rch program during the 1980s, Dr.Johnson helped pioneer development of basic nonmarket valuationtechniques. These techniques are now widely used for cost-benefitanalysis in health and environmental economics. He has designed andanalyzed numerous surveys for measuring willingness to pay fori m p roved health and environmental quality. His current re s e a rc hincludes developing improved methods for quantifying patient andphysician stated pre f e rences for health care interventions and benefit-risk tradeoff s .

A n d reas Laupacis MD, MSc, FRCPC is a GeneralI n t e rnist who is currently the President and CEO ofthe Institute for Clinical Evaluative Sciences (ICES).He is a Professor in Medicine and Health Policy,Management and Evaluation at the University ofTo ronto. His re s e a rch interests include randomizedc o n t rolled trials, economic evaluations, drug policy

and the evaluation of diagnostic tests. He is a Senior Scientist at theCanadian Institutes of Health Research, and has published close to 200p e e r- reviewed articles. He has been a member of the Drug Quality andTherapeutic Committee in Ontario and is currently the Chair of theCanadian Expert Drug Advisory Committee.

D r. Laupacis received his medical degree from Queen’s University. He didhis internship at Dalhousie and residency in internal medicine at theUniversity of We s t e rn Ontario.

His research training includes two years as a Medical Research Councilof Canada (MRC) Research Fellow with Dr. Calvin Stiller at theUniversity of Western Ontario studying the efficacy of cyclosporine asan immunosuppressant in transplantation and diabetes. He also has aMasters degree in Design, Measurement and Evaluation fromMcMaster University.

Monique Mrazek PhD is a Health Economist at theWorld Bank currently working in the Europe andCentral Asian region. Prior to joining the Wo r l dBank, Monique worked both for the World HealthO rganization/ European Observ a t o ry on Health CareSystems and the London School of Economics andPolitical Science. In the latter, she was involved in

teaching on MSc courses in Health Economics, Cost-effectiveness Analysis,and International Comparative Health Policy. In addition to experiencein the pharmaceutical industry, Monique has extensive intern a t i o n a lconsulting experience working with governments, intern a t i o n a lo rganizations and pharmaceutical companies. She holds a PhD from theLondon School of Economics and Political Science and an MSc in HealthEconomics from the University of York. Forthcoming publicationsinclude Regulating Pharmaceuticals in Europe: Striving for Eff i c i e n c y,Equity and Quality co-edited with Elias Mossialos MD, PhD and To mWalley MD to be published by Open University Press in mid-2004.

Jean R. Slutsky PA, MSPH has served as actingd i re c t o r, Center for Outcomes and Evidence (COE),Agency for Healthcare Research and Quality (AHRQ)of the U.S. Department of Health and HumanS e rvices since June 2003. Prior to Ms. Slutsky’sappointment as acting director of COE, she served asacting director of the Center for Practice and

Technology Assessment at AHRQ. Ms. Slutsky oversees the Evidence-based Practice Center program; Technology Assessment Pro g r a m ;extramural and intramural re s e a rch portfolios concerning translating

re s e a rch into practice, outcomes and effectiveness includingp h a rmaceutical outcomes, and cost-effectiveness analyses; and theNational Guideline and Quality Measures Clearinghouses.

Prior to becoming acting director of the Center for Practice andTechnology Assessment, Ms. Slutsky directed the development of theNational Guideline Clearinghouse™ (NGC) Project. The NGC is anI n t e rnet-based re p o s i t o ry (www.guideline.gov) for comparativei n f o rmation on evidence-based clinical practice guidelines. In addition,Ms. Slutsky served as project director of the U.S. Preventive Services Ta s kF o rce, an internationally recognized panel of experts who makeevidence-based recommendations on clinical preventive services.

Ms. Slutsky received her Bachelor of Science degree at the University ofIowa, a Masters of Science in Public Health (Health Policy andAdministration) from the University of North Carolina at Chapel Hill, andtrained as a Physician Assistant at the University of Southern Californ i a .

Adrian Towse MA, MPhil is the Director of theO ffice of Health Economics. The OHE commissionsre s e a rch, publications and meetings on theeconomics of the pharmaceutical industry, healthc a re systems and the use of health technologyassessment. It also advises the ABPI (who fund OHE)and undertakes consultancy. He is a Visiting Pro f e s s o r

at the University of York and a Non-executive Director of the OxfordR a d c l i ffe Hospitals NHS Trust, one of the UK’s largest hospitals. He alsochairs the Health Economics Advisory Group of the Intern a t i o n a lFederation of Pharmaceutical Manufacturers Associations whichcomprises the heads of global health outcomes of the major companies.His current re s e a rch interests include the use of “risk-sharing”a rrangements between health c a re payers and pharm a c e u t i c a lcompanies; the economics of pharmacogenetics for health care payersand the pharmaceutical industry; economic issues around access to, andR&D for the development of, treatments for less developed countrydiseases; the economics of medical negligence; and measuringp roductivity in health care .

Sean Tunis MD, MSc is the Director of the Off i c eof Clinical Standards and Quality (OCSQ) and ChiefMedical Officer at the Centers for Medicare andMedicaid Services (CMS). OCSQ makes evidence-based national coverage policies; sets qualitys t a n d a rds for Medicare and Medicaid pro v i d e r s ,leads CMS’s quality measurement and impro v e m e n t

activities, and manages Medicare ’s Peer Review Program.

As Chief Medical Off i c e r, Dr. Tunis works on overall Agency clinical policyand purchasing initiatives. Dr. Tunis was previously the Director of theCoverage and Analysis Group within OCSQ. Prior to joining CMS, Dr.Tunis was a Senior Research Scientist with The Lewin Group where helead the design and conduct of prospective comparative eff e c t i v e n e s sstudies. Dr. Tunis also served as the Director of the Health Program atthe Congressional Office of Technology Assessment and as a healthpolicy advisor to the U.S. Senate Committee on Labor and HumanR e s o u rces, where he participated in policy development re g a rd i n gp h a rmaceutical and device regulation.

D r. Tunis holds an adjunct faculty position in the Department ofMedicine at the Johns Hopkins School of Medicine, and practices as anE m e rgency Room physician in Baltimore, Maryland. He received a B.S.d e g ree in History of Science from Cornell University, and a medicald e g ree and masters in Health Services Research from Stanford University.D r. Tunis did his residency training at UCLA and the University ofM a ryland in Emergency Medicine and Internal Medicine, and is board -c e rtified in Internal Medicine.

I SPOR 9TH ANNUAL INTERNAT IONAL MEET ING B IO GRAPHICAL INFORMAT I O N

68

• P R A P • P R A P • P R A P • P R A P • P R A P • P R A P • P R A P • P R A P • P R A P • P R A P •


Visit the ISPOR Professional Recruitment Assistance Program (PRAP) Centerin the Alexandria Room, 2nd FloorPRAP Center Hours: Sunday, May 16, from 7:00AM to 6:00PM,Monday, May 17, from from 7:00AM to 6:00PM and Tuesday, May 18, from 7:00AM to 6:00PM

The International Society for Pharmacoeconomics andOutcomes Research (ISPOR) provides CONFIDENTIAL,EFFICIENT AND PROFESSIONAL ASSISTANCE to individualsseeking employment and to employers with availablepositions. Note: Candidates who request confidentiality will NOT have their

names listed in the Candidates Dire c t o ry.

The ISPOR PRAP Center provides the following services: • A list of available positions from participating employers

• A list of candidates participating in the service

• A mailbox system for candidates and employers

• Private rooms for interv i e w s

A P P L I C A N T S : Bring at least 4 copies of your CV or resume to the

C e n t e r. Complete the PRAP “Applicant Registration Form” at the

PRAP Center and follow the basic instructions to obtain a mailbox.

[Please note: applicants who request confidentiality do not have to

have their resumes posted.] This service is free for ISPOR members and

meeting registrants. If you are not an ISPOR member or registrant the

cost is USD $30 for students, and USD $135 for non-students.

E M P L O Y E R S : Bring a one-page description of each position to the

PRAP Center, complete the “Employer Registration Form”, and follow

the basic instructions to obtain a mailbox. The participation fee is USD

$1000 for the first position and $500 for each additional position.

T h e re is a 50% discount for academic teaching positions.

C O N TA C T: For more information about PRAP during the meeting, go to

the ISPOR PRAP Center in the Alexandria Room located on the second

f l o o r, or ask for Va n d rei Scudder, PRAP C o o rd i n a t o r.

Abt Associates❏ P roject Manager❏ Senior Pharm a c o e c o n o m i s t❏ D i rector of Statistics & Outcomes Researc h

Analysis Group❏ Statistician/Health Economist

Boehringer Ingelheim❏ Associate Dire c t o r / M a n a g e r, US Health Economics

Caremark❏ Trend Consultant❏ R e s e a rch Analyst❏ Analytic Research Pharm a c i s t❏ Health Management Analyst

Eli Lilly❏ Health Outcomes Researc h e r s

Johnson & Johnson❏ Health Economics Manager

MedTap❏ R e s e a rch Scientist

Merck❏ Associate Director or Dire c t o r, OutcomesR e s e a rch ❏ M a n a g e r / D i re c t o r, Outcomes Research andM a n a g e m e n t

NDC Health❏ M a n a g e r / D i re c t o r, Outcomes Researc h

Pfizer❏ Senior Dire c t o r, Outcomes Researc h❏ Team Leader, Outcomes Researc h

PharMetrics❏ Senior Research Consultant❏ Assistant Research Consultant

UBC Pharma❏ Health Outcomes Researc h e r

THE FOLLOWING IS A PA RTIAL LISTING OF THE POSITIONS POSTED AT THE PRAP CENTER:


We invite your application to join theHERQuLES team of Abt Associates Inc.

With 40 years of experience, Abt Associates’ capabilitiesinclude health economics, outcomes research, clinical

trials, policy research and epidemiology. HERQuLES is aleader worldwide in analyzing the use of health careproducts and their clinical, economic, and patient-

reported outcomes.

Open positions include: Outcomes Research Project Manager

Senior Pharmacoeconomist Director of Statistics and Outcomes Research

For detailed position descriptions and more informationabout these positions, please visit us at PRAP or contact

[email protected] 1.301.913.0522

69



Associate Director/Manager, U.S. Health Economics Boehringer Ingelheim Pharmaceuticals, Inc.Ridgefield, CTBoehringer Ingelheim (B I) is seeking an AssociateDirector/Manager, U.S. Health Economics to develop domestichealth economic strategies and drive the design, implementation,and delivery of health economic/outcomes research studies orprograms to support US commercialization of BI products anddemonstrate brand value.

Position responsibilities include leading the design and implemen-tation of health economic/outcomes studies or economicmodels/tools to demonstrate economic and humanistic benefits ofBI products; effectively managing projects with external consult-ants/CROs/third parties to achieve project goals within timelinesand budgets; collaborating with interdisciplinary teams to provideUS health economic input for Phase IIIb/IV clinical trials, marketingstrategies, and managed care programs; and, interacting with fed-eral and state government agencies, health policy institutions, pay-ers and others to communicate health economic data.

The ideal candidate will have a Doctorate or Masters degree inhealth economics, epidemiology, or public health or a Doctoraldegree in a clinical discipline (medicine, pharmacy), and at least 3-6 years of pharmaceutical-related experience in an outcomesresearch/health economics setting. In depth knowledge of phar-macoeconomics, pharmacoepidemiology, Quality of Life, clinicalresearch, and the US health care system is essential.

To apply, send letter and CV to: [email protected]

Health Outcomes ResearchThe Global Health Outcomes research department (GHO) of Eli Lilly andCompany seeks candidates with an expertise in epidemiology, health eco-nomics, health services research, policy analysis, political science or psy-chology. The GHO research agenda spans a broad range of therapeuticareas (e.g. infectious disease, cardiovascular disease, endocrinology, oncolo-gy and neuroscience) and geographies (e.g. US, Europe, Japan). The GHOresearch department works in drug development Phases I through III.Current research projects include economic modeling, instrument develop-ment, patient-reported outcomes and the evaluation of randomized clinicaltrial data, prospective naturalistic observational study data and retrospectivedatabases. Submission of research results for publication in leading clinical,economic and policy journals is highly encouraged. Candidates must haveexcellent written and oral communication skills and ease in communicatingthe relevance of health outcomes topics to colleagues in new product plan-ning, marketing, medical and regulatory departments. This is a highly visibleposition on a cross-functional team. Successful candidates will possessgraduate training in a relevant field in addition to relevant work experience.

At Eli Lilly our future depends on our global community of employees whosevaried perspectives, experiences and training fuel the creativity and energy topioneer pharmaceutical innovation. Send resume and the names of threereferences to: Jennifer A. Flynn, Eli Lilly and Company, Lilly Corporate CenterDC 1834, Indianapolis, Indiana 46285 (email: [email protected]). No phone calls please.

Eli Lilly and Company is an Equal Employment Opportunity/Affirmative Action employer.For more information, see http://www.Lilly.com.

STATISTICIAN/HEALTH ECONOMIST:

Analysis Group offers a range of pharmacoeconomic and epidemiologicservices to pharmaceutical, biotechnology and medical device companies,including drug adverse event analysis, cost-of-illness, cost-effectiveness,cost-benefit, and cost-utility analysis. In addition, we work closely withthese firms to provide sophisticated statistical analysis of health insuranceclaims data as well as clinical trials datasets, including both RCT and open-label community studies in phases III and IV of clinical development. Wealso provide expert economic and financial analysis in all areas of econom-ics applied to law, including product liability (e.g., drug withdrawal), patentinfringement, and complex commercial litigation in the health care sector.

We are seeking a manager with a Doctoral degree in economics, statistics, or epidemiology who has outstanding abilities in using quantitative methods of health care investigations, including observational study design,biometrics, econometrics, and claims data analysis. In addition to this experience with empirical research in health care, the successful candidate must have strong interpersonal skills, exceptional written/verbal communication skills, and must be capable of directing several people in conceptualizing and executing analytical plans.

We work in collaboration with faculty from top universities to develop rigorous analyses based on current academic research. Analysis Group fosters a progressive and academically oriented work environment.

Visit our web site at www.analysisgroup.com for more information.

Send letter and resume to Recruiting Coordinator, Analysis Group, 111 Huntington Avenue, Tenth Floor, Boston, MA 02199 or e-mail to:[email protected]

Analysis Group is an Equal Opportunity Employer.

70



ResearchScientistPositions

MEDTAP International provides health economic andoutcomes research to industry (including pharmaceutical,biotechnology and devices), health service, and govern-ment clients around the world. MEDTAP scientists perform challenging work in a stimulating, collegial environment where everyone is dedicated to conductingthe highest quality research in the industry.

MEDTAP International is seeking Research Scientistsin the areas of Health Economics and Health Outcomesto join our team. Qualified candidates will have demon-strated expertise in their respective field, including publi-cations in peer-reviewed journals; the ability to developand foster client relations; and the desire to work in ateam-oriented and collaborative environment.

Please visit us at ISPOR’s Professional RecruitmentAssistance Program (PRAP) or email your CV [email protected] for consideration.

Associate Director or Director, Outcomes ResearchWorldwide Human Health Marketing (WHHM)Merck & Co., Inc.

POSITION OVERVIEW - BASIC FUNCTIONS & RESPONSIBILITIESThe Associate Director/Director will be responsible for developing outcomes research (OR)plans, and directing/implementing OR activities to support developmental compounds and/or in-line products globally. The scope of responsibility includes all phases of OR activities. As part ofhis/her primary responsibilities, the Associate Director/Director acts as a co-chair of the OR Sub-team and leads the development of OR strategy and program plan guiding OR activities throughoutclinical development, implements OR programs and generates data on a worldwide basis to sup-port pricing and reimbursement, collaborates with the Merck Research Laboratories, Merckcountry affiliates and external experts to write, coordinate, and validate as required, study design,protocols, measurement questionnaires, case report forms, data analysis plans, final reports andpublications, and remains abreast of scientific developments in areas of expertise, both in termsof new methodologies and new activities and establishes communications with key outcomesresearch opinion leaders.

SKILL REQUIREMENTSThe Associate Director/Director should have a graduate degree (preferably a Ph.D.) from anaccredited institution in the fields of medicine, public health, management, pharmacy, or econom-ics with demonstrated expertise in the field of outcomes research, epidemiology, or health eco-nomics and at least three years of relevant experience. He/she should have excellent leadershipand strategic skills, and ability to communicate clearly and effectively both in writing and orally.

ABOUT MERCK & CO., INC.Enhancing and preserving the quality of life. This is the commitment that Merck & Co., Inc. standson and, it is what has distinguished us as one of the world's leading research-driven health prod-ucts company. Consistently ranked by Fortune as one of the “100 Best Companies to Work for inAmerica,” we discover, develop, manufacture and market a wide range of innovative products.Merck develops novel medicines and vaccines that offer a new lease on life. At Merck, improvingpatient health isn't just what we do; it's who we are, sharing a passion for life that brings out thebest in a diverse workforce of 63,000 people.

CONTACTTo apply, please go to www.Merck.com, and apply for Director, Outcomes Research, position no.MAR000940. For additional information you may contact Sheldon Kong, Ph.D., OutcomesResearch, Merck & Co., Inc., One Merck Drive (PO Box 100, WS-2E50); Whitehouse Station, NJ08889-0100. Phone: 908-423-4273; Fax: 908-735-1688; email: [email protected].

71



PfizerSr. Director, Outcomes ResearchTeam Leader, Outcomes ResearchUS Medical Outcomes Research(Title Commensurate With Experience)New York, NY

Requirements: Ideal candidate should have a Doctoral degree (PhD, DrPH, ScD) inhealth services research, public health, epidemiology or health economics or Doctoraldegree in a clinical discipline with a Masters degree in a relevant discipline with 8+years experience in the pharmaceutical industry. The candidate should have experienceutilizing Outcomes Research in support product commercialization, indepth knowledgeof the following: Pharmacoepidemiology, Pharmacoeconomics, and Quality of LifeResearch; Ability to understand and respond to the multiple internal and external cus-tomers demands and manage conflict constructively; Indepth knowledge of clinicalresearch drug studies; Excellent process and project management skills; Experience inthe evaluation of health care interventions and conducting health related quality of lifeand/or health services research studies for the pharmaceutical industry; Knowledge ofmanaged care organizations; Experience in preparing and reviewing materials for drugformularies; Supervisory experience required.

Job Description: In both positions you will play a key role in optimizing OutcomesResearch support of clinical and commercial product teams; Assures participation in thedevelopment of clinical, marketing, and Outcomes Research strategy to support productdevelopment, marketing, reimbursement, and formulary support. Demonstrate leader-ship in pharmaceutical issues among industry colleagues.

Team Leader: Manages staff responsible for implementing Outcomes Research projectsand disease management activities in support of these strategies; Provide assistance withproducts in assigned therapeutic areas; Interact with key external customers and inter-nal stakeholders; Managing the research budget; Contribute to the overall managementof the outcomes research department.

Senior Director: Provides input to complex issues across multiple products, mentorjunior staff, and play a key role in leading the department as a member of the VicePresident’s Leadership Team.

The Pharma Sector of UCB isdeploying worldwide activities inresearch, development,

manufacturing and marketing of ethic drugs in the fields of thecentral nervous system and immuno-allergology.

The Outcomes Research Unit is dedicated to measuring the clinical, economic and humanistic (quality of life, productivity) outcomes of the implemented projects. In order to expand theOutcomes Research Unit, situated in Braine-L’Alleud, Belgium, UCBis recruiting a Health Outcomes Researcher to be based in Atlanta.

HEALTH OUTCOMES RESEARCHER Ref : ATL-HORCA

Job Description• Initiate and conduct exploratory searches in order to produce

reports on specific/new outcomes in the Outcomes Researchfiles (Health Economics, Epidemiology, Patient ReportedOutcomes) in the US primarily.

• Conduct investigations on external & internal databases in orderto collect, retrieve and report information/data (direct and indi-rect cost parameters, costing data, or any in other information)required for health economic submissions.

If you are interested in this position, please send your applicationwith complete CV to UCB Pharma, att Ms. Berry Natasha, H.R.Dept., 1950 Lake Park Drive, Smyrna, GA 30080. More informationabout UCB: www.ucb-group.com or http://www.careers.ucb-group.com. It will be treated in utmost confidence.

PharMetrics, Inc., is the leading provider ofhealthcare insights to the pharmaceutical,biotech, medical device and health plan sec-tors of the market. We are looking for quali-fied candidates to join our talented scienceteam in the following areas:

• SENIOR RESEARCH CONSULTANT

• ASSOCIATE RESEARCH CONSULTANT

We encourage you to visit us at theProfessional Recruiting Assistance Program(PRAP) center to learn more about thesepositions and our organization. If you areunable to visit us at the center, please visitour website at www.pharmetrics.com toview the positions in full detail.

72

Abt Associates

Adis International

A e g i s n e t

The American Journal of

Managed Care

Analysis Group

Applied Health Outcomes

Assist Technologies

BioMedCom Consultants Inc

Boston Health Economics Inc.

Cardiff Research Consortium

( H O G )

Cerner Health Insights

Clinical Therapeutics

Consumer Health Science

CORE – Center for Outcomes

R e s e a r c h

Covance Inc

Current Medical Research and

Opinion (CMRO)

Dymaxium Inc.

GE Medical Systems Information

Te c h n o l o g i e s

General Practice Research

Database (GPRD)

H e a l t h C o r e

Health Utilities Inc. (HUInc.)

Heron Evidence Development

IMS Health

I n g e n i x

I n n o v u s

Mapi Research Institute

Mapi Va l u e s

Medtap International

M e t a Works Inc.

M - TAG Pty Ltd.

N D C H e a l t h

N i n a z a

OHE-IFPMA Database Limited

( H E E D )

Outcomes Research

Outcome Technologies Ltd

O v a t i o n

PA I

Pharmacy Consulting Group

PharMetrics, Inc

PharmIdeas Research &

Consulting Inc.

PHARMO Institute

PJB Publications

Premier Inc.

Quantros, Inc.

RTI Health Solutions

The Medical Multimedia

Company Ltd.

The MEDSTAT Group

The National Library of Medicine

Thomas Jefferson University

TreeAge Software Inc.

ValueMedics Research, LLC

ISPOR9TH ANNUAL

INTERNATIONALMEETING

EXHIBIT PROGRAM

73

E X H I B I T O R S

EVENT SPONSORS

Abt Associates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 9

Adis Intern a t i o n a l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4

A e g i s n e t * . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11, 12

American Journal of Managed Care . . . . . . . . . . . . . . .8

Analysis Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6

Applied Health Outcomes* . . . . . . . . . . . . . . . . . . . . .4 3

Assist Technologies . . . . . . . . . . . . . . . . . . . . . . . . . . .T 2

BioMedCom Consultants Inc . . . . . . . . . . . . . . . . . . . .3 9

Boston Health Economics Inc. . . . . . . . . . . . . . . . . . . .2 5

C a rd i ff Research Consortium (HOG) . . . . . . . . . . . . . . .7

C e rner Health Insights . . . . . . . . . . . . . . . . . . . . . . . . . .3

Clinical Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . .1 5

Consumer Health Science . . . . . . . . . . . . . . . . . . . . . . .5 4

CORE – Center for Outcomes Researc h . . . . . . . . .48, 49

Covance, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 2

C u rrent Medical Research and Opinion (CMRO) . . . . . . .2 7

Dymaxium Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 0

GE Medical Systems Information Te c h n o l o g i e s . . . . . .2 6

General Practice Research Database (GPRD) . . . . . . . .3 5

H e a l t h C o re . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9, 10

Health Utilities Inc. (HUInc.) . . . . . . . . . . . . . . . . . . . . . .2

H e ron Evidence Development* . . . . . . . . . . . . . . . . .1 6

IMS Health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 3

Ingenix* . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33, 34

I n n o v u s * . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 0

Mapi Research Institute . . . . . . . . . . . . . . . . . . . . . . . .2 4

Mapi Va l u e s * . . . . . . . . . . . . . . . . . . . . . . . . . .17, 18, 29

M E D S TAT Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 5

M E D TA P I n t e rn a t i o n a l * . . . . . . . . . . . . . . . . . . . . .41, 42

Medical Multimedia Company Ltd. . . . . . . . . . . . . . . .2 3

M e t a Works Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 8

M - TAG Pty Ltd. . . . . . . . . . . . . . . . . . . . . . . . . . . . .20, 21

National Library of Medicine . . . . . . . . . . . . . . . . . . . . .1

N D C H e a l t h * . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 8

N i n a z a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 5

OHE-IFPMA Database Limited (HEED) . . . . . . . . . . . . .3 0

Outcomes Researc h . . . . . . . . . . . . . . . . . . . . . . . . . . .4 6

Outcome Technologies Ltd . . . . . . . . . . . . . . . . . .T3, T4

O v a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 4

PA I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 2

P h a rmacy Consulting Group . . . . . . . . . . . . . . . . . . . .T 1

PharMetrics, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 7

P h a rmIdeas Research & Consulting Inc. . . . . . . . . . . . .4 7

PHARMO Institute . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 4

PJB Publications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 6

P remier Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5

Q u a n t ros, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 1

RTI Health Solutions* . . . . . . . . . . . . . . . . . . . . . . . . . .3 1

Thomas Jefferson University . . . . . . . . . . . . . . . . . . . .5 2

TreeAge Software Inc. . . . . . . . . . . . . . . . . . . . . . .48, 49

ValueMedics Research, LLC . . . . . . . . . . . . . . . . . . . . .1 3

* Event Sponsor


Aegisnet

Appplied Health Outcomes

C a ro Research

H e ron Evidence Development

I n g e n i x

I n n o v u s

Mapi Va l u e s

M E D TA P I n t e rn a t i o n a l

N D C H e a l t h

Q u a l i t y M e t r i c

RTI Health Solutions

University of Maryland School of Pharmacy

74

booth19

booth4

EXHIBITING FLOOR PLAN

75

booth1 1 ,1 2

sponsor

76

boothT2

booth39

Assist Technologies provides touch-screen data collectionand data management for clinical trails. Assist specializesin collecting questionnaire-based outcomes at the studysite. These include Patient Reported Outcomes (quality-of-life, symptoms, re s o u rce use and satisfaction) and outcomes re p o rted by the caregiver or investigator.

A s s i s t ’s Touch Outcomes Collector has been used in clini-cal trials and marketing studies by over 20,000 patients, in70 studies in over 26 countries and 24 languages.

With a 10 year history of delivery, Assist Technologies isthe leader in electronic questionnaire products and serv i c e sfor clinical trials. Only Assist Technologies has 8 peerreviewed, publications validating our technology, showingan overwhelming patient and investigator pre f e rence, andp roving a 30% increase in usable data for analysis, all at aprice on par with or less than paper!

C o n t a c t :Jay M. CanterV P, Global Business DevelopmentPhone: 518-893-2515Email: jay. c a n t e r @ a s s i s t t o u c h . c o m

Les consultants

BBiiooMMeeddCCoommConsultants inc.

Biomedical,health economic and outcomes research application

Application de la recherche biomédicale, évaluative et en économie de la santé

Montréal • Québec • CanadaTel (514) 745-0915 o Fax (514) 745-0916

www.biomedcom.org

BioMedCom focuses on theeffective and ethical application

of health economic & healthoutcomes research, developing

scientifically sound & usefulresources addressed to your

target audiences—otherresearchers, healthcare policy-

and decision-makers, healthprofessionals, or the general

public.Over the last eight years we

have consistently and success-fully helped our clients meettheir business objectives in atimely fashion, providing highquality products at good value.

BioMedCom serves as the interface between your message

and your target audience.

booth8

booth6

■ Burden of illness analysis■ Cost-effectiveness analysis■ Pricing and contracting strategy■ Biostatistics■ Epidemiologic studies

Analysis Group Inc. has provided experteconomic, financial and strategy consultingsince 1981. For more information regarding our pharmacoeconomics capabilities, pleasecontact Howard G. Birnbaum or Paul E.Greenberg at 617-425-8000.

H E A LTH OUTCOMES RESEARCH

Pharmacoeconomic assessment requires a

wealth of detailed information. Analysis Group's

research relies on numerous data sources that

we use to perform in-depth analysis to support

your outcomes research requirements.Since 1995, The A m e rican Jo u rnal of Manage dC a re has p rovided an independent, p e e r -rev i ewed fo rum for publishing cl i n i c a lre s e a rch and opinion related to q u a l i t y, va l u e ,and policy in healthcare delive ry.

R e s e a rch e rs pre fer it because of its stro n gre pu t a t i o n , fair a n d timely peer review, wide-spread indexing, and strong i m p a c t fa c t o r. R e a lworld decision make rs re ly on it for the care-f u l ly vetted re s e a rch and dive rse cove rage ine a ch issue.

Visit us at Booth #8 to learn more about thejourn a l , our plans for special issues, and detailsabout the editorial pro c e s s .

w w w. a j m c. c o m .

The first choice. The last word.

77

booth25

booth7

booth15

booth3

The Health Outcomes Data Repository (HODaR) is a unique database com-prising both inpatient and outpatient & primary care Quality of Life (QoL),cost and clinical information (such as biochemistry and haematology), drugand resource use across all disease groups.

HODaR can undertake project-specific studies custom-designed to meetyour individual product needs. For example, we can easily and quicklymodify the ongoing survey to capture further data, or introduce analternative humanistic instrument.

We are able to offer data analysis in two ways. Analysis of only HODaR datais undertaken within HODaR at an additional charge based on a daily rate.Additional analysis, such as the development of disease models that useHODaR and additional sources of data, are undertaken by our sister compa-ny Cardiff Research Consortium.

All eligible PHARMACEUTICAL COMPANIES, HEALTH ECONOMICS CON-SULTANCIES and UNIVERSITIES may fully evaluate the HODaR databasefor a period of 30 days, free of charge, by registering with HODaR.

To evalute HODaR’s capabilities and a demonstration of how it would beapplied to your research, please visit us on Booth 7.

Download your free trial evaluation straight onto your desktop atwww.hodar.co.uk

CARDIFF RESEARCH CONSORTIUM LTDTHE MEDICENTREHEATH PARK, CARDIFF,CF14 4UJ UK

78

booth4 8 ,4 9

79

booth40

booth27

booth54

booth22

Founded in 1996, CHS is an international consumerhealthcare research and consulting company. Ourmission is to help the pharmaceutical industryunderstand and incorporate consumer attitudes andbehaviors into their strategic thinking and marketingplanning process.

We are single-mindedly focused on consumers -from how they think and act to how they interactwith their physicians. We have dedicated significantresources to building an “Information Warehouse”with an unparalleled breadth and depth of informa-tion reported directly by consumers. These datamarry healthcare attitudes and behaviors to the therapeutic class and, often, even to the brand levelin over 60 therapeutic categories.

www.CHSInternational.com

609-924-4455 Phone

888-717-4242

Covance, Inc.Capture and Convey the Value of

Your Product with Outcomes Research

• Design, implement, and analyze patient-reported outcomes measurement strategies for clinical trial programs and stand-alone prospective studies.

• Conduct prospective and retrospective healtheconomic evaluations throughout productdevelopment and commercialization.

• Prepare outcomes findings for global regulatory and payer audiences.

• Disseminate outcomes research through presentations at scientific meetings and peer-reviewed publications.

Outcomes Data, Intelligently Applied.

80

booth2

Health Utilities Inc.

H U I® f o rUtilities PROs QALYs CEA/CUA

and more …

Provides community preference-based, single summary utilityscores as recommended by the US Panel, CCOHTA, CDHA

and other national organizations.

A generic system for patient reported outcomes (PROs) in clinical studies and population health surveys.

Integrates morbidity and mortality effects of HRQL for calculating QALYs and HALE.

Versions for face-to-face or telephone interviewing, as well asmail-out or take-home for self-completion.

Available in Self- and Proxy-assessment versions in both the Self- and Interviewer-administered formats.

Many language versions available and more under development.Used in 100s of studies world wide.

Come see us at Booth 2

www.healthutilities.com [email protected] [email protected]

Phone: 905-525-9140Ext: 22389 and 22377

FAX: 905-627-7914

booth26

booth35

81

booth3 3 ,3 4

Before you commit funds to marketingor research activities, give yourself everyopportunity to hit the nail on the head —the first time.

Short of LabRX, you risk swinging blindlyand expensively every time you commit budgetto key marketing or research activities.

Building with rich LabRx Data

• Rolling 3-year database with integrated prescription and medical claims on over 19,000,000 covered lives

• More than 3,600,000 patients with lab analyte test results; 75% havingmore than 10 lab analyte test results

• Snapshot (point in time) covered lives consistently over 9,000,000• Blinded to protect patient privacy, yet allow patient-linked, longitudinal

analysis• Updated monthly

Enriched Research Database

Visit our booth at ISPOR | For more information call 1-800-765-6793 or email us at [email protected]

82

booth53

booth24

M api Research Institute founded in 1994 is an

i n t e r n ational non-profit health outcomes organisation established to support and

promote collaborative research in the field of patient-reported outcomes (PRO). O u r

non-profit philosophy means we constantly reinvest in the field through the develop-

ment of important initiatives and in providing the most comprehensive library and

expert network available in the field of PRO. The Institute’s team of experienced

professionals offers a wide range of expertise and research services incl u d i n g :

- PRO information searches

- Extensive literature reviews in PRO

- Publication twice a year of the Quality of Life Newsletter since 1991

- Development of “ Q O L I D ” , the Quality of Life Instruments Database (www. q o l i d . o r g )

- Tr a n s l ation and linguistic validation of PRO measures

- Development and presentation of practical and interactive PRO educational pro-

grammes (Wo r k m at s )

- Creation and coordination of research projects:

• European Regulat o ry Issues on Quality of Life Assessment (ERIQA) project

• Patient-reported Outcomes (PRO) Harmonization Group

• I n t e r n ational Health-Related Quality of Life Outcomes Database (IQOD)

P r o g r a m m e

• Cochrane health-related quality of life Methods Working Group

All the team will be happy to meet you at our booth # 24.

M api Research Institute

27 rue de la V i l l e t t e , 69003 Ly o n , Fr a n c e

Phone : +33 (0)4 72 13 66 67 Fax : +33 (0)4 72 13 66 68

E-mail : I n s t i t u t @ m api.fr We b s i t e :w w w. m ap i - r e s e a r c h - i n s t . o r g

booth16

sponsor

booth30

HEED: the Health Economic Evaluations Database

The Problem: Number of economic studies in many fragmented sources The Solution: HEED:the Health Economic Evaluations Database Features:

■ HEED is the world’s leading data-base of economic evaluation in healthcare• International database • Non-English language evaluations• Coverage of evaluations from 1967to current date

■ HEED comprises in excess of28,000 evaluations • Easy to read structured forma t• 60 field search capability tha tincludes free text and Expert searching

■ HEED is ideal for researchers in:• Pharmaceutical industry• Academia• Health care organizations• Consultancies

■ HEED database covers several typesof economic evaluation:• Cost consequence analysis

• Cost effectiveness analysis• Cost utility analysis• Cost benefit analysis • Cost minimization analysis

■ HEED also includes studies on:• Cost of illness• Cost analysis

■ HEED is updated on a monthly basis

■ HEED is available as an annual sub-scription service

■ HEEDis available on either CD-ROMor via the Internet

■ HEED exports to ReferenceManager, EndNote and Procite

For information: Web site: www.ohe-heed.comE-mail: [email protected]

83

booth17, 18,

29

sponsor

booth50

sponsor

84

7101 Wisconsin Ave nu eSuite 600B e t h e s d a , M D 2 0 8 1 43 0 1 - 6 5 4 - 9 7 2 9i n f o @ M E D TA P. c o mw w w. M E D TA P. c o m

C o n g rat u l at i o n s

to I S P O R o n

A n o t h e r

Successful

Ye a r !

booth4 1 ,4 2

sponsor

M E D TA PI N T E R NAT I O NA L

Your Global Health Economics and

Outcomes Research P a rtner

■

■

■

Visit Us atB O OTH 42

and Enter to Win our Daily D r a w i n g s

85

booth38

booth1

ISPOR 2004, Marj Cahn, NICHSR The National Library of Medicine(NLM) provides health serv i c e sresearch (HSR) informat i o n(including health policy and publichealth information) through a vari-ety of products and serv i c e s .Foremost are databases on:litera-

ture in bibliographic format and full text, citations to researchin progress, and information on health services and sciencesresearch resources (datasets,instruments, and analytical soft-ware). Other products and services include: pre-formulatedsearch strategies on selected topics; special web-texts andbibliographies on issues ranging from basic health literacy, toHSR collection development and information resources, tohealth informatics; print, video, and audio historical materials;outreach and training on the web and in conjunction with theN ational Network of Libraries of Medicine (NN/LM(c)); improvingaccess to information for public health practitioners; supportfor research and development in HSR information infrastructure;and links to websites with health services research informationat NLM and beyond. To access the resources and staff of theHSR Information Program, visit http://www.nlm.nih.gov/nichsr.

booth23

booth45

Medstat Pharmaceutical Solutions…

A leader in providing re s e a rch and normative databases tos u p p o rt drug discovery and post-launch analytics.

M e d s t a t ’s products and services focus on:• Market assessment• Economic and clinical evaluation of the marketplace• Clinical trial design• Clinical trial re c ru i t m e n t• Decision analytic modeling and interactive tools• Market share monitoring

M e d s t a t ’s well-published re s e a rchers are supported by theMarketScan® Research Databases, the analytical and nor-mative gold standard for the pharmaceutical industry.

Please contact us for more inform a t i o n :I S P OR booth 45 · www.medstat.com

re s e a [email protected] · (734) 913-3000

86

booth46

booth55

Ninaza offers web-based clinical trials softwareand customized database solutions to Pharma,Device and Biotech companies, as well as CROs.

The Ninaza EDC platform provides the flexibility,reliability and speed re q u i red across the spectru mof peri-approval and post-marketing studies._ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

Please visit us at: www.ninaza.com1900 O’Farrell Street, Suite 250 San Mateo, CA

94403650.638.4259 (main) 650.638.4266 (fax)

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

booth2 0 ,2 1

87

booth1 4

boothT3, 4

N D C H e a l t h ’s Outcomes Research group a s s i s t spharmaceutical companies in measuring andmonitoring brand performances, helping them tocompete in today’s marketplace. Our OutcomesResearch group has comprehensive data sourcesavailable for research:

• The NDCHealth Intelligent Health Repository –the industry’s best diagnosis-to-drug linkedrepository containing encrypted information on more than 100 million in any of over 1200+hospitals, 80,000 physician practices or receivingprescriptions from over 800,000 prescribersusing over 40,000 pharmacies across theUnited States. State of the art encryptionmethodology is used ensure 100% HIPA A(privacy) readiness

• Hospital Patient Encounter data – encrypted patient-level utilization data fromover 350 hospitals across the U.S., providing for treatment patterns and outcomes data from the inpatient setting

• Numerous relationships with clinicians, dataconsortiums/companies and academic centers

• Extensive research experience – more than25 years of collective experience working withvarious data assets to provide meaningful,actionable information. Findings from NDCHealthoutcomes research studies have been publishedin numerous peer-reviewed journals and presented at professional meetings aroundthe world

N D C H e a l t h® is a world leader in healthcare information solutions. We provide point-of-servicesystems, intelligent network and information management services to hospitals, pharmacies, pharmaceutical manufacturers, physicians and payers. Our offerings help to enhance businessoperations, revenues and the delivery of quality healthcare. We hold a unique position at the center ofhealthcare. Through our connectivity, we can offer unmatched market insights and information productsto support healthcare delivery, as well as sales and marketing efforts.

If you would like more information, please call (800)778-6711 or visit our Web site at www.ndchealth.com.

booth28

sponsor

Outcome Technologies is a dedicated outcome services providersupplying software, services, and data for outcomes research andhealth economics. Formed by doctors to meet the increasing needsof managing outcome data in the clinical environment, OutcomeTechnologies prides itself on meeting and understanding both theclinical and technical issues of rapidly deploying and evolving anoutcomes study to fulfil business need.

Located in London and operating globally, Outcome Technologiessystems are used by a variety of outcomes stakeholders includingpharmaceutical and medical device companies, clinician groupsand government agencies. Outcome Technologies is backed byBUPA, a leading international health and care group caring for 7.2million people globally with a turnover in excess of $7 billion.

Tel: +44 (0)20 7656 2460 www.outcometechnologies.com

NDCH E A LT H®

88

booth47

booth37What if you could…

• Go beyond prescription-only information & electronic transaction data to get a complete, nationallyrepresentative picture of patients?• Find a resource that has the analytic capabilities tohelp you prove the value of your products to yourpatient, provider, and payor customers?• Power many of your company’s research activities withone, best-in-class data source?

Now you can. PharMetrics, Inc. is a leading provider of healthcaremarket insights based on longitudinal, patient-level information. PharMetrics’ integrated, anonymous,patient-level database is comprised of over 55 millioncovered lives from over 70 health plans, including med-ical service and prescription drug information across theentire continuum of care.

Products and Services Include:• Pharmacoeconomic, Outcomes, and Safety /

Epidemiology Studies• Data Licensing• Subscription Market Assessment Products

www.pharmetrics.com800-783-6362

booth32

boothT1

Visit us at

Display #T1

innovative solutions for

better health outcomesOne of the nation’slargest providers and innovators of eldercareservices now offers:• Retrospective analysis• Prospective analysis• Phase III and IV clinical trials

detailed outcomes data from

the industry’s eldercare expertsInformation on more than 200,000 patients includes:• More than 1 million MDS

assessments • Nursing progress notes• Related care plans• Medication and treatment records• Physicians’ orders• Accounts payable/receivable• Cost accounting

(877) 8BEVERLY, Ext. 5349

For more information, contact:

John Van Vleet, Pharm.D. Vice President, Pharmacy ConsultingSiva NarayananDir, Outcomes Research

89

booth5

booth51

booth44

booth36

For quality inOutcomes Research

> Readily access to large databases including high qualityprescription, medical (GP), laboratory, hospital, pathologyand cost data.

> To assist you to have the right information at the righttime!

> Patient-centric data to give unparalleled insights intoreal-world treatment and factors driving prescribing decisions.

> Our services and products give new dimensions for

• pharmaco-epidemiology• disease epidemiology• outcomes research and economic evaluations• risk management• drug development PHARMO Institute

P.O. Box 852223508 AE UtrechtThe NetherlandsPhone: +31 30 2345 620Fax: +31 30 2345 568Email: [email protected]

90

booth52

booth48,49Jefferson Medical College

Department of Health Policy

The Department of Health Policy is one of the few academically-based outcomes research centers in the nation. The Department’smission is to foster quality, safety, and cost-effectiveness in healthcare through its robust research and education programs. Underthe leadership of David B. Nash, M.D., M.B.A., the Department hasachieved a reputation of quality and excellence for its work in pharmacoeconomics, outcomes research, quality measurement andimprovement, and professional education. Research projects conducted with federal, foundation, and industrial support, span abroad array of clinical areas and policy-relevant topics. TheDepartment’s research staff has expertise in a broad array of designsand methodologies including survey research, economic modeling,retrospective data analysis, and prospective randomized trials.Educational training and consulting services also are provided bythe Department, including development and implementation oftraining programs for the pharmaceutical industry, policymakersand providers, and convening of advisory boards for clients. A portfolio of publications edited by the Department fosters opportuni-ties for disseminating research and education program findings andreaching key stakeholder groups.

For more information on the Department of Health Policy, pleasecall (215) 955-6969 or visit our website: www.jefferson.edu/dhp.

Now in our 15th year of innovation, we are pleased tointroduce the TreeAge Pro™ product family:> TreeAge Pro 2004> TreeAge Pro Healthcare> TreeAge Pro Excel> TreeAge Pro Suite

TreeAge Pro™ updates and replaces our DATA™ soft-ware, making it easier than ever to build and analyzedecision models and communicate results.

With a host of new features, capabilities and complimenta-ry modules, the TreeAge Pro™ product family helps you:MODEL PROBLEMS as decision trees, Markov models orinfluence diagrams

ANALYZE MODELS using expected value calculations,cost-effectiveness analysis and Monte Carlo simulation

COMMUNICATE RESULTS interactively, including recom-mended strategy, underlying analysis, and supportingassumptions

(Be sure to visit our exhibit booth (48 & 49) to pick up your ISPOR membersonly discount coupon and free trial versions of our new software!)

TreeAge Software, Inc.

RTI Health Solutions is a business unit of RTI International.

RTI Health Solutions | w w w. rt i h s . o rg

3040 Cornwallis Road | P.O. Box 12194 | Research Triangle Park, NC | 27709-2194

US 1.919.316.3788 / 1.800.262.3011 | U K 44(0)161.232.3400

RTI Health Solutions (RTI-HS) helps pharmaceutical and medicaldevice companies evaluate and manage products throughout theirdevelopment and marketing lifecycle. We provide leading scientificexpertise in epidemiology, clinical operations, psychometrics, database analysis, biostatistics, health economics, and outcomesresearch. With extensive experience in survey research, using state-of-the-art technology for data collection, RTI-HS offersleading capabilities for projects that require primary data.

To learn more about how we can help maximize the potential of your new and existing products, visit us at Booth 31.

Economic models

Longitudinal database studies

Patient-reported outcomes

Product value dossiers

Benefits valuation

Therapeutic risk management

Patient registries

booth31

sponsor

Leading researchto o p t i m i z e d e c i s i o n - m a k i n g

for p roduct development and lifecycle m a n a g e m e n t

91

From Concepts to ResultsCredible, Unbiased and Pragmatic Solutions

515 West Lombard Street, 2nd FloorBaltimore, Maryland 21201

410-706-0133email: [email protected]

web: www.pharmacy.umaryland.edu/cdpp/

Need to Support Product Value?Our cl i n i c a l , r e s e a r c h , and businessexperts have over 150 years of experienceguiding pharmaceutical companies as theyseek to determine,demonstrate,com-municate and capture a product’svalue.Regardless of the stage inits lifecycle, we can identifythe drivers of value,bench-mark it against competi-t o r s , and designresearch or com-m u n i c ations programsto improve market access.

Research and Analytic ExpertiseOur scientific staff are formally trained andwidely experienced in health economics,outcomes research, decision analysis,epi-demiology, biostatistics, health policy, andclinical pharmacy. We have worked in vir-tually every therapeutic area and are wide-ly published in peer-reviewed journals.

Value CommunicationsValueMedics knows the many audiences who need to receive and understand a product’s value messages. They includeexternal decision makers (payers, regu-lators, providers, and patients) as well asinternal players (upper management, mar-

keting, the clinical team, and the salesforce). Better than a medical commu-n i c ations firm, we understand thereimbursement environment and theclinical/economic research on whichvalue messages are founded.When it’stime to communicate value, we exe-

cute proven strategies.

Global Strategy; Local ImplementationValueMedics is affiliated witha e g i s n e t , the internat i o n a lnetwork of health economics,out-comes, pricing and reim-bursement firms. C o l l e c t i v e l y, we arestaffed with over 100 advance-degreedexperts in seven countries on two conti-nents.

Outcomes Research• Design and analysis of prospective outcomes studies• Retrospective studies using administrative data• Studies of compliance and persistence• Assessment of patient-reported outcomes• L i t e r ature review and synthesis (including meta-analysis)

Health Economics• Economic evaluation of clinical trials• Burden of illness models• Cost-effectiveness and cost-minimization models• Budget impact and medical cost offset models• Field-ready model interfaces

Pricing and Access • Pricing• Contracting support• Reimbursement

Please contact Jonothan Tierce,Principal 703.536.2467 or [email protected]

booth13

SPONSOR ADVERT I S E M E N T S

92

I S P O RL E A D E R S H I PD I R E C T O RY

2 0 0 4

ISPOR STAFF DIRECTORYMarilyn Dix Smith RPh, PhDExecutive DirectorTelephone Extension: [email protected]

Lindsay AugustyniakManager, Meetings & EducationServicesTelephone Extension: [email protected]

Jennifer CasillasManager, Membership & MeetingRegistrationTelephone Extension: [email protected]

Daniel KlimDirector, Meetings &CommunicationsTelephone Extension: [email protected]

Nadia NaamanDirector, Marketing & MemberServicesTelephone Extension: [email protected]

Stephen PrioriDirector, PublicationsTelephone Extension: [email protected]

SUPPORTING STAFF

Sue CaponCoordinator, Member ServicesTelephone Extension: [email protected]

Rebecca CoreyCoordinator, Member ServicesTelephone Extension: [email protected]

Elizabeth MolsenCoordinator, Member ServicesTelephone Extension: [email protected]

Iman NadyCoordinator, PublicationsTelephone Extension: [email protected]

Andrei ScudderCoordinator, Member ServicesTelephone Extension: [email protected]

ISPOR VISITING SCHOLAR

Yen-Huei (Tony) TarnTelephone Extension: [email protected]

Office Address:ISPOR, 3100 Princeton Pike, Building 3, Suite E, Lawrenceville, NJ 08648 USA

Tel: 1-609-219-0773 Fax: 1-609-219-0774 Email: [email protected] Website: www.ispor.org

93

PRESIDENT Sean Sullivan PhD, Pro f e s s o r, University of

Washington, Department of Pharm a c y

Seattle, WA, USA

PRESIDENT-ELECTLieven Annemans PhD, MSc, Mman, Dire c t o r,

HEDM University of Ghent, Meise, Belgium

PAST PRESIDENTPeter Davey MD, FRCP, Head of

P h a rmacoeconomics, University of Dundee,

Dept. of Clinical Pharm a c o l o g y, Ninewells

Hospital & Medical School, Dundee, Scotland

DIRECTOR (2002-2004)Kerstin (Chris) Bingefors MSc, PhD, Associate

P ro f e s s o r, Research Dire c t o r, Biomedical Centre ,

Uppsala University, Dept of Pharm a c y ;

P h a rmacoepidemiology & PE, Uppsala, Sweden

DIRECTOR (2002-2004)D.S. (Pete) Fullerton PhD, Professor (Aff i l i a t e ) ,

University of Washington/Strategic Pharm a c y

Innovations, Seattle, Washington, USA

DIRECTOR (2002-2004)Mark Nuijten PhD, MD, MBA, Director of

E u ropean Business Development, MEDTA P

I n t e rnational, Molenpad, The Netherlands

DIRECTOR (2003-2005)Randel Richner BSN, MPH, Vice Pre s i d e n t ,

Federal Affairs, Reimbursement and Outcomes

Planning, Boston Scientific Corp, Natick, MA,

USA

DIRECTOR (2003-2005)M a rcus Wilson PharmD, President & CEO, Health

C o re, Inc, Wilmington, DE, USA

TREASURER (2001-2004)Jean Paul Gagnon PhD, Dire c t o r, Public Policy,

Aventis Pharmaceuticals Inc., Bridgewater, NJ,

U S A

TREASURER (2004-2007)L o rne E. Basskin PharmD, Clinical Coord i n a t o r,

N o rth Shore Medical Center, Cooper City, FL,

U S A

EXECUTIVE DIRECTORMarilyn Dix Smith RPh, PhD, Executive Dire c t o r,

ISPOR, Lawrenceville, NJ, USA

2002-2003Peter Davey MD, FRCPHead of Pharmacoeconomics,University of Dundee, Dept. of ClinicalPharmacology, Ninewells Hospital &Medical School, Dundee, Scotland

2001-2002Eva Lydick PhDLovelace Foundation, Albuquerque, NM , USA

2000-2001Jon Clouse RPh, MSDirector, PharmacoeconomicEvaluations, United Health Care,Brevard, NC, USA

1999-2000Bryan Luce PhD, MBASenior Research Leader & CEO, MED-TAP International, Bethesda, MD, USA

1998-1999Robert S. Epstein MD, MSChief Medical Officer, Senior VicePresident, Medical Affairs, Merck-Medco Managed Care, LLC, FranklinLakes, NJ, USA

1997-1998Jean Paul Gagnon PhDDirector, Public Policy, AventisPharmaceuticals Inc, Bridgewater, NJ, USA

1996-1997James Smeeding RPh, MBAAssociate Director Center forPharmacoeconomic Studies, Universityof Texas, Athens, GA, USA

1995-1996William McGhan PharmD, PhDProfessor, University of the Sciences inPhiladelphia, PA, USA

ISPOR 2003-2004 BOARD OF DIRECTORS

ISPOR PAST PRESIDENTS

ISPOR LEADERSHIP DIRECTORY

94


ISPOR BOARD COMMITTEE CHAIRS

AUDIT COMMITTEE Marcus Wilson PharmD, President & CEO, HealthCore, Inc, Wilmington, DE, USA

FINANCE COMMITTEEJean Paul Gagnon PhD, Director, Public Policy,Aventis Pharmaceuticals Inc., Bridgewater, NJ, USA

VALUE IN HEALTH MANAGEMENT ADVISORY BOARDCHAIRMark Nuijten PhD, MD, MBA, Director of EuropeanBusiness Development, MEDTAP International,Molenpad, The Netherlands

ISPOR STANDING COMMITTEE CHAIRS

BY-LAWS COMMITTEEHugh Tilson MD, DrPH, Senior Advisor to the Dean,The Univ of North Carolina at Chapel Hill, PublicHealth Leadership Program, Chapel Hill, NC, USA

NOMINATIONS COMMITTEEPeter Davey MD, FRCP, Head of Pharmacoeconomics,University of Dundee, Dept. of Clinical Pharmacology,Ninewells Hospital & Medical School, Dundee,Scotland

ISPOR MEETING PROGRAM COMMITTEECHAIRS

ANNUAL MEETING PROGRAM COMMITTEE (9th Annual) Bernie O'Brien PhD, BA, MSc, Professor,Dept. of Clinical Epidemiology & Biostatistics, Directorof The Program for Assessment of Technology inHealth (P.A.T.H.), Hamilton, ON, Canada

EUROPEAN CONGRESS PROGRAM COMMITTEE(6th Annual): Joan Rovira PhD, Senior HealthEconomist (Pharmaceuticals), Health, Nutrition andPopulation, The World Bank, Washington, DC, USA Xavier Badia PhD, General Director, Health OutcomesResearch Europe, Barcelona , Spain

ASIA-PACIFIC CONFERENCE PROGRAM COMMITTEEIsao Kamae MD, DrPH, Professor of Biostatistics andHealth Decision Sciences, Graduate School ofMedicine, Kobe University, Kobe, Japan

OTHER ISPOR COMMITTEE/INITIATIVECHAIRSAWARDS COMMITTEEC. Daniel Mullins PhD, Associate Professor and Chair,Pharmaceutical Health Services Research, Universityof Maryland School of Pharmacy, Baltimore, MD, USA

•AVEDIS DONEBEDIAN AWARD TASK FORCE Bryan Luce PhD, MBA, Senior Research Leader &CEO, MEDTAP International, Bethesda, MD, USA

•RESEARCH EXCELLENCE AWARDS TASK FORCE -METHODOLOGICAL EXCELLENCE

John Brooks, PhD, Assistant Professor, University ofIowa, College of Pharmacy, Iowa City, IA, USA

•RESEARCH EXCELLENCE AWARDS TASK FORCE -PRACTICAL APPLICATION EXCELLENCE

Joanna Siegel, ScD, Director, Research Initiative inClinical Economics, Agency for Healthcare Research& Quality, Rockville, MD USA

•CONTRIBUTED PAPERS AWARDS TASK FORCE-ANNUAL MEETING

9th Annual International Meeting-Podium: Ya-Chen Tina Shih, MS, PhD, Associate Professor,M.D. Anderson Cancer Center, Houston, TX, USA9th Annual International Meeting-Poster: Les Noe RPh, MPA, Vice President, Ovation ResearchGroup, Highland Park, IL, USA

95

•CONTRIBUTED PAPERS AWARDS TASK FORCE-EUROPEAN CONGRESS

6th Annual European Congress-Podium: Hans L. Severens, PhD, Professor of MTA, UniversityMaastricht, Dept. Health Organization, Policy, andEconomics, Maastricht, The Netherlands 6th Annual European Congress-Poster: Pedro Plans-Rubio, Evaluation Unit, G.D. PublicHealth, Department de Sanitat, Sant Pol, Spain

EDUCATION COMMITTEEKaren Rascati RPh, PhD, Professor, University ofTexas, College of Pharmacy, Austin, TX, USA

•INTERNET EDUCATION STEERING COMMITTEEZ. Tom Grapes PhD, Associate Professor, MercerUniversity, Atlanta, GA, USA

•LEARNING OUTCOMES TASK FORCELieven Annemans PhD, Mman, MSc, Health EconomistGhent University, Director HEDM, Meise, BelgiumPeter Davey MD, FRCP, Head of Pharmacoeconomics,University of Dundee, Dept. of Clinical Pharmacology,Ninewells Hospital & Medical School, Dundee ,Scotland

•SHORT COURSE DEVELOPMENT & QUALITY ASSURANCE TASK FORCE

Lorne E. Basskin PharmD, Clincal Coordinator, NorthShore Medical Center, Cooper City, FL, USAJ. Jaime Caro MD, Scientific Director, Caro Research,Concord, MA, USA

ISPOR STRATEGIC PLANNING INITIATIVES

•STRATEGIC OUTREACH COMMITTEEMichael Drummond PhD, Director, University of York,Centre for Health Economics, Heslington, York, UK

•ISPOR VISION 2005 IMPLEMENTATION COMMITTEEPeter Davey MD, FRCP, Head of Pharmacoeconomics,University of Dundee, Dept. of Clinical Pharmacology,Ninewells Hospital & Medical School, Dundee,Scotland

•ISPOR VISION 2010 COMMITTEEMarc Berger MD, Vice President, Outcomes Research& Management, Merck & Company, Inc., West Point,PA, USA Gerry Oster PhD, Vice President, PAI, Brookline, MA,USA

HEALTH SCIENCE INITIATIVES

•RCT-CEA TASK FORCE Scott Ramsey MD, PhD, Associate Member, FredHutchinson Cancer Research Center, Seattle, WA ,USARichard Willke PhD, Senior Director, Group Leader,Global Outcome Research, Pfizer, Inc., Bridgewater,NJ, USA

•QUALITY OF LIFE REGULATORY GUIDANCE TASKFORCE CHAIR

Patrick Marquis MBA, MD Managing Director, MapiValues, Boston, MA, USA

ISPOR ADVISORY COUNCIL CHAIRS

INSTITUTIONAL COUNCILPhillip Sarocco RPh, MSc, Director of HealthEconomics and Outcomes Research, AventisPharmaceuticals, Parsippany, NJ, USA

NORTH AMERICAN MEDICAL DEVICE & DIAGNOS-TICS COUNCILStephen Hull, Vice President, Global Strategy andAnalysis, Advanced Medical (AdvaMed), Washington,DC, USA

EUROPEAN MEDICAL DEVICE & DIAGNOSTICS COUNCILMarkus Siebert MS, Business Area Director –Economic Affairs, EUCOMED, Brussels, Belgium

HEALTH SCIENCE COUNCILTBD

HEALTH CARE STRATEGY COUNCILTBD

ISPOR DISCUSSION GROUP CHAIRS

CENTRAL & EASTERN EUROPEAN DISCUSSIONGROUPPawel Sztwiertnia MD, Deputy Director, Public SectorFinancing Department, Ministry of Finance, Warsaw,Poland

ASIA-PACIFIC DISCUSSION GROUPKenneth KC Lee BSc(Pharm), MPhil, PhD, AssociateProfessor and Head, Division of Pharmacy Practice,School of Pharmacy, The Chinese University of HongKong, Shatin, N.T. Hong Kong

ISPOR PUBLICATIONS CHAIRS/EDITORS

VALUE IN HEALTHEditor-in-ChiefJo Mauskopf PhD, Global Director, Health Economics,RTI Health Solutions, North Carolina, USACo-Editors Andrew Briggs DPhil, MSc, Health EconomicsResearch Centre, University of Oxford, Institute ofHealth Sciences, Headington, Oxford, UKWilliam R. Lenderking PhD, Director, OutcomesResearch, Pfizer Inc., Groton, CT, USAGordon G. Liu PhD, University of North Carolina atChapel Hill, School of Pharmacy, Chapel Hill, NC, USA Richard J. Milne BDc(Hons), MSc, PhD, University ofAuckland, Auckland, New ZealandC. Daniel Mullins PhD, Associate Professor and Chair,Pharmaceutical Health Services Research, Universityof Maryland, School of Pharmacy, Baltimore, MD, USADavid Paltiel PhD, Yale University School of Medicine,New Haven, CT, USA Sean Sullivan PhD, Professor, University ofWashington, Department of PharmacySeattle, WA, USA Johan L. Severens PhD, University Masstricht, Dept.of Health Organization, Policy, and Economics,Maastricht, The Netherlands

ISPOR CONNECTIONSEditorSteve Marx PharmD, MS, Manager,Pharmacoeconomics & Outcomes Research, AbbottLaboratories, Abbott Park, USA

HEALTH CARE COST, QUALITY, AND OUTCOMES:ISPOR BOOK OF TERMSCo-EditorsKerstin (Chris) Bingefors MSc, PhD, AssociateProfessor, Uppsala University, Dept of Pharmacy,Pharmacoepidemiology & PE, Uppsala , SwedenMarc Berger MD, Vice President, Outcomes Research& Management, Merck & Company, Inc., West Point,PA, USAEdwin Hedblom PharmD, Global Health EconomicsManager, Medical Division. 3M, St. Paul, MN USAChris Pashos PhD, Vice President & ExecutiveDirector of Pharmacoeconomics & OutcomesResearch, Abt Associates Clinical Trials, Cambridge,MA USAGeorge Torrance PhD, Vice President, McMasterUniversity and Innovus Research Inc., Burlington,Ontario, Canada

SPECIAL INTEREST GROUP (SIG) CHAIRS &WORKING GROUP CHAIRS

CLINICAL PRACTICE (CP) SIG Pamela Chavis, MD, Associate Clinical Professor,Department of Ophthalmology, Virginia CommonwealthUniversity Medical Center, Richmond, VA, USA

•CP EDUCATION (CPED) WORKING GROUP Lawrence D. Goldberg, MD, MBA, President,Goldberg, MD & Associates, Battle Ground, WA, USA

•CP LECTURE (LECT) WORKING GROUP Sara Shull MBA, PharmD, Drug Policy and EconomicsPharmacist Specialist, Nebraska Health System,Omaha, NE, USA

•CP PE/OR EVALUATION (EVAL) WORKING GROUPF. Randy Vogenberg RPh, PhD, Senior Vice President& National Practice Council Leader, Aon Consulting,Life Sciences Consulting Practice, Wellesley, MA,USA

•CP CLINICIAN RESEARCH NETWORK (CRNT)WORKING GROUP

Ramon Bautista MD, MBA, Department of Neurology,University of Florida HSC/ Jacksonville, Jacksonville,FL, USA

MANAGED CARE_PHARMACY BENEFIT MANAGEMENT (MC_PBM) SIGDell Mather PharmD, Senior Director,Pharmacotherapy Assessment & Policy, PrimeTherapeutics,Eagan, MN, USAEdwin Hedblom PharmD, Global Manager, HealthEconomics, 3M Medical, St. Paul, M, USA

•MC_PBM EDUCATION (ED) WORKING GROUP Jon Clouse RPh, MS, Consultant, United Health Care,Brevard, NC, USA

•MC_PBM RESEARCH AGENDA (RAG) WORKINGGROUP

Peter Neumann ScD, Associate Professor of Policy &Decision Sciences, Harvard School of Public Health,Boston, MA, USA•MC_PBM RESEARCH NETWORK (RN) WORKING

GROUP Elinor CG Chumney PhD, MSc, Medical University ofSouth Carolina, College of Pharmacy, Department ofPharmacy Practice, Charleston, South Carolina, USA

•RESEARCH DIGESTDennis Raisch RPh, PhD, Associate Director, VACooperative Studies Program, Clinical ResearchPharmacy, Albuquerque, NM, USA


96


MEDICATION COMPLIANCE (MED COMP) SIGJoyce Cramer MS, Associate Research Scientist, YaleUniversity, School of Medicine, Department ofPsychiatry, West Haven, CT, USA

•ISSUES & METHODS DEFINITIONS (IMD) WORKINGGROUP

Peter K. Wong PhD, MBA, RPh, Vice President,Clinical Effectiveness & PI, Good Samaritan Hospital,Dayton, Ohio, USA

•ANALYSES STANDARDS (AS) WORKING GROUPMichael B. Nichol PhD, Chair, Dept PharmaceuticalEconomics & Policy, School of Pharmacy, University ofSouthern California, Los Angeles, CA, USA

•EDUCATION (MDED) WORKING GROUP Andrea Adamus, PhD, Research Specialist,Department of Pharmacoeconomics, Division ofPharmacy, University of Texas M.D. Anderson CancerCenter, Houston, TX, USA Hieu T. Tran PharmD, Associate Professor and Chair,Department of Pharmacy Practice, LECOM School ofPharmacy, Erie, PA, USA

•BIBLIOGRAPHY GROUPJasmanda H. Wu PhD, MPH, MBA, Epidemiologist,Aventis Pharmaceuticals, Somerset, NJ, USA

•ECONOMICS OF COMPLIANCE (ECON) WORKINGGROUP

Tamas Andras Koncz PhD, Senior Health Economist,AARDEX Ltd, ZUG, Switzerland

PATIENT REGISTRY (PR) SIGJeffrey Trotter MBA, President, Ovation ResearchGroup, Highland Park, IL, USA

•COMMERCIAL APPLICATIONS (CA) WORKINGGROUP

Leanne Larson MHA, Vice President, Strategy &Development, Ovation Research Group, HighlandPark, IL, USA

•SAFETY SURVEILLANCE APPLICATIONS (SSA)WORKING GROUP

Peter Malamis MBA, Vice President, Galt Associates,Sterling, VA, USA

•ANALYTICAL APPROACHES (AA) WORKING GROUP Mohan Bala PhD, Director, Outcomes Research,Centocor, Inc., Parkway, Malvern, PA, USA

•TECHNOLOGY (TECH) WORKING GROUPHugh Levaux PhD, CEO, The Lewin Group, SanFrancisco, CA, USA

•INTERNATIONAL APPLICATIONS (IA) WORKINGGROUP

Melva T. Covington MPH, PhD, Outcomes ProjectDirector, Roche Labs, Inc, Nutley, NJ, USA

QUALITY OF LIFE (QOL) SIGPennifer Erickson PhD, Co-founder, Online Guide toQOL Assessment (OLGA), State College, PA, USA

•POPULATION HEALTH (PH) WORKING GROUP Eva Lydick PhD, Lovelace Clinic Foundation,Albuquerque, NM, USA

•CROSS-CULTURAL & TRANSLATIONAL ADAPTATION(CTA) WORKING GROUP

Diane Wild MSc, Partner, Oxford Outcomes, BuryKnowle Coach House, Headington, Oxford, UK

•ANALYSIS & INTERPRETATION (AI) WORKINGGROUP

Kathleen W. Wyrwich MS, Asst. Professor ofResearch Methodology & Health Services Research,Saint Louis University, St. Louis, MO, USA

•CONCEPTS & DEFINITIONS (CD) WORKING GROUP Margaret Rothman PhD, Executive Director of HealthEconomics, Johnson & Johnson PharmaceuticalResearch & Development, Raritan, NJ, USA

•VALUES & VALUATION (V&V) WORKING GROUPJohn Brazier PhD, Professor of Health Economics,ScHARR, University of Sheffield, Sheffield, UK

RISK MANAGEMENT (RM) SIGDennis Raisch RPh, PhD, Associate Director, VACooperative Studies Program, Clinical ResearchPharmacy, Albuquerque, NM, USA

HEALTH TECHNOLOGY ASSESSMENT (HTA) SIG (in development)

ISPOR REGIONAL CHAPTERS

CHINA CHAPTERKenneth KC Lee BSc (Pharm), MPhil, PhD, AssociateProfessor and Head, Division of Pharmacy Practice,School of Pharmacy, The Chinese University of HongKong, Shatin, N.T. Hong Kong

POLAND CHAPTERAleksander Mazurek PhD, MD, Institute of PublicHealth, Warsaw, Poland

RUSSIA CHAPTERPavel Vorobiev, Professor, Moscow Medical Academynamed after Sechenov, Head of the ResearchDepartment on Health Care Standardization Problems,Moscow, Russia

ISPOR STUDENT NETWORK / STUDENTCOUNCIL

CHAIRRitesh Kumar B.S.Pharm, M.S., Doctoral Candidate,University of Michigan, College of Pharmacy, AnnArbor, MI, USA

ADVISORZeba Khan PhD, Head Health Economics & Pricing,Cardiovascular and Metabolism Business Franchise,Novartis Pharma AG, Basel, Switzerland

PAST CHAIRCher Beilfuss PharmD, Amgen, Health Outcomes andPharmacoeconomics, Regional Medical Liaison,Thousand Oaks, CA

AUBURN UNIVERSITY – CHAPTER PRESIDENTNikhil Khandelwal BS Pharm., M.S., Doctoral Student

FLORIDA A&M UNIVERSITY – CHAPTER PRESIDENTBenita D. Williams BS, Master’s Candidate

OHIO STATE UNIVERSITY – CHAPTER PRESIDENTSatish Valluri MS

PURDUE UNIVERSITY – CHAPTER PRESIDENTHemant Phatak MS

RUTGERS UNIVERSITY – CHAPTER PRESIDENTConcetta Crivera PharmD, Master’s Candidate

UNIVERSITY OF ARIZONA – CHAPTER PRESIDENTDurgesh D. Bhandary BS Pharm, MS, Pre-DoctoralFellow

UNIVERSITY OF FLORIDA – CHAPTER PRESIDENTDionne Mayhew MPH, Doctoral Student

UNIVERSITY OF GEORGIA – CHAPTER PRESIDENTHua Chen MS

UNIVERSITY OF HOUSTON – CHAPTER PRESIDENTMonali Bhosle BS Master’s Candidate

UNIVERSITY OF ILLINOIS – CHAPTER PRESIDENTHayley Park PharmD

UNIVERSITY OF LOUSIANA AT MONROE – CHAPTERPRESIDENTLarry Humbel BS Pharm., Doctoral Student

UNIVERSITY OF MARYLAND – CHAPTER PRESIDENTShelly Dhir, Doctoral Student

UNIVERSITY OF MICHIGAN – CHAPTER PRESIDENTMathew C. Garber BS Pharm, PharmD, MA in Economics, Doctoral Student

UNIVERSITY OF MINNESOTA – CHAPTER PRESIDENTShuchita Agarwal BS Pharm, MBA , DoctoralCandidate

UNIVERSITY OF NEW MEXICO – CHAPTER PRESIDENTRupali Naik BS Pharm, MBA, Master's Candidate

UNIVERSITY OF NORTH CAROLINA – CHAPTER PRESIDENTMelissa Butler MPH, PharmD

UNIVERSITY OF RHODE ISLAND – CHAPTER PRESIDENTGreg Low BS Pharm, MS, Doctoral Student

UNIVERSITY OF SOUTH CAROLINA – CHAPTER PRESIDENTBrian Meissner PharmD, Doctoral Student

UNIVERSITY OF SOUTHERN CALIFORNIA – CHAPTER PRESIDENTVaishali Patel PharmD, Master’s Candidate

UNIVERSITY OF TENNESSEE – CHAPTER PRESIDENTCameron James BA, PharmD/Doctoral student

UNIVERSITY OF TEXAS – CHAPTER PRESIDENTHoma B. Dastani BS Pharm., MS, Doctoral Candidate

UNIVERSITY OF TOLEDO – CHAPTER PRESIDENTJason Lundy BA Economics and Political Science,Graduate Student

VIRGINIA COMMONWEALTH UNIVERSITY – CHAPTER PRESIDENTAnuprita Patkar

WEST VIRGINIA UNIVERSITY – CHAPTER PRESIDENTAshish V. Joshi BS Pharm, MS, Pfizer Fellow/ DoctoralCandidate

UNIVERSITY OF DUNDEE – CHAPTER PRESIDENTBenjamin D Ofori BS Pharm, MSc, MRPharmS,Doctoral Student/Research Training Fellow

UNIVERSITY OF TORONTO – CHAPTER PRESIDENTColin Vicente BSc (Hons), Master’s Candidate

UNIVERSITY OF UTAH – CHAPTER PRESIDENTMei-Jen Ho PharmD

97

P G # C o d e D i s e a s e / d i s o r d e r To p i c S u b c a t e g o r y3 5 2 P I N 5 A l l e r g y, Respiratory Clinical Outcomes Studies EE 3 1 1 PA A 7 A l l e r g y, Asthma Cost Studies CoI, CC 3 1 3 H P 2 A l l e r g y Health Policy D H P, DU, HE, PB 2 4 0 PA R 2 A r t h r i t i s Clinical Outcomes Studies EE 2 4 0 PA R 3 A r t h r i t i s Clinical Outcomes Studies EE 2 4 2 PA R 8 A r t h r i t i s Clinical Outcomes Studies EE 2 4 0 PA R 1 Arthritis,

C a r d i o v a s c u l a r Clinical Outcomes Studies EE 2 4 1 PA R 5 A r t h r i t i s Cost Studies CE 2 4 1 PA R 6 A r t h r i t i s Cost Studies CE 2 4 1 PA R 4 A r t h r i t i s Cost Studies CE 2 2 3 A R 2 A r t h r i t i s Cost Studies CE, CoT, CC 2 2 3 A R 1 A r t h r i t i s Cost Studies CE, CU 3 6 8 P H P 4 Arthritis, Cancer,

P a i n Cost Studies CoI 2 4 5 PA R 1 6 A r t h r i t i s Health Policy DHP 2 6 3 PA R 1 7 A r t h r i t i s Health Policy D H P, DU 2 2 4 A R 4 A r t h r i t i s Methods and Concepts2 4 2 PA R 7 A r t h r i t i s Quality of Life/Utility/Preference Studies PRO 2 4 4 PA R 1 3 A r t h r i t i s Quality of Life/Utility/Preference Studies PRO 2 2 3 A R 3 A r t h r i t i s Quality of Life/Utility/Preference Studies QoL 2 4 4 PA R 1 5 A r t h r i t i s Quality of Life/Utility/Preference Studies QoL 2 4 3 PA R 1 1 A r t h r i t i s Quality of Life/Utility/Preference Studies QoL 2 6 3 P E S 1 7 A r t h r i t i s Quality of Life/Utility/Preference Studies QoL 2 4 3 PA R 1 0 A r t h r i t i s Quality of Life/Utility/Preference Studies QoL, PRO 2 4 4 PA R 1 4 A r t h r i t i s Quality of Life/Utility/Preference Studies WP 2 4 3 PA R 1 2 A r t h r i t i s Quality of Life/Utility/Preference Studies W T P, PP 2 4 2 PA R 9 Arthritis, Pain Quality of Life/Utility/Preference Studies QoL 3 0 9 PA A 1 A s t h m a Clinical Outcomes Studies EE 3 1 2 PA A 1 0 A s t h m a Cost Studies CC 3 1 1 PA A 6 A s t h m a Cost Studies CC 2 2 5 C E 1 A s t h m a Cost Studies CoI, CoT, CS,

CC, RU PA A 2 1 A s t h m a Cost Studies CoI, CoT, RU

3 1 1 PA A 9 A s t h m a Cost Studies C o T, RU 2 2 1 R I 1 A s t h m a Cost Studies RU 3 1 0 PA A 5 Asthma,

R e s p i r a t o r y Cost Studies C o T, CC, RU 3 1 4 PA A 1 6 A s t h m a Health Policy AD 3 1 3 PA A 1 5 A s t h m a Health Policy AD 3 0 9 PA A 2 A s t h m a Health Policy AD, DHP, DU,

GD, QC 3 1 0 PA A 3 A s t h m a Health Policy CRH, DM, DHP,

EH, GD, HM, HI 3 1 3 PA A 1 3 A s t h m a Health Policy D H P, HE 3 1 0 PA A 4 A s t h m a Health Policy DU 3 1 2 PA A 1 1 A s t h m a Health Policy DU, GD, HM 3 1 2 PA A 1 2 A s t h m a Health Policy GD, HE 3 7 0 P H P 1 4 Asthma, Cardiovascular, Diabetes,

Mental health Health Policy DU, HE, HM, HI 3 0 3 P M D 1 1 A s t h m a Methods and Concepts3 1 5 PA A 1 9 A s t h m a Quality of Life/Utility/Preference Studies PS 2 2 7 H M 3 A s t h m a Quality of Life/Utility/Preference Studies QoL 3 1 4 PA A 1 7 A s t h m a Quality of Life/Utility/Preference Studies QoL, PP 3 1 4 PA A 1 8 A s t h m a Quality of Life/Utility/Preference Studies QoL, WTP, PP 2 5 7 P C O 6 Asthma, COPD Quality of Life/Utility/Preference Studies QoL 2 4 6 P C N 1 C a n c e r Clinical Outcomes Studies EE 2 4 7 P C N 5 C a n c e r Clinical Outcomes Studies EE 2 4 8 P C N 8 C a n c e r Clinical Outcomes Studies EE 2 3 2 P E 2 C a n c e r Clinical Outcomes Studies EE 2 4 6 P C N 2 C a n c e r Clinical Outcomes Studies EE 2 4 6 P C N 3 C a n c e r, Infection Clinical Outcomes Studies EE 2 5 1 P C N 1 9 C a n c e r Cost Studies CE 2 4 9 P C N 1 3 C a n c e r Cost Studies CE 2 4 9 P C N 1 1 C a n c e r Cost Studies CE 2 4 7 P C N 7 C a n c e r Cost Studies CE 2 2 1 C N 3 C a n c e r Cost Studies CE

P G # C o d e D i s e a s e / d i s o r d e r To p i c S u b c a t e g o r yP C N 3 3 C a n c e r Cost Studies CE

2 5 0 P C N 1 5 C a n c e r Cost Studies CoI 2 4 9 P C N 1 2 C a n c e r Cost Studies CoI, CoT, CC 2 5 1 P C N 1 8 C a n c e r Cost Studies CoT 2 5 5 P C N 3 2 C a n c e r Cost Studies CoT 2 5 0 P C N 1 6 C a n c e r Cost Studies CS, RU 2 2 6 C E 3 C a n c e r Cost Studies CU 2 4 6 P C N 4 C a n c e r Cost Studies RU 2 5 1 P C N 1 7 C a n c e r, Cardiovascular Cost Studies CB 2 5 1 P C N 2 0 C a n c e r Health Policy DHP 2 4 7 P C N 6 C a n c e r Health Policy DM, GD, PB 2 5 4 P C N 2 7 C a n c e r Health Policy DM, QC 2 2 8 S C 3 C a n c e r Health Policy EA, HCM 2 2 0 C N 2 C a n c e r Health Policy HE, HM 2 2 0 C N 1 C a n c e r Methods and Concepts3 0 3 P M D 1 0C a n c e r Methods and Concepts2 5 4 P C N 2 9 C a n c e r Methods and Concepts2 2 6 C E 4 C a n c e r Methods and Concepts2 5 5 P C N 3 1 C a n c e r Methods and Concepts3 7 1 P H P 1 6 C a n c e r Methods and Concepts3 1 7 P B R 5 C a n c e r Methods and Concepts2 2 1 C N 4 C a n c e r Methods and Concepts2 5 4 P C N 2 8 C a n c e r Methods and Concepts3 0 7 P M D 2 4C a n c e r Methods and Concepts2 5 5 P C N 3 0 C a n c e r, Osteoporosis Methods and Concepts2 5 2 P C N 2 2 C a n c e r Quality of Life/Utility/Preference Studies 2 5 3 P C N 2 6 C a n c e r Quality of Life/Utility/Preference Studies PP 2 5 3 P C N 2 5 C a n c e r Quality of Life/Utility/Preference Studies QoL, PP, PS,

PRO, TS 2 5 2 P C N 2 1 C a n c e r Quality of Life/Utility/Preference Studies QoL, PRO 2 5 2 P C N 2 4 C a n c e r Quality of Life/Utility/Preference Studies QoL, PRO 2 5 2 P C N 2 3 C a n c e r Quality of Life/Utility/Preference Studies QoL, PRO 2 2 8 S C 1 C a n c e r Quality of Life/Utility/Preference Studies W T P, PP 2 4 8 P C N 9 C a n c e r, Osteoporosis Quality of Life/Utility/Preference Studies QoL 3 2 1 P C V 1 3 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 3 1 9 P C V 6 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 2 1 9 C V 3 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 3 2 1 P C V 1 1 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 3 2 0 P C V 1 0 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 3 2 0 P C V 9 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 3 2 1 P C V 1 2 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 3 1 8 P C V 2 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 3 1 8 P C V 3 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 3 1 9 P C V 5 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 3 2 5 P C V 2 5 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 3 2 0 P C V 8 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 2 1 9 C V 2 C a r d i o v a s c u l a r Clinical Outcomes Studies EE 2 2 0 C V 4 C a r d i o v a s c u l a r, Diabetes Clinical Outcomes Studies EE 2 2 8 S C 4 C a r d i o v a s c u l a r Cost Studies CE 3 2 6 P C V 2 9 C a r d i o v a s c u l a r Cost Studies CE 3 2 2 P C V 1 5 C a r d i o v a s c u l a r Cost Studies CE 3 2 3 P C V 1 9 C a r d i o v a s c u l a r Cost Studies CE 3 2 3 P C V 1 8 C a r d i o v a s c u l a r Cost Studies CE 3 2 7 P C V 3 1 C a r d i o v a s c u l a r Cost Studies CE, CC 3 2 6 P C V 2 8 C a r d i o v a s c u l a r Cost Studies CE, CoT, CS 3 2 4 P C V 2 2 C a r d i o v a s c u l a r Cost Studies CoI 3 2 2 P C V 1 6 C a r d i o v a s c u l a r Cost Studies CoI, CoT, CS,

CC, RU 3 2 5 P C V 2 3 C a r d i o v a s c u l a r Cost Studies CoI, CoT, RU 3 2 6 P C V 2 7 C a r d i o v a s c u l a r Cost Studies CoI, CS, RU 2 2 5 H R 4 C a r d i o v a s c u l a r Cost Studies C o T, CS 3 2 4 P C V 2 0 C a r d i o v a s c u l a r Cost Studies C o T, RU 3 2 5 P C V 2 4 C a r d i o v a s c u l a r Cost Studies C o T, RU 3 2 3 P C V 1 7 C a r d i o v a s c u l a r Cost Studies CU 3 2 4 P C V 2 1 C a r d i o v a s c u l a r Cost Studies RU 3 2 5 P C V 2 6 C a r d i o v a s c u l a r Cost Studies RU 2 3 0 A C 1 C a r d i o v a s c u l a r Health Policy A D

RESEARCH IN DEX

98

P G # C o d e D i s e a s e / d i s o r d e r To p i c S u b c a t e g o r y2 3 0 A C 2 C a r d i o v a s c u l a r Health Policy AD 2 3 0 A C 3 C a r d i o v a s c u l a r Health Policy AD 3 3 0 P C V 4 2 C a r d i o v a s c u l a r Health Policy AD 3 3 4 P C V 5 4 C a r d i o v a s c u l a r Health Policy AD, DHP 3 3 4 P C V 5 2 C a r d i o v a s c u l a r Health Policy AD, DU 3 3 0 P C V 4 1 C a r d i o v a s c u l a r Health Policy AD, DU 3 3 5 P C V 5 8 C a r d i o v a s c u l a r Health Policy DM 3 3 4 P C V 5 3 C a r d i o v a s c u l a r Health Policy DU, GD, PB 3 3 3 P C V 5 1 C a r d i o v a s c u l a r Health Policy DU, PB 3 3 0 P C V 4 0 C a r d i o v a s c u l a r Health Policy DU, QC, PB 3 3 6 P C V 6 0 C a r d i o v a s c u l a r Health Policy EE 2 2 8 S C 2 C a r d i o v a s c u l a r Health Policy GD 3 3 5 P C V 5 7 C a r d i o v a s c u l a r Health Policy QC 3 3 5 P C V 5 5 C a r d i o v a s c u l a r Health Policy QC 3 3 2 P C V 4 6 C a r d i o v a s c u l a r Health Policy QC 3 2 2 P C V 1 4 C a r d i o v a s c u l a r Health Policy QC 3 3 6 P C V 5 9 C a r d i o v a s c u l a r Health Policy QC 3 3 5 P C V 5 6 C a r d i o v a s c u l a r Health Policy QC 3 3 3 P C V 4 9 C a r d i o v a s c u l a r Methods and Concepts2 3 8 H P 3 C a r d i o v a s c u l a r Methods and Concepts3 0 5 P M D 1 8 C a r d i o v a s c u l a r Methods and Concepts3 0 0 P M D 1 C a r d i o v a s c u l a r Methods and Concepts3 3 0 P C V 3 9 C a r d i o v a s c u l a r Quality of Life/Utility/Preference Studies HS 3 2 8 P C V 3 4 C a r d i o v a s c u l a r Quality of Life/Utility/Preference Studies QoL 3 2 8 P C V 3 5 C a r d i o v a s c u l a r Quality of Life/Utility/Preference Studies QoL 2 1 9 C V 1 C a r d i o v a s c u l a r Quality of Life/Utility/Preference Studies QoL, PP 3 2 9 P C V 3 6 C a r d i o v a s c u l a r Quality of Life/Utility/Preference Studies QoL, WTP 3 2 9 P C V 3 8 C a r d i o v a s c u l a r,

Mental health Quality of Life/Utility/Preference Studies QoL 2 5 6 P C O 1 C O P D Clinical Outcomes Studies EE 2 5 6 P C O 2 COPD, Urinary/Kidney Clinical Outcomes Studies EE 2 5 6 P C O 3 C O P D Cost Studies CE, CU 2 5 7 P C O 4 C O P D Cost Studies CoI, CoT, RU 2 2 2 R I 2 C O P D Cost Studies CoI, RU 2 5 7 P C O 5 C O P D Cost Studies CoI, RU 3 3 7 P D B 4 D i a b e t e s Clinical Outcomes Studies EE 3 4 0 P D B 1 1 D i a b e t e s Clinical Outcomes Studies EE 3 3 7 P D B 3 D i a b e t e s Clinical Outcomes Studies EE 3 3 9 P D B 9 D i a b e t e s Clinical Outcomes Studies EE 3 3 7 P D B 2 D i a b e t e s Clinical Outcomes Studies EE 3 3 9 P D B 8 D i a b e t e s Clinical Outcomes Studies EE 3 3 6 P D B 1 Diabetes, Eye/Ear/Skin, Neurological Disorders,

U r i n a r y / K i d n e y Clinical Outcomes Studies EE 3 4 0 P D B 1 2 D i a b e t e s Cost Studies CB 3 4 2 P D B 1 8 D i a b e t e s Cost Studies CC 3 4 2 P D B 2 0 D i a b e t e s Cost Studies CE 3 4 1 P D B 1 7 D i a b e t e s Cost Studies CoI 2 3 5 D B 3 D i a b e t e s Cost Studies CoI, CoT, CS,

CC, RU 3 3 9 P D B 1 0 D i a b e t e s Cost Studies CoT 3 4 0 P D B 1 4 D i a b e t e s Cost Studies C o T, CC, RU 3 4 1 P D B 1 6 D i a b e t e s Cost Studies C o T, CS, CC 3 4 1 P D B 1 5 D i a b e t e s Cost Studies CU 3 4 0 P D B 1 3 D i a b e t e s Cost Studies RU 3 4 5 P D B 2 7 D i a b e t e s Cost Studies RU 3 0 4 P M D 1 3D i a b e t e s Health Policy AD 3 4 2 D B 2 D i a b e t e s Health Policy AD, HE 2 3 4 H M 1 D i a b e t e s Health Policy DM 3 3 8 P D B 5 D i a b e t e s Health Policy DM 3 3 8 P D B 7 D i a b e t e s Health Policy DM, QC, HM, HI 3 3 8 P D B 6 D i a b e t e s Health Policy EA, QC 3 0 8 P M D 2 5 D i a b e t e s Methods and Concepts3 0 4 P M D 1 2 D i a b e t e s Methods and Concepts2 3 4 D B 1 D i a b e t e s Methods and Concepts3 4 6 P D B 2 9 D i a b e t e s Methods and Concepts3 4 6 P D B 3 0 D i a b e t e s Methods and Concepts3 4 5 P D B 2 8 D i a b e t e s Methods and Concepts

P G # C o d e D i s e a s e / d i s o r d e r To p i c S u b c a t e g o r y3 4 4 P D B 2 4 D i a b e t e s Quality of Life/Utility/Preference Studies PP 2 3 5 D B 4 D i a b e t e s Quality of Life/Utility/Preference Studies P P, PRO, TS 3 4 4 P D B 2 6 D i a b e t e s Quality of Life/Utility/Preference Studies P P, PS 3 4 3 P D B 2 1 D i a b e t e s Quality of Life/Utility/Preference Studies QoL 3 4 3 P D B 2 3 D i a b e t e s Quality of Life/Utility/Preference Studies QoL, PRO 3 4 3 P D B 2 2 D i a b e t e s Quality of Life/Utility/Preference Studies W T P, PP, PS 3 4 4 P D B 2 5 Diabetes, Pain Quality of Life/Utility/Preference Studies HS 2 5 8 P E S 1 E y e / E a r / S k i n Clinical Outcomes Studies EE 2 6 1 P E S 1 1 E y e / E a r / S k i n Clinical Outcomes Studies EE 2 5 8 P E S 2 E y e / E a r / S k i n Clinical Outcomes Studies EE 3 5 1 P I N 2 E y e / E a r / S k i n Clinical Outcomes Studies EE 2 4 8 P C N 1 0 E y e / E a r / S k i n Cost Studies CE 2 5 9 P E S 7 E y e / E a r / S k i n Cost Studies CE 2 6 0 P E S 1 0 E y e / E a r / S k i n Cost Studies CE 2 5 9 P E S 5 E y e / E a r / S k i n Cost Studies CE 2 6 0 P E S 8 E y e / E a r / S k i n Cost Studies CoI 3 5 6 P I N 1 8 E y e / E a r / S k i n Cost Studies CoI 2 6 1 P E S 1 2 E y e / E a r / S k i n Cost Studies CoI 2 6 2 P E S 1 4 E y e / E a r / S k i n Cost Studies CoI, CoT, CS, RU 2 5 9 P E S 6 E y e / E a r / S k i n Cost Studies CoI, RU 2 6 0 P E S 9 E y e / E a r / S k i n Cost Studies C o T, CC, RU 2 5 9 P E S 4 E y e / E a r / S k i n Cost Studies CU 2 6 1 P E S 1 3 E y e / E a r / S k i n Cost Studies RU 3 5 6 P I N 2 0 Eye/Ear/Skin, Infection Cost Studies CoI 2 5 8 P E S 3 E y e / E a r / S k i n Health Policy D H P, FD, PB 3 6 0 P I N 3 3 E y e / E a r / S k i n Health Policy DU 2 6 3 P E S 1 8 E y e / E a r / S k i n Health Policy DU, PB 2 6 2 P E S 1 6 E y e / E a r / S k i n Quality of Life/Utility/Preference Studies QoL, PRO 2 6 2 P E S 1 5 E y e / E a r / S k i n Quality of Life/Utility/Preference Studies QoL, PRO 3 4 6 P G I 2 GI Disorders Clinical Outcomes Studies EE 3 4 6 P G I 1 GI Disorders Clinical Outcomes Studies EE 3 4 8 P G I 7 GI Disorders Cost Studies CE 3 4 8 P G I 8 GI Disorders Cost Studies CE 3 4 7 P G I 4 GI Disorders Cost Studies CoI, CC 3 4 7 P G I 5 GI Disorders Cost Studies CU 3 3 4 7 P G I 3 GI Disorders Cost Studies CU 3 4 8 P G I 6 GI Disorders Cost Studies PI 3 5 0 P G I 1 1 GI Disorders Health Policy DHP 3 5 2 P I N 8 GI Disorders Health Policy D H P, DU, PB 3 5 0 P G I 1 2 GI Disorders Methods and Concepts3 0 9 P M D 2 8 GI Disorders Methods and Concepts3 4 9 P G I 1 0 GI Disorders Quality of Life/Utility/Preference Studies WP 3 4 9 P G I 9 GI Disorders Quality of Life/Utility/Preference Studies WP 3 1 6 P B R 3 H e m a t o l o g i c / P i t u i t a r y Quality of Life/Utility/Preference Studies QoL 3 5 1 P I N 3 Infection (including HIV, CAP) Clinical Outcomes Studies EE 3 5 2 P I N 7 Infection (including HIV, CAP) Clinical Outcomes Studies EE 3 5 0 P I N 1 Infection (including HIV, CAP) Clinical Outcomes Studies EE 3 5 1 P I N 4 Infection (including HIV, CAP) Clinical Outcomes Studies EE 3 5 5 P I N 1 7 Infection (including HIV, CAP) Cost Studies CE 3 5 5 P I N 1 6 Infection (including HIV, CAP) Cost Studies CE 3 5 4 P I N 1 2 Infection (including HIV, CAP) Cost Studies CE 3 5 9 P I N 2 9 Infection (including HIV, CAP) Cost Studies CE 2 2 2 R I 4 Infection (including HIV, CAP) Cost Studies CE 3 5 8 P I N 2 6 Infection (including HIV, CAP) Cost Studies CE 3 5 4 P I N 1 3 Infection (including HIV, CAP) Cost Studies CE 3 5 7 P I N 2 1 Infection (including HIV, CAP) Cost Studies CE, CC 3 5 7 P I N 2 3 Infection (including HIV, CAP) Cost Studies CM, CoI, CS,

CC 3 5 7 P I N 2 2 Infection (including HIV, CAP) Cost Studies CoI, RU 3 5 5 P I N 1 5 Infection (including HIV, CAP) Cost Studies CoT 3 5 8 P I N 2 5 Infection (including HIV, CAP) Cost Studies C o T, CC 3 5 4 P I N 1 4 Infection (including HIV, CAP) Cost Studies C o T, RU 3 5 8 P I N 2 7 Infection (including HIV, CAP) Cost Studies CS 3 5 7 P I N 2 4 Infection (including HIV, CAP) Cost Studies RU 2 3 1 A C 4 Infection (including HIV, CAP) Health Policy AD 3 5 3 P I N 9 Infection (including HIV, CAP) Health Policy DM, EA, HE, HM 3 5 3 P I N 1 0 Infection (including HIV, CAP) Health Policy DU

RESEARCH INDEX

99

P G # C o d e D i s e a s e / d i s o r d e r To p i c S u b c a t e g o r y3 5 3 P I N 1 1 Infection (including HIV, CAP) Health Policy DU 2 2 2 R I 3 Infection (including HIV, CAP) Methods and Concepts3 5 9 P I N 3 0 Infection (including HIV, CAP) Methods and Concepts3 0 1 P M D 2 Infection (including HIV, CAP) Methods and Concepts3 6 0 P I N 3 1 Infection (including HIV, CAP) Quality of Life/Utility/Preference Studies PRO 3 6 1 P S D 1 Men's Health Clinical Outcomes Studies EE 3 6 2 P S D 3 Men's Health Cost Studies CC 2 6 7 P M H 1 5 Mental health Clinical Outcomes Studies EE 2 6 3 P M H 1 Mental health Clinical Outcomes Studies EE 2 6 4 P M H 3 Mental health Clinical Outcomes Studies EE 3 1 8 P C V 1 Mental health Clinical Outcomes Studies EE 2 6 8 P M H 1 6 Mental health Clinical Outcomes Studies EE 2 6 9 P M H 1 9 Mental health Clinical Outcomes Studies EE 2 6 3 P M H 2 Mental health Clinical Outcomes Studies EE 2 6 7 P M H 1 3 Mental health Clinical Outcomes Studies EE 2 6 7 P M H 1 4 Mental health Clinical Outcomes Studies EE 2 6 6 P M H 1 1 Mental health Clinical Outcomes Studies EE 2 6 7 P M H 1 2 Mental health Clinical Outcomes Studies EE 2 6 5 P M H 7 Mental health Clinical Outcomes Studies EE 2 8 1 P M H 5 7 Mental health Cost Studies CC 2 3 5 M H 1 Mental health Cost Studies CC 2 7 2 P M H 2 9 Mental health Cost Studies CE 2 3 6 M H 3 Mental health Cost Studies CE 2 7 0 P M H 2 3 Mental health Cost Studies CE 2 7 2 P M H 2 8 Mental health Cost Studies CE 2 7 1 P M H 2 5 Mental health Cost Studies CE, CS, PI 2 7 3 P M H 3 4 Mental health Cost Studies CE, CS, RU 2 7 2 P M H 3 1 Mental health Cost Studies CoI 2 7 3 P M H 3 2 Mental health Cost Studies CoI 2 7 1 P M H 2 7 Mental health Cost Studies CoI 2 8 1 P M H 5 8 Mental health Cost Studies CoI 2 7 4 P M H 3 6 Mental health Cost Studies CoI 2 7 5 P M H 3 8 Mental health Cost Studies CoI 2 7 3 P M H 3 5 Mental health Cost Studies CoI, CC 2 7 1 P M H 2 6 Mental health Cost Studies CoI, RU 2 7 2 P M H 3 7 Mental health Cost Studies CoT 2 7 6 P M H 4 1 Mental health Cost Studies C o T, RU 2 7 3 P M H 3 3 Mental health Cost Studies CS 2 7 0 P M H 2 2 Mental health Cost Studies CU 2 7 0 P M H 2 4 Mental health Cost Studies RU 2 6 9 P M H 2 0 Mental health Cost Studies RU 2 6 9 P M H 2 1 Mental health Cost Studies RU 2 9 2 P N L 1 5 Mental health, Neurological

D i s o r d e r s Cost Studies CE, CU, CC 2 6 4 P M H 4 Mental health Health Policy AD 2 6 6 P M H 9 Mental health Health Policy AD 2 8 8 P M H 6 6 Mental health Health Policy AD 2 8 3 P M H 6 5 Mental health Health Policy AD 2 8 1 P M H 5 9 Mental health Health Policy AD 2 6 5 P M H 8 Mental health Health Policy AD 2 6 8 P M H 1 8 Mental health Health Policy DHP 2 8 3 P M H 6 3 Mental health Health Policy DHP 2 8 2 P M H 6 2 Mental health Health Policy D H P, DU 2 3 6 M H 2 Mental health Health Policy D H P, HE 2 8 5 P M H 7 1 Mental health Health Policy DM 2 8 3 P M H 6 4 Mental health Health Policy DM 2 8 0 P M H 5 6 Mental health Health Policy DM, DHP, DU, HE2 6 8 P M H 1 7 Mental health Health Policy DM, DU, GD,

QC, HM 2 6 5 P M H 6 Mental health Health Policy DU 2 6 6 P M H 1 0 Mental health Health Policy DU 2 8 4 P M H 7 0 Mental health Health Policy DU 2 8 5 P M H 7 2 Mental health Health Policy PB 2 8 2 P M H 6 1 Mental health Health Policy PB 2 8 4 P M H 6 9 Mental health Health Policy PB 2 8 4 P M H 6 8 Mental health Health Policy PB 2 8 2 P M H 6 0 Mental health Health Policy PB

P G # C o d e D i s e a s e / d i s o r d e r To p i c S u b c a t e g o r y2 8 4 P M H 6 7 Mental health Health Policy QC 2 8 7 P M H 7 9 Mental health Methods and Concepts2 8 6 P M H 7 4 Mental health Methods and Concepts2 8 6 P M H 7 5 Mental health Methods and Concepts2 8 5 P M H 7 3 Mental health Methods and Concepts2 8 6 P M H 7 6 Mental health Methods and Concepts2 3 1 P E 1 Mental health Methods and Concepts2 8 7 P M H 7 7 Mental health Methods and Concepts2 7 8 P M H 4 7 Mental health Quality of Life/Utility/Preference Studies HS 2 7 9 P M H 5 3 Mental health Quality of Life/Utility/Preference Studies HS 3 6 1 P S D 2 Mental health Quality of Life/Utility/Preference Studies PRO 2 7 8 P M H 4 8 Mental health Quality of Life/Utility/Preference Studies PRO 2 7 9 P M H 5 0 Mental health Quality of Life/Utility/Preference Studies PRO 2 3 6 M H 4 Mental health Quality of Life/Utility/Preference Studies QoL 2 7 6 P M H 4 3 Mental health Quality of Life/Utility/Preference Studies QoL 2 8 0 P M H 5 4 Mental health Quality of Life/Utility/Preference Studies QoL 2 7 7 P M H 4 4 Mental health Quality of Life/Utility/Preference Studies QoL 2 7 5 P M H 4 0 Mental health Quality of Life/Utility/Preference Studies QoL 2 8 0 P M H 5 5 Mental health Quality of Life/Utility/Preference Studies QoL 2 7 9 P M H 5 2 Mental health Quality of Life/Utility/Preference Studies QoL 2 7 7 P M H 4 6 Mental health Quality of Life/Utility/Preference Studies QoL, HS 3 0 7 P M D 2 3 Mental health Quality of Life/Utility/Preference Studies QoL, HS, PP 2 7 7 P M H 4 5 Mental health Quality of Life/Utility/Preference Studies QoL, PP, PRO 2 7 6 P M H 4 2 Mental health Quality of Life/Utility/Preference Studies QoL, PRO 2 7 8 P M H 4 9 Mental health Quality of Life/Utility/Preference Studies QoL, PRO 2 8 8 P N L 2 Neurological Disorders (Migraine, Alzheimer's)

Clinical Outcomes Studies EE 2 8 8 P N L 1 Neurological Disorders (Migraine, Alzheimer's)

Clinical Outcomes Studies EE 2 3 7 N D 2 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies CB, CE, CoT 2 2 7 H M 4 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies CE 2 9 0 P N L 1 0 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies CE 2 8 9 P N L 5 Neurological Disorders (Migraine, Alzheimer's)




Cost Studies CE 2 3 8 N D 4 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies CoI 2 9 2 P N L 1 4 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies CoI 2 9 1 P N L 1 1 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies CoI, RU 2 8 9 P N L 7 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies CoT 2 9 1 P N L 1 3 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies CoT 2 3 7 N D 3 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies C o T, RU 2 9 1 P N L 1 2 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies CU 2 8 9 P N L 4 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies PI 2 8 8 P N L 3 Neurological Disorders (Migraine, Alzheimer's)

Cost Studies PI 2 9 4 P N L 2 1 Neurological Disorders (Migraine, Alzheimer's)

Health Policy DM 2 9 4 P N L 2 0 Neurological Disorders (Migraine, Alzheimer's)

Health Policy DU 2 3 7 N D 1 Neurological Disorders (Migraine, Alzheimer's)

Methods and Concepts

RESEARCH INDEX

100

P G # C o d e D i s e a s e / d i s o r d e r To p i c S u b c a t e g o r y2 9 5 P N L 2 3 Neurological Disorders (Migraine, Alzheimer's)

Methods and Concepts2 9 5 P N L 2 4 Neurological Disorders (Migraine, Alzheimer's)



Quality of Life/Utility/Preference Studies PRO 2 3 4 O P 4 Neurological Disorders (Migraine, Alzheimer's)

Quality of Life/Utility/Preference Studies QoL, HS, PS, PRO2 9 3 P N L 1 7 Neurological Disorders (Migraine, Alzheimer's)

Quality of Life/Utility/Preference Studies QoL, PRO 2 9 3 P N L 1 8 Neurological Disorders (Migraine, Alzheimer's)

Quality of Life/Utility/Preference Studies QoL, PRO 2 9 2 P N L 1 6 Neurological Disorders (Migraine, Alzheimer's)

Quality of Life/Utility/Preference Studies WP 3 2 8 P C V 3 3 O b e s i t y Cost Studies RU 3 3 2 P C V 4 8 O b e s i t y Health Policy EH 3 3 3 P C V 5 0 O b e s i t y Methods and Concepts3 3 1 P C V 4 3 O b e s i t y Quality of Life/Utility/Preference Studies HS 3 3 1 P C V 4 4 O b e s i t y Quality of Life/Utility/Preference Studies QoL, PRO 2 9 5 P O S 1 O s t e o p o r o s i s Clinical Outcomes Studies EE 2 9 7 P O S 5 O s t e o p o r o s i s Cost Studies CC, RU 2 9 7 P O S 6 O s t e o p o r o s i s Cost Studies CE 2 9 6 P O S 4 O s t e o p o r o s i s Cost Studies CE 2 9 6 P O S 3 O s t e o p o r o s i s Cost Studies CoI 2 9 7 P O S 7 O s t e o p o r o s i s Cost Studies CU 2 9 6 P O S 2 O s t e o p o r o s i s Cost Studies RU 3 0 4 P M D 1 4O s t e o p o r o s i s Methods and Concepts2 9 8 P P N 1 P a i n Clinical Outcomes Studies EE 2 9 8 P P N 4 P a i n Cost Studies CC 2 9 9 P P N 5 P a i n Cost Studies CE 2 9 8 P P N 3 P a i n Cost Studies CoI 2 9 8 P P N 2 P a i n Cost Studies CoI, CC, PI 3 0 0 P P N 9 P a i n Health Policy D H P, DU 3 0 0 P P N 8 P a i n Health Policy D H P, DU 2 9 9 P P N 7 P a i n Health Policy D H P, DU, RHS 2 4 5 PA R 1 8 P a i n Health Policy EA 2 9 9 P P N 6 P a i n Quality of Life/Utility/Preference Studies HS 3 5 9 P I N 2 8 R e s p i r a t o r y Cost Studies CE 3 6 0 P I N 3 2 R e s p i r a t o r y Health Policy PB 3 0 3 P M D 9 R e s p i r a t o r y Methods and Concepts3 1 5 PA A 2 0 R e s p i r a t o r y Quality of Life/Utility/Preference Studies PP 3 6 2 P U K 1 U r i n a r y / K i d n e y Clinical Outcomes Studies EE 3 6 3 P U K 2 U r i n a r y / K i d n e y Cost Studies CC 3 6 4 P U K 7 U r i n a r y / K i d n e y Cost Studies CC 3 6 5 P U K 8 U r i n a r y / K i d n e y Cost Studies CE 3 6 3 P U K 3 U r i n a r y / K i d n e y Cost Studies CE 3 6 3 P U K 4 U r i n a r y / K i d n e y Cost Studies CoI 3 6 4 P U K 6 U r i n a r y / K i d n e y Cost Studies C o T, RU 3 6 5 P U K 9 U r i n a r y / K i d n e y Cost Studies CS, CC 3 6 5 P U K 5 U r i n a r y / K i d n e y Cost Studies CU 3 6 6 P U K 1 1 U r i n a r y / K i d n e y Health Policy AD 3 6 6 P U K 1 2 U r i n a r y / K i d n e y Methods and Concepts3 6 6 P U K 1 3 U r i n a r y / K i d n e y Methods and Concepts3 6 5 P U K 1 0 U r i n a r y / K i d n e y Quality of Life/Utility/Preference Studies PP 3 6 9 P H P 1 8 xNo Specific Disease Clinical Outcomes Studies EE 2 2 9 R X 3 xNo Specific Disease Clinical Outcomes Studies EE 3 7 2 P H P 1 9 xNo Specific Disease Cost Studies CC 3 1 5 P B R 1 xNo Specific Disease Cost Studies CoI 3 6 7 P H P 1 xNo Specific Disease Cost Studies CM 3 6 8 P H P 6 xNo Specific Disease Cost Studies CoI 3 6 8 P H P 7 xNo Specific Disease Cost Studies CoI 3 6 8 P H P 5 xNo Specific Disease Cost Studies CoI, CS, PI 3 7 2 P H P 1 7 xNo Specific Disease Cost Studies CoT 3 6 7 P H P 2 xNo Specific Disease Cost Studies C o T, RU 3 6 7 P H P 3 xNo Specific Disease Cost Studies C o T, RU 2 2 4 H R 1 xNo Specific Disease Cost Studies CU, CoT

P G # C o d e D i s e a s e / d i s o r d e r To p i c S u b c a t e g o r y3 6 9 P H P 9 xNo Specific Disease Health Policy AD, CRH, DM,

GD, QC, HM 3 7 0 P H P 1 2 xNo Specific Disease Health Policy CRH, DHP, HE,

HM 3 7 8 P H P 3 8 xNo Specific Disease Health Policy CRH, EA, HCM,

HE, HM 3 7 7 P H P 3 5 xNo Specific Disease Health Policy CRH, HCM 3 7 0 P H P 1 3 xNo Specific Disease Health Policy DHP 3 7 9 P H P 4 0 xNo Specific Disease Health Policy DHP 3 1 6 P B R 4 xNo Specific Disease Health Policy DHP 3 7 8 P H P 3 9 xNo Specific Disease Health Policy DHP 2 2 9 R X 1 xNo Specific Disease Health Policy D H P, DU 2 3 8 H P 1 xNo Specific Disease Health Policy D H P, DU, FD,

HCM, HR 3 6 1 P I N 3 4 xNo Specific Disease Health Policy D H P, DU, GD,

HM, PB 3 7 7 P H P 3 6 xNo Specific Disease Health Policy D H P, DU, HCM 2 2 5 H R 3 xNo Specific Disease Health Policy D H P, FD, HR 2 2 9 R X 2 xNo Specific Disease Health Policy D H P, PB 3 7 9 P H P 4 1 xNo Specific Disease Health Policy D H P, PR 3 3 2 P C V 4 7 xNo Specific Disease Health Policy DU, QC, PB 3 6 9 P H P 1 0 xNo Specific Disease Health Policy EA 2 2 4 H R 2 xNo Specific Disease Health Policy EA 2 2 7 H M 2 xNo Specific Disease Health Policy HCM, PB 3 7 0 P H P 1 1 xNo Specific Disease Health Policy HE 3 7 4 P H P 2 4 xNo Specific Disease Health Policy HR 3 7 3 P H P 2 2 xNo Specific Disease Health Policy HR 3 7 3 P H P 2 3 xNo Specific Disease Health Policy HR, HE, HM, PB 3 7 2 P H P 2 0 xNo Specific Disease Health Policy PB 3 8 0 P H P 4 3 xNo Specific Disease Health Policy PR 3 7 7 P H P 3 4 xNo Specific Disease Health Policy QC 3 7 6 P H P 3 1 xNo Specific Disease Health Policy QC 3 6 9 P H P 8 xNo Specific Disease Health Policy QC, HM 3 0 2 P M D 5 xNo Specific Disease Methods and Concepts3 7 4 P H P 2 7 xNo Specific Disease Methods and Concepts3 0 1 P M D 4 xNo Specific Disease Methods and Concepts2 3 0 R X 4 xNo Specific Disease Methods and Concepts2 3 2 P E 3 xNo Specific Disease Methods and Concepts2 3 9 H P 4 xNo Specific Disease Methods and Concepts3 0 8 P M D 2 6 xNo Specific Disease Methods and Concepts2 3 2 P E 4 xNo Specific Disease Methods and Concepts3 0 1 P M D 3 xNo Specific Disease Methods and Concepts3 0 2 P M D 8 xNo Specific Disease Methods and Concepts3 7 9 P H P 4 2 xNo Specific Disease Methods and Concepts3 0 5 P M D 1 7 xNo Specific Disease Methods and Concepts3 0 2 P M D 6 xNo Specific Disease Methods and Concepts3 0 8 P M D 2 7 xNo Specific Disease Methods and Concepts2 2 6 C E 2 xNo Specific Disease Methods and Concepts3 0 2 P M D 7 xNo Specific Disease Methods and Concepts2 3 3 O P 1 xNo Specific Disease Methods and Concepts3 0 6 P M D 2 0 xNo Specific Disease Methods and Concepts3 7 4 P H P 2 6 xNo Specific Disease Methods and Concepts3 7 4 P H P 2 5 xNo Specific Disease Methods and Concepts3 1 7 P B R 6 xNo Specific Disease Methods and Concepts3 0 6 P M D 2 1 xNo Specific Disease Quality of Life/Utility/Preference Studies PP 2 3 3 O P 3 xNo Specific Disease Quality of Life/Utility/Preference Studies PP 2 3 3 O P 2 xNo Specific Disease Quality of Life/Utility/Preference Studies PP 3 7 5 P H P 2 9 xNo Specific Disease Quality of Life/Utility/Preference Studies P P, PS 3 7 5 P H P 2 8 xNo Specific Disease Quality of Life/Utility/Preference Studies PS 3 7 5 P H P 3 0 xNo Specific Disease Quality of Life/Utility/Preference Studies PS, PRO 3 2 9 P C V 3 7 xNo Specific Disease Quality of Life/Utility/Preference Studies QoL 3 0 5 P M D 1 5 xNo Specific Disease Quality of Life/Utility/Preference Studies QoL, HS 3 7 6 P H P 3 2 xNo Specific Disease Quality of Life/Utility/Preference Studies QoL, HS, PP 3 7 7 P H P 3 3 xNo Specific Disease Quality of Life/Utility/Preference Studies QoL, HS, PP 3 0 7 P M D 2 2 xNo Specific Disease Quality of Life/Utility/Preference Studies QoL, PP 3 0 6 P M D 1 9 xNo Specific Disease Quality of Life/Utility/Preference Studies QoL, PRO 3 0 5 P M D 1 6 xNo Specific Disease Quality of Life/Utility/Preference Studies QoL, PRO 3 7 1 P H P 1 5 xNo Specific Disease Quality of Life/Utility/Preference Studies QoL, WP

RESEARCH INDEX

101

WELCOME TO CRYSTAL CITYThe Marriott Crystal Gateway is conveniently located acro s s

the Potomac River from Washington, DC; only three miles

f rom the White House, the US Capitol, the Smithsonian

Museum and historic monuments; two miles from historic

Old Town Alexandria and just minutes from Georg e t o w n ,

the Kennedy Center and other historic and cultural

attractions. Nearby shopping includes one of the

Washington area's premier shopping malls, The Fashion

Center at Pentagon City. Additional shopping and dining is

below the hotel at The Crystal City Shops. The Marriott is

happy to offer complimentary shuttle service to and fro m

National Airport. Please feel free to visit the Concierge Desk

in the lobby for more information on area attractions.

Washington's Metrorail (or METRO) is one of the world's

safest, cleanest and most efficient subway systems. METRO

system maps can be found at the Concierge Desk.

M a rriott Crystal Gateway 1700 Jefferson Davis HwyArlington, VA 22202

HOTEL INFORMAT I O N

HOTEL FLOOR PLAN

102

real world insight

real data.real time.real world.

real insight.It’s true. No one can show you thebreadth and depth of quality patientdata that HealthCore can. But we’reso much more than a data company.

Our mission is to measure the valueof therapies in the real world, andthen communicate these findings ina meaningful and actionable way.T h a t ’s real insight. That’s who we are .

www. h ealth c o re . c o m30 2-2 3 0-20 0 0

health outcomes re s e a rch • clinical re s e a rch • consulting • data solutions • outcomes support

If you’d like to take a closer look, v isit us at booths 9 and 10 .

A p p l i e d Health Outcomes®

For more information contact,Brian Nightengale, PhD at 800.320.6497b n i g h t e n g a l e @ a p p l i e d - o u t c o m e s . c o mw w w. a p p l i e d - o u t c o m e s . c o m

Booth 43Applied Health Outcomes® would like to invite you to visit our team at booth43 during the ISPOR 9th Annual International Meeting in Arlington, VA .

Applied Health Outcomes® is the pre m i e re p rovider of strategies ands e rvices that measure and communicate the value of pharm a c e u t i c a l sand other healthcare technologies through e x p e rtise, commitmentand integrity.

The right people. The right solutions.

The right methodology.

Documents

Meeting Program - Pdf Format